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Abstract
The ubiquitous and oncogenic human herpesvirus Epstein-Barr virus (EBV) establishes a 
latent infection and promotes the long-term survival of the infected host cell by targeting 
the molecular machinery that controls cell fate decisions (apoptosis, proliferation and 
differentiation) These host-virus interactions are likely to play a crucial role in the 
development of EBV-associated malignancies mcludmg African endemic Burkitf s 
lymphoma, nasopharyngeal carcinoma, Hodgkin’s disease and lymphoprohferative 
disorders in immunodeficient individuals We have previously shown that (1) EBV- 
mfected Burkitt’s lymphoma cell lines exhibit elevated levels of expression of the anti- 
apoptotic bfl-\ gene (also known as A l)  compared to their uninfected counterparts, (11) 
ectopic expression of Bfl-1 can protect a Burkitt’s lymphoma (BL) cell line from 
apoptosis induced by serum deprivation (D’Souza, B , Rowe, M and Walls, D 2000 J 
Virol, 74, 6652) and (m) the EBV Latent Membrane Protein 1 (LMP1) stimulates bfl-1 
promoter activity through interactions with components of the cellular Tumour Necrosis 
Factor Receptor (TNFR/CD40)-signallmg pathway by a mechanism which includes an 
essential role for the transcription factor NFkB (D’Souza et al, submitted) Bfl-1 is an 
anti-apoptotic protein o f the Bcl-2 family, whose preferential expression in hematopoietic 
and endothelial cells is controlled by inflammatory stimuli This study reports the novel 
finding that the EBV nuclear antigen 2 (EBNA2), a second major effector of phenotypic 
change m EBV-infected cells, can independently upregulate bfl-1 mRNA levels m BL 
cell lines This thesis presents the novel finding that EBNA2 regulates bfl-1 promoter 
activity through interactions with components of the cellular Notch signalling pathway 
EBNA2-mediated /ram-activation of bfl-1 is dependent upon its ability to bind CBF1 (a 
nuclear component of the Notch signalling pathway) and involves a novel CBF-l-hke 
binding site on the bfl-1 promoter This EBNA2-mediated effect on bfl-1 is modulated by 
other EBV latent proteins that are known to co-operate with EBNA2 (EBNA-LP) or 
which have been shown to interact with the CBF1 -co-repressor complex (EBNA3A, 3B, 
3C and RPMS) These findings are relevant to our understanding of EBV persistence, its 
role m malignant disease, and the B cell developmental process
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C h a p t e r  1  
I n t r o d u c t i o n
Epstein Barr Virus (EBV)/Human Herpes Virus 4 (HHV4)
1.0 Classification.
EBV/HHV4 is a gamma herpesvirus and the only human herpes virus in the gamma 
herpes virus subfamily The gammaherpesvirus subfamily includes both the 
lymphocryptovirus and rhadinovirus genera EBV is the prototype lymphocryptovirus 
Humans are the exclusive natural host for EBV Other lymphocryptoviruses have only 
been found in old world primates such as chimpanzees The gamma herpes viruses were 
classified on the basis o f their biological properties rather than their genomic 
organization Thus the gamma herpes virus family consists of viruses, which can 
establish latent infection in lymphocytes and are associated with cell proliferation 
Although some members of the beta herpes virus group such as HHV6 and HHV7 are 
capable of latent infection of lymphocytes they do not corrupt the cell proliferation 
pathways of the latently infected cells (Kieff 1996)
It is precisely these biological properties, particularly the involvement of the gamma 
herpes viruses in cell proliferation and thus cancer, which has generated most of the 
interest and study of this viral subfamily The link between herpes viruses and oncogenic 
disease however, is restricted to the gamma herpes virus subfamily (Rickinson, 2002) 
EBV in particular has been associated with several human cancers (See table 1 0 below) 
and was originally isolated from a human tumor biopsy, Burkitts Lymphoma (BL) 
(Epstein et a l , 1964)
1.1 Virus Structure
Similar to other herpes viruses, EBV has a toroid-shaped protein core that is wrapped 
with double stranded DNA Surrounding this is a nucleocapsid comprised of 62 
capsomeres, a protein tegument between the nucleocapsid and the envelope and an outer 
envelope with external glycoprotein spikes The major EBV capsid proteins are 160,47, 
and 28kd The most abundant EBV proteins within the envelope and tegument are 
350/220 and 152kd respectively EBV also differs from other herpes viruses in the 
predominance of a single glycoprotein m the outer envelope
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F ig u r e  1.0. Sc h e m a t ic  R e pr e se n t a t io n  o f  H e r p e s  V ir u s  St r u c t u r e
Schematic Representation of Herpes Virus Structure
Envelope
Tegument
DSDNA
Glycoprotein spikes
Capsid DNA- Associated
Figure 1.0. Schematic representation of herpes virus structure. All major structural components 
including the icosotetrahedron shaped capsid, the tegument and the envelope are shown.
1.2 EBV Genome Structure
The EBV genome is a linear, double-stranded, 172-kbp DNA with a 60% 
guanine/cytosine composition (KiefF 1996). The EBV genome includes 85 known genes 
that occupy most of the viral DNA (Wensing and Farrell 2000). As with many viruses, 
however, complicated differential splicing of RNA transcripts means the number of 
proteins transcribed may far exceed the number of genes. The characteristic features of 
EBV and other lymphocryptovirus genomes include (i) a single overall format and gene 
arrangement, (ii) reiterated 0.5kbp terminal direct repeats (TR) and, (iii) reiterated 3kbp 
internal direct repeats that divide the genome into short and long largely unique sequence 
domains. The major repeat domains serve as landmarks on the EBV genome map 
however isolates from serial passage may have different numbers of repeat domains thus
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repeat domain length is not an invariant feature of EBV DNA, however these differences 
can be exploited when determining the difference between different isolates or strains In 
addition since some o f these repeat domains may encode particular proteins, differences 
in protein size on immunoblots can be used to identify particular viral isolates or strains 
However, each time EBV establishes latent infection in a proliferating cell, the genome 
persists as an episome that has a number of repeats TR characteristic of that infected 
cell Thus the number of TRs in latently infected cells are useful in determining whether 
latently infected cells arose from a common progenitor (Kieff 1996) Figure 1 1 below 
outlines EBV genome arrangement
Figure l . l  the EBV Genome
The EBV genome
Co-ordinates (kb)0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190
1 I I I I_____I___ I___ !___ I___ I___ I I I I I I I I I I
BamH\ restriction map 
fiamHI W repeats z B95-a del
I II I II FI I l'l I KI B I I Dill 111 iiÎÜFrÂ
TR IR1
EBERs
*IR2 
EBNA2
*IR3
EBNA1
♦IR4CSTs---
TR
BARF1 
^ LMPs
Figurel 1 A schematic representation of the EBV genome. Upper panel coordinates of a linearised 
version of a composite EBV genome Lower panel m vuions EBV exists in a linear form such as shown 
here, but in infected cells, including tumours, the genome is circularised through terminal repeats, 
designated TR Some landmarks on the viral genome include the various families of repetitive elements 
IR1-IR4 , as well as the terminal repeats TR. The gene locations of EBNA1 and EBNA2, LMP1 and the 
small RNAs EBERs, as they relate to the BmnHI restriction map of the viral genome, are indicated 
LMP2A and 2B are expressed across the TRs, and thus can only be produced from circularised DNA Also 
shown are the location of transcription of the BARF1 and the highly spliced RNAs CSTs
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EBV was the first herpes virus to be completely sequenced and was sequenced from the 
EBV strain B95-8 Since this viral strain was initially cloned as a BamHl fragment 
library, nomenclature for the open reading frames (ORFs), for transcription or RNA 
processing are commonly referenced to specific BamHl fragments (Farrelll992) An 
example o f this is the BARF1 ORF, which is found in the BamHl A fragment (BA) and 
is the first ORF (FI) extending in a nghtward direction (R) The schematic above shows 
the location of the various ORFs on the EBV genome (Figurel 1)
Two EBV types have been identified in most human populations These two types are 
generally referred to as EBV type 1 and EBV type 2 (formerly types A and B 
respectively) The two types differ only by the manner o f a few genes however these 
differences are responsible for consistent type specific genetic and biological activities 
The genomes for the two strains are identical except for the genes that encode some of 
the Epstein Barr nuclear antigens (EBNAs) such as EBNA2, EBNA3A,3B 3C and 
EBNALP, m latently infected cells These differences are reflected in type-specific and 
type-common EBNA epitopes for antibodies (Young et a l , 1987) and T-cell recognition 
(Moss et a l , 1988) Because type 1 is more common in developed societies, most EBV 
immune human sera from developed societies react preferentially or exclusively with 
EBV type 1 EBNA2, 3 A, 3B and 3C African sera are more evenly split in their serologic 
reactivity however the recovery of type-2 virus from blood is unusual (Young et a l , 
1987, Rowe et a l , 1989)
1.3 Strategy of Infection
Humans provide the natural host for Epstein Barr Virus and it is estimated that over 95% 
of the world’s population carry this herpesvirus (Rowe 2001) EBV target cell tropism is 
generally accepted to be the B cell Evidence suggesting possible dual-tropism involving 
epithelial as well as B cells has been debated, though evidence to date suggests EBV 
mainly infects and replicates m B cells in the healthy host (Faulkner et a l , 2000, Power 
and Walls 1993)
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Primary infection in vivo occurs at the oropharynx and viral replication at this site 
amplifies the orally transmitted virus (Rickinson 2002) It is at this site at this stage of 
primary infection that EBV either gams direct access to B cells by exploiting the 
structural arrangement of the tonsil epithelium, (which is infiltrated in places by 
lymphoid cells) or alternatively, accesses B cells at this point by an infection independent 
mechanism called transcytosis
At a molecular level, EBV B lymphocyte infection in vitro involves a number of steps 
including virus adsorption, viral penetration and uncoating, as well as a number of early 
intracellular events A number of B cell lines, particularly Burkitts lymphoma (BL) cell 
lines and lymphoblastoid cell lines (LCLs), are particularly useful for studying EBV 
infection m vitro
1,4 E a r ly  E vents in EBV In fectio n
1.4.1 Viral Adsorption, Penetration and Uncoating
EBV is adsorbed to infected B-lymphocytes by binding to a cell surface protein called 
CD21 CD21 (also known as CR2) is a member of the immunoglobulin super family and 
consists of 15 or 16 imperfect repeats of a 60-amino-acid domain, a transmembrane 
domain and a short carboxy-temunal cytoplasmic domain The EBV binding activity 
maps to the amino terminal repeat domains The major EBV outer envelope glycoprotein 
gp350/220 is the CD21 ligand (Kieff 1996) However other modes of entry are also likely 
to exist since a virus lacking gp350 is still able to infect and immortalize B cells (Janz et 
a/,2000)
Super infection of established BL cell lines is somewhat different in that EBV binding the 
envelope fuses with the plasma membrane, releasing the nucleocapsid and the tegument 
into the plasma membrane The differences between the mechanism of infection between 
primary B-lymphocytes and BL cells are likely to be due to the cytoskeletal abnormalities 
of the tumor cells (Kieff 1996) Another viral envelope glycoprotein gp85 has been 
implicated in the fusion of the envelope with the plasma membrane (Miller et a l , 1988)
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At this point the EBV capsid dissolves, the viral genome is transported to the cell nucleus 
and the viral DNA circularizes The viral DNA circularizes within 16 to 20 hours post 
infection (Hurley, and Thorley-Lawson 1988) by a process involving fusion of the 
terminal repeats Details regarding these intracellular post-infection processes are still 
unclear
1.5 In trod u ction  t o  th e  L y tic  and L a ten t Programmes, o f  EBV Infection .
Two “programmes” of EBV-cellular infection are recognized, these are known as the 
lytic (or replicative) programme and the latent programme (Thorley-Lawson, and 
Babcock 1999) The virus lytic programme is the series of events describing the process 
of active replication and production of infectious progeny EBV vtnons This cycle 
involves expression of the “lytic programme genes” in an ordered cascade These genes 
are involved in viral DNA replication and some encode structural glyco-protems or 
proteins that modify the infected cells m order to permit viral envelopment or egress 
(IARC Monographs 1997) Like several other herpesviruses, EBV also encodes lytic 
cycle genes that can prevent or delay death o f the host cell, which can result from 
apoptosis triggered by the cell recognizing virus replication as DNA damage (Henderson, 
et a l , 1993) Details of the viral lytic genes, and their protein products, involved in the 
viral lytic programme are given in section 1 9 below The most common outcome of B 
lymphocyte infection with EBV, however, is a persistent latent infection in memory B 
cells In fact the virus replicates poorly in recently infected B-lymphocytes (Niedobitek et 
a l , 1997), which instead become stably latently infected Latent infection requires 
expression o f a specific set o f EBV latent genes encoding nuclear (EBNA/Epstem Barr 
Nuclear Antigens) and membrane proteins (LMP/Latent Membrane Proteins) and small 
RNAs (EBERs/Epstein Barr encoded RNAs) Expression o f these genes allows viral 
persistence and ultimately causes continual proliferation of the infected B-lymphocytes 
(Allday et a l , 1989, Alfien et a l , 1991) a process also known as immortalization Some 
of these B cells then manage to avoid immunosurveilance and certain death by apoptosis 
and persist in the host in the memory B cell pool In vivo, only a small number of B cells
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enter the memory B cell pool, by a specific selection process, unselected cells die by 
apoptosis It is thought that EBV can mimic the “selection process” and protect EBV 
infected cells from apoptosis, while allowing their passage to the memory B cell pool 
Figure 1 2 below shows the mechanisms whereby EBV can persist in vivo (adapted from 
Faulkner et a l , 2000)
8
F ig u r e  1.2. EBV P e r s is t e n c e  in  V iv o
Fig. 12 Epstein-Barr virus (EBV) persistence in vivo (reviewed by Faulkner et al, 2000) EBV persists 
in circulating resting B cells, hidden from T-cell lmmunosurveillance by limited viral gene expression 
[Epstein-Barr nuclear antigen (EBNA) 1 and latent membrane protein (LMP) 2] and the absence of cellular 
receptors necessary to elicit a cytotoxic T lymphocyte (CTL) response (‘latency programme’) Should such 
a cell enter lymphoid tissue and become activated by encounter with antigen or T cell signaling via CD40, 
the resulting cell divisions would allow viral genome replication, although still without engendering a CTL 
response, because viral gene expression is limited to being non-immunogemc (‘EBNA 1-only programme’) 
The fate of the dividing cells can be as follows to apoptose, but not before the virus has entered the ‘lytic 
programme’, releasing infectious vinons, to terminally differentiate into a plasma cell with the same effect, 
or to become a memory B cell, with the virus returning to the latency programme An infected cell can also 
begin to proliferate under virus-driven mechanisms analogous to B cells infected in vitro These become 
immortalized owing to the expression of nine viral genes EBNAs 1,2, 3a, 3b, 3c, LP and LMPs 1, 2a and 
2b (‘growth programme') Under normal circumstances these cells would be killed by CTLs, but some 
might enter one of the alternative 'programmes’ before this occurs
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1.6 EBV L a t e n t  I n f e c t io n
In latent infection, the virus penetrates the cell in the usual manner after binding to CD21 
and remains present either as circular episomal DNA or less frequently as linear DNA 
integrated into the host genomic DNA Episomes present in low copy number in the host 
cell nucleus are copied by host cell DNA replicating enzyme and are passed to daughter 
cells by mitosis (Joske and Knecht 1993) The effect of EBV infection on cell growth in 
vitro is immediate and efficient with most cells beginning DNA synthesis 48 to 72 hours 
post infection At least 11 EBV genes are expressed m latent infection Expression o f a 
subset of 9 of these genes ultimately leads to B cell immortalization These nine genes 
include six nuclear proteins (EBNA1, 2, 3A, 3B, 3C and EBNA-LP, three membrane 
proteins (LMP1, LMP2A and LMP2B), and two small non-polyadenylated nuclear RNAs 
(EBER1 and EBER2) Five o f these genes are essential for primary B cell 
immortalization these are, EBNA1, 2, 3A, 3C, and LMP1 It was originally though that 
EBNALP was also essential for B cell immortalization however recent studies showed 
that although it is not essential, it substantially enhances proliferation (Rowe 2001, Izumi 
2001) Table 1 0 below, adapted from (Wensing and Farrell 2000, Rowe 2001), 
summarizes the functions of the EBV latent proteins and their requirement for 
immortalization The first viral proteins to be expressed in B lymphocytes after EBV 
infection are EBNA2 and EBNALP, these are transcribed from the Wp promoter in a 
rightward direction (See Figure 1 3A below), and protein can be detected m the cells 
within 12-16 hours post infection The Wp promoter is present in multiple copies in the 
major internal repeat Forty-eight hours after EBV infection, expression of EBNA1, 
EBNA3s and LMP1 is induced, this is then followed by expression of EBERs and LMP2 
such that by 72 hours post infection all 11 latent proteins are at detectable levels 
Transcription of nuclear proteins is initiated at RNA polymerase II -dependent promoters 
in the BamHl C (Cp) and the BamHl W (Wp) regions in the viral genome Once 
immortalization has been reached, transcription of the EBNA2 and EBNALP proteins 
from the strong Wp promoter declines and transcription of the genes switches to the Cp 
promoter (Woisetschlaeger et a l , 1990) The switching mechanism is not folly 
understood at the molecular level However Cp activity is highly dependent on several
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cellular transcription factors, including nuclear factor Y (NF-Y) and Spl (Borestrom et 
a l , 2003) All EBNA mRNAs are denved from the same transcriptional unit by 
alternative splicing and alternative polyadenylation This can be seen by following the 
outer long arrowed red line m Figure 1 3A below, where all the EBNA genes are 
transcribed from either the Cp or Wp promoter Further detail can be seen in figure 1 3 B 
below The coding exons for most of the EBNAs are towards the 3’ end and are preceded 
by the highly spliced leader exons, which are encoded within the major internal repeat of 
the genome (Farrell 1995)
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F ig u r e  1.3A. L o c a t io n  o f  E B V  G e n e s  o n  t h e  D o u b le  S t r a n d e d  V i r a l  E p isom e
Figure 1.3A The Epstein-Barr virus (EBV) genome. The Diagram below, adapted from (Murray, and 
Young 2001) shows (a) the location of the EBV latent genes on the double-stranded viral DNA episome. 
The origin of plasmid replication (oriP) is shown in orange. The large solid blocks (in purple) represent 
coding exons for each of the latent proteins and the arrows indicate the direction in which they are 
transcribed. EBNA2 is transcribed from the Wp promoter until cells become immortalized where after 
transcription is initiated from the Cp promoter. All EBNA mRNAs are transcribed from the same 
transcriptional unit by alternative spicing and polyadenylation (Details on this are shown in l.xB below.) 
EBNA-LP is transcribed from variable numbers of repetitive exons. LMP2A and LMP2B are composed of 
multiple exons located either side of the terminal repeat (TR) region, which is formed during the 
circularisation of the linear DNA to produce the viral episome. The orange arrows at the top represent the 
highly transcribed non-polyadenylated RNAs EBER1 and EBER2. Transcripts from the BamA region can 
be detected during latent infection, but no protein arising from this region has been definitively identified. 
Shown here are the locations of the BARFO and BARF1 coding regions.
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F ig u r e  1.3 B. D e t a i l s  o f  EBNA mRNA T r a n s c r ip t io n .
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Figure 1.3B. A simplified outline of the splicing of the EBV nuclear antigen coding mRNAs. All the
EBNAs are transcribed from either the Cp or Wp promoter; the different EBNAs are encoded by individual 
mRNAs generated by differential splicing of the same long primary transcript.
1.7 Three Forms of Latency, Latency I, II and m
Three forms of latent infection have been characterized in EBV carrying B cell lines and 
EBV tumor carrying biopsies. These are frequently described as latency I, II and HI (Kerr 
et al.9 1992). These different forms of viral latency were suggested on the basis of 
differential expression of viral latent genes and promoter usage in EBV associated tumors 
and immortalized B cell lines. The locations of the latency genes in the viral genome and 
their patterns of expression in the different latency states are shown in Figure 1.3 A above 
(Murray and Young 2001). The outer long arrowed red line represents EBV transcription 
during a form of latency known as latency in  (Lat IE) where all the EBNA mRNAs are 
transcribed from either the Wp or Cp promoter. The inner shorter arrowed blue line 
represents the EBNA1 transcript originating from the Qp promoter during Lat I and Lat
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In latency I defined by BL, only the EBV EBNA1 antigen is expressed as well as high 
copy numbers of EBER1 and 2 Also known as the EBNA1 only programme, this 
describes the form of latency in B cells dnven to proliferate in response to physiological 
signals All the EBV latent proteins elicit a strong immune response except EBNA1 thus 
the EBNA1 only programme may explain the ability o f the virus to persist undetected by 
the immune system of infected individuals In latency II as defined by Nasopharyngeal 
carcinoma (NPC) and Hodgkins Lymphoma (HD) both LMP1 and LMP2 are expressed 
in addition to EBNA1 and the EBER RNAs Latency III, also known as the growth phase 
is designed to drive the limited proliferation of B cells prior to differentiation and the 
establishment of persistent infection in memory B cells Latency ID is the best 
characterized latency programme and is found in LCLs, immunoblastic B cell 
lymphomas of the immunosuppressed and some B cell blasts in patients with infectious 
mononucleosis All the known latency genes are expressed Other less well-characterized 
patterns of EBV gene expression have been identified m other EBV associated diseases 
For example it had been proposed that EBV may be associated with some breast and 
hepatic cancers where EBNA1 but not EBER expression has been observed, however 
more recent studies indicate that breast and hepatic cancers are not EBV associated 
diseases Reviewed by (Herrmann and Niedobitek 2003) EBV latent gene expression and 
the form of latency identified in a number of EBV-associated diseases are detailed in 
table 1 0 below
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Ta bl e  l .o
Type of Latency Gene Product Examples Reference
I EBERs, EBNA1 Burkitts Lymphoma, (Rowe et al., 1987)
Gastric Carcinoma (Imai et al., 1994)
II EBERs, Hodgkins Disease, (Deacon et al., 1993)
EBNA1,LMP1,2A, 2B, Nasopharyngeal (Hitt etal., 1989)
BARFO Carcinoma (Brooks et al., 1992)
in All EBV Latent Genes PTLD*, (Young etal., 1989)
IM* (Tierney et al., 1994)
Other EBNA1, 2, LMP1 T cell Lymphomas (Harabuchi et al, 1990)
Other EBERs, EBNA1,2 Smooth Muscle tumors (Lee et al, 1995)
Other EBNA1, 2, LP, LMP1 OHL* (Webster-Cyriaque et al.,
2000)
*PTLD- Post Transplant Lymphoproliferative Disorder, *EM- Infectious Mononucleosis, *OHL- Oral 
Hairy Leukoplakia.
1.8 EBV Latent Genes 
1.8.1 EBNA1
EBV Nuclear Anitgen 1 (EBNA1) is a multifunctional 73kDa phosphoprotein of 641 
amino acid residues. The protein consists of a short amino terminal region, a, 20-40kDa 
glycine-alanine repetitive sequence flanked by arginine rich regions and a highly charged 
acidic carboxy terminal sequence (Hennessy and Kieff 1983). The EBNA1 protein plays 
a number of important roles during latent infection of human host cells during EBV 
infection. Firstly, EBNA1 activates replication of the episomal viral genome once every 
cellular S phase (Adams 1987; Yates and Guan 1991). Secondly, EBNA1 governs 
segregation of the viral episomes during cell division so that the EBV genome is stably 
maintained. Thirdly, EBNA1 trans-activates transcription of other EBV latent gene 
products. All three o f these functions require a direct interaction with oriP, the origin of 
viral replication (See Figure 1.1 for position on the EBV genome). EBNA1 binds as a 
dimer to a specific sequence within the oriP, TGGATAGCATATGCTATCCA. OriP is 
comprised of two non-contiguous functional elements, a dyad symmetry element (DS) 
and a family of repeats (FR). The DS contains four DNA binding sites and is the likely
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site for initiation of DNA synthesis The FR contains 20 EBNA1 binding sites and when 
bound by EBNA1 plays an important role m activating DNA replication from the DS, 
activating expression of other EBV latent genes and governing stable segregation of the 
EBV genome (Chittenden et al 1989, Sugden and Warren 1989, Rawlins et al 1985, 
Wysokenski and Yates 1989) The diagram below (Figure 1 4) Adapted from (Avolio- 
Hunter and Frappier 1998) shows the various functional domains of the EBNA1 protein
Figure 1.4. EBNA1 Functional Domains
Gly-Ala rep ea t n|_s 
G ly-Arg 1 DNA looping^
D NA binding & 
dim en zation  
1
FRNA1 1 IS
1 40  90 327 376 459 607 641
Figurel 4 Functional domains of EBV nuclear antigenl (EBNA1). The gly-Ala box is a repetitive 
region composed entirely of glycine and alanine, it vanes m length between viral strains Adapted from 
Avolio-Hunter and Frappier 1998
OnP was originally interpreted as being the replication origin of EBV but it is now 
thought that in the whole, EBV plasmid replication may initiate at other locations in the 
plasmid (Little and Schildkraut 1995) The main role of EBNAl/oriP may be to ensure 
stability of the replicated DNA and segregation into the daughter cells at division 
(Mackey and Sugden 1999) EBNA1 binding to onP also activates a transcription 
enhancer activity in onP that can activate expression of linked viral genes EBNA1 also 
activates expression of the lymphoid recombmase genes (RAGs), through an as yet 
unidentified mechanism (Snmvas and Sixbey 1995) Activation of the RAGs could 
promote chromosomal rearrangements and translocations and possibly also facilitate viral 
integration Expression of EBNA1 in EBV negative cell lines has no obvious effect on 
cellular growth characteristics However the expression of EBNA1 in the B cells of 
transgenic mice has been shown to be associated with the development of lymphocytic
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lymphoma and leukaemia suggesting that EBNA1 predisposes the mouse lymphocytes to 
oncogenic change (Wilson and Levine 1992)
EBNA-1 can also act as a strong RNA binding protein and can bind RNA in vitro through 
arginine/glycine containing (so-called 'RGG') motifs These motifs have been found in an 
increasing number of proteins that interact with RNA The EBV antigen contains three 
potential ’RGG* motifs located around an internal glycine/alanine-nch repetitive sequence 
in the protein (Avoho-Hunter and Frappier 1998)
1.8 2 EBNA2
1.8.2.1 Id en tifica tion  and C h a ra cter iza tio n  o f  EBNA2.
In vitro infection of B cells with EBV leads to the immortalization of these cells and the 
establishment of permanently growing lymphoblastoid cell lines (LCLs) Thirty-four 
years ago, a mutant form of EBV, the so-called P3HR1 virus was isolated, which had lost 
the ability to transform B cells m vitro (Hinuma et a l , 1967, Miller et a l , 1974) In this 
transformation-incompetent strain a deletion had been mapped which spans the open 
reading frame (ORF) of EBNA2 and also parts of EBNALP (Bomkamm et a l , 1982, 
Dambaugh et a l , 1984, Hennessy and Kieff 1985, Dillner et a l , 1986) The 
immortalizing capacity of the virus was restored when the DNA fragments spanning the 
EBNA2 ORF were reintroduced (Hammerschmidt and Sugden 1989) EBNA2 has found 
to be essential not just for initiation of B cell immortalization but also for maintaining the 
transformation process (Kempkes et a l , 1995a)
1.8.2.2 S tru ctu re  o f  EBNA2
The EBNA2 gene encodes an 83kDa protein that localizes m large nuclear granules and 
is associated with nucleoplasmic chromatin and nuclear matrix fractions (Petti et al 
1990) EBNA2 differs extensively between typel and type 2 EBV isolates (Aitken et a l , 
1994) and is responsible for the biological difference that enables the typel strains to 
transform B lymphocytes more efficiently (Rickinson et al 1987) The EBNA2 proteins 
identified in typel and 2 EBV called EBNA2A and 2B respectively only share about 50%
17
sequence homology (Adldmger et a l , 1985) Characteristic structures of the EBNA2 
protein are (1) a negatively charged region at the ammo-terminus, thought to play a role 
in homodimenzation (Zimber-Strobl and Strobl 2001) (11) a polyproline region consisting 
of 10-40 consecutive prohnes depending on the virus strain, (111) a diversity region m the 
middle of the protein where the homology between EBNA2A and 2B is very low, (iv) a 
domain responsible for the interaction with the DNA binding protein RBP-jk/CBFl, (v) 
an arginine-glycme nch stretch of around 18aa, (vi) a negatively charged region, which 
harbors a trans-activation domain, and (vu) a nuclear localization signal at the 
carboxyterminus (Zimber-Strobl and Strobl 2001)
Figure 1.5. S tru c tu re  o f  th e  EBNA2 P rote in
Figure 15 Structure of the EBNA2 protein of the B95 8 virus strain Characteristic parts of the EBNA2 
protein are a negatively charged region at the anuno~termmus, which likely plays a role in 
homodimenzation (Dim), a polyproline stretch (Pro), a diversity region, where the homology between 
EBNA2A and EBNA2B is very low, a domain responsible for the interaction with CBFl/RBP-j (CBF1), an 
argmine-glycme nch stretch (ArgGly), a trans-activation domain (TAD) and a nuclear localization signal 
(NLS) at the carboxyterminus
Sequence comparison between EBNA2A, EBNA2B and the homologous protein from 
the closely related baboon Herpes virus Papio (HPV), revealed a series of nine conserved 
regions (CR) within EBNA2 (Ling et a l , 1993b) Subsequent analyses identified regions 
within EBNA2, which were essential for its immortalization and transcriptional activities 
Regions essential for the transforming capacity of EBNA2 have been mapped by 
extensive mutational analysis (Cohen et a l , 1991, Yalamanchili et a l , 1994, Harada et 
a l , 1998) At the amino-terminus, the region between 94-110, encompassing a
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polyprolme region (PPR) was found to be essential for B cell transformation. However, 
the role of this highly unusual PPR motif for immortalization remains enigmatic as recent 
studies (Gordadze et a l , 2002) suggest that the EBNA2 Polyprolme Region is 
dispensable for EBV-mediated immortalization maintenance, postulating that the loss o f  
the polyprolme region increases LMP transcription which can be cytostatic for B cells 
when over expressed thereby explaining previous studies which showed loss of 
immortalization function of a PPR negative EBNA2 Two other regions absolutely 
necessary for B cell transformation were identified (1) between aa 280-337 in which CR5 
and CR6 are located and (u) in the region between ammo acids 425-462 (See Figures 1 5 
above and 1 7 below) Subsequent analyses revealed that the region between 425 and 462 
contains the EBNA2 acidic trans-activation domain (TAD) (Cohen et a l , 1991, Cohen, et 
a l , 1991) and that the sequence between 280-337 contains sequences which allow 
EBNA2 bind to CBF1 and SKIP, members o f a repression complex which when bound 
by EBNA2 free up EBNA2 responsive promoters to trans-activation by the EBNA2 TAD 
(Ling et a l , 1993a) Also present m this region is part of the arginine glycine region 
EBNA2 binds to the survival motor neuron protein (SMN) via the methylated arginine- 
glycine region and this may be a critical step m B cell transformation (Barth et a l , 2003)
1.8 2.3 Function o f  EBNA2
EBNA2 is essential for the immortalization of primary B-lymphocytes and along with 
EBNALP is the first protein expressed during this process EBNA2 is also essential for 
the maintenance of the transformed state Using an LCL conditional for functional 
EBNA2 expression in the presence of estrogen, it was shown that cells deprived of  
functional EBNA2 entered a quiescent non-prohferative state or die by apoptosis 
(Kempkes et a l , 1995a)
The other vital function o f EBNA2 is as a specific trans-activator of latent viral genes, 
and a number of cellular genes EBNA2 activates the transcription o f all other viral 
proteins expressed in LCLs by trans-activatmg (i) the BamHI-C promoter Cp 
(Woisetschlaeger et a l , 1990, Sung et a l , 1991), from which transcription of all EBNA 
genes is controlled (See Figure 1 3 above), and (n) the promoters of the latent membrane
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proteins LMP1 and LMP2 (Abbot et a l , 1990, Fahraeus et a l , 1990, Wang et a l , 1990, 
Zimber-Strobl et a l , 1991, Laux et a l , 1994) EBNA2 also activates the transcription of 
cellular genes including CD21, the B lymphocyte differentiation marker (Cordier et a l , 
1990), CD23, the B cell activation marker (Wang et a l , 1987, Wang et a l , 1990, Wang, 
et a l , 1991), the oncogene, c-fgr (Knutson, J C 1990, Patel et a l , 1990), BATF which 
induces expression of a B cell specific transcription factor of the same name (Johansen et 
a l , 2003) as well as the chemokme receptor BLR2/EBII (Burgstahler et a l , 1995] 
EBNA2 also acts as a transcription repressor and represses transcription of the 
immunoglobulin heavy chain locus (Jochner et a l , 1996) resulting in the down-regulation 
of the proto-oncogene c-myc (Kaiser et a l , 1999)
EBNA2 has also been shown to play an important role in the maintenance of proliferation 
of LCLs and this effect is mediated by its ability to regulate the expression o f the cell 
cycle related proteins, cyclin D2, and cdk4 (which drive cell cycle progression from GO 
to G l) (Kempkes et a l , 1995c, Zimber-Strobl et a l , 1996)
1.8.2.4 EBNA2, CBF1 ANDTHECBF1 Repression COMPLEX
EBNA2 does not bind to DNA directly but is tethered to responsive promoters by a 
ubiquitously expressed cellular DNA binding protein CBF1 (also called RBP-jk, KBF2, 
RBP-j, or CSL) (Henkel et a l , 1994, Grossman et a l , 1994, Waltzer et a l , 1994, Zimber- 
Strobl et a l , 1994) The cognate DNA sequence element to which CBF1 binds is 5’- 
CGTGGGAA-3’ and this sequence was first described in the EBNA2 responsive element 
(ERE) of the LMP2A promoter (Zimber-Strobl et a l , 1993) Binding sites for CBF1 have 
subsequently been identified in other known EREs of promoters activated by EBNA2 
including the Cp, LMP1 and CD23 promoters (Ling et a l , 1993, Laux et a l , 1994, Ling 
e ta l,  1994)
CBF1 was initially cloned by T Honjos group (Hamaguchi et a l , 1989, Matsunami, et 
a l , 1989) CBF1 is a transcriptional repressor and repression is effected in part by 
tethering a histone deacetylase (HDAC) co repressor complex to the promoter (Henkel et 
a l , 1994, Hsieh and Hayward 1995, Waltzer et a l , 1995, Kao et a l , 1998) The co 
repressor proteins SKIP, Sin3A, SMRT, CIR, SAP30, HDAC1 and HDAC2 have been
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shown to be components of this complex (Zhou et al., 2000a; 2000b; Hsieh et al., 1999; 
Kao et a l 1998). Repression occurs as a result of histone deacetylation, which leads to 
chromatin remodeling and a loss of transcription factor access to the nucleosome- 
associated promoter sequences. It has also been demonstrated that CBF1 binds to 
elements of the basal transcription machinery, disturbing the TFIIA-TFIID interaction, 
which is essential to transcription initiation (Olave et al., 1998).
EBNA2 trans-activates promoters by binding to the repression domain of CBF1 to relieve 
repression and bringing a transcriptional activation domain to the promoter (Hsieh and 
Hayward 1995). Shown in Figure 1.6 below is a model for EBNA2 activation of CBF1- 
repressed promoters. The various members of the CBF1 repression complex are also 
shown.
Figure 1*6. M odel f o r  EBNA2 A ctiv a tio n  o f  CBFl Repressed Prom oters
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Figure 16 Model for EBNA2 activation of CBFl-repressed promoters CBF1 bmds to the DNA
sequence GTGGGAA in responsive promoters SKIP is bound to CBF1 SMRT contacts both SKIP and 
CBF1 SMRT is a component of a co repressor complex that includes Sm3A, SAP30, CIR, HDAC1, and 
HDAC2 and potentially other Sm3-associated protems (indicated by x) This complex mediates promoter 
repression through chromatin remodelling EBNA2 competes with SMRT for contacts on both SKIP and 
CBF1 Displacement of the SMRT-co repressor complex relieves repression, ami introduction of the 
EBNA2 activation domain induces transcriptional activation. EBNA2 mutants in CR5 and CR6 lose the 
ability to interact with SKIP and CBF1, respectively Loss of either interaction impairs the ability of 
EBNA2 to activate CBFl-repressed promoters
1.8 2.5 Co-A ctiv a tin g  P rotein s In te r a c t  w ith  EBNA2.
The acidic domain of EBNA2 interacts with factors of the basal transcription machinery 
including TFIIH, TATA, box binding protein (TBP), associated binding factor TAF40, 
TFHB, and the co-activator p i00 that interacts with TFIIE (Tong et a l , 1995a 1995b 
1995c) The trans-activation domain also interacts with the histone acetyltransferases 
(HATs) p300/CBP and PCAF (Wang et a l , 2000) and with the viral protein EBNALP 
that acts as a co-activator of EBNA2 (Nitsche et a l , 1997, Harada et a l , 1997) Apart 
from the activation domain, EBNA2 interacts with the chromatin remodeling complex 
hSWl-SNF, which converts the chromatin structure to facilitate transcription (Wu et a l , 
1996, 2000) Another protein DP 103, the dead box protein, which is complexed to the 
survival neuron protein SMN, also bmds to EBNA2 and these can cooperatively trans- 
activate the LMP1 promoter (Voss et a l , 2001)
The portions o f EBNA2 which are important for facilitating contact between EBNA2 and 
the CBF1 repression complex have been identified m the CR5 and CR6 region (See 
Figure 1 7 below) between ammo acids 280-337 Interactions with both CBF1 and SKIP 
have been shown to be required for EBNA2-mediated trans-activation for CBF1 
repressed promoters (Zhou et a l , 2000a) CR6 in the EBNA2 protein proved to be the 
CBF1 targeting domain Mutation of two tryptophan residues in this region abolished 
CBF1 interaction (Ling et a l , 1995, Ling et a l , 1993) This mutation, (creating a mutant 
EBNA2 named WW323SR) also abolished the activity of EBNA2 to activate reporters 
carrying CBF1 binding sites (Hsieh and Hayward 1995, Ling et a l , 1993) and when
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transferred into the open reading frame for the EBV genome resulted in a non­
immortalizing strain of the virus (Yalamanchili et al., 1994). Mutation of the CR5 region 
resulted in an EBNA2 that retained CBF1 interaction but had a diminished ability to 
activate a Cp promoter driven reporter (Ling et al., 1995). In the context of the EBV 
genome, deletion of the CR5 region results in a non-immortalizing EBV mutant (Harada 
et al., 1998). The deletion in CR5 prevented the binding of SKIP, a member of the CBF1 
repression complex.
Figure 1.7. Schematic Representation of EBNA2 and the Positions at which 
it Binds to CBF1 and SKIP
Figure 1.7 Schematic representation of EBNA2 illustrating the relative locations of characterized 
functional domains and of the positioning of the WW323SR mutation used in this study. The amino acid 
numbers are indicated. CR5, CR6 and a nuclear localization signal (NLS) are also indicated.
The behavior of the CR5 and CR6 EBNA2 mutants suggests that contacts on both CBF1 
and SKIP are required for EBNA2 mediated trans-activation for CBF1 repressed 
promoters (Zhou et al., 2000a). Figure 1.7 above shows a schematic illustration of 
EBNA2 and its functional domains as well as the location of the various mutations which 
identified the essential domains for relieving CBF1 mediated promoter repression. In the 
studies described in this thesis, the mutant WW323SR EBNA2 was employed as a tool 
for determining the region of EBNA2 required to trans-activate the promoter of a cellular 
apoptosis related gene bfl-1.
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1 8.2.6 EBNA2 Responsive Promoter Elements
EBNA2 regulates expression of the viral Cp latency promoter that dnves expression of 
the EBNA family of nuclear proteins in type in  latency and also contributes to the 
positive regulation of the LMP2A, LMP2B and LMP1 promoters (Jin and Speck 1992, 
Sung et a l, 1991, Tsang et a l , 1991, Zimber-Strobl et a l , 1993) As well as the cellular 
CD23, CD21 and cyclin D2 promoters The EBNA2 responsive elements for the Cp, 
LMP1, LMP2 CD21 and CD23 promoters have all been characterized (Woisetschlaeger 
et a l , 1990, Sung et a l , 1991, Abbot et a l, 1990, Fahraeus et al, 1990, Wang et a l , 
1990b) as orientation independent sequences, which contain at least one CBF1 binding 
site (Zimber-Strobl and Strobl 2001) Although the EBNA2-CBF1 interaction is 
important for regulation of these target genes, optimal activation by EBNA2 also requires 
cooperation with other transcription factors (Meitinger et a l , 1994)
In the LMP1 promoter, multiple transcription factor binding sites have been identified 
One transcription factor, PU 1/Spi-B, which also interacts directly with EBNA2, has been 
found to be essential in mediating EBNA2 activation of LMP1 (Johannsen et a l , 1995, 
Laux et al 1994) PU 1, a DNA binding protein which is a member of the ets oncogene 
family, recognizes a punne rich sequence 5’-GAGGAA-3’ (known as a PU Box) The 
PU 1 protein was shown to be a tissue specific transcriptional activator that is expressed 
in macrophages and B cells (Klemsz et a l , 1990) PU 1 protein complexes are required 
for Normal B Cell Receptor-Mediated Signal Transduction (Garrett-Sinha et a l , 1999) 
and regulation of its expression is essential for mature B cell survival (Hu et a l , 2001) It 
has also been shown that a POU domain protein is involved in the EBNA2 mediated 
trans-activation of LMP1 (Sjoblom et a l , 1995)
In the Cp promoter, the EBNA2 responsive element also contains a CBF2 binding site 
adjacent to the CBF1 binding site and this also contnbutes to EBNA2 responsiveness 
(Fuentes-Panana and Ling 1998) The cellular proteins that comprise CBF2, include the 
hnRNP protein AUF1 (Fuentes-Panana et a l , 2000) In the LMP2A promoter, beside
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CBFl, two other as yet unidentified proteins bind to the EBNA2 responsive element to 
contribute to EBNA2 responsiveness (Hofelmayr et a l , 1999)
Although the regulation of many o f the EBNA2 target genes such as those listed above» 
and also including CD23, interleukin 1 and beta-interferon have been shown to be 
mediated by CBF1 (Kanda et a l , 1999, Krauer et a l , 1998, Ling et a l , 1994, Wang et 
a l , 1991), there are many other responsive genes such as the cychn D2 which lack CBF1 
bindmg sites in their promoter regions (Spender et a l , 2001) These genes may be 
activated either directly or indirectly as part of a downstream response cascade (Kaiser et 
a l , 1999)
1 8.2.7 V ir a l  a n d  C e l l u l a r  P r o t e in s  C o u n t e r r e g u l a t e  T r a n s-a c t iv a t io n  
T h r o u g h  CBFl.
EBNA2 mediated trans-activation through CBFl can be disrupted by a number of viral 
and cellular genes The viral EBNA3A, and 3C proteins repress EBNA2 mediated trans- 
activation by bindmg directly and exclusively to CBFl thereby preventing CBFl binding 
to DNA (Le Roux et a l , 1994, Johannsen et a l , 1996, Robertson et a l , 1995, Waltzer et 
a l , 1996, Zhao et a l, 1996) Furthermore EBNA3C can form complexes with a member 
of the CBFl repression complex, namely HDAC1 HDAC1 and CBFl/RBP-Jkappa bind 
to the same or adjacent regions o f EBNA3C (Radkov et a l , 1999) (See Figure 1 9) One 
of the Epstein-Barr Virus BamUl-A Rightward Transcripts- (BARTs) contains an open 
reading frame designated RPMS1 This encodes a nuclear protein RPMS (Smith et a l ,
2000) RPMS interacts with CBFl and the CBFl-associated co repressor CIR to stabilize 
the CBFl co repressor complex, thereby negatively regulating the trans-activational 
effect of EBNA2 (Zhang et a l , 2001) (See Figure 1 14 adapted from Zhang et a l , 2001) 
A cellular LIM protein KyoT2 has also been identified which dislocates CBFl from 
DNA by competing with EBNA2 for binding to CBFl (Tamguchi et a l , 1998)
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1.8.2.8 CBF1 Links EBNA2 and the Cellular Notch Pathway.
CBFl is a ubiquitously expressed cellular DNA binding protein, which is well conserved 
throughout evolution In Drosophila this protein is known as Suppressor of Hairless Su 
(H) Notch receptors are a family o f cell surface receptor proteins which are activated 
after ligand binding, by a series o f cleavage events which lead to translocation of the 
intracellular domain of the receptor (NIC) to target cell nuclei (Schroeter et al, 1998) 
After translocation to the nucleus, NIC activates genes by binding to CBFl (Struhl and 
Adachi 1998, Lecourtois and Schweisguth 1995) Thus CBFl is a downstream target of 
the Notch signaling pathway Since both EBNA2 and Notch associate with the CBFl 
repression complex m order to relieve repression and subsequently trans-activate target 
genes, EBNA2 can be regarded as a functional homologue of the activated Notch 
receptor (Hsieh et a l , 1996)
Studies have shown that the Notch signaling pathway operates to regulate cell 
differentiation in a variety of vertebrate developmental and cell maturation processes 
including, muscle cell differentiation, pancreatic cell differentiation, granulocyte 
differentiation, early embryogenesis, neural development and lineage commitment of 
lymphocytes (Swiatek et a l , 1994, Hamada et a l , 1999, Nye et a l , 1994, Kopan et a l , 
1994, Apelqvist et al, 1999, Milner et a l , 1996, Schroeder and Just 2000, Pui et a l , 
1999, Radtke et a l , 1999) Recent studies indicate that in addition to cell differentiation, 
Notch signaling has direct effects on proliferation and programmed cell death (Artavams- 
Tsakonas et a l , 1999), reviewed by (Miele and Osbourne 1999)
1.8.2 9 STRUCTURE OF NOTCH RECEPTORS
In mammals four Notch genes have been identified (Notch 1-4) these all encode receptors 
consisting of a single trans-membrane domain (TM) The ammo-terminus contains a 
signal peptide followed by multiple epidermal growth factor-like repeats (EGF), which 
functions as a ligand binding domain, and a cysteine-nch Lm 12/Notch repeats (L/N) 
These repeats are highly conserved in mammalian Notch receptors, particularly Notch-1
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1
and -2, and represent the putative main ligand-binding site The intracellular part contains 
the RAM domain a high-affimty-binding site for transcription factors of the Suppressor 
of Hairless/CBF-l group (see Figure 1 8 below, Tamura et a l , 1995, Miele and Osbourne
1999) and ankynn repeats which are also important for CBF1 interaction Also in the 
intracellular region is located the NLS a nuclear localization domain, and a C terminal 
PEST region which regulates protein stability A possible trans-activation domain has 
also been identified at the carboxy-terminus (Kurooka et a l , 1998, Dumont et a l , 2000)
i
(Notch structure is reviewed by Weinmaster 1997 and Miele and Osbourne 1999)
i
Figure 1.8 Structure of The Notch Receptor
Figure 1 8 Structure of the Notch proteins The amino-terminal part contains a signal peptide followed 
by multiple epidermal growth factor (EGF)-like repeats, that function as ligand-binding domain, and 
cysteine rich Lin 12/Notch repeats (LNR) The intracellular part (N IC) harbors the RAM domain and a 
senes of ankynn repeats, which both interact with RBP-J, 3 nuclear localization signals (NLS), and a C-
i
terminal PEST region The arrows (SI to S3) indicate the sites of proteolytic cleavage during protein 
maturation and after ligand binding
1.82.10 Activation of Notch Receptors
i
Notch receptors are activated by binding membrane-bound ligands Numerous Notch 
ligands have been identified in mammals and these are homologous to the Drosophila 
Su(H) ligands Delta and Serrate and the C Elegans ligand Lag-1, ollectively referred to 
as DSL from the initials o f Delta, Serrate, ¡and Lag-1 (Weinmaster, 1997) Mammalian 
Delta homologues are denominated “Delta-like” and mammalian Serrate homologues are
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denominated “Jagged” (Miele and Osbourne 1999) Notch proteins are produced as single 
300kDa polypeptide precursors that are processed to a mature heterodimenc form via a 
series of post ligand binding proteolytic cleavage events
Notch receptors have three sites termed SI to) S3 at which cleavage occurs A funn-like 
convertase (Logeat et a l , 1998) catalyzes the cleavage of the Notch pre-protein at SI 
generating an ammo terminal and a carboxy terminal fragment The ammo terminal 
subunit contains the extracellular element (N^), which consists of multiple epidermal 
growth factor (EGF)-hke repeats The carboxy terminal subunit contains a short 
extracellular region, the trans-membrane domain (TM) and the intracellular region (NIC) 
(Blaumueller et a l , 1997)
Two further hgand-bindmg induced cleavages occur at S2 and S3 TACE, tumour 
necrosis factor a-converting enzyme catalyses the cleavage at S2 which removes most of 
the extracellular part of the carboxyterminal subumt (Mumm et a l , 2000, Brou et a l,
2000) Removal of this region then induces cleavage at S3 which releases the activated 
Notch receptor NIC This final cleavage at S3 is catalyzed by a y-secretase-hke protease 
whose activity requires presemlm (De Strooper et a l , 1999, Wolfe et a l , 1999) The 
intracellular domain is then translocated to the nucleus where it binds to CBF1 and 
regulates target gene expression (Struhl and Adachi 1998, Jamault et a l , 1995)
i
1.8.2.11 NotchI-IC Also Modulates Gene Expression by Association with
I
THE CBF1 CO-REPRESSOR COMPLEX.
Like EBNA2, Notch-IC binds to the repression domain of CBF1 , disturbing it from its 
position on DNA as a repression complex i As described above, one particular region 
containing sequential tryptophan residues j in CR6 is required to mediate EBNA2 
interaction with CBF1 (Yalamanchih et a l , 1994) Two domains within Notch-IC 
mediate its interaction with CBF1 these are the RAM domain and the ankynn repeats 
(Tamura et a l , 1995, Aster et a l , 1997) EBNA2 binds to SKIP as well as CBF1 in order 
to relieve repression and bring its activation domain into contact with target promoters, 
Notch-IC also interacts with SKIP but via its ankynn repeats (Zhou et a l , 2000b)
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Different amino acids within the CBF1 protein may be critical for the binding o f either 
EBNA2 or Notch-IC (Fuchs et a l, 2001)
1.8.2.12 Notch-IC Co-Activating Proteins
As with EBNA2, Notch-IC mediated transactivation via CBF1 is also enhanced by a
(
number of co-activatmg proteins The Notch-IC transactivation domain and ankynn
repeats also interact with two co-activating histone acetyltransferases (HATs), PCAF and
protein MAML1, which interacts with 
C transactivational effect has also been
GCN5 (Kurooka and Honjo 2000) Another, 
Notch-IC and CBF1 to enhance the Notch 
described (Wu, L et a l , 2000)
1.8.2.13 EBNA2 AND NOTCH-IC OVERLAP IN THEIR FUNCTIONS AND IN THEIR TARGET 
G e n e s .
Since both EBNA2 and Notch-IC protems share a common mechanism for regulating 
target gene expression it is then unsurprising that they also overlap in the range of
i
functional activities and m the genes that they regulate
EBNA2 is essential for the immortalization of EBV infected B cells, as already outlined 
above (section 18 2 1) Notch-IC, also has the ability to immortalize cells Constitutive 
activation of any o f the four Notch receptorsj can lead to neoplastic transformation in a 
number of different cell types Expression o f the human homoiogue of Notch 1, TAN! 
can be oncogenic for T cells (Ellisen et a l , 1991) Constitutive activation of the Notch2
gene is implicated m thymic lymphomas in cats (Rohn et a l , 1996) Similarly transgenic
11
mice expressing constitutively activated Notch3 developed T cell leukemias (Bellavia et 
a l , 2000) while expression of high levels o f Notch 4 are associated with mammary 
adenocarcinomas in mice (Jhappan et a l , 19J92) The exact mechanisms by which the 
different activated Notch receptors exert jtheir transforming function is not fully 
understood however, two oncogenes c-myc and El A have been shown to cooperate with 
activated notch receptors in neoplastic transformation (Girard et a l , 1996, Capobianco et
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a l , 1997) The ankynn repeats have been identified as essential in conferring the 
transforming capacity to Notch m E l A immortalized kidney cells while the other CBF1 
interaction domain RAM, as well as the Notch trans-activation domain were not required 
(Jeffries et a l , 2000) In T cell leukaemiogenesis, however, the ankynn repeat and trans- 
activation domains were essential, while the PEST and RAM domains were not crucial 
(Aster et a l , 2000)
Both EBNA2 and Notch also act as trans-activators o f  viral and cellular genes Transient 
transfection assays showed Notch 1-IC could also regulate EBNA2 target genes in B cells 
Transient transfection assays involving promoter reporter constructs for various viral 
promoters, showed that Notch 1-IC trans-activated the Cp, LMP1 and LMP2A promoters 
albeit to a lesser extent than EBNA2 Transfections involving stably expressed Notchl-IC  
resulted in the up-regulation o f  LMP2A but not LMP1 Studies by the same group also 
showed that Notchl-IC can induce CD23 but not CD21 expression (Hofelmayr et a l , 
1999)
Another EBNA2 target gene, IgH, the only gene known so far to be down-regulated by 
EBNA2, has also been identified as a gene which is down-regulated by Notchl-IC in 
human and chicken B cells (Strobl et a l , 2000, Monmura et a l , 2000) Although 
Notchl-IC can regulate certain EBNA2 responsive genes it cannot replace EBNA2 in 
maintaining B cell immortalization as unlike EBNA2, it cannot up-regulate LMP1 
expression However in an LCL where LMP1 was expressed m an EBNA2-independent 
manner, Notchl-IC along with LMP1 was able to maintain the B cells in an immortalized 
state, thus Notchl-IC can transiently substitute for EBNA2 in the maintenance of  
proliferation in LMP1 expressing immortalized B cells (Hofelmayr et a l , 2001) Very 
recent studies have also showed that both EBNA2 and NotchIC activate a cellular gene 
named BATF, which induces expression o f a B cell specific transcription factor o f the 
same name [Johansen, 2003] BATF is a member o f the AP-1/basic leucine zipper family 
o f transcnption factors, which form heterodimers with the Jun proteins to bind 
preferentially to AP-1 consensus sites BATF may have a role in negatively regulating 
AP-1 activity since the BATF-Jun heterodimers display a reduced activity relative to Fos- 
Jun heterodimers and thus inhibit the expression o f AP-1 target genes and retard AP-1
30
mediated growth Also both EBNA2 and Notch-IC have been shown to protect cells by 
binding to the cellular Nur77 (TR3/NGF1B), transcription factor that is a member o f the 
nuclear hormone receptor super family (Jehn et a l , 1999, Lee et a l , 2002)
1.8.3 EBNA3A, 3B AND 3C.
The EBNA3 family consists o f 3 nuclear proteins, EBNA-3A, -3B and -3C encoded by 
tandemly arranged genes located in the middle o f the linear viral genome They are 
encoded by alternatively spliced transcripts initiated at the Cp (See Figurei 3B) and are 
each composed o f a small 5’-and a large 3 ’-exon (Ricksten et a l , 1988a, Bomkamm and 
Hammerschmidt 2001) The proteins themselves are composed o f 944, 937 and 992 
ammo-acid residues, respectively and are located in large nuclear clumps m the nuclear 
matrix, chromatin and nucleoplasmid fractions (Petti et a l , 1990) The mRNAs encoding 
these proteins are the least abundant EBNA mRNAs occurring in latently infected cells 
(Kallin et a l , 1986)
Although the EBNA-3A, -3B and -3C proteins differ in their ammo acid sequences in 
type 1 and type 2 strains o f EBV (Sample et a l , 1990b) Studies have shown both 
EBNA-3A and -3C are required for immortalization whereas EBNA-3B is not 
(Tomkinson et a l , 1993) EBNA3A is essential for the initiation but not for the 
maintenance o f  B cell transformation (Kempkes et a l , 1995c) Since EBNA2 is the 
transcription factor that activates the expression o f EBNA3A, it could well be that 
EBNA3A induced by EBNA2 is the key protein for the initiation o f immortalisation o f B 
cells (Manet et a l , 1998)
EBNA-3B is one o f the dominant primary targets for recognition o f immortalized cells by 
cytotoxic T cells (Rickinson and Moss 1997) and as such represents a potential target for 
CTL treatment o f EBV associated malignancies Evidence for this is available from 
studies in patients with post-transplant lymphoproliferative disease (PILD) treated with 
EBV-specific T cells Treatment with EBV-specific T cells failed to arrest proliferation,
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as the CTLs could not recognize an EBNA3B deleted virus strain (Gottschalk et a l , 
2001)
EBNA3B has also been shown to modulate the expression o f the cellular CD40, CD77 
and vimentin genes (Silins and Sculley 1994)
Similarly to EBNA2, EBNA3C may be regarded as a trans-activator of viral and cellular 
genes, transfection assays demonstrate that expression ofEBNA3C up-regulates CD21 in 
an EBV-negative BL cell line while expression o f EBNA3C in Raji cells (where the 
EBN3C ORF is deleted) up-regulates the levels o f LMP1, CD21 and vimentin proteins 
(Wang et a l , 1990a, Allday et a l , 1993, Ring 1994) EBNA3C can also trans-activate 
genes via a CBF1-independent mechanism, studies by (Zhao et a l , 2000) showed that 
EBNA3C could cooperate with EBNA2 to trans-activate the LMP1 promoter through an 
Spi-l/(Pu l)/SpiB binding site in the promoter Binding o f the two viral proteins together 
forms a stable complex, which allows trans-activation o f LMP1 
EBNA-3C has furthermore been described to counter the action o f cyclin-dependent 
kinase inhibitor pl6/INK4A, to functionally inactivate Rb in a similar way to the viral 
proteins human papillomavirus E7 and adenovirus E l A, and to override a number o f cell- 
cycle checkpoints (Parker et a l , 1996, Parker e ta l , 2000, Wade and Allday 2000)
The most well documented function o f the EBNA-3A, -3B and -3C proteins is that they 
inhibit transcriptional activation o f EBNA-2-responsive promoters including the LMP2A, 
LMP1 and Cp promoters EBNA3A, 3B and 3C bind to CBF1, (Le Roux et a l , 1994, 
Robertson et a l , 1995, Waltzer et a l , 1995) thereby preventing CBF1 and CBF1-EBNA- 
2 complexes from binding to their cognate CBF1-binding sites (Bam et a l , 1996, 
Johannsen et a l , 1996, Radkov et a l , 1997, Radkov et a l , 1999), Waltzer et a l , 1995, 
Zhao et a l , 1996) Binding o f EBNA3A to CBF1 results in down-regulation o f c-myc 
and EBV transformed lymphoblast growth (Cooper et a l, 2003) A model showing 
EBNA3A/3B and 3C repression o f EBNA2-CBF1 mediated trans-activation is shown 
below (adapted from Zhao et a l , 2000)
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Figure 1.9. Model for EBNA3A/3B/3C Repression of EBNA2-CBF1 Mediated 
Trans-activation.
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Figure 1.10. A model for EBNA3 mediated repression of EBNA2-CBF1 associated trans-activation.
A ll three EBNA3s bind directly to CBF1 thereby preventing EBNA2 associating with CBF1 and the other 
members of the repression complex. Thus preventing EBNA2 mediated trans-activation of target promoters
The EBNA3 proteins are thus understood to counterbalance and fine-tune the action of 
EBNA2. By inhibiting CBF1-EBNA2 mediated trans-activation o f the Cp promoter, the 
EBNA3 proteins also inhibit their own synthesis thus setting up an auto regulatory loop 
controlling their own expression (Waltzer et a/., 1995; Robertson et a l , 1995).
1.8.4 EBNA-LP
EBNA-LP (also referred to as EBNA5) is encoded by the 5’ leader sequence o f  
bicistronic mRNAs, which encode the other EBNAs (See Figure 1.3B). The ATG 
translation initiation codon for LP is created by a splicing event that occurs near the 5’ 
end o f the message (Wang et a i , 1987). EBNA-LP consists o f a multirepeat domain 
(W1W2) and a unique carboxyl-terminal domain (Y1Y2) (Fig. 1.10) and is therefore
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detected as a protein ladder m immunoblot analyses, possibly as the result o f  
heterologous polypeptides with different numbers o f W1AV2 repeats
Figure 1.10. EBNA2 and EBNA-LP are Generated by Alternate Splicing
Figure L10 Detailed representation of how EBNA2 and EBNA-LP mRNAs are generated from a 
unique RNA precursor by facultative splicing. Boxes represent exon sequences and broken lines 
represent mtron sequences The exons coding for EBNA2 or EBNALP respectively, are indicated by the 
grey boxes The EBNA-LP protein AUG is created following the use of an alternative acceptor splice site, 
five bases into the W1 exon This alternate splice provides the G of the EBNA-LP initiation codon In 
latency HI, only the Cp promoter is active (adapted from Manet et a l, 1998)
In freshly infected cells, EBNA-LP and EBNA-2 appear as the first detectable virus- 
encoded proteins (Alfien et a l , 1991) EBNA-LP localizes to the nucleus in distinct foci 
now recognized as nuclear domain 10 (ND10) bodies or promyelocytic leukemia- 
associated protein (PML) oncogenic domains (PODs) (Jiang et al y 1991, Petti et a l ,
1990) Genetic studies, using recombinant EBNA-LP mutants lacking the Y1 and Y2 
exons, or mutants which had a stop codon inserted after the first amino acid in Y l, 
showed reduced, but still detectable, transforming ability. Thus EBNA2 is not essential to 
but greatly enhances the process o f transformation (Hammerschmidt and Sugdenl989, 
Manmck et a l , 1991) Although the actual role o f EBNA-LP in EBV-induced B-cell 
immortalization remains unclear, other studies suggest two major biological functions o f  
EBNA-LP Firstly as a co-activator o f EBNA2 and secondly as a protein which associates 
with several cellular proteins and structures
EBNA2
EBNA-LP
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EBNA-LP is primarily known as a co activator of EBNA-2 It has been reported that 
EBNA-LP and EBNA-2 cooperatively stimulate the gene expression of cellular and viral 
proteins such as cychn D2 (Sinclair et a l , 1994) LMP-1 and LMP2B (Hammerschmidt 
and Sugden 1989, Nitsche et a l , 1997, Harada et a l , 1997) The mechanism by which 
EBNA-LP functions as a co-activator to EBNA2 is unknown, however, conserved 
regions within EBNA-LP required for co-operation with EBNA2 are also important for 
nuclear localization and/or nuclear matnx local-ization (Peng et a l , 2000b, Yokoyama et 
al, 2001)
Apart from enhancing EBNA2 trans-activational effects, EBNA-LP also interacts with 
various cellular proteins and structures EBNA-LP was shown to bind to p53 and pRb in 
vitro binding assays (Szekely et a l , 1993) and to be co-localized with an antigemcally 
distinct form of pRb in a nuclear domain named ND10 (Jiang e ta l , 1991, Szekely et a l,
1996) Although EBNA-LP binds to p53, results from transient transfections 
demonstrated that neither p53, pRb nor E2F transcription was up-regulated thus the in 
vivo relevance of EBNA-LP-p53/pRB interaction is unknown (Inman and Farrell 1995) 
EBNA-LP also associates with the 70-kDa family of heat shock proteins (hsp70s) in vivo, 
which co localize m ND10, and trans-located to the nucleolus under conditions of cellular 
stress (Kitay et a l, 1996b, Manmck et a l , 1995 and Szekely et a l , 1995)
EBNA-LP is also localized in the cytoplasm as well as the nucleus o f EBV-infected cells 
and interacts with a cellular cytoplasmic protein, HAX-1 (Kawaguchi et a l, 2000) which 
is involved in B-cell signal transduction and apoptosis Although the biological 
significance of the interaction between EBNA-LP and the cellular proteins is unclear at 
present, these results suggest that EBNA-LP is not only a co-activator o f EBNA-2 but 
also a multifunctional protein that modulates various components of cellular machinery 
and that the functions of EBNA-LP in EBV-induced B-cell immortalisation result from 
the sum of these interactions with viral and cellular proteins
Like the other EBV regulatory proteins, EBNA-LP is phosphorylated in EBV-infected 
cells (Petti et a l , 1990, Sauter et a l , 1988) The pattern of EBNA-LP phosphorylation is 
dependent on the cell cycle stage m that EBNA-LP is hyperphosphorylated m G2 /M
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phase and hypophosphorylated m G1 /S phase (Kitay et a l , 1996a) Studies by the same 
group revealed that EBNA-LP is phosphorylated at multiple sites, and p34 cdc2 and 
casein kinase II mediates the phosphorylation of EBNA-LP in vitro
A senne residue at position 35 in the W2 repeat has been identified as the major 
phosphorylation site for EBNALP in vivo, and replacement of this residue with alanine 
abolishes EBNA-LP co-operation with EBNA2 m the induction of LMP1 Further, 
replacement of the senne residue with glutamic acid (which mimics constitutive 
phosphorylation), restored the EBNA2 cooperative function (Yokoyama et a l , 2001) 
Taken together these results support the hypothesis that the phosphorylation of EBNA-LP 
is crucial to at least its EBNA2 cooperative function in infected cells
1.8.5 LMP1
Among the proteins involved in B-cell immortalization, LMP1 is the only latent protein 
that exhibits oncogenic properties The expression of LMP1 leads to the transformation 
of rodent fibroblast cell lines and renders them tumongemc in nude mice (Wang et a l , 
1985) The expression of LMP1 in Burkitt’s lymphoma cell lines induces many of the 
phenotypic changes observed in EBV infection including the up-regulation of B cell 
activation markers, cell adhesion molecules and an increased resistance to stimuli that 
induce apoptosis (Rowe et a l , 1994) In epithelial cells, LMP1 expression blocks the 
normal process of differentiation, reminiscent of the undifferentiated phenotype 
frequently observed in NPC (Dawson et a l , 1990) In keeping with these in vitro 
findings, targeted expression o f LMP1 in the skin or B cell compartment of transgenic 
mice leads to the induction of epithelial hyperproliferation and lymphomagenesis 
respectively (Kulwichit et a l , 1998) The detection of LMP1 expression m many EBV- 
associated malignancies such as Hodgkin’s disease, immunoblastic lymphomas and 
nasopharyngeal carcinomas suggests that this protein contnbutes to EBV-associated 
tumongenesis
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1.8,5.1 Structure and Functions of LMPl
LMPl is an integral membrane protein of the Tumour Necrosis Factor Receptor 
(TNFR)/CD40 super family and is composed o f a short cytoplasmic N-termmus of 24 
amino acids, six trans-membrane domains that total 186 ammo acids and a cytoplasmic 
C-terminus of, 200 ammo acids (Baker and Reddy 1996, Clausse et a l , 1997) LMPl 
functions as a constitutively active receptor and signals principally from intracellular 
compartments (Gires et a l , 1999, Lam and Sugden 2003b) Both oligomerisation and 
localization within glycosphingolipid-nch membrane rafts are essential for the initiation 
of signaling (Higuchi et a l , 2001, Ehopoulos and Young 2001) (See Figure 111 below)
F ig u r e  1.11. Sc h e m a t ic  D ia g r a m  o f  t h e  St r u c t u r e  o f  LMPl
Figure 111 Schematic Diagram of LM Pl LMPl consists of a 24 amino acid N terminal, cytoplasmic 
domain, six transmembrane domains and a, 200 ammo acid C terminal cytoplasmic tail LMPl aggregates 
to lipid rafts m the plasma membrane and associates with TRAFs via a PxQxT motif in Transformation 
Effector site 1(TES1) or Carboxytennmal activation regionl (CTAR1), (residues 187 to 231) and with 
TRADD and RIP via a YYD motif m Tes2/CTAR2 (residues 352-386) The region between amino acids 
275 and 307of LMPl is responsible for activation of Jak3 (Adapted from Cahir-McFarland, 1999)
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The cytoplasmic carboxyl-terminal tail of LMP1 contains two major effector domains, C- 
terminal activating region 1 (CTAR1), also known as Transformation Effector Site 1 
(TES1), and CTAR/TES2 (Figure 1 12) CTAR1 is located proximal to the membrane, 
binds the Tumor Necrosis Factor (TNF) receptor-associated factors (TRAFs) (Devergne 
et a l , 1996, Huen et a l , 1995) and is essential for EBV-mediated B-cell immortalization 
(Kaye et a l , 1999, Kaye et a l , 1995, Izumi et a l , 1997) CTAR2/TES2, which is located 
near the C terminus, supports the long-term growth of immortalized B cells (Izumi and 
Kieff 1997) and recruits the TNF receptor-associated death domain protein (TRADD) and 
receptor-interacting protein (REP) (Ehopoulos et a l , 1999, Huen et a l , 1995, Izumi et a l , 
1999) (Figure 111) Consequently, LMP1 triggers several signaling pathways that lead to 
the activation of several transcription factors, including NF-kB, STATs, AP-1, and ATF2 
(Brennan 2001, Richardson et a l , 2003, Kieser et a l, 1997, Ehopoulos et a l , 1999a, 
Eliopoulis et a l , 1999b, Ehopoulos and Young 2001, Gires et a l , 1999, Huen et a l , 
1995) NF-kB plays a key role in most LMP1-stimulated gene expression (Devergne et 
a l , 1998, He et a l , 2000, Mehl et a l , 2001, Pai et a l , 2002, Zhang et a l , 2001) (Figure 
1 12)
Figure 1.12 Schematic Representation of the Molecular Interactions and 
Signalling Pathways Engaged by LMPl
LMPl
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Figure 112 Schematic representation of the molecular interactions and signaling pathways engaged 
by LMP1. LMP1 has a short cytoplasmic N-termmus, six trans-membrane segments which confer 
aggregation and oligomerization at the plasma membrane and a long cytoplasmic C-tail containing two 
effector domains, CTAR1/TES1 (aa, 194-232) and CTAR2/TES2 (aa 351-386) CTAR1, which is 
essential for EBV-mediated B cell immortalization, binds TRAF1, TRAF2, TRAF3 and TRAF5 through a 
P204 xQ206 xxD209 motif and activates the NF-kB and p38 signahng pathways CTAR2 supports the 
long-term growth of immortalized B cells and recruits TRADD through a YYD386 motif to activate 
downstream signals, such as NF-kB, JNK and p38 Both LMP1 C-terminal domains also mediate the 
activation of the JAK/STAT pathway, although an intermediate region enclosing two copies of a prolrne- 
nch PxxPxP sequence has been shown to bind JAK3 and induce STAT binding activity independently of 
CTAR1/CTAR2 The trans-membrane domains of LMP1 are responsible for the activation of the small 
GTPase Cdc42 leadmg to cytoskeletal changes (adapted from Brennan, 2001)
LMP1 mimics a constitutively active CD40 receptor in many respects and both molecules 
can activate overlapping signaling pathways (Gires et a l , 1999, Baker and Reddy 1996) 
CD40 also recruits TRAFs and can activate the NF-kB, JNK and p38MAPK pathways 
(Kehry 1996, Aicher et a l , 1999, Hatzivassihou et a l , 1998) Signaling pathways 
initiated from LMP1 and CD40 regulate cell fate decisions including proliferation, 
differentiation and apoptosis and involve the modulation of similar sets of genes 
including those encoding B-cell surface markers (CD54, CD23, LFA-1), cytokines (IL-6) 
and anti-apoptotic proteins (A20, Bcl-x) (Eliopoulos et a l , 1997, Kilger et a l , 1998, Van 
Kooten and Banchereau 1997, Zimber-Strobl et a l , 1996, Kehry 1996) Despite many 
similarities shared between CD40 and LMP1, they also differ substantively (reviewed by 
Lam and Sugden 2003) In this regard, it has been demonstrated that although LMP1 and 
CD40 can independently bind several of the same TRAF molecules (namely TRAF2, 3 
and 5), TRAF6 binds to CD40 but not to LMP1 and TRAF1 and TRADD have been 
reported to bind to LMP1 but not to bind CD40 directly (Busch and Bishop1999)
The suppression of apoptotic death is a function of LMP1 that contributes to its 
oncogenicity One well-documented mechanism by which LMP1 can protect against 
apoptosis is by up regulating the expression of several anti-apoptotic proteins including 
Bcl-2, A20 and Mcl-1 (Milner et a l , 1992, Henderson et a l , 1991, Fries et a l , 1996,
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Wang et a l , 1996, Laherty et a l , 1992) thus raising the apoptotic threshold o f the 
infected cell and also providing protection against a range of apoptosis-inducing stimuli 
We have previously shown that elevated mRNA levels from an additional bcl-2 family 
member, bfl~l/al, are a feature of EBV-infected B lymphocytes exhibiting type 3 latency, 
and that the expression of LMP1 in an EBV-negative BL cell line coincided with a 
dramatic increase in bfl-l/a mRNA levels (D'Souza et a l , 2000) In that study, Bfl-1 
protected against serum-depletion-mduced apoptosis when expressed in the same cell 
context Bfl-1 is an anti-apoptotic protein whose preferential expression in hematopoietic 
and endothelial cells is controlled by inflammatory stimuli such as TNF and interleukin-1 
(Choi et a l , 1995, Karsan et a l , 1996)
1.8.6 LMP2A/LMP2B
The latent membrane protein 2 (LMP2) gene is expressed in latently infected B cells and 
encodes two messages of 2 0 and 1 7 kb in length, which are produced by alternative 
promoter usage (Laux et a l , 1988, Sample et a l , 1989) The longer message encodes 
LMP2A, while the shorter message is initiated from a promoter, approximately 5 KB 
downstream, that is bi-directional and responsible for LMP1 expression in the leftward 
direction (Laux et a l , 1988) and LMP2B expression in the rightward direction Both 
LMP2A and 2B are integral membrane proteins but the difference between the two 
isoforms is that LMP2A has an N- terminal 119 aa cytoplasmic signaling domain that is 
not present in LMP2B The main function of LMP2A and 2B is that they are capable of 
preventing viral lytic cycle activation (Wensing and Farrell 2000) LMP2A, co-locahzes 
in patches m B cell membranes with LMP1 (Longnecker and Kieff 1990)
In B-lymphocytes antigen cross-linking leads to the activation of the B cell receptor 
(BCR) (De-Franco 1997) A particular domain of the BCR, the immunoglobulin a/p 
immunoreceptor tyrosine-based activation motif (ITAM) is phosphorylated and it and 
sequences adjacent to it act as binding sites for Syk kinase and members of the Src family 
of tyrosine kinases including Lyn (De-Franco 1997) The kmases sequestered by the BCR 
are then activated and stimulate a cascade o f phosphorylations and kinase activity which
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eventually results m B cell differentiation and proliferation (De-Franco, 1997) Interest in 
LMP2A began with the discovery that BCR mediated signal transduction is abolished by 
LMP2A expression (Miller et a l , 1993) Mutational analyses of the LMP2A protein 
explains this finding A functional IT AM region has been identified in the LMP2A N  
terminal around tyrosine residues 74 and 85 The ITAM domain m LMP2A has been 
identified as crucial for association with the Lyn, Fyn, Syk and Csk kinases as well as for 
inhibition of BCR signals (Burkhardt et a l , 1992, Fruehlmg et a l , 1997, Fruehling et a l , 
1998, Longnecker 2000, Longnecker, et a l, 1991, Scholle et a l , 1999 Recent Studies 
also show that LMP2A associates with lipid rafts (Dykstra et a l , 2001, Higuchi et a l ,
2001) thus LMP2A blocks BCR signaling by interfering with raft association of the BCR 
(Dykstra et a l , 2001) One of the repercussions of BCR activation is the induction of the 
EBV lytic cycle (Miller et a l , 1995, Kieff et a l , 2001) This results in the expression of 
EBV genes, many o f which are highly immunogemc Expression of these genes targets 
them for destruction by the immune system, and thus by inhibiting BCR activation, 
LMP2A may have an important function in maintaining EBV latency and helping EBV to 
avoid detection by the immune system (Kieff et a l , 2001) Although LMP2A expression 
is not essential to EBVs immortalizing properties, LMP2A expression seems to mediate 
signals involved in cellular proliferation and survival in mouse transgenic models 
(Caldwell et a l , 1998, Longnecker 2000) Regions within the C terminal of LMP2A are 
implicated in the molecular association of LMP2A molecules and the association of 
LMP2A molecules and other molecules carrying the LMP2A C-terminal domain 
(Matskova et a l , 2001) Studies by the same group also identified cysteine nch repeats 
which are targets of palmitoylation, though LMP2A localization to the lipid rafts in the 
cell membrane is not dependent on palmitoylation (Matskova et a l , 2001) Because of 
the number of motifs identified in LMP2A, a putative role for LMP2A in signal 
transduction has been proposed particularly in light of the ability of LMP2A to enhance 
LMP1 mediated activation o f the AP-l/JNK and NF-kB pathways (Dawson et a l , 2001, 
Kieser et a l , 1997, Murono et a l , 2000) Recent studies found that LMP2A regulates c- 
Jun protein through extracellular signal-regulated kmase (ERK) (Chen et a l , 2002)
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Most of the studies to date focus on the LMP2A product, and as such there has been no 
comprehensive phenotypic analysis of the LMP2B isoform This is partly because of the 
hydrophobic character of LMP2 proteins Recent studies (Lynch et a l , 2002) revealed 
that LMP2B co-locahzes with LMP2A m perinuclear regions in transiently transfected 
cells Although mRNAs for both proteins are expressed m immortalized B cells, genetic 
analyses of the LMP2 gene have shown that neither product is required for 
immortalization of B cells by the virus (Longnecker et a l , 1992, Longnecker et a l , 1993, 
Kim and Yates 1993) Later studies with LMP2A-knockout viruses revealed no 
discemable defect in their ability to generate immortalized cell lines from primary B cells 
(Komshi et a l , 2001) Virus mutants that disrupt LMP2A but leave LMP2B intact and, 
presumably, expressed, indicate that LMP2B possesses no independent role in producing 
the B cell receptor signaling blockade phenotype of the LMP2 gene While the 
significance of LMP2B and its role in pathogenesis remains unclear, homology studies 
comparing the LMP2 gene of EB V with that of rhesus and baboon lymphocryptoviruses 
have revealed that the ability to make the LMP2B transcript is well conserved (Rivailler 
et a l, 1999) This implies that there is an as yet unrecognized role for LMP2B in the 
EBV life cycle
1.8.7 EBERS
EBV encodes two small non-polyadenylated RNAs termed EBERs EBER1 and EBER2 
are the most abundant viral transcripts in latently EBV infected cells and are encoded by 
the right hand 1000 base pairs of the EcoRl J fragment of the EBV genome (Lemer et 
a l , 1981, Rymo 1979) EBER1 is 167 nucleotides long while EBER 2 is 172 nucleotides 
long (Rosa et a l , 1981) The EBER genes are separated by 161 base pairs and are 
transcribed from left to right on the EBV map by RNA polymerase HI Although the 
primary sequence homology is only about 54%, a high degree of homology is observed m 
their extensively base paired secondary structures which consist of a series of short stem 
loop structures As yet no definitive role m EBV infection has been found for the EBERs, 
but the conservation of the EBER primary sequences within the EBV strains suggests 
some essential function for these RNAs (Arrand et a l , 1989)
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Following primary infection of B-lymphocytes with EBV, EBNA2 and EBNALP 
expression is detectable after 6 hours, after this point, the LMPs and EBERs are 
expressed However, infection with the P3HR1 strain in which the EBNA2 gene is 
deleted, results in cells expressing only EBNALP and trace amounts of EBER m primary 
B lymphocytes, meanwhile, infection with the same virus in EBV genome negative BL 
cell lines leads to the expression of EBNA1, EBNALP, EBNA3 and the EBERs (Rooney 
et a l , 1989) Thus EBER expression may be dependent on the host cell, possibly due to 
the requirement for particular cell cycle products or the state of B cell differentiation 
(Takada and Nanbo 2001) Although debate surrounds EBER expression m permissively 
infected cells, it is generally accepted that EBERs are consistently expressed in latently 
infected cells, and as such, EBER1 detection through in situ hybridization studies has 
been used as a marker for EBV infection in tissue samples (Chang et a l , 1992) EBERs 
are localized in both the cytoplasm and nuclei of mterphase cells and exist in 
ribonucleoprotein (RNP) complexes that can be precipitated by antibodies to a systemic 
lupus erythematosis protein, La (Chang et a l , 1992, Howe and Steitz 1986, Schwemmle 
et a l , 1992, Lemer et a l , 1981)
Another highly abundant nbosomal protein EAP/L22 has been identified in the La 
containing RNP complexes (Toczyski et a l , 1991, Toczyski et a l , 1994) L22 binds to 
the stem loop structure of EBER I and the putative function of this association is to 
sequester the cellular L22 molecules (Takada and Nanbo 2001) The L22 gene is 
translocated in certain leukemias and as such, L22 levels may influence cell 
transformation, (Nucifora et a l , 1993) the association of the EBERs with a cell 
immortalization protein (L22) may indicate a possible role in not only EBV driven 
immortalization but also in oncogenesis The EBER genes have also been implicated as 
having an oncogenic role in the Akata cell line in that transfection of the EBERs into 
EBV negative clones restored the capacity for growth in soft agar, tumourgemcity in 
SCED mice, resistance to apoptosis inducers and up-regulated expression of bcl-2 that 
was originally a feature of EBV infected Akata cell clones but was lost in the negative 
clones (Komano et a l , 1999) The role of EBERs in oncogenesis is also supported by 
findings, which showed the EBERs induce human IL-10 expression, which acts as an 
autocrine growth factor m BL cells (Kitagawa et a l , 2000)
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1.8.8 CSTs/BARTs
In latently EBV infected cell lines and tumors, expression of a family of alternatively 
spliced polyadenylated transcripts that arise from the BamHl region of the EBV genome 
are consistently observed (Chen et a l , 1992, Gilligan et a l , 1990, Gilligan et a l , 1991, 
Karran et a l , 1992) These so-called BamHl A rightward transcripts (BARTS) or 
complimentary strand transcripts (CSTs) are transcribed in a rightward direction 
antisense to a group of lytic genes also present in the BamHl-A region The antisense 
nature of the transcripts relative to the lytic cycle genes suggested a role in regulating the 
lytic cycle gene expression (Karran et a l , 1992) Apart from this function however, the 
discovery of a polyadenylation site at 160,964 on the EBV genome implies that these 
transcripts may encode functional proteins A number of potential protein products have 
been identified although protein expression from this family of transcripts is still unclear 
Analysis of the transcripts has identified putative open reading frames (ORFs) and the 
best studied of these include BARFO, RKBARFO, A73, and RPMS1 all o f which are 
initiated at an ATG site (Chen et a l , 1992, Fries et a l , 1997, Gilligan et a l , 1991, Karran 
et a l , 1992, Sadler and Raab-Traub 1995, Smith et a l , 2000, Smith et a l , 1993)
Figure 1.13. R ela tiv e  Positions o f  th e  RPMS1 a n d  BARFO ORFs in th e  EBV 
BARTS.
BamHl
'  1 I
“W W V =W -
RPMSl BARFO
FIG. 113 Relative positions of the RPM Sl and BARFO ORFs in the EBV BARTs are shown These 
are transcribed in the rightward direction and their relative positions in the BamHIA region of the EBV 
genome are detailed (adapted from Zhang et a l , 2001)
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1.8.8.1 BARFO Proteins and A73
The A73 spliced CST was one of the first identified, and RPA analyses suggest that this 
spliced product is one o f the more abundant of the CST proteins expressed (Chen et a l , 
1992, Smith et a l , 2000) As yet no full-length cDNA clone encoding the A73 protein 
has been identified The A73 product has been shown to be a cytoplasmic protem which 
in yeast two hybnd assays interacts with RACK1 (Smith et a l , 2000), a cellular protem 
involved in regulating signaling from protem kinase C and Src tyrosine kinases (Smith
2001) Two potential BARfD encoded proteins have been descnbed in detail, BARFO a 
174 ammo acid protein (Koslowski et a l, 1999), and RK-BARF0, a splice variant of a 
possible 279 ammo acids A complete RKBARfl) clone has not yet been isolated and it 
has been discovered that the RK-BARF0 cDNA is a chimera of two overlapping cDNAs 
(Sadler and Raab-Traubl995)
1.8.8.2 RPMS1
The RPMS1 ORF was originally identified from a composite of overlapping cDNA 
clones (Hitt et a l , 1989, Smith et a l , 1993) but the isolation of cDNAs representing 
complete CSTs facilitated identification of RPMS1 as the most 5’ ORF in one of these 
full length cDNA species (Smith et a l , 2000) Expression of the RMPS1 protem has 
only been detected m cell lines transfected with vectors expressing the RPMS1 ORF, and 
in these transfected cells, the protein is localized to the nucleus (Chen et a l , 1999, Smith 
et a l , 2000) The RPMS1 protem was shown to have a low level of homology to the 
EBNA2 protein (Smith et a l , 1993), including the WWP motif required for EBNA2 
binding to CBF1 (Ling et a l , 1995)
The RPMS1-CBF1 interaction was shown to interfere with EBNA2 and Notch mediated 
trans-activation of promoters containing CBF1 binding sites and hence repressed 
transcription from these reporter constructs (Smith et a l , 2000) This effect has been 
further investigated and it has been shown that RPMS1 also binds Sin3a and CIR, both 
members o f the CBF1 repression complex (Figure 114) One possible implication of this 
is that RPMS1 may function to down-regulate transcription of the other latent proteins
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from the Cp promoter in an attempt to prevent recognition of viral antigens by the 
immune system, thereby assisting EBV persistence (Smith 2001).
F igu re 1.14. M o d e l f o r  RPMS M ed iated  R epression  o f  EBNA2-CBF1 
A sso c ia ted  T ra n s-a c tiv a tio n  o f  T a r g e t  G enes
Figure 1.14. A model for RPMS mediated repression of EBNA2-CBF1 associated trans-activation of 
target genes. RPMS binds to CBF1 and CIR to stabilize the co repression complex thereby preventing 
EBNA2 mediated trans-activation of target genes.
1.9 G e n e s  o f  t h e  V ir a l  L y t ic  C y c l e .
The EBV viral lytic cycle is the replicative stage of the virus life cycle and is essential for 
the production of infectious pathogens, which can be transmitted by virus shedding in the 
saliva from, infected to EBV naive individuals. Only a small number of latently infected 
lymphocytes spontaneously enter the replicative cycle, and in these cells the viral DNA is 
amplified several hundred fold by a lytic origin of replication ori Lyt (Hammerschmidt 
and Sugden 1988). In vitro, lytic infection is induced mainly by the addition of phorbol 
esters, these chemicals drive the infected cells into the lytic cycle and this effect is 
probably mediated by protein kinase C activation of Jun-fos interactions with AP-1 
upstream of the immediate early viral genes (Farrell et al., 1983; Farrell et a l , 1989; 
Laux et a l , 1988). Lytic replication has also been induced in the Akata cell line (which 
carries an LMP2A deleted virus), by cross linking of surface immunoglobulins, studies 
revealed that greater than 50% of the cells entered the lytic cycle under these conditions 
(Takada 1984; Takada and Ono 1989). Another approach used to induce lytic replication
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of EBV involves super infection of Raji cells with the defective EBV from the P3HR1 
cell line (Mueller-Lantzch et a l , 1980) Raji is an EBV positive BL cell line, which has 
an unusually high EBV episome copy number The Raji cell line is defective for viral 
replication and late gene expression and infection is thus tightly latent (Polack et a l , 
1984) EBV vinons from P3HR1 contain rearranged DNA molecules in which the 
intermediate early trans-activators of the lytic cycle are expressed after super infection 
(Cho et a l , 1984, Miller et a l , 1984) Thus super infection of the Raji cell line with the 
P3HR1 EBV induces lytic replication m the Raji cell line Studies using these cell lines 
permitted the identification o f the EBV replicative proteins and their classification into 
early antigens (EA), membrane antigens (MA), and viral capsid antigens (VCA) The 
early antigens have been further subdivided into diffuse early antigens (EA-D) and 
restricted early antigens (EA-R), on the basis o f their sensitivity to methanol fixation 
(Henl e e ta l, 1971)
Following induction of the lytic cycle, cells that have become permissive to viral 
replication, undergo cytopathic changes characteristic o f herpesviruses, including 
migration of nuclear chromatin, synthesis o f viral DNA, assembly of nucleocapsids, 
envelopment of the virus by budding through the inner nuclear membrane and inhibition 
of host macromolecular synthesis (IARC Monographs 1997) Lytic cycle gene expression 
follows a temporal and sequential order (Farrell 1992, Takada and Ono 1989) and some 
viral genes are expressed independently of new protein synthesis, early after induction, 
such genes are classified immediate early genes, the early lytic viral genes are expressed 
after the immediate early genes and their expression is not affected by inhibition of viral 
DNA synthesis (Kieff 1996)
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Figure 1.15 A Schematic Representation of Early and Late EBV Gene 
Expression
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Figure 1.15 A schematic representation of early and late £BV gene expression The VGA, the MA and
the £ A are illustrated and their open reading frames are written in bold
1.9.1 Immediate Early Genes
After induction of the lytic cycle in response to super infection of the Raji cell line or 
immunoglobulin cross linking m the Akata cell line, in the presence of protein synthesis 
inhibitors, three leftward mRNAs are transcribed The BZLF1, BRLF1 and BL’LF4 
encoded proteins are potent trans-activators of early EBV lytic gene expression (Takada 
and Ono 1989, Kieff E 1996) The functional and physical interaction o f BZLF1 with 
NfkB is an important mediator of LMP1 effects m EBV latent infection BZLF1 can also 
down-regulate the EBNA Cp promoter possibly facilitating the transition from latent to 
lytic infection (Sinclair et a l , 1992) BZLF1 has also been shown to inhibit both cellular
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differentiation and cell cycle progression in epithelial cells The mechanism mediating 
this effect is not known however activation o f cell cycle inhibitors p21 and p27b was not 
observed (Swenson et a l , 1999) BRLF1 was also shown to bind Rb in vivo shortly after 
induction of the viral lytic cycle in EBV infected Akata cells This interaction may 
initiate cell cycle progression and facilitate viral DNA synthesis during lytic replication 
(Zacnye/a/, 1998)
1.9.2 Early Genes
The early genes are expressed when the lytic cycle is induced in the presence of  
inhibitors of DNA synthesis By this criteria at least 30 EBV mRNAs are early gene 
products (Hummel and Kieff 1982) Two very abundant early proteins have been mapped 
to specific DNA sequences The BALF2 protein is homologous to a HSV DNA binding 
protein and is important m DNA replication (Hummel and Kieff 1982, Kieff 1996) The 
BHRF1 protein, which is expressed in moderate abundance, has extensive collinear 
homology with bcl2 (Pearson et a l , 1983, Austin et a l , 1988) BHRF1 can protect EBV 
negative BL cells from apoptosis (McCarthy et a l , 1996), however EBV recombinants 
lacking the BHRF1 ORF are fully capable of initiating and maintaining cell growth 
transformation and they can also enter the lytic cycle and produce virus (Lee and Yates 
1992, Marchmi et a l , 1991) Several of the early genes are linked to DNA replication as 
indicated m Figure 1 15 above Transfection experiments indicate that some of these 
genes are activated m the process o f cell differentiation in the absence of other viral gene 
products, suggesting a possible role for cellular factors in regulating the productive cycle 
at least m certain cell types
1.9.3 Late Genes.
The late genes code for structural glycoproteins or proteins that modify the infected cells 
in order to permit viral envelopment or egress (IARC Monographs 1997) Among the 
non-glycoproteins, the major nucleocapsid protein is encoded by BCLF1 BNRF1 
encodes the major external non-glycoprotem of the vinon, and BXRF1 is likely to encode
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a basic core protein The genes encoding the EBV glycoproteins are illustrated in bold in 
Figure 1 15 above The late BCRF1 gene, which is located in the middle of the EBNA 
regulatory domain between on-P and Cp, is a close homologue of the human IL-10 gene 
with nearly 90% collinear identity in ammo acid sequence (Moore et a l , 1990, Vieira et 
a l , 1991, Touitou etal, 1996) BCRF1 has most of the activity o f human IL lOincluding 
negative regulation of macrophages and NK cell functions and inhibition of lFNy 
production Thus, virally expressed IL-10 may have a local effect on these responses to 
reactivate infection (IARC Monographs 1997)
1.10 Apoptosis
Apoptosis is a genetically pre programmed form of cell suicide involving dramatic 
morphological changes including cell shrinkage, nuclear re-organization, blebbing and 
eventual fragmentation of the cell into membrane bound apoptotic bodies (Allday 1996) 
Although apoptosis can occur to eliminate redundant cells dunng development, it is also 
an emergency active programme triggered in response to radiation damage, viral 
infection, or aberrant growth induced by the activation of oncogenes In order to 
maximize their replicative capacity many viruses deregulate normal cell cycle controls 
and some have also ensured selective advantage and biological success by evolving 
mechanisms which suppress either the triggers o f apoptosis or the programme itself, EBV 
is one such virus (Shen et a l, 1995) By preventing infected lymphocytes from 
undergoing apoptosis EBV ensures survival/persistence m the host system at least until 
such time as sufficient viral numbers have been produced to transmit infection to other 
individuals
The morphological features associated with apoptosis involve a cascade of proteolytic 
cleavage events resulting in the cleavage o f genomic DNA in a pattern identified on 
agarose gels as a distinctive “ladder” effect The proteolytic events characteristic of 
apoptosis are effected by a family of related caspases, and their activation is regulated by 
another family o f proteins the Bcl2 family The Bcl2 family of intracellular proteins is the 
central regulator of caspase activation, and includes both pro and anti-apoptotic proteins
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It is generally agreed that the combined action of these proteins in the cell sets the 
threshold for activation o f the apoptosis programme Anti-apoptotic members of the Bcl2 
family include Bcl2, BclXl and Bfl-1, while the pro-apoptotic members o f the family 
including proteins such as Bax, BclXs, Bik, Bak and Bad accelerate apoptosis (White et 
a l , 1996) Other proteins such as Mcl-I (a Bcl2 homologue), A l, A20 and the C elegans 
CED9 have also been identified as apoptosis inhibitors (Fries et a l , 1996, Laherty et a l , 
1992, Wang et al, 1999) All members of the Bcl2 family possess 1 of 4 conserved 
regions o f homology, known as Bcl2 homology domains (BH1 to BH4) (reviewed by 
Adams et a l , 1998) Certain regions of homology namely BH1 and BH2 appear to be 
essential to the anti-apoptotic proteins while the BH3 domain is crucial to a subset of the 
pro-apoptotic proteins
1 .1 0 1 EBV and Apoptosis
EBV is interesting because it manipulates both pro and anti-apoptotic proteins to its 
advantage in the course of its life cycle This duality of purpose is facilitated by the 
ability o f EBV to (i) regulate host cell apoptotic death machinery often by inducing the 
expression of anti-apoptotic proteins such as Bcl2, Bfl-1, Mcl-1 and A20 (Fries et a l, 
1996, Laherty et a l , 1992, Wang et a l, 1999, D'Souza et^al, 2000), or by (n) 
deregulating the function o f oncogenes and tumor suppressor genes involved in the cell 
cycle such as c-myc, p53 and pRb and (111) by encoding its own gene products which 
mimic anti-apoptotic proteins o f the host cell such as BHRF1 and BZLF1 (Henderson et 
a l , 1993, Tarodi et a l , 1994) In terms o f EBV infection, protection from apoptosis is 
desirable in the latent stage to ensure persistence in the host memory B cell compartment 
and in the lytic stage to delay cell death until vinon numbers have been sufficiently 
amplified Although EBV infection is primarily associated with an asymptomatic latent 
disease state, infection in adolescence is associated with infectious mononucleosis, also 
unsurprisingly as a result of its subversion o f proliferation and apoptotic pathways, EBV 
is also associated with several lymphoprohferative disorders in immunocompromised 
individuals such as Oral Hairy Leukoplakia (Thomas et a l , 1991) and a number o f  
human cancers, including undifferentiated Nasopharyngeal Carcinoma (NPC) (Zur
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Hausen et a l , 1970, De-The 1981), Hodgkin’s disease (Pallesen et a l , 1993, Brousset et 
a l , 1993), rare Nasal T cell lymphomas (Pallesen e ta l , 1993), gastric carcinoma (Shibata 
and Weiss 1992, Selves et a l , 1996), breast carcinoma (Labrecque et a l , 1995) and B 
and T cell lymphomas in immunocompromised individuals (Miller et a l , 1990, Pallesen 
e ta l, 1993, Young ei a /, 1989, Gratamaei a l, 1991, Shibata etal, 1991)
110.2 EBV Induces the Expression of Anti-Apoptotic Proteins,
1.10.2.1 BCL2
Three EBV proteins -LMP1, EBNA2 and EBNA3B -have been shown to up-regulate 
expression of the antiapoptotic Bcl2 protein (Henderson et a l , 1991, Finke et a l , 1992, 
Silins and Sculley 1995) In addition to inducing proliferation, EBV latent proteins may 
also facilitate cell survival by suppressing the apoptotic programme The first evidence to 
support this theory comes from studies involving Type I and Type III BL cell lines These 
cell lines exhibit the latency I and latency HI latent gene expression profiles respectively 
(Table 1 0), thus only EBNA1 is expressed in the type I BLs whereas the full 
complement of latency associated proteins are expressed in the type Hi BLs Type I cells 
are apoptosis sensitive while the type HI BLs like the LCLs display an increased 
resistance to apoptosis induced by a number of triggers including, serum deprivation and 
Ca-H- lonophores (Gregory et al y 1991) Further studies determined that type I BLs 
express little or no Bcl2, however the apoptosis-resistant type HI BLs were found to 
express Bcl2 (Henderson et al, 1991) Transfections with EBV LMP1 also resulted in 
enhanced survival of these cells The ability of LMP1 to confer resistance to apoptosis to 
the type I BLs resulted from its ability to induce endogenous Bcl2 expression (Gregory et 
a l , 1991, Henderson et a l , 1991) EBNA2 was also found to enhance the ¿¿/¿-inducing 
effect of LMP1 in BJAB cell lines but not induce bcl2 itself in the same expenment 
Other transfection studies however showed that EBNA2 could independently up-regulate 
Bcl2 expression in a range of EBV negative cell lines as could LMP1, with the strongest 
effect on bcl2 conferred by transfection with LMP1 (Finke et a l , 1992) Also Ectopic 
expression of EBNA2 has been shown to independently induce bcl2 expression in Bjab
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cell lines, as has LMP1 however in this system no co-operative effect between LMP1 and 
EBNA2 in inducing Bcl2 expression was observed (Martin et a l , 1993) Another EBV 
latent protein EBNA3B has also been identified as up-regulating Bcl2 expression in an 
EBV negative cell line (Silins and Sculley 1995)
Although in vitro LMP1 and EBNA2 appear to up-regulate Bcl2 expression, in vivo, the 
recirculating B cells o f peripheral blood which are a normal target of EBV, already 
express relatively high levels of Bcl2 and EBV infection and thus LMPlor EBNA2 or 
combined expression of the two, does not significantly increase this, thus the role of 
LMP1/EBNA2 may be m maintaining the high constitutive level pf Bcl2 in uninfected 
cells rather than inducing it (Martin et a l , 1993)
Over expression of Bcl2 in group I BL cell lines following gene transfer results in 
reduced apoptosis in response to a number o f stimuli compared with group HI cell lines, 
with the inhibition of cell death being proportional to the amount of Bcl2 expressed 
(Henderson et a l , 1991, Milner et a l , 1992) However m a panel of group I cell lines, 
including group I, group I 6c/2+, (bcl2 Transfectants of the group I cell line) and group 
III cells from the same parental BL line, it was found that the degree of apoptosis 
inhibition imparted by the group HI phenotype far outweighed that apparent from the 
levels of BcI2 protein measured m the group HI cells compared to the levels of Bcl2 in 
the group I Bcl2 transfectants Two explanations are obvious here, firstly in the group I 
cells, bcl2 function is suppressed/antagonized or secondly other additional bcl2 
independent survival pathways are operational m group HI cells With respect to the first 
possibility, bcl2 homologues bax and bclxs which can suppress bcl2 function have been 
identified Reviewed by (Allday 1996, Korsmeyer 1995) However no consistent 
differences in the expression of these proteins in group I and group in  cells has been 
identified (Spender et a l , 1999) In support of the second possibility, it is conceivable 
that EBV induced apoptosis suppressor proteins, such as the Bcl2 homologues Bclxl, 
Mcll, or A20 act in concert with Bcl2 m group III cells to promote survival In this 
regard, LMP1 has been shown to up-regulate the expression of other anti-apoptotic 
proteins including Mcl-1, A20 and Bfl-1 (Wang et a l , 1996, Laherty et a l , 1992, 
D’Souza et a l , 2000)
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1.10.2.2 MCL-1
The maximum induction o f Bcl-2 by LMP1 takes about 48-72 h (Rowe et a l , 1994) 
However transient up-regulation o f the anti-apoptotic Bcl2 homologue Mcl-1 occurred 
pnor to LMPl-induced Bcl2 up-regulation and Mcl-1 levels decreased when Bcl-2 levels 
started to increase (Laherty et a l , 1992) These findings support the hypothesis that Mcl- 
1 functions as a rapidly inducible, short-term effector of cell viability LMP1 also blocked 
the decline m the Mcl-1 levels in response to apoptotic stimulation triggered by elevated 
cyclic AMP This effect of LMP1 was associated with a delayed cell death in the EBV- 
negative Burkitt lymphoma cell line BL41 The maintenance of Mcl-1 expression by 
LMP1 is likely to be a crucial immediate-early response that enables cells to survive until 
Bcl-2 can be up-regulated (Wang et a l , 1996)
1.10.2.3 A20
A20 was identified as a tumor necrosis factor a  (TNF) -inducible gene, and encodes a 
790 amino acid zinc finger protein A20 conferred resistance to apoptosis induced by 
TNFa Transcriptional activation of the A20 gene is mediated by binding NF-kB to two 
KB sequences within the A20 promoter (Beyaert et a l , 2000) and A20 expression is 
induced in response to inflammatory mediators and cellular activators in several cell 
types including fibroblasts, lymphocytes and endothelial cells (Beyaert et a l , 2000) The 
widespread distribution o f A20 suggests that its anti-apoptotic function may also be 
widespread (Laherty et a l , 1992) A20 expression has also been shown to be mediated by 
LMP1 LMP1 has been shown to up-regulate A20 expression in B-lymphocytes as well 
as epithelial cells and this effect is mediated by NF-kB, mapping to both CTAR1 and 
CTAR2 (Laherty et al , 1992, Fries et a l, 1996, Miller et a l , 1995, Miller et a l , 1997) 
A20 is also constitutively expressed in EBV immortalized B cells (Spender et a l , 1999) 
LMP1 mediated protection of epithelial cells from p53 induced apoptosis has been shown 
to involve A20, while A20 expression in BL cells has been shown to enhance LMP1 
mediated protection from apoptosis (Fnes et a l , 1996, Laherty et a l , 1992) A20 has also 
been identified as functioning m a negative feedback loop by inhibiting the activation of 
NF-kB from both CTAR1 and CTAR2 (Ehopoulos et a l , 1999b) This effect was
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mediated by the binding of A20 to TRAF2, this effect is also evident in CD40 signaling 
which also induces expression of A20 in BL cells (Sarma et a l , 1995)
1.10 2.4 Bfl-1
Recent studies in our laboratory have also identified another anti-apoptotic protein, Bfl-1, 
that is up-regulated by LMP1 expression m BL cell lines (D'Souza et a l , 2000) Bfl-1 is 
especially relevant to the subject matter of this thesis as, in this study, EBNA2 was 
identified as another EBV latent protein, which regulates the expression of Bfl-1 in BL 
cell lines This anti-apoptotic protein was initially identified as being over expressed in 
stomach cancers (Choi et a l , 1995) Although bfl-1 exhibits -72% homology with its 
murine homologue A l, their distribution appears to be quite different, while Al 
expression is restricted to haematopoetic tissues, bfl-1 expression has been reported in 
endothelial cell lines, numerous cancer cell lines, and normal leukocytes as well as 
haematopoietic cells (Karsan et a l , 1996, Kenny et a l , 1997) A possible protective role 
for bfl-1 in the inflammatory response has been proposed as expression of the bfl-1 gene 
is up-regulated in cultured epithelial cells and leukocytes in response to phorbol ester, 
and inflammatory cytokines, TNFa and ELI (Karsan et a l , 1996, Moreb and Schweder
1997) bfl-1 expression is also up-regulated during differentiation of leukemic cells to 
granulocytes and macrophages (Moreb and Schweder 1997) The protein product of the 
bfl-1 gene also called Bfl-1 is 175 ammo acids long and is considered a member of the 
Bcl2 family of proteins as Bcl2 homology domains, (BH1 BH2 and BH3) have been 
identified in the Bfl-1 protein (D'Sa-Eipper and Chinnadurai 1998) Analysis of the 
functions o f the Bfl-1 protein have shown that it suppresses p53-mediated apoptosis, 
protects BL cells from apoptosis induced by growth factor withdrawal and exhibits cell 
proliferation and transforming activities in vitro, these studies also propose that Bfl-1 
anti-apoptotic and transforming activities may be related (D'Sa-Eipper and Chinnadurai 
1998, D'Sa-Eipper et a l , 1996, D’Souza et a l , 2000) bfl-1 gene expression was 
originally identified in a proportion of colon and stomach cancers (Choi et a l , 1995) as 
well as in cell lines derived from leukemias and lymphomas (Choi et a l , 1995, Kenny et 
a l , 1997) however, more recent studies have extended this list to include EBV positive 
BL cell lines exhibiting a group HI phenotype (D'Souza et a l , 2000) Type III EBV
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positive BL cell lines and LCLs in which the full set of EBV latent proteins was 
expressed, exhibited elevated levels of bfl-1 mRNA relative to their type I counterparts 
Using a system in which the expression of LMP1 was mducibly regulated by tetracycline, 
D ’Souza et al 2000, showed that LMP1 when expressed as the sole EBV protein, can up- 
regulate transcription from the bfl-1 gene in a B cell specific manner Further studies 
using the bfl-1 promoter also revealed that LMP1 trans-activates the bfl-1 promoter and 
that this trans-activational effect may be mediated by the NF-kB signaling pathway 
(D’Souza et a l , 2000) These findings further substantiate the growing link between EBV 
and the regulation of apoptosis
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1.10.3 EBV In te r a c ts  w ith  Components o f  th e  C e l l  C y c le  t o  P r o te c t  
A gainst Apoptosis.
Apart from inducing the expression o f anti-apoptotic proteins, EBV, particularly EBNA2 
and LMP1 also control apoptosis by regulating the expression of tumor suppressor 
proteins involved in the cell cycle including pRb, and p53
1.10.3.1 Cell Cycle Events.
Figure 116 Phases of the Lymphocyte Cell Cycle and some of the factors involved therein
The cell cycle progresses through four distinct phases designated Gl, S G2 and M The 
G1 phase is the longest and occurs prior to DNA synthesis DNA is synthesized in the S 
phase while cell division or mitosis occurs m the M phase (Brennan 2001) Certain EBV 
latent proteins notably LMP1, EBNA2, EBNALP and EBNA3C have been shown to 
regulate cell cycle related genes in order to induce lymphocyte proliferation and escape 
apoptosis, thereby facilitating viral persistence and survival
The first biochemical event observed in early Gl is the induction of D-type cyclins and 
their partners the cychn dependant kinases (cdks) cdk4 and cdk6 The induction of D type 
cyclms is paralleled by a loss in cdk inhibitors such as p27kipl (Brennan 2001) The most 
important substrate for the cyclinD/cdk4/6 complex is a family of pocket proteins typified 
by pRb (the retinoblastoma susceptibility gene product, (Nevms 1997) The mam
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function of pRb and its familial proteins is to suppress a family of transcription factors 
termed E2F, which are important m driving cells onto the S phase of the cell cycle 
(Nevins 1997) The fact that cells in which the E2F transcription factors are deregulated, 
either apoptose or proliferate depending on the down or up regulation of target genes 
respectively, indicates the crucial link between these factors and cell fate choices 
Phosphorylation of pRb inactivates the protein during late G1 at a point in the cell cycle 
that coincides with the late G1 restriction point Phosphorylation of pRb by cdk4 releases 
E2F proteins bound to the dephosphorylated pRb, thereby relieving repression o f these 
genes or activating their transcription (Taya 1997, Levine 1997) pRb is the principal 
target for inactivation by several tumor virus oncoproteins including Simian Virus 40, 
large T antigen, human papilloma virus E7 protein and adenoviral El A suggesting that 
active pRb acts as a restraint to the mitogemc actions of these virus proteins (Taya 1997) 
and the same may be true for EB V
110 3.2 EBV, pRb and the Cell Cycle
Mostly, cell cycle events in B cell proliferation, have been studied in mouse models 
(Solvason et a l , 2000) however a number of studies have examined the induction of cell 
cycle proteins in human B cells in response to EBV infection and it is these which 
provide the compelling evidence linking EBV to cell cycle control as a method of 
avoiding apoptosis and ensuring its own survival (Spender et a l , 2001, Cannell et a l , 
1996, Spender et a l , 1999, Kempkes et a l , 1995a) The first cell cycle protein expressed 
after EBV infection of B-lymphocytes is cyclin D2, which is detected approximately 24 
hours after EBV infection (Spender et a l , 1999) There is a concomitant loss of the cyclin 
dependent kinase inhibitor p27kipl, and 6 hours later, phosphorylation/de-activation of 
the pRb protein occurs All these events occur during normal B cell proliferation as well 
as proliferation after EBV infection in B lymphocytes suggesting EBV exploits normal 
cell pathways to regulate pRb phosphorylation/inactivation dunng the cell cycle (Cannell 
et a l , 1996, Kempkes et a l , 1995a 1995b 1995c) By up-regulating cychns involved in 
phosphorylation or by directly inactivating pRb itself, EBV could free E2F transcription 
factors to dnve potentially infected cells through the cell cycle It has been shown
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(Sinclair et a l , 1994), that co expression o f EBNA2 and EBNALP was sufficient to 
induce cyclin D2, and that this event closely followed the induction o f the two latent 
EBV proteins The mechanism by which EBNA2 links to cyclin D2 remains to be 
characterized, as does the cooperative function of EBNA2 and EBNALP in regulating 
cyclin D2 expression However c-Myc which has been shown to be a direct target gene of  
EBNA2 has also been shown to trans-activate the D2 promoter (Spender et a l , 2001, 
Kaiser et a l , 1999, Bouchard et a l , 1999) and c-Myc was therefore proposed as a link 
between EBNA2 and cyclin D2 Nevertheless, c-Myc was shown to trans-activate the 
cyclin D2 promoter using an E box located outside the region of the promoter trans- 
activated by EBNA2 thus the prospect of c-Myc as a link between EBNA2 and cyclin D2 
is unlikely (Bouchard et a l , 1999) Apart from up-regulating cychns involved in the 
inactivation o f pRB, EBV may also repress cyclin dependent kinase inhibitors again to 
facilitate the inactivation of pRB The induction of cyclm D2 is paralleled by the loss o f  
the cyclm dependent kinase inhibitor p27kipl in response to EBV and in many other 
systems (Spender et a l , 2001, Slingerland and Pagano 2000) Although the regulation of 
p27kipl is well studied in other systems, only one EBV protein has been shown to 
regulate its expression, namely EBNA3C (Parker et a l , 2000) Because o f the 
relationship between cychnD2 and p27kipl, the link between EBNA3C and p27kipl 
suggests that EBNA3C along with EBNA2, EBNALP and LMP1 are important in driving 
cells through the G1 phase of the cell cycle
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F ig u r e  1.17. E B V  P r o t e in s  I n t e r a c t  w it h  a  N u m b e r  o f  E l e m e n t s  In v o l v e d  in  
R e g u l a t in g  C e l l  C y c l in g  a n d  P r o l if e r a t io n
Figure 1.17. EBV interacts with a number of elements involved in regulating cell cycling, and 
proliferation, which ultimately may decide the apoptotic fate of the cell. The p53-Rb Pathway and the 
interrelationship between a number of oncogenes (purple circles) and tumor suppressor genes (green 
squares) that regulate the G l-S  phase restriction point, its relation to a DNA damage checkpoint mediated 
by p53, and the choice by p53 whether to initiate a G1 arrest (via p21) or apoptosis. Shown are the p53- 
MDM2 autoregulatory loop that reverses this checkpoint control and the gene products that positively or 
negatively act on the probability o f entering apoptosis. Those proteins which can also be regulated by EBV 
after infection are also indicated (adapted from Levine 1997)
1.10.3.3 C-MYC
c-Myc is a sequence specific DNA binding phosphoprotein that is a transcriptional 
activator and whose expression is required to drive cells through the G1 into the S phase 
of the cell cycle. A model explaining the role of c-Myc in the seemingly diverse roles of
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apoptosis and proliferation, predicts that c-Myc expression preferentially results in 
proliferation under favorable growth conditions with this activity being dependent on its 
apoptosis-promoting activity being blocked (Evan et a l , 1995) Thus c-Myc deregulation 
is regarded as priming normal proliferating cells for apoptosis
1.10.3.4 EBV AND C-MYC.
EBV-negative BL cells which display deregulated c-Myc expression due to the t(8,14) 
translocation proliferate rapidly in culture but are highly sensitive to apoptosis induced by 
growth factor withdrawal (Gregory et a l , 1991) However, expression of either LMP1 or 
EBNA2 m these cell lines has been shown to have growth inhibitory and anti-apoptotic 
effects which may be in part due to down regulation of c-Myc in response to 
transcriptional down regulation of the translocated Ig-ji locas (Floettmann et a l , 1996, 
Jochner et a l , 1996) In the same way that deregulated c-Myc expression primes normal 
proliferating cells for apoptosis, EBV infection, primes LCLs for apoptosis by 
deregulating c-Myc expression Thus under favourable growth conditions LCLs 
immortalized by EBV infection proliferate rapidly, however under serum starvation 
conditions the cells die by apoptosis (reviewed by Chemey et a l , 1994) C-Myc was 
specifically implicated in these effects since antisense oligonucleotides to c-myc 
specifically inhibited apoptosis in the growth factor depnved LCLs but suppressed 
growth of undepnved LCLs (Chemey et a l , 1994) These studies showed that although 
deregulated c-Myc expression exerts these effects on cell growth and death, one or some 
of the EBV latent proteins expressed in LCLs must be responsible for the deregulation of 
c-Myc
Studies usmg an LCL m which the function of EBNA2 is dependent on the presence of  
estrogen designated ER/EB have revealed that EBNA2 is the EBV gene predominantly 
responsible for deregulating c-Myc m LCLs (Kempkes et a l , 1995c) Later studies also 
revealed that cMyc is a direct target gene of EBNA2 (Kaiser et a l , 1999) In the initial 
studies, primary B lymphocytes were infected with recombinant virus such that in the 
presence of estrogen, growth transformation o f the infected B cells was achieved leading 
to the formation of estrogen dependent LCLs expressing EBNA2 (as a fusion protein
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attached to the estrogen receptor hormone binding domain), in addition to the other EB V 
latent proteins Removal of estrogen, thus m the absence of EBNA2 activation, about 
50% of the cells entered a quiescent non-growth phase while the remainder succumbed to 
apoptosis Growth arrest was recorded at both G1 and G2 phases of the cell cycle, which 
is indicative o f a requirement for EBNA2 function at these two stages However only 
those arrested at G1 could be rescued (into continuing through the cell cycle), on 
induction o f EBNA2 and this was shown to correlate with the induction of c-Myc and 
LMP1 expression, followed by the induction of cychnD2 (G1 specific cychn) and cdk4 
and then the phosphorylated form of pRb In conjunction with the expression o f the 
phosphorylated/inactive pRb, E2F also became detectable, thus EBNA2 sets a cascade 
into action which results in the activation of the E2F transcrption factors allowing cells to 
cycle through to the S phase (Zimber-Strobl et a l , 1996) These findings confirmed, that 
in LCLs functional EBNA2 is required not only for the induction and maintenance of  
deregulated c-Myc expression but also for cellular (B cells) proliferation 
Since expression of EBNA2 leads to the up-regulation of LMP1, further studies were 
carried out to assess if the EBNA2 effect on proliferation was actually due to LMP1 
expression In the absence of functional EBNA2 it was found that LMP1 could not 
sustain B cell proliferation (at levels of expression similar to that in LCLs), but did 
promote increased cell viability (Zimber-Strobl et a l , 1996) Only in the presence of 
functioning EBNA2 was proliferation resumed These results, showing that LMP1 was 
not sufficient to maintain B cell proliferation m the absence o f functional EBNA2 proved 
that EBNA2 acts independently o f the up-regulation o f LMP1 to maintain the 
proliferation of EBV immortalized B cells (Zimber-Strobl et a l , 1996)
1.10.3.5 P53
Apart from pRb another transcriptional repressor p53, has a crucial function in regulating 
the passage of cells through the cell cycle P53 functions to limit the progression of cells 
containing damaged genomes through the cell cycle and it does this by either enforcing 
cell cycle arrest or triggering apoptosis (Levme 1997, Bates and Vousden 1996) The 
high incidence of p53 functional mutation in human tumours indicates its critical role in 
limiting neoplastic progression By inducing damaged cells to apoptose, p53 prevents the
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progression of potentially mutant cells together with the tumoungemc risk they present 
Following DNA damage p53 levels increase swiftly as a result o f stabilisation of the p53 
protein which appears to be an important stage m the G1 arrest and apoptosis, which 
occurs m response to DNA damage Tumour cells that have lost functional p53 exhibit 
resistance to induction of apoptosis by a range of genotoxic agents (Allday 1996)
P53 can act as a transcription factor and its function in inducing growth arrest is 
facilitated by its ability to regulate specific target genes notably p21 (also known as 
WAF-1 or Cip-1), a cyclin dependent kinase inhibitor whose action arrests cells m late 
G1 High quantities of p21 inhibit kinase activity and thus cell cycle progression The 
link between p53 and apoptosis is still under investigation
1.10.3.6 EBV ANDP53.
High incidences o f p53 mutation have been identified in Burkitts lymphoma tumor 
biopsies and BL cell lines, occurring in 33% and 63% of cases respectively (Farrell, 
1991) BL cells with p53 mutations have been shown to be relatively resistant to DNA- 
damagmg drugs such as cisplatin compared to those cell lines harboring wild-type p53 
(Allday 1995) LMP1 however can protect against wild-type p53 mediated apoptosis, a 
phenomenon observed in both BL and epithelial cell backgrounds based on the use of cell 
lines expressing temperature sensitive p53 In BL cells, protection by LMP1 is probably a 
result of inducing Bcl2 expression (Okan et a l , 1995) However in epithelial cells 
protection against p53 mediated apoptosis was as a result of the induction of the A20 
protein (Fries et a l , 1996) In both cases protection afforded by LMP1 did not involve an 
effect on the trans-activation function of p53 Another EBV latent gene EBNALP can 
also interact with p53 m vitro and also with pRb, however the functional significance o f  
these interactions has yet to be identified as LP does not alter the role of these molecules 
when bound (Szekely et a l , 1993)
Resting primary B cells are essentially p53 negative (Allday 1995) Some of these cells 
spontaneously undergo apoptosis when placed m culture through a p53 independent 
mechanism EBV infection of resting B cells rescues them from spontaneous cell death 
and also results in the accumulation of p53 (Allday 1995) This accumulation o f p53 was
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shown to be dependent on EBV gene expression as infection with a UV inactivated virus 
did not result in p53 accumulation (Chen 1996)
The observation that the presence of dephosphorylated pRb correlates with apoptosis in 
LCLs suggests that EBV must encode a function which enables the Gl/S restriction point 
to be overcome and thus allow progression through the cell cycle, converting the p53 
arrest response to apoptosis (Levine 1997) Candidate mechanisms by which EBV may 
overcome the Gl/S restriction point include deregulation o f c-myc or utility of a virally 
encoded El A-like function, which generates high levels o f transcriptionally active E2F
1.10*3.7 C y t o k in e s
EBV induces the synthesis o f various cytokines following B cell activation Cytokines 
are involved in lymphocyte proliferation and their expression suppresses apoptosis The 
most relevant cytokines m terms o f EBV induced cell proliferation and apoptosis escape 
are IL-6 and IL-10 which both play an important role in the growth of EBV transformed 
cells (Haddad et a l , 2001, Kitagawa et a l , 2000) An IL-6 antibody has been shown to 
inhibit the growth of EBV immortalized cells in vivo in a recent clinical trial (Haddad et
•s
a l , 2001) and IL-6 differentiated B cells die by apoptosis (Altmeyer et a l , 1997) Both 
IL-10 and IL-6 have been shown to be regulated by LMP1 through NF-kB and the p38 
stress activated protein kinase (Eliopoulos et al y 1997, Ehopoulos et a l, 1999a, 
Nakagomi et a l , 1994, Vockerodt et a l , 2001)
New observations have also suggested that IL-10 may be regulated by EBV EBERs 
(Kitagawa et a l , 2000) EBERs are expressed in EBV positive BL cells and in normal 
EBV transformed LCLs EBV positive Akata and Mutu BL cell lines express higher 
levels of IL-10 than their EBV negative subclones Transfection of EBV negative Akata 
BL cells with EBERs resulted in the induction of IL-10 while EBER1 or EBER2 was 
sufficient, the optimal induction o f IL-10 was seen when both were introduced (Kitagawa 
et a l , 2000) Increase in the levels of the cytokines as a result of EBER expression 
conferred tumoungemc and apoptotic resistance phenotypes in several BL cell lines 
(Akata, Mutu I and Bjab) (Kitagawa et a l , 2000)
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Another cytokine TGFP is also targeted by EBV TGFp peptides belong to a family of 
structurally related molecules with a variety of biological functions including 
differentiation and apoptosis on a variety of cell and tissue culture types including human 
B and T lymphocytes (Arvamtakis et a l , 1995) EBV negative BL lines and EBV positive 
BL lines with a group I phenotype are generally sensitive to the growth inhibitory and 
apoptotic effects o f TGFp and this results from cells accumulating in G1 and undergoing 
apoptosis However EBV immortalized LCLs and EBV positive BLs that express the 
type m  phenotype are resistant to the growth inhibitory effects of TGFp (Altiok et a l , 
1993, MacDonald et a l , 1996)
LMP1 can independently reproduce the ability of EBV to confer TGFp resistance on 
infected B-lymphocytes and group HI BLs (Arvamtakis et a l , 1995) TGFp is known to 
arrest cells in the mid to late G1 phase of the cell cycle in not only mitogen-activated 
human B cells but also in non-lymphoid cell systems (MacDonald etal y 1996, Chaouchi 
et a l, 1995) This G1 arrest has been linked to an up-regulation o f at least 3 inhibitors of 
cychn dependent kmases (cdks) namely p i5, p27, and p21 and in some cells to a down 
regulation of cdk4 (MacDonald et a l , 1996) Binding of these inhibitors to cdk inhibits 
the formation of cdk-cychn complexes that are required for progression through the cell 
cycle The inhibition of cychn D function leads to a block in phosphorylation of pRb and 
this in turn represses the activity o f the E2F transcription factors thus preventing cells 
from making the transition from G1 to S phase of the cell cycle The protection against 
TGFP induced G1 arrest afforded by LMP1 was shown to be related to the induction of 
cychn D 2 expression by LMP1 leading to the maintenance o f pRb in a 
hyperphosphorylated state (Taya 1997) The maintenance of pRb in the 
hyperphosphorylated state by LMP1 thus leads to cell cycle progression regardless of the 
negative growth regulatory signal imposed by TGFP
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F ig u r e  1.18. M o l e c u l a r  In t e r a c t io n s  B e t w e e n  EBV P r o t e in s  a n d  C e l l  
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Figure 1.18. Overview of Molecular Interactions Between EBV Proteins and Cell Survival and 
Proliferation Machinery.
1.10.4 E B V  L y t ic  P r o t e in s  E n c o d e  An t i-A p o p t o t ic  F u n c t io n s .
Unlike most viruses EBV maintains a very stable persistent infection in vivo. Another 
state in which EBV may be found is in the process of active replication and the 
production of progeny virions, the lytic cycle. If the cells are driven to proliferate by 
EBV then (as in type H latency), apoptosis will be the most likely outcome. In this 
situation additional repressors of apoptosis can provide a selective advantage. Consistent 
with this model, there are at least two known virally encoded proteins BHRF1 and BZLF 
that are synthesized during the lytic cycle that can provide a survival advantage to the 
infected cells (Allday 1996). These lytic gene products can therefore delay apoptosis in 
order to maximize viral production. Expression of BHRF1 in epithelial cells has been
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shown to confer enhanced resistance to cisplatin induced apoptosis and can also inhibit 
differentiation (Dawson et a l, 1995, Dawson et a l , 1990) In lymphoid cells BZLF1 has 
been shown to interact with p53 and inhibit its trans-activating function, thereby 
providing a mechanism for preventing p53-mediated apoptosis However in epithelial 
cells expression of this EBV protein was shown to result in growth arrest without 
inhibiting the trans-activation function of p53 (Cayrol and Flemmgton 1996) EBV also 
encodes a viral homologue of IL-10 albeit expressed m the lytic virus productive cycle, 
which enhances the growth transformation of B cells infected with EBV (Stuart et a l , 
1995)
1.11.0 Relevance and Objectives of this Study.
Apoptosis can be induced in Type I BL cells and EBV negative cell lines with relative 
ease, compared to EBV positive, type HI cell lines and LCLs which display a higher 
resistance to apoptosis induced by a variety of stimuli including growth factor 
withdrawal, and over expression of the p53 tumor suppressor protein (Henderson et a l,
1991) and (Okan et a l, 1995) This increase in resistance to apoptosis has been linked to 
the up-regulation of the anti-apoptotic bcl-2 gene by EBV latent proteins including LMP1 
and EBNA2 (Henderson et a l , 1991, Rowe et a l , 1994, Finke et a l , 1992) and also the 
anti-apoptotic stress response proteins A20 and Mcl-1 (Fries et a l , 1996, Laherty et a l, 
1992, Wang et a l , 1996) More recently however, studies m our lab have shown that 
LMP1 also transcriptionally up-regulates another anti-apoptotic cellular gene, bfl-1, 
which similarly to bcl2 also encodes an anti-apoptotic protein, namely Bfl-1 (D'Souza et 
al, 2000)
Bfl-1 suppresses apoptosis induced by p53, serum starvation and TNFa-mduced 
cytotoxicity and exhibits proliferative and potent cooperative transforming properties in 
vitro (D'Souza et a l , 2000, D'Sa-Eipper et a l, 1996, Karsan et a l , 1996, Zong et a l ,
1999) In the study by D’Souza et al, elevated bfl-1 mRNA levels were shown to be a 
consistent feature of EBV immortalized B cell lines (LCL) and BL cell lines expressing 
the full spectrum of EBV latent proteins (Type III BL) In addition however, although 
LMP1 expression accounted for part of this up-regulation of bfl-1 mRNA, other EBV
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proteins were also likely to be involved as the steady state levels o f bfl-1 mRNA m LCLs 
and type III BL cell lines were dramatically higher than in cell lines in which LMP1 was 
being expressed as sole EBV protein In this study we pursued evidence for LMP1 
independent mechanisms involved in the regulation of the bfl-1 gene As the second 
major effector of phenotypic change in EBV infected cells, EBNA2 was a likely 
candidate for regulating the bfl-1 expression and this study focuses on the role of EBNA2 
in regulating the expression of this anti-apoptotic gene
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C hapter 2
Materials and 
Methods
2.0 MATERIALS AND METHODS
2.1 BIOLOGICAL MATERIALS
2.1.1 CELL LINES
T a b l e  2.1 C e l l  l in e s  u se d  in  t h is  stu d y
Cell Line EBV
Status
Cell
Classification
Description
DG75 EBV negative BL Lymphoid B cell line derived from an 
Israeli Burkitt-like lymphoma case 
(Ben-Bassat et al., 1977)
DG75 tTA EBNA2 - BL (Stable 
transfectants)
Tetracycline-regulated system 
established in DG75 whereby the
DG75 tTA LMP1 expression of EBNA2/LMP1 can be 
induced by the removal of tetracycline 
from the growth media (Floettmann et 
al., 1996)
DG75-SG5 - BL (Stably EBV negative BL cell pools stably
DG75-Sg5EBNA2 - Transfected cell transfected to express EBNA2 and the
DG75- - pools) CBF1 binding mutant
SG5EBNA2WW32 EBNA2WW323SR. DG75 Cells were
3SR also stably transfected with the 
background pSG5 vector (Stratagene).
BL41-ER/EBNA2 - BL (Stable EBV negative BL cell line stably
(K3) transfectant) transfected with an EBNA2 expression 
plasmid in which the EBNA2 
activation domain is fused to the 
estrogen binding domain, rendering 
the activation of EBNA2 dependent on 
the presence o f estrogen (Kempkes, et 
al., 1995a)
BL41P3HR1- + EBV Positive BL EBV negative BL infected with the
ER/EBNA2 (9A) (Stable transfectant) P3HR1 strain of EBV and 
subsequently transfected with an 
EBNA2 fusion protein where EBNA2
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activation is dependent on the 
presence o f estrogen as above 
(Kempkes et al., 1995a]
BL41P3HR1- + EBV positive BL EBV negative BL infected with the
mNotchlC (cl31) (Stable transfectant). P3HR1 strain of EBV and 
subsequently stably transfected to 
express mouse NotchIC where Notch 
activation is dependent on the 
presence o f estrogen (Strobl et at., 
2000)
Bjab - BL
Mutu 1 + TypelB L Early passage BL cell line expressing 
EBNA1 as the sole viral latent gene 
(Gregory eta\.y 1990)
Mutu 3 c95 + Type m  BL A clone of Mutu I cells that have upon 
serial passage in culture, “drifted”  to 
express the entire complement o f EBV 
latent genes (Gregory et al, 1990).
Mutu 3 (LMP1-) + Type III BL This is a partially characterized Mutu 
3 clone which no longer expresses 
LMP-1
BL41, - EBV-negative BL These cell lines are a matched set.
IARC 171 + Type III phenotype 
LCL
BL41-an EBV negative BL cell line 
(Calender et a!., 1987). IARC 171 is a 
spontaneously transformed LCL 
established from the same patient from 
whom the BL41 cell line was derived 
(Andersson et al., 1991)
IARC 290B + LCL A spontaneously transformed LCL
X50-7 + LCL A spontaneously transformed LCL 
(Wilson and M iller 1979)
Ag876 + Type III BL Type III BL cell line expressing all of 
the EBV latent genes
Jurkat - T cell Acute T-lymphocytic leukemic cell 
line (Brattsand et al., 1990)
C33A, • Epithelial cell These are cervical epithelial cell lines. 
C33A is the parental cell line. (M iller,
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VSMC - Vascular Smooth Bovine Smooth muscle cell line
Muscle Cell Line (Professor Paul Cahill DCU).
1995)
All BL cell lines, LCLs, and the Jurkat cell lines were obtained from Professor Martin 
Rowe, University of Wales, Cardiff. The epithelial cell line C33 A and its derivatives 
were a gift from Dr. Nancy Raab-Traub, University of North Carolina, USA. The 
estrogen responsive Cell Lines K3, 9A and C131 were gifts from Dr. Bettina Kempkes 
GSF Munich Germany. The vascular Smooth muscle Cell line was a gift from Professor 
Paul Cahill, Centre for Vascular Research DCU. Ireland.
2.1.2 Antibodies
The monoclonal antibodies against LMP-1, CS1-4, and the anti EBNA2 antibody PE2 
were generous gifts from Professor Martin Rowe, University of Wales, Cardiff. The 
antibodies were supplied as cell culture supernatants and stored at 4°C or -20°C prior to 
dilution. The anti-EBNA2 antibody R3 was a gift from Dr. Bettina Kempkes GSF, 
Munich Germany. The anti Al/Bfl-1 antibody was purchased from Santa Cruz 
Biotechnology California. The Anti Notch Antibody Tanl was obtained from Dr. Gerry 
Weinmaster. The alkaline-phosphatase (AP) conjugated anti-mouse antibodies were 
purchased from Promega and the alkaline-phosphatase (AP) conjugated anti-rabbit 
antibody was purchased from Boehringer Mannheim. The HRP conjugated anti-rabbit 
antibodies were purchased from Amersham Biosciences.
2.1.3 Bacterial Strains
E.COLIDHSol, GENOTYPE: F-, END Al, HSDR17 (Rk-,Mk=), SUPE44, 7H /-1,A ,-, REC Al, GYR 
A96, RELAX,  <|> 80L4CZ8M15
E.COU  JM 109, GENOTYPE: ENDA1, RECAl, GYRA96, Tffl, HSDR17 (RK -, MK + ), RELA1, 
SUPE44,. X-, A(LAC- PROAB), [F\ TRAD36,
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PROA + B + , LACLQ D&M15]
E C O I/E S 1301 m u t S, g e n o ty pe : LACZ53, m u t S201::Tn 5, THYA36, r h a -5, m e tB I,  
DEOC, IN ( RRND- RRNE)
E c o u X L10 G o ld , g e n o ty p e T e tr  A (m crA)183  . A (m c rCB-hsdSMR-m r r )1 7 3 endA I  
SUPE44 THI-1 RECAI GYRA96 RELÁ1 LAC H TE[F ' PROAB LACIqZ  . A M I5 TNlO (TET11) 
AMY CAMR ]
2.1.4 E x pr essio n  and  R e p o r t e r  C o n st r u c t s .
T a ble  2.2 P la sm id s  Used  in  T in s study
PLASMID GIFT FROM DESCRIPTION
pSG5
pSG5EBNA2 
*pSG5EBNA2 WW323 SR
pSG5 LMP-1
p-1374/+81Bfl-l CAT 
p-1240/+81Bfl-l CAT 
p-367/+81Bfl-l CAT 
p-129/+81Bfl-l CAT
p -1374/+81 B fl-1 Luc
Lindsey Spender. Ludwig Institute 
for Cancer Research. Imperial 
college school o f medicine 
London. *Proffessor Diane 
Hayward. Johns Hopkins School 
o f Medicine, Baltimore, Maryland 
21231, USA
Professor Martin Rowe, 
University o f Wales College o f 
Medicine, Cardiff, U.K.
Dr. Celine Gelinas, University o f 
Medicine and Dentistiy of New 
Jersey, New Jersey. U.S.A.
Dr. Brendan D'Souza, Laboratory 
for molecular and cellular biology. 
Dublin City University,
Glasnevin, Dublin 9.
PSG5EBNA2 (pPDL151) expresses 
the wild type B95-8 EBNA2 gene 
which has been cloned into pSG5 
(Stratagene). The
pSG5EBNA2WW323SR plasmid is 
identical to the pSG5EBNA2 vector 
except that EBNA2 has had two 
tryptophan residues mutated to a 
serine and arginine residues at 
positions 323 and 324 respectively. 
Thus pSG5EBNA2WW323SR does 
not bind CBF1. (Ling et al., 1993) 
pSG5 LMP-1 is an LMP-1 
expression plasmid in which the 
LMP-1 gene from the B95.8 virus 
was cloned in front of the SV40 
promoter contained in pSG5 
(Stratagene).
p-1374/+81Bfl-l CAT contains the 
region -1374 to +81 of the human 
b fl-1 gene cloned in the promoter 
less vector, pCAT-basic, expressing 
a CAT reporter gene, p -1240/+81 
Bfl-1 CAT, p-367/+81 Bfl-1 CAT 
and p-129/+81 Bfl-1 CAT contain 
the regions -1240 to +81, -367 to 
+81 and -129 to +81 o f bfl-1 
cloned into pCAT-basic. (Zong et 
a l ,1999)
Consists of the BamHl-Xbal 
fragment of —1374/+81 Bfl-1 CAT 
inserted into the Bam Hl-H indlll 
portion of the pG12 basic vector 
which contains the luciferase 
reporter (D'Souza et al., 2000)
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pcDNA3 HABfl-1
pUCCD21
pGa50-7
pGA981-6
pCMV
pCMV EBNA3 A 
pCMV EBNA3B 
pCMV EBNA3C 
pcDNA3RPMSl
*pSG5Lp (4x W repeats) 
pSG5LpAY2 (4 x W repeats) 
pRSP211
pSG5Lp (2x W 
repeats)pJT125 
pSG5Lp.RRR47/l 13 AAA(2x 
W repeats) pRSP 83
pPHACSl
pEDl
pED4
Dr. G. Chinnadurai, Saint Louis 
University School of Medicine, 
Missouri. U.S.A.
Dr. Bettina Kempkes. Laboratrie 
fur Molekular biologie und Tumur 
genetik. GSF. Munich Germany.
Dr. Bettina Kempkes. Laboratorie 
fiir Molekular biologie und Tumur 
genetik. GSF. Munich Germany.
Dr Celine Gelinas University of 
Medicine and Dentistry of New 
Jersey, New Jersey. U.S.A.
Expresses Bfl-1 protein tagged to 
the influenza virus HA epitope 
(D'Sa-Eipper et al, 1996).
Contains a 1.6Kb portion of the 
CD21 cDNA inserted into the 
multiple cloning site of pUC19 
(Weiss et a l, 1986; Strobl et a l ,
2000)
The pGa981-16 reporter construct 
was generated using a 50-bp 
oligonucleotide harboring both 
RBP-J binding sites of the EBV 
TPJ promoter, which then was 
ligated as a hexamer into plasmid 
pGa50-7 (Minoguchi et al, 1997).
Contains the EBNA3A/3B/3C 
cDNA inserted into the pCMV 
vector (Staratagene). (Le Roux et 
al, 1994)
Dr. Paul J. Farrell. Ludwig 
Institute For Cancer Research, 
Imperial College School of 
Medicine, London.
* Professor Elliot Kieff. 
Department of microbiology and 
molecular genetics, Harvard 
Medical School, Massachusetts. 
Dr. Paul Ling, Department of 
Molecular Virology and 
Microbiology, Baylor College of 
Medicine. Baylor Plaza, Houston, 
Texas.
Contains the full length RPMS1 
cDNA ORF cloned into the 
pcDNA3HA vector (Invitrogen) 
(Smith et al, 2000).
pSG5Lp expresses wild type 
EBNA-Lp containing 4W repeats. 
PRSP is a non functional mutant of 
pSG5Lp, which also contains 4 W 
repeats, however the Y2 region of 
Lp has been deleted. This 
expression plasmid is also known 
as pRSP2111. pSG5Lp containing 
only two W repeats is also known 
as pJT125 and the non functional 
partner for this pRSP83 also 
consists of the EBNA-Lp isoform 
with 2 W repeats however site 
directed mutagenesis changed three 
serine residues in each of the W2 
repeats to alanine residues. All the 
EBNA-Lp expression plasmids are 
cloned into the pSG5 vector 
(Stratagene) (Harada and Kieff, 
1997; Peng et al, 2000).
Dr. Bettina Kempkes. Laboratorie EDI expresses NotchlC. PED4 
fur Molekular Biologie und expresses NotchlC without its
Tumorgenetik GSF, Munich, RAM domain rendering it unable to
Germany. interact with CBF1. pPHACSl is
the HA tagged vector into which 
NotchlC and NotchlC delta Ram 
were c l o n e d ___________
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p J T lll Dr. Paul Ling, Department of (pJT ll 1) Human NotchllC cDNA
pJT112 Molecular Virology and
with 3’ terminal Flag epitope.
Microbiology, Baylor College of EcoRI-Bgin fragment cloned into
*pGK3puro Medicine. Baylor Plaza, Houston, EcoRI-Bgin site of pSG5.
Texas. PJT112Human Notch2IC cDNA 
with 3’ Flag epitope. EcoRI-BamHI 
fragment cloned into EcoRI-Bglll 
site of pSG5. (Gordadze et al.y 
2001).
pCEP4 Dr. Hiroshi Sato, Department of The cDNA sequence encoding Ets-
pCEP4-EtsDN Molecular Virology and
DN, which lacks transcription
Oncology, Cancer Research activation domain and corresponds
Institute, Kanazawa University to amino acids residues 306 ± 441,
Japan. was obtained by PCR amplification 
o f human Ets-1 cDNA. The cDNa 
fragment thus obtained was inserted 
behind the ATG start codon 
introduced into pCEP4 expression 
plasmid, which contains 
hygromycin resistant gene 
(Invitrogen) (Kim et al., 2000).
2.1.5 Oligonucleotides 
MWG Biotech Ltd.
Oligo for introducing the CBF1 Mutation in the bfl-1 promoter (For use with Altered 
sites mutagenesis kit: Promega)
-1374/+81MCBF1
5’-CCTTGTAGATTCGTGGTTCTAGAGTGAAATGGTACAACCC-3’
(Ph o s p h o r y la te d )
Oligos for introducing the Etsl/PU. 1 Mutations in the bfl-1 promoter (For use with the 
XL Quickchange site Directed Mutagenesis kit: Stratagene)
-213 Fwd
5’-GGATTCTAATTTCTCCACCTGCAGCATTTAAGACTTGCAAAGCTG-3’
-213 Rev
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5 ’ -C AGCTTTGC AAGTCTT AAATGCT GC AGGT GGAGAAATT AG AATCC-3 ’
-177Fwd
5’-GCAAAGCTGAATTAA TCACAGGCTGCAGAAGTGGCTTCTCTG-3’ 
-177REV
5’- CAGAGAAGCCACTTCTGCAGCCTGTGATTAATTCAGCTTTGC-3’ 
-146Fwd
5 ’-GGAAGTGGCTTCTCTGAAAC ATCT GC AGCTTTC AC ATTTT-3 ’ 
-146REV
5 ’ -AAAATGTGAAAGCTGC AGATGTTTCAGAGAAGCCACTTCC-3 ’ 
Oligonucleotides used in the EMSA Analyses.
Cp [Ling, 1994]
5’ -GATCTGGTGTAAACACGCCGTGGGAAAAAATTTATG-3 ’ (TOP) 
5’-GATCCATAAATTTTTTCCCACGGCGTGTTTACACCA-3’ (BOTTOM) 
Bflp
5’-GATCCCATTTCACATTCCCACCAGCAATCTACAAGG-3’ (TOP) 
5’-GATCCCTTGTAGATTGCTGGTGGGAATGTGAAATGG-3’ (BOTTOM)
2.1.6 C o m m e r c ia l  K it s  a n d  r e s t r ic t io n  E n z y m e s
Restriction enzymes Roche Biochemicals and
Random Priming kit 
Sp6 DNA Polymerase 
BCA Protein assay kit 
Qiagen Tip-100
In Vitro Transcription kit
RPAkit
New England Biolabs
Pharmingen
Boehringer Mannheim
Boehringer Mannheim
Pierce
Qiagen
Pharmingen
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Wizard PCR Preps DNA purification system Promega
Altered sites II In Vitro Mutagenesis System Promega
Quickchange XL, Site Directed Mutagenesis kit Stratagene 
Luciferase Reporter Reagents Promega
ECL (Chemiluminescent reagent) Pierce
2.2 CHEMICAL MATERIALS
Protein prestamed markers 
DNA Markers
2-log DNA Ladder 
1Kb Ladder 
oc32P labeled UTP (3000Ci/mol) 
a 32P labeled dCTP (3000Ci/mol) 
dNTPs 
Rnase A 
Poly (dl-dC)
MicroSpm™ G-25 columns
Marvel
Chloroform
Isopropanol
Sigma Colourburst 
NEB
Invitrogen
New England Nuclear 
New England Nuclear 
Pharmacia Biotech 
Pharmacia Biotech 
Pharmacia Biotech 
Pharmacia Biotech 
Premier Beverages 
BDH 
BDH
Sigma-Aldrich-Fluka Chemical Co..
Urea, Dithothreitol, Coomassie blue R, BCIP/NBT, Tetracycline, Liquid Phenol, 
Nitocellulose, Ampicillin, Potassium acetate, Tween-20, BSA, Sodium azide, Sigmacote, 
Ammonium phosphate, Mineral oil, a-Thiol-glycerol, PMSF, MOPS, BCS K coh tRNA, 
Aprotinm, Formaldehyde, Micophenolic acid, BCS, DEAE-dextran, okadaic acid 
Rhubidium chloride
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Merck:
Bone acid, Ammonium persulphate, Sodium acetate, Magnesium chloride, Glucose, 
Sodium chlonde, Potassium chloride, Sodium hydroxide, Sodium dodecylsulphate, 
Calcium chlonde, Glycine, Methanol
BDH*
TEMED, Bromophenol blue, Potassium dihydrogen phosphate, Potassium hydrogen 
phosphate, Sodium phosphate, Glycerol, Tns (hydroxymethyl) methylamine, EDTA, 
Magnesium sulphate, Ethidium bromide, Isoamyl alcohol, Hydrochloric acid, Acetic 
acid, Methanol, Isopropanol, Nondent P40, Sucrose, Paraformaldehyde
Boehnnger Mannheim:
Agarose, Low melt agarose, IPTG, Hygromycin B, Geneticin (G418), Leupeptm 
Oxoid-
Agar technical, Bacto-Tryptone, Yeast extract 
KODAK:
X-ray film, X-ray film developer, X-ray film fixer
National diagnostics:
Acrylagel, Bis-acrylagel, Accugel
Gibco-BRL:
RPMI 1640, DMEM-H, Trypsin EDTA, Fetal calf serum, Penicillin, Streptomycin, L- 
Glutamine, Hepes, Sodium Pyruvate, 1Kb DNA ladder
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2.3 DNA MANIPULATION
2.3.1 STORAGE OF DNA SAMPLES
DNA samples were stored in TE buffer pH 8 0 at 4°C EDTA was used to chelate heavy 
metal ions that are needed for DNase activity while storage at pH 8 0 minimizes 
deamidation DNA was also stored in sterile distilled H20  ((ftfcO)
2 3.2 E q u il ib r a t io n  o f  P h e n o l
Before use, phenol was equilibrated to pH 8 0 with TnsCI pH 8 0 as DNA partitions into 
the organic phase at <pH 7 8 Solid phenol was melted at 68°C, hydroxyquinohne was 
added to a final concentration of 0 1% (w/v) (acts as an antioxidant, a chelator of metal 
ions, and an RNase inhibitor) An equal volume of buffer (0 5 M TnsCI pH 8) was added 
to the liquified phenol and stirred for 15 mins The two phases were then allowed to 
equilibrate and as much as possible of the upper aqueous phase was removed The 
extraction was repeated using equal volumes of 0 1 M TnsCI pH 8 until the pH of the 
phenol was > 7 8  An equal volume of TnsCI pH 7 and 0 2% (w/v) (3-mercapthoethanol 
were added to the phenol, which was then stored at -20°C m the dark
2 3 3 PHENOL/CHLOROFORM EXTRACTION AND ETHANOL PRECIPITATION
Phenol/chloroform extraction and ethanol precipitation was earned out to concentrate 
nucleic acid samples or change the buffers in which a sample was dissolved An equal 
volume of phenol/chloroform/isoamyl alcohol (25 24 1) was added to the DNA solution, 
mixed by vortexing and centnfuged for 10 min at 13,000 x g The upper aqueous phase 
was removed, taking care not to take any matenal from the interphase, this was placed in 
a stenle microfuge tube An equal volume of chloroform/isoamyl alcohol (24 1) was 
added to the aqueous phase, vortexed as before and centnfuged for 5 min at 13,000 x g 
Again the upper aqueous phase was removed to a fresh tube One tenth volume of 3 M 
sodium acetate (pH 5 2) was added to the solution of DNA, mixed and then 2 volumes of 
100% (v/v) ethanol This mixture was vortexed and incubated at room temperatures for 5
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min The DNA samples were then centrifuged for 30 min at 12,000 x g at 4°C, the 
supernatant was removed and pellets were washed with 1 ml 70% (v/v) ethanol to remove 
excess salts The tube was centrifuged for 5 min at 10,000 x g, the supernatant was 
removed and pellets were air dried for approximately 10 min Pellets were resuspended 
in an appropriate volume of stenie Tns-EDTA (TE) (pH 8 0) or cffifcO
2 3.4 RESTRICTION DIGESTION OF DNA
Restriction enzymes bind specifically to and cleave double-stranded DNA at specific 
sites within or adjacent to a particular sequence known as the recognition site The 
restriction enzymes used were supplied with incubation buffers at a concentration of 10X 
(working concentration IX) DNA was digested with restriction endonucleases for 
identification purposes or to linearise or cut fragments from a plasmid DNA digests 
were performed by adding
200 ng -  1 jig of DNA (Final concentration of <300 ng/^1) 
lfiil of enzyme/(ig of DNA solution (10 U)
10 X buffer to a final concentration of IX 
dH20  to the final volume required
The reaction was gently mixed, centrifuged, then incubated for 2 hr at the optimum 
enzyme temperature (between 37°C and 50°C, usually 37°C)
2.3.5 REPAIR OF DNA TERMINI
The majority of restriction endonucleases digest DNA leaving either a 5’ or a 3’ 
overhang When DNA is ligated together these ends must be compatible, if they are not 
the ends must be repaired and a blunt ended ligation earned out This was achieved using 
the Klenow fragment of Ecoh DNA polymerase I The DNA was resuspended at a 
concentration of 50 Mg/ml in IX Eco Pol buffer (supplied with the Klenow), dNTPs were 
added to a final concentration of 33 jjM each, 1 |il of Klenow was added and the reaction 
was placed at 25°C for 15 min The enzyme was inactivated by heating to 70°C for 10
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min This DNA was then purified by phenol/chloroform extraction and ethanol 
precipitation (see Section 2 3 3)
2.3 6 PREPARATION OF COMPETENT CELLS
A modified Rhubidium chloride (RbCk) method was employed to prepare competent 
cells This rubidium chloride protocol gives better transformation efficiencies than the 
CaC12 procedure for most strains The procedure is an adaptation of one descnbed by 
Hanahan et al 1985 (Altered Sites Mutagenesis Kit Promega) An Ecoh strain was 
streaked from a glycerol stock on to an LB agar plate and incubated at 37°C overnight 
An isolated colony was then picked using a sterile inoculating loop and used to inoculate 
5 ml of LB (appendix A) broth This culture was incubated m a shaking incubator at 200 
rpm overnight 37°C The resulting culture (2 5 ml) was then used to inoculate 250 ml of 
sterile Lb supplemented with 20mM MgS04 and incubated in a 1L flask at 37°C until the 
O D of the culture at 640 mm was between 0 4 and 0 8 (approximately 4-5 hours) The 
cells were then transferred to two sterile 250 ml centrifuge tubes and pelleted by 
centrifugation at 4,500 x g, 4°C for 5 mm The resulting pellets were resuspended in 0 4 
original volume ice cold TFB1 (Appendix) (100ml for 250ml culture- 50ml/centnfuge 
tube) and the two pellets combined Cells were kept on ice for all subsequent steps and 
pipettes tubes and flasks were chilled The resuspendend cells were then incubated on ice 
at 4°C for 5 minutes and pelleted by centrifugation at 4500x g , 4°C for 5 minutes Cells 
were then gently resuspended in 1/25 of the original volume of ice-cold TFB2 (For 250ml 
subculture use 10ml) Cells were then incubated on ice for lhr, aliquoted at lOOul/tube 
for storage at -70°C Prior to storage the aliquoted cells were snap frozen m a dry 
ice/isopropanol bath JM109 and DH5a competent cells prepared by this method are 
stable for 1 year ESI301 mutS competent cells generally are stable for 3-6 months
2 3.7 TRANSFORMATIONS
Two hundred microhters of competent cells were placed in a pre-chilled microcentifiige 
tube containing lOjil The contents were mixed gently and incubated on ice for 30 min,
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during which time an aliquot of SOC (appendix A) was pre-heated at 42°C After 30 mm 
on ice the cells were heat-pulsed at 42°C for 90 s followed by incubation on ice for a 
future 2 mm One mililiter of preheated SOC was then added to the cells and incubated at 
37°C in a shaking incubator for 1 hr 10 min The cells were concentrated by 
centrifugation following which -800 \i\ o f supernatant was removed and discarded The 
cells were resuspended in the remaining supernatant and plated out with the appropriate 
controls on LB plates containing ampicilhn (125ug/ml) or tetracycline (12 5ug/ml) and 
incubated overnight at 37°C If the cells are transformed they become 
ampicilhn/tetracycline resistant thus only transformed cells will yield colonies These 
were used to prepare broth cultures by inoculating 5 ml of LB containing ampicilhn 
(125ug/ml) or tetracycline(10ug/ml), and incubated overnight at 37°C and DNA 
minipreparations were earned out as desenbed in section 2 3 10
2.3.7.1 Transforming XL-1 0-Gold Ultracompetent Cells
XL-10-Gold ultracompetent cells were provided with the QuickChange XL Site Directed 
Mutagenesis kit™(Stratagene) The XL-10-Gold cells were thawed on ice and 45ul of 
ultracompetent cells per transformation were aliquoted into pre-chilled eppendorfs Two 
microlitres of p-ME mix provided with the kit was added to each of the 45ul aliquots of 
cells and the mixture was incubated on ice for 10 minutes with gentle mixing every 2 
minutes Two microlitres of DpnI-treated DNA from each sample reaction was then 
added to the eppendorfs containing the cell-p-ME mixture and incubated on ice for 30 
minutes after gentle mixing The transformation mixes were then heat pulsed at 42°C for 
30 seconds in a water bath and incubated on ice for 2 minutes Next, 500ul of preheated 
(42°C) NZY4 broth (Appendix) was added to each eppendorf and incubated at 37°C for 1 
hour with constant agitation at 225 rpm Two hundred and fifty microlitres of the 
transformation reaction was then plated on two plates containing the appropnate 
antibiotic as well as X-gal (80ug/ml) and IPTG(20mM)
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2.3.8 SMALL SCALE PREPARATION OF PLASMID DNA (MINIPREP)
This is a modification of the method of Bimboim and Doly, (1979) and Ish-Horowicz and 
Burke (1981) A single bacterial colony was used to inoculate 5 mil o f LB medium (with 
appropriate antibiotic) and incubated overnight at 37°C An aliquot (15 ml) of this 
culture was added to a sterile microfuge tube and centrifuged for 30 s at room 
temperature, the remainder was stored at 4°C The medium was removed from the tube, 
leaving the pellet as dry as possible The pellet was resuspended thoroughly in 100 ¡x\ of 
solution I by vigorous vortexmg To this 200 of freshly prepared solution II was 
added, the tube contents were mixed by inverting the tube rapidly a number of times 
Ice-cold solution HI (150 1^) was added and the tubes were vortexed gently for 10 s
The lysate was centrifuged for 5 min at 12,000 x g, the supernatant was transferred to a 
fresh tube, taking care not to carry over any of the white precipitate An equal volume of  
phenol/chloroform/isoamyl alcohol (25 24 1) was added, mixed by vortexmg and 
centrifuged for 5 min at 12,000 x g The upper aqueous phase was removed to a fresh 
table, to which 2 volumes of 100% (v/v) ethanol were added, the solution was vortexed 
and centrifuged for 5 min at 12,000 x g The supernatant was discarded, the pellet was 
washed with 1 ml 70% (v/v) ethanol, centrifuged as before and the supernatant was 
removed The pellet was air-dned, then resuspended in 50 \i\ o f TE (pH 8 0), 1 \x\ of 
Dnase-free Rnase A (20 |ig/ml) was also added, vortexed, incubated at 37°C for 1 hr then 
stored at 4°C Glycerol stocks of all bacterial cultures were prepared at this stage by the 
addition of 0 5 ml o f a 50% (v/v) glycerol solution to 0 5 ml o f the overnight bacterial 
culture of interest and storing at -80°C
2.3.9 QIAGEN™ PLASMID DNA PURIFICATION PROTOCOL
Plasmid DNA was purified using the QIAGEN-tip 100 solution system from Promega 
All buffers used are described in appendix A A glycerol stock of the bacteria of interest 
was streaked out on LB ampicillin/tetracychne agar and incubated overnight at 37°C, an 
isolated colony from this plate was used to inoculate a 5 ml LB ampicillin/tetracychne
83
starter culture and incubated m a shaking incubator at (-300rpm) 37°C for 8 hrs One 
millilitre of the starter culture was used to inoculated 25 ml of LB (containing the 
appropriate antibiotic) in a 250 ml sterile flask and incubated overnight in a shaking 
incubator at 37°C The 0  D of the culture must read 1-1 5 at 600 m m The following 
centrifugation steps were earned out using a JA-20 rotor in a Beckman centnfuge The 
bacteria culture was transferred to a centnfuge tube and centnfuged by spinning at 6,000 
x g for 15 min at 4°C The supernatant was removed and the pellet was dned by 
inverting the tube on tissue paper and allowing the supernatant to dram off The bactenal 
pellet was resuspended completely in 4 ml of Buffer PI containing RnaseA (100|ig/ml), 4 
ml of freshly prepared Buffer P2 was added and incubated at room temperature for 5 mm 
Following incubation, 10 ml o f prechilled Buffer P3 was added, mixed gently by 
inverting the tube 5-6 times then incubated on ice for 20 mm The mixture was then 
centnfuged for 1 hr at 20,000 x g at 4°C
The Qiagen-tip 100 was equilibrated by applying 4 ml of QBT buffer and allowing the 
column to empty by gravity The column does not dry out at this stage as the flow of 
buffer will stop when the buffer reaches the upper filter After the centnfugation step the 
supernatant was removed immediately from the tube without disturbing the pelleted 
matenal and applied to the column by filtenng through 1MM filter paper The QIAGEN- 
tip was washed with 2 x 10 ml of Buffer QC DNA was then eluted with 5 ml of Buffer 
QF DNA as precipitated by adding 0 7 volumes of room-temperature isopropanol and 
centnfuged immediately at 15,000 x g for 30 min at 4°C and the supernatant was 
carefully removed The resulting pellet was washed with 70% (v/v) ethanol, allowed to 
air dry for 5 min and re-dissolved in a suitable volume of TE or (fflfeO DNA was then 
quantified by spectrophotometnc analysis as desenbed in section 2 3 13
2.3.10 AGAROSE GEL ELECTROPHORESIS OF DNA
Electrophoresis through agarose gel is the standard method used to separate, identify, and 
punfy DNA fragments The technique is simple, rapid to perform and can be used for the 
isolation of DNA fragments
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An appropriate quantity of agarose or low melt agarose was added to 100 ml IX 
TBE/TAE buffer The amount of agarose depends on the percentage agarose required 
This was decided in relation to the size o f the DNA fragments being separated The 
mixture was boiled to dissolve, when cooled sufficiently (~60°C) the gel was cast into the 
Hybaid horizontal gel electrophoresis system, the comb was inserted The gel was 
allowed to set before filling the chamber with IX TBE/TAE, the comb was then 
removed To a 20 fxl sample, 4 |xl o f DNA sample buffer was added and loaded into the 
wells made by the comb DNA sample buffer was also added at IX concentration to 500 
ng o f a 1Kb DNA ladder which was loaded as a size marker The gel was run at constant 
voltage (5 V/cm) for 1-2 hr When complete, the gel was stained in ethidium bromide 
(0 5 mg/ml) for 30 mm, placed m distilled water to destain for 15 mm and viewed under 
UV illumination
2 3.11 ISOLATION OF DNA FROM AGAROSE GELS
Low melting point agarose were prepared in IX TAE buffer (gel isolation is not earned 
out m TBE buffer as borate ions are difficult to remove from the resultant DNA solution) 
Ethidium bromide was added to the samples before electrophoresis so as to liquefy 
manipulations with the fragile low melting point agarose gels After electrophoresis, the 
gels were viewed under 70% UV illumination The time of exposure to UB light was 
kept to a minimum, as overexposure to UV would cause damage to the DNA The DNA 
band of interest was excised from the gel using a clean scalpel, excess agarose was cut 
away to liquefy the size of the gel which was then placed in a stenle microfiige tube
2.3.12 PURIFICATION OF DNA FROM LOW MELT AGAROSE
All DNA fragments of interest were punfied from agarose using the Wizard PCR Preps 
DNA Punfication System from Promega as follows, the agarose gel slice (300 mg) was 
placed in a stenle microcentifuge tube at 70°C until the agarose had melted completely
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One mihhtre of the resin provided was added to the liquefied solution and mixed gently 
but thoroughly for 20 s (not vortexed)
A 2 ml syringe (plunger removed) was attached to the Wizard mmicolumn the 
DNA/agarose/resm mix was added to the synnge, the plunger was replaced and the mix 
was pushed gently through the column The synnge was detached and the plunger 
removed again, then it was reattached and the column was washed with 2 ml of 80% 
(v/v) isopropanol The column was then spun at 10,000 x g for 2 mm to dry the resin 
The DNA was eluted by adding 50 jul of TE or dH20  to the mmicolumn and allowed to 
stand for 1 min at room temperature and centrifuged again at 10,000 x g for 20 s The 
punfied DNA was stored at 4°C or at ~20°C
2.3.13 SPECTROPHOTOMETRIC ANALYSIS OF NUCLEIC ACIDS
DNA and RNA concentration was determined by measunng the absorbance at 260 nm, 
which is the wavelength at which nucleic acids absorb maximally (x max) A 50 jig/ml 
preparation of pure DNA has an absorbance of 1 unit at 260 nm while 40 jig/ml o f pure 
RNA also has an absorbance reading o f 1 at this wavelength The punty of an RNA or
DNA preparation was determined by reading absorbance at 260 nm, the k max for nucleic
j
acids and at 280 nm, the x max for proteins and obtaining the ratio for these absorbances 
Pure DNA and RNA have A26o/A28o ratios of 1 8 and 2 0 respectively Lower ratios 
indicate the presence of protein while higher ratios often indicate residues of organic 
reagents
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2.314 Site Directed Mutagenesis Reactions.
2.3.14.1 A l t e r e d  S i te s  n  In  V i t r o  M u ta g e n e s is™  r e a c t i o n s  
This kit was used to mutate the putative CBF1 binding site at position -243 to -249 on 
the bfl-1 promoter Initially, the -1374/+81 portion of the bfl-1 promoter was excised 
from the -1374/+81bfl-l CAT vector by Xbal-Hindin restriction with the appropriate 
fragment excised from an agarose gel (Section X above) and purified in the usual 
manner The pAlterl vector was similarly digested and the bfl-1 promoter was ligated 
into pAlter Recombinant clones were selected as white colonies on tetracycline 
(125ug/ml), X-gal IPTG plates (See Results chapter page X and Figure3 24i) The double 
stranded DNA from the recombinant plasmids was purified using Quiagen Tip 100 kit 
(Quiagen) and denatured by alkali denaturation, heat-denaturation does not work for this 
application because the two strands reanneal too quickly The mutagenesis reaction was 
then earned out, this reaction involved annealing the mutagenic oligonucleotide to the 
denatured DNA template while also annealing an ampicillin repair and a tetracycline 
knockout oligonucleotide The mutant strand incorporating these oligonucleotides was 
synthesized with T4 DNA polymerase and the DNA was transformed into the mismatch 
repair-minus E coli strain ES1301mutS, which were selected in liquid medium 
containing ampicillin(100ug/ml) DNA was prepared from this strain using mimprep 
procedure and transformed mto JM109cells Mutants were screened on ampicillin plates 
and again DNA was prepared via the mimprep method and analysed by restnction 
analysis with the Xbal restnction endonuclease The mutated promoter was then excised 
by BamHI-Hindlll restnction and ligated between BgUI and Smal in the multiple clomng 
site ofpGL2~Basic (Figure 3 24i) Again the presence of the mutation was confirmed by 
endonuclease restnction with the Xbal enzyme The same procedures and sub cloning 
were undertaken without mutagemsing the bfl-1 CBF1 site thus a pair of promoter 
constructs were generated, identical except that one no longer contained a CBF1 
consensus sequence and instead contained an extra Xbal site
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2.13.14.2 Alkaline Dénaturation Reaction.
This generates enough DNA for 10 mutagenesis reactions
dsDNA template 0 5pmol X^l (approx 2fig)
2M NaOH, 2mM EDTA 2\il
sterile, deionized water to a final volume of 20^1
This mixture was incubated for 5 minutes at room temperature and 2^1 of 2M ammonium 
acetate (pH 4 6) and 75^1 of 100% ethanol were added This Reaction mixture was then 
incubated -70°C for 30 minutes The DNA was precipitated by centrifugation at top 
speed in a microcentnfuge for 15 minutes The pellet was washed with 200^1 of 70% 
ethanol and pelleted by centrifugation again as before The pellet was then dissolved in 
\00\i\ ofTE buffer (pH 8 0)
2.1314.3 A n n e a l in g  R e a c t i o n  a n d  M u t a n t  S t r a n d  S y n th e s i s
Mutagenesis Reaction (to synthesize -1374/+81 mCBFlbfl-1 Luc)
Alkaline-denatured dsDNA (bfl-lpAlterl) 10|il (0 05pmol)
Repair Oligonucleotide (2 2ng/^l), phosphorylated 1 \i\ (0 25pmol)
Knockout Oligonucleotide (2 2ng/jil), phosphorylated 1 jil (0 25pmol)
mutagenic oligonucleotide, phosphorylated (-1374/+81 mCBFl) Xul (1 25pmol)
Annealing 1 OX Buffer 2 1^
Sterile, deionized water to a final volume of 20|nl
2.13.14.4 C o n tr o l  R e a c t io n  (t o  sy n t h e s iz e -1374/+81 w t b fl - 1 L u c )
Alkaline-denatured dsDNA (bfl-1 pAlter 1)
Repair Oligonucleotide (2 2ng/^l), phosphorylated 
Knockout Oligonucleotide (2 2ng/fil), phosphorylated 
Annealing 1 OX Buffer 
Sterile, deionized water to a final volume of
lOfil (0 05pmol) 
1 \i\ (0 25pmol) 
l i^l (0 25pmol) 
2\x\
20\x\
2 .1314.5  C o n t r o l  R e a c t i o n
Alkaline-denatured nonrecombinant pALTER ® dsDNA IOjaI (0 05pmol)
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Repair Oligonucleotide (2 2ng/pl), phosphorylated 
Knockout Oligonucleotide (2 2ng/jil), phosphorylated 
Annealing 1 OX Buffer 
sterile, deionized water to a final volume of
lfxl (0 25pmol) 
5fxl (1 25pmol)
2\i\
20\il
The annealing reactions were heated to 75°Cfor 5 minutes and allowed to cool slowly to 
room temperature to minimize nonspecific annealing o f the oligonucleotides The 
annealing reactions were then placed on ice and the following components were added in 
the order listed The final volume was 30^1
The reactions were then incubated at 37°C for 90 minutes to perform mutant strand 
synthesis and ligation The mutant plasmid DNA was then transformed (1 Sul of the 
above mixture) into competent ESI301mutS cells, mmiprepped and JM109 competent 
cells were then transformed with the mutant/non mutant plasmid DNA After restriction 
analysis, the mutated/non-mutated promoter was sub cloned back into the pGL2Basic 
luciferase reporter vector
2 3.14.6 Q u ik C h a n g e  XL S i te  D i r e c t e d  M u ta g e n e s is™  R e a c t io n s  
This kit was used to introduce mutations at putative Etsl and PU 1 binding sites on the 
bfl-1 promoter (Positions o f these sites are shown Chapter3, Figure 3 22A) A control 
reaction was set up as indicated below to test for the efficiency o f transformation and 
mutant plasmid generation using blue white screening for the pWhitescnpt plasmid The 
pWhitescnpt contains a stop codon (TAA) at the position where a glutamine codon 
(CAA) would normally appear in the P-galactosidase gene of the pBluescnptllSK(-) 
phagemid XL-10-Gold cells transformed with this plasmid appear white on LB Amp
Sterile, deionized water 
Synthesis 10X Buffer 
T4 DNA Polymerase 
T4 DNA Ligase
5|il
3|il
lfil (5-1 Ou) 
Ijd (l-3u)
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plates, containing IPTG and X-gal because P-galactosidase, activity has been destroyed, 
however the oligonucleotide control pnmers create a point mutation that reverts the T 
residue m the stop codon to the C residue of the glutamine codon thus reinstating p- 
galactosidase activity, therefore colonies which have bacteria expressing the functional P- 
galactosidase gene appear blue on the IPTG, X-gal plates
2.3.1.4.7 Control Reaction.
1 OX reaction buffer Sul
pWhitescnpt 4 5Kb control plasmid(5ng/ul) 2ul (10ng)
Oligonucleotide control primer #1 (34-mer lOOng/ul) 1 25ul (125ng) of
Oigonucleotide control primer #2 (34-mer lOOng/ul) 1 25ul (125ng)
dNTP mix lul
QuickSolution 3ul
Double-distilled water to a final volume of 50ul 36 Sul
Then lul of PfuTurbo DNA polymerase (2 5U/ul) was added
2.3 14.8 Sample Reaction
1 OX reaction buffer Sul
dsDNA template (-367/+81 bfl-1 Luc) Xul (10ng)
oligonucleotide primer #1 ( -213 Fwd/-177Fwd/-146Fwd) Xul (125ng) 
oligonucleotide primer #2 (-213Rev/-177Rev/-146Rev) Xul (125ng)
dNTP mix lul
QuickSolution 3ul
ddH20 to a final volume of SOul
Then lul of PfuTurbo DNA polymerase(2 5U/ul) was added
The control reaction and sample reactions were then placed in a Hybaid Ommgene 
thermocycler and cycled according to the table below in order to denature the plasmid, 
anneal the oligonucleotide pnmers containing the desired mutation and extend and 
incorporate the mutagenic pnmers to produce mutated plasmids containing mcked 
circular strands
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Table 2.3. Thermocycling Conditions for generating Bfl-1 Mutation
Segment Cycles Temperature Time
1 1 95°C 1 minute
2 18 95°C 50 seconds
60°C 50 seconds
68°C 2 minutes/kb of plasmid length*
3 1 68°C 7 minutes
♦Since the template DNA (-367/+81 bfl-1 Luc) is 5.8Kb, the time allowed here was 11 minutes.
Following the temperature cycling, the reaction tubes were placed on ice for 2 minutes to 
allow the temperature to cool to 37°C. One microlitre of the restriction enzyme Dpnl 
(lOU/ul) was added to each reaction to digest non-mutated parental supercoiled DNA. 
The reactions were then gently mixed and spun down by quick centrifugation for 1 
minute. The reactions were then placed in a water bath at 37°C for 1 hour. XL-10-Gold 
ultracompetent cells were then transformed with the various reaction mixtures. The 
number of blue colonies on the control plates were then used to assess a suitable number 
of colonies to pick for analysis from the sample reaction plates which contained 
lOOug/ml ampicillin. Since the XL-10-Gold cells are Tetracycline resistant but ampicillin 
sensitive, in theory the only colonies on the ampicillin plates should contain the mutated 
plasmid DNA. The presence of the mutated plasmid DNA was then verified by restriction 
digestion of purified DNA using the PstI endonuclease, as an additional PstI site had been 
introduced in each of the mutated plasmids. (See Results Figure 3,42).
2.4 C e l l  C u l t u r e  M e th o d s
All cell culture techniques were performed in a sterile environment using a Holten 
laminar air flow cabinet. Cells were visualised with an Olympus CK2 inverted phase 
contrast microscope.
2.4.1 C u l t u r e  o f  C e l l s  in  S u sp en sio n
All media compositions and media supplements are given in Appendix A. The cell lines 
DG75, DG75 tTA EBNA2, DG75 tTA LMP1, Mutu 1, Mutu 3 c95, Mutu 3 LMP1-, X50-
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7, BL41, I ARC 171, IARC 290B, Ag876 ID, Jurkat, BL41ER/E2 (K3), BL41P3HR1- 
ER/E2 (9A) and BL41P3HR1 -ER/mNotchIC were maintained in supplemented RPMI 
1640 Additional supplements were added to some culture media (see section 2 4 3) 
Cultures were seeded at a density of 2 x 105 to 5 x 105 cells per ml m 25 cm2 flasks and 
expanded m 75 cm2 flasks Cells were sub-cultured two or three times per week by 
harvesting into a sterile centnfuge tube and centrifuge at 1000 x g for 5 mm at room 
temperature The cell pellet was resuspended gently m an appropriate volume of fresh 
media and replaced into the tissue culture flask All cell lines were incubated m a humid 
5% CO2 atmosphere at 37°C m a Heraeus cell culture incubator
2.4*2 C u l t u r e  o f  a d h e r e n t  c e l l s
C33A VSMC were maintained in high glucose DMEM supplemented with 10% (v/v) 
FCS, penicillin (100 units/ml) and streptomycin (1 |ng/ml) VSMC were maintained in 
Cultures were seeded into 25 cm2 and 75 cm2 tissue culture flasks As the cells were 
strongly adherent trypsimsation was required for harvesting prior to sub-cultunng For 
trypmisation the medium was decanted and the cells were washed with 2 ml of sterile IX 
PBS to remove any residual FCS which contains a trypsin-inhibitor activity (012 -  
macroglobulm) Two millilitres of IX trypsin EDTA solution was placed in each flask 
and the flasks incubated at 37°C for 5 min or until all the cells could be visualized as 
having detached form the flask surface The cell suspension was then decanted into a 
sterile centnfuge tube containing 5 ml of stenle supplemented media (FCS inhibits 
trypsin) and centnfuged at 1000 x g for 5 mm Cells were resuspended m supplemented 
medium at 2 to 5 x 105 cells/ml, using 5 ml per 25 cm2 flask and 15 ml per 75 cm2 flask 
Cells were then incubated as in section 2 4 1
2 4.3 M e d ia  S u p p le m e n ts
Supplements were added to the growth media of certain cell lines to (a) improve cellular 
proliferation or (b) to select cells containing transfected plasmids L-cysteme is required 
for the survival and proliferation of most group 1 BL cell lines However, L-cysteme is
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rapidly oxidated under normal culture conditions To improve proliferation of the group 
1 Burkitt lymphoma cell line Mutu 1 a-thioglycerol was added to growth media as a 
stable substitute for L-cysteine The a-thioglycerol was dissolved in bathocupnne 
disulfonic acid (BCS) which effectively prevents autoxindation o f thiols in liquid 
solutions Sodium pyruvate was also added to protect against H20 2, which may be 
generated HEPES was added to maintain an alkaline pH of 7 4 The cell lines DG75 
tTA EBNA2 and DG75 tTA LMP1 are tetracycline responsive cell lines m which the 
gene of interest is cloned downstream if a promoter containing a binding site for a hybrid 
tetracycline regulated trans-activator (tTA) which is constitutively expressed from a 
second co-transfected plasmid Tetracycline binds the tTA and prevents it binding to the 
promoter, which remains silent, but upon removal of tetracycline from the growth 
medium the tTA binds the promoter sequence and activates transcription Theses cell 
lines were maintained in supplemented RPMI containing 1 jig/ml of tetracycline Every 
three weeks the transfected cells were reselected by the addition of 500 jig/ml of 
hygromycin to DG75 tTA 500 pig/ml o f hygromycm and 1,000 |ig/ml of geneticm (G418) 
to DG75 tTA EBNA 2 and 800 |ig/ml of hygromycin and 2,000 jig/ml of geneticm 
(G418) to DG75 tTA LMPI
The stably transfected cell lines BL41ER/E2 (K3), BL41P3HR1ER/E2 (9A) and 
BL41P3HR1 -ER/mNotchIC (C131) were maintained in supplemented RPMI 1640 these 
cell lines were maintained under permanent selection with 800ug/ml and 1200ug/ml of  
G418 in the K3 and 9A media respectively Hygromycin at a final concentration of  
150ug/ml was added to the C131 media
2.4.4 C ell  Counts
Cell counts were performed using an improved Neubauer haemocytometer slide Trypan 
blue exclusion dye was routinely used to determine cell viability Ten microlitres of 
trypan blue was added to 90 pd of a cell suspension and mixed A sample of this mixture 
was added to the counting chamber of the haemocytometer and cells were visualized by 
light microscopy Viable cells excluded the dye and remained clear while dead cells
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stained blue Cell numbers were ascertained by multiplying the average cell count by the 
dilution factor and again by the volume o f the haemocytometer
2 4.5 C e l l  Sto r a g e  and  R e c o v e r y
Cell stocks were prepared for long term storage as follows Suspension cells 1 x 107 cells 
in exponential phase were pelleted and resuspended in 800 \i\ o f supplemented RPMI to 
which 100 [il o f FCS was added, then placed on ice for 10 min DMSO was added to a 
final concentration o f 10% (v/v), mixed gently and transferred to a stenie cryotube 
Adherent cells one confluent 75 cm2 flask o f adherent cells was used per cell stock 
Adherent cells were washed with IX PBS followed by trypsmization and resuspension in 
900 |il of FCS and 100 \x\ of DMSO The cells were mixed gently and added to a stenie 
cryotube The cryotubes were slowly lowered into the gas phase o f liquid nitrogen and 
immersed in liquid nitrogen in a cryofreezer (Cooper Cryoservices Ltd) Cells were 
recovered form liquid nitrogen by thawing rapidly at 37°C and transferring to a stenie 
centrifuge tube containing 5 ml o f prewarmed supplemented media The cells were 
centrifuged at 1000 x g for 5 min, the pellet was resuspended in 5-10 ml of fresh 
supplemented medium, transferred to a culture flask and incubated at 30°C in 5% CO2
2.4.6 Ind u ctio n  o f  G e n e  E x pr essio n  u sin g  t h e  T e tr a c y c l in e-R eg u la ted  
Sy ste m
After counting cells, an appropnate volume was pelleted at 1,000 x g for 5 mm and 
washed three times in stenie PBS Cells were then incubated m supplemented RPMI 
medium for 1 h at 37°C Cells were then washed again once in stenie PBS and seeded at 
approximately 2 x 105 cells per ml in the presence or absence of tetracycline Umnduced 
cells (Tet+) were washed as per induced cells (Tet -) but were constantly maintained in 
the presence of tetracycline
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2.4.7 A c t iv a t io n  o f EBNA2 o r  m N o t c h IC  in  t h e  K 3 ,9 A  and  C l 31 C e l l  L ines
In the case o f the Estrogen responsive K3, 9A and C131 cell lines, the EBNA2 or Notch 
activation domains are fused to the estrogen receptor binding domain such that the 
activity of EBNA2 or NotchIC is dependent on the presence of estrogen In experiments 
where EBNA2 or Notch activation was required, cells were washed twice m PBS and 
placed m fresh supplemented RPMI with the appropriate antibiotics for selection, 
estrogen (p estradiol) was then added to a final concentration of luM
2.4.8 T ra n sien t  T ra n sfec tio n s
Transient transfection o f cells was performed by the DEAE-dextran protocol, by 
electroporation or by the Lipofectamine method In all cases, cells were seeded at a 
density of 5 x 105 per ml o f medium 24 h prior to transfection Total DNA for 
transfection was normally co-precipitated in 100% ethanol, then washed in 70% ethanol 
and resuspended m a final volume of 30 jil T E pH 7 4 (this pH is very important), using 
the same total quantity of DNA per transfection
2.4.8.1 E lectroporation  o f  B  Lym phocytes
On the day of transfection, cells were centrifuged at 1,000 x g for 5 min, washed once in 
a small (one-fifth) volume of cold complete RPMI medium and resuspended in cold 
complete RPMI medium at a density o f 2 x 107 cells per ml For each transfection, a 60 
mm culture dish with 5 ml complete medium (RPMI 1640/glutamme/10 %FCS) was 
preincubated at 37°C for at least 1 h prior to transfection The DNA to be transfected 
(dissolved in 30 jul T E pH 7 4) was added to the bottom of labeled cuvettes (Biorad, 0 4 
mm) placed on ice 500jli1 of the cell suspension (= 1 x 107 cells) was then dispensed into 
the cuvettes and mixed with the DNA Each cell/DNA mix was then pulsed at either 270 
V m the case o f Mutu I cells or 300 V in the case of IARC 290B and IB4 cells with a 
capacitance of 960jiF (with capacitance extender) in a Biorad electroporator, and the 
cuvettes returned to ice immediately after electroporation Cells must not stay longer 
than 10 mm on ice before being transferred to media Contents of cuvettes were
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transferred to culture dishes using a micropipette and yellow tip, treating the cells gently 
Cuvettes were washed with media from the culture dish, and placed at 37°C m a 5% CO2 
incubator for the required amount of time
2.4.8 2 D EAE-D extran -M e d ia t ed  T ra n sfec tio n
Details of all solutions required for this protocol are given in the Appendix section The 
day before transfection, cells were seeded at 5 x 105 cells/ml After 24 h m culture, cells 
were counted again -  it was essential for cell numbers to have almost doubled before 
beginning the transfection, thus ensuring that cell growth is in logarithmic phase and that 
cells are at their optimum for the uptake of DNA during transfection 1 4 x 107 cells were 
used for each transfection On the day o f transfection, cells were centrifuged at 1,000 x g 
for 5 min, resuspended in sterile TBS and 1 4 x 107 cells dispensed into 25 ml stenlin 
tubes After centrifugation, all o f the supernatant was removed with any traces of TBS 
carefully (without disturbing the cell pellet) removed using a pipette tip The DNA- 
DEAE dextran mixes were prepared in microfuge tubes as follows A total of between 11 
and 16 0 ^g of DNA made up to a volume of 30 |il with TE buffer pH 7 4 was used per 
transfection and 570 ¡il TBS was then added to the DNA m a microfuge tube For any 
transfection set the total amount of DNA was kept constant with any deficiencies made 
up with the corresponding empty vector Then, 600 of 1 mg/ml DEAE dextran 
solution made up in TBS was mixed with the DNA solution and the cell pellet gently 
resuspended in the DNA-DEAE dextran mix The transfection cocktails were incubated 
at room temperature for 30 min (40 min m the case o f Jurkat T cells) with gentle swirling 
every 5-10 mm to allow homogenisation Transfections were terminated by adding 10 ml 
of warm (37°C) complete RPMI medium and the cells pelleted by centrifugation at 
l,000g for 5 min The cells were then washed once more with 10 ml complete medium 
and then transferred in 10 ml o f medium to 25 cm2 cell culture flasks for incubation
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2.4.8 3 Lipofectamineplus™ Mediated Transfection
The day before transfection, cells were trypsinized and counted so that they were 50-90% 
confluent on the day o f transfection At the time of plating and during transfection, no 
antibiotics were added - this helps cell growth and allows transfection without nnsing the 
cells DNA for transfection was diluted into serum free DMEM, mixed, and the PLUS 
Reagent added This pre-complexed DNA mixture was then incubated at room 
temperature (RT) for 15 mm It was important to dilute the DNA into medium and mix 
before adding PLUS Reagent as DNA may precipitate LIPOFECTAMINE Reagent was 
then diluted into serum free medium in a second tube and mixed and this diluted 
LIPOFECTAMINE Reagent was combined with the DNA-plus reagent mixture and 
incubated at room temperature for 15 minutes to allow complexes to form At this point, 
fresh serum free media was placed on the cells The DNA-Plus- LIPOFECTAMINE 
reagent complexes were then added to the cells, mixed gently and incubated at 37°C at 
5% C02 for 3 h After 3hr incubation, the volume of medium was increased to the 
normal volume (2ml) and serum was added to each well to a final concentration of 10% 
Luciferase reporter activity was then measured after 48 hours using the luciferase assay
2.4.9 L u c i f e r a s e  A s s a y
Cells for luciferase assay were normally harvested 24 or 48 h post-transfection Cells 
were pelleted by centrifugation at 1,000 x g for 5 min at room temperature, washed once 
in sterile PBS and then transferred to a microfuge tube in 1 ml of sterile PBS After 
centrifugation at 5,000 x g for 5 min at room temperature, the supernatant was completely 
removed and the cell pellet resuspended in 100 fj,l of Reporter lysis buffer (1 X, 
Luciferase Assay System, Promega) The tubes were vortexed for 10-15 s and lysis 
allowed to proceed for 15 min on ice The lysates were clarified by centrifugation at
12,000 x g for 5 min and the supernatant saved m a fresh tube Samples were stored at -  
80°C until required, when 20 \xl was taken for assay Samples are stable in lysis buffer 
over several freeze-thaw cycles At the time of assay, it was important to allow sufficient 
time for the detection reagent (stored at - 80°C) to equilibrate to room temperature
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Subsequently, 100 jil o f detection reagent was added to the sample, mixed by repetitive 
pipetting (3 times) and light emission integrated over a penod o f 60 s after lag period of 
10 s Luciferase activity levels were adjusted for transfection efficiencies, estimated 
using P-galactosidase activities expressed from pCMVlacZ construct (l|ig) included in 
the transfections
2.4.10 p-GALACTOSIDASE ASSAY
The p-galactosidase assay was performed using the same lysates as that used for 
measuring the luciferase activity Mock-transfected (lacking DNA) cells were included as 
a control to account for endogenous enzyme activity and these values used to calculate 
the activity due to transfection of the lac Z construct Cell extract (30 jjl) was added to 3 
\i\ 100X Mg solution, 66 \x\ ONPG and 201 \x\ 0 1 M sodium phosphate (see Appendix 
A) and incubated at 37°C for 30 mm or until a faint yellow color developed A reaction 
tube was included in which ONPG substrate was omitted m order to obtain a background 
reading Reactions were terminated by adding 500 pi 1 M Na2C0 3  Optical densities 
were read at 420nm over a linear range of 0 2-0 8
2.4.11 S t a b l e  T r a n s f e c t i o n s
2.4.1 l . l  E s t a b l i s h m e n t  o f  s e n s i t i v i t y  o f  c e l l s  t o  P u r o m y c in
DG75 cells, in logarithmic phase of growth, were seeded at a density o f 1 x 105 cells per 
ml m media containing, 0, 0 25, 0 5, 1 0, 2 0, 5 0, and 10 0 ug of active puromycin per ml 
and grown for 10 days under standard conditions Media was changed every 3 days 
during this time and cell viability measured every 3 days by trypan blue exclusion The 
minimum concentration o f puromycin which killed > 95% of the cells after the 10 day 
penod was determined and this concentration then used m subsequent selection 
procedures for the generation of stable transfectants (section 2 4 112)
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2.4.11.2 G e n e r a t i o n  o f  a  p o o l  o f  t r a n s f e c t a n t s  OF DG75 c e l l s  E x p r e s s in g  
EBNA2 AND EBNA2 WW323SR
Stable transfectants of DG75 expressing EBNA2 or EBNA2WW323SR were established 
by electroporation of the cells with 10 ng of pSG5EBNA2 or pSG5EBNA2WW323SR as 
well as 3ug of the antibiotic resistant pGK3puro vector which expresses the pac gene 
The expression of the pac gene confers puromycin resistance to transfected mammalian 
cells expressing it and was useful for the selection of cells harboring the EBNA2 and 
pGK3puro plasmids carrying puromycin resistance genes, it is also useful m that it 
quickly kills eukaryotic cells that do not contain the pac gene A mock transfection 
(without DNA) was also set up and the cells maintained under similar experimental 
conditions as the pSG5EBNA2 or pSG5EBNA2WW323SR transfected cells Also a 
transfection with pGK3Puro and pSG5, the vector into which 
EBNA2/EBNA2WW323SR had been cloned was undertaken At 48 h post- 
electroporation, the media was replaced with selection medium le  normal growth 
medium but containing 1 fig o f active puromycin per ml Media containing antibiotic was 
changed every 3 - 4  days for the next 12 days by which time all of the mock-transfected 
cells were killed The transfected population of cells was then examined for the 
expression of EBNA2 or EBNA2WW323SR and their functional consequences on 
apoptosis and cell cycling withm the next 14 days
2 4.12 A p o p to s is  A s s a y s
2.412.1 A c r id in e  O r a n g e  S t a in i n g
A sample of the cell culture was mixed with acndine orange at a final concentration of 
5jag/ml, placed on a glass slide and immediately visualised under a fluorescence 
microscope Non-apoptotic cells display a diffuse chromatin staining pattern while 
apoptotic cells display a characteristic condensed chromatin-staming pattern (Gregory et 
a l, 1991) Acridine orange is a metachromatic dye which differentially stains double 
stranded(ds) and single stranded(ss) nucleic acids When acridine orange intercalates into 
the dsDNA of healthy cells it emits green fluorescence upon excitation at 480-490nm On
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the contrary it emits orange fluorescence when it interacts with the ssDNA of apoptotic 
cells or RNA The percentage of apoptotic cells was determined from counts on at least 
150 cells per individual culture Images were captured using Kodak ID image analysis 
software
2 4.12 2 L i g h t  S c a t t e r  a n d  C e l l  C y c l e  A n a ly s i s .
Flow Cytometry may be defined as a technology to measure properties o f cells as they 
move, or flow, in liquid suspension Most flow cytometers can measure two kinds of light 
from cells, Light scatter and fluorescence Light scatter is the interaction of light and 
matter All materials, including cells, will scatter light In the flow cytometer, light scatter 
detectors are located opposite the laser (relative to the cell), and to one side of the laser, 
m-lme with the fluid-flow/laser beam intersection The measurements made by these 
detectors are called forward light scatter and side light scatter, respectively Forward 
light scatter provides some information on the relative size o f individual cells, whereas 
side light scatter provides some information on the relative granularity of individual 
cells In this case these two are combined to identify the characteristic light scatter pattern 
emitted by condensed, shrunken apoptotic cells, presented as dot plots
Fluorescence is the property o f a molecule to absorb light of a particular wavelength and 
re-emit light of a longer wavelength The wavelength change relates to an energy loss 
that takes place in the process Propidium Iodide is a fluorescent dye that binds to 
nucleotides Propidium iodide (PI) penetrates only damaged cellular membranes 
Intercalation complexes are formed by PI with double-stranded DNA, which effect an 
amplification of the fluorescence The resulting data is displayed as a histogram which 
depicts the relative numbers of cells in the various phases of the cell cycle
In order to stain cells with propidium iodide, cells were washed twice with ice cold PBS 
Cell pellets were then resuspended in ice-cold Ethanol PBS 70 30, and fixed at 4°C for at 
least 40 minutes Cells were then pelleted by centrifugation at 2000xg for 5 minutes in a 
microfuge and resuspended m 40ug/ml Propidium iodide made up in PBS and incubated 
on ice for 15 minutes Pnor to analysis, RnaseA was added to a final concentration of
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50ug/ml Light scatter and cell cycling were then analysed using a Flow Cytometer 
(FacsCalibur, Beckton Dickinson) at 488nm, measunng forward and side (orthogonal) 
light scatter CellQuest software deconvaluted the data to create dot plots depicting cell 
density and granularity and histograms depicting cell cycle distribution
2.5 RNA A n a ly s is
2 .5 1  RNa se-F r e e  E n v ir o n m en t
RNA is easily degraded by ubiquitous RNases thus measures were employed to avoid 
this potential hazard All glassware and metal spatulas were baked prior to use at 180°C 
for 16 - 24 h in order to inactivate any RNases Stenle disposable plasticware is 
generally considered RNase-free and thus did not require treatment RNases are resistant 
to autoclavmg but they can be deactivated by the chemical diethylpyro-carbonate (DEPC) 
when it is added to solutions at a final concentration of 0 1 % (v/v), incubated at room 
temperature for 18 hr and autoclaved Solutions, which contain amines such as Tris, 
cannot be DEPC-treated as the DEPC is inactivated by these chemicals Solutions 
containing these chemicals were prepared using DEPC-treated upH20  followed by 
autoclavmg Hands are a major source of RNase contamination, thus, gloves were used 
at all times and changed frequently
2.5.1 RNA E x t r a c t i o n  F ro m  C u l t u r e d  C e l l s
Prior to RNA isolation the cells were examined by phase contrast microscopy to 
determine the condition of the cells A cell count was performed as described in section 
2 4 4  RNA was extracted from cultured cells using the commercial reagent RNA 
ISOLATOR™ Cells grown in suspension were pelleted and then lysed in RNA 
ISOLATOR™ repetitive pipetting One millilitre of RNA ISOLATOR™ was used per 1 
x 107 cultured cells Cells grown m monolayers were lysed directly in the cell culture 
flasks as trypsm can lead to the introduction of Rnases, cells were removed from the flask 
by a stenle cell scraper and homogemzed as above The homogenised sample was
101
incubated at room temperature for 5 mm to allow complete dissociation o f nuclear 
protein complex, (the procedure may be stopped at this point by storing samples at -  
70°C) Phase separation was achieved by adding 0 2 ml o f chloroform per 1 ml of RNA 
ISOLATOR The samples were covered and shaken gently but thoroughly for 15 s or 
until completely emulsified Samples were incubated at room temperature for 15 m The 
resulting mixture was centrifuged at 12,000 x g for 15 min at 4°C Following 
centrifugation the mixture separates into a lower red, phenol-chloroform phase, an 
interphase and a colorless upper aqueous phase The aqueous phase, which contains the 
RNA, was removed to a fresh tube and RNA was precipitated by adding 0 5 ml o f  
isopropanol per ml o f RNA ISOLATOR used initially The samples were stored for 10 
mm at room temperature, then centrifuged at 12,000 x g for 10 mm at 4°C The resulting 
RNA pellet was washed using 1 ml of 75% (v/v) ethanol by inverting the tube 5 times 
The pellets were then recentrifiiged at 10,000 x g for 5 mm at 4°C and the 75% (v/v) 
ethanol was removed Pellets were air dried and dissolved m DEPC treated upffeO The 
resulting RNA preparation was heated at 60°C and mixed gently to ensure a 
homogeneous solution prior to aliquoting An aliquot was removed for 
spectrophotometnc and gel electrophoretic analysis
2.5.2 RNA Ana ly sis  by  G e l  E l e c t r o p h o r e sis .
In order to check the integrity of RNA, isolated samples were run on 1% (v/v) agarose 
gels These gels were prepared as outlined m section 2 3 12 The RNA samples (5 jjlI) 
were prepared for electrophoresis by adding 15 jil o f RNA sample buffer and 3 jul o f  
RNA loading buffer The samples were heated to 65°C for 10 mm pnor to loading on the 
gel The gel was run in IX TAE as descnbed in section 2 3 12 As ethidium bromide is 
included in the RNA loading buffer the gels did not require further staining and could be 
visualized directly on a UV transilluminator The presence of two strongly staining 
bands represent the 28 S and the 18 S nbosomal RNAs, which indicated intact RNA 
Degradation is observed by a smear running down the length of the gel
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2.5.3 Northern Blotting
Northern blotting was earned out according to Sambrook et al, (1989) RNA of interest 
was first separated on a formaldehyde gel
2.5.3.1 T r e a t m e n t  o f  E l e c t r o p h o r e s i s  A p p a r a tu s
Pnor to running an RNA gel, the electrophoresis apparatus was treated to remove any 
RNase The tank, gel tray, comb and lid were washed m detergent and nnsed well in 
DEPC-treated H2O then air dned in 100% (v/v) ethanol The tank, gel tray and comb 
were immersed in a 3% (v/v) solution of Hydrogen peroxide for 15 minutes The 
apparatus was then nnsed thoroughly in DEPC-treated upftO and allowed to dry
2.5.3.2 E l e c t r o p h o r e s i s  o f  RNA/mRNA T h r o u g h  G e l s  C o n t a in i n g  
F o r m a l d e h y d e
As formaldehyde vapours are toxic these gels were prepared in a fume hood The gel 
was prepared by melting the appropnate amount of agarose in water cooling to 60°C and 
adding 5X formaldehyde gel running buffer and formaldehyde to give a final 
concentration of 1 X and 2 2 M respectively The gel was cast m a fume hood and 
allowed to set for at least 1 h The samples were prepared by mixing the following in a 
microcentifuge tube
RNA (up to 30 ng) 1 5^ 1
5X formaldehyde gel running buffer 2 Optl
Formaldehyde 3 5pJ
Formamide lOpl
Ethidium bromide was added to samples (0 01 jig/sample), which were to be used for 
northern blots m order to examine the RNA bnefly under UV (70% strength) for equal 
loading pnor to blotting The samples were incubated at 65°C for 15 min, chilled on ice
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then centrifuged briefly to collect the sample Stenie DEPC-treated gel loading buffer 
(2 til) was added to each sample and applied to the gel immediately after prerunning the 
gel for five minutes at 5V/cm Gels were run while submerged m IX formaldehyde gel 
running buffer for approximately 3 hr or until the dye front had migrated two thirds of the 
way down the gel The gel was removed from the buffer and viewed under UV light 
Samples to be blotted were treated as described in the next section.
2.S.3.3 T r a n s f e r  o f  d e n a t u r e d  RNA t o  N i t r o c e l l u l o s e  F i l t e r s
Gels which contained formaldehyde were first washed in several changes of DEPC- 
treated H2O As the percentage agarose used to prepare the gel was greater than 1% 
(w/v), the gel was soaked in 0 05 M NaOH for 20 mm this treatment partially hydrolyses 
the RNA and improves the efficiency o f transfer The gel was then rinsed in DEPC 
treated H2) and soaked m 20X SSC for 45 mm (Sambrook et a l, 1982) Unused areas of  
the gel were trimmed away and the top left hand comer was cut for orientation purposes 
in this and succeeding operations Capillary transfer was used to transfer the RNA onto 
the filter transfer was set up as illustrated m Fig 2 1
F i g u r e  2.1. C a p i l l a r y  T r a n s f e r  i n  N o r t h e r n  B l o t t i n g
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A solid support was placed m a bath of 20X SSC A sheet of 3MM Whatman paper was 
cut to cover the support and dip down either side into the buffer The washed gel is then 
placed (wells facing down) on to the Whatman and covered by a piece o f nitrocellulose 
membrane cut to the size of the gel This membrane had been floated on a bath of 
deionized water and wetted completely from below then soaked in 20X SSC for at least 5 
mm prior to placing it on the gel The buffer chamber was then covered with cling film 
Two pieces of 3MM Whatman paper which had been soaked in 2X SSC were then placed 
on top of the filter paper, care was taken at all times to ensure that no bubbles were 
trapped when preparing the transfer A stack of paper towels were then placed on top of 
the gel and held in place by a weight Transfer was allowed to continue overnight After 
transfer was completed the saturated paper towels were removed, as was the Whatman 
paper The gel and the filter paper were removed together and turned upside down on a 
clean piece of towel The position of the wells were marked using a ballpoint pen, the gel 
was then discarded The filter was washed briefly m 6X SSC to remove any remains of  
the gel then placed on a fresh sheet of Whatman paper and allowed to dry for at least 30 
mm The dried filter was then placed between two pieces of 3MM Whatman paper and 
baked in an oven at 80°C for 2 hr The filter was then used directly for prehybndisation 
or stored at room temperature wrapped in aluminium foil
2.S.3.4 G e n e r a t io n  o f  t h e  b f l -1  a n d  GAPDH R ib o f ro b e s .
GAPDH template DNA was purchased from Pharmmgen and this was used in a T7 RNA 
polymerase driven in-vitro transcription reaction as per probe synthesis for the RPA assay 
(Section 2 5 4 below) The bfl-1 nboprobe was generated by linearising the 
pcDNA3Habfl-l construct by BamHI restriction and subsequent in vitro transcription of 
the linearised product with Sp6 RNA polymerase (Boehnnger Mannheim) again the same 
reaction components employed in the RPA in vitro transcription reaction were employed 
here As per RPA the reactions were stopped by addition of Rnase free Dnase and EDTA, 
the nboprobes were precipitated by the addition of 2jig of yeast tRNA and 2 volumes of 
ice-cold ethanol and incubated at -20°C for at least 2 hours After centrifugation at
13,000 x g for 30 mm at room temperature, the pellet was washed with 75% ethanol, air 
dried and dissolved in 50|il o f DEPC-treated upH2Q A l|il sample of the purified
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nboprobe was used to measure the level o f incorporation o f radiolabel using a 
scintillation counter
2.5.3.5 G e n e r a t i n g  t h e  CD21 DNA P r o b e .
A 1 6Kb portion of the CD21 cDNA was excised from pUC19CD21 by EcoRl restriction 
and excision from an agarose gel The CD21 cDNA was then purified using a Promega 
Wizard spin column and resuspended m sterile nuclease free H2O A Random Priming 
DNA labeling kit (Boehnnger Mannheim) was used to synthesize a uniformly labeled 
DNA probe Twenty five nanogramms of linearised CD21cDNA was added to a final 
volume of 9ul of distilled water and denatured by heatmg at 95°C for 10 minutes using a 
water bath The reaction mixture was then placed on ice for 5 minutes and 3ul of dNTP 
stock mix was added as well as 2ul o f reaction mixture containing reaction buffer and 
hexanucleotides (both supplied, Boehnnger Mannheim) Five microlitres of a -32PdCTP 
(3000uCi/mMol) and lul of Klenow enzyme The reaction was incubated at 37°C for 30 
minutes and stopped after this point by addition of 2ul o f 0 2M EDTA and heating at 
65°C for 10 minutes Unincorporated deoxynbonucleoside tnphosphates were removed 
using Quickspin microspin columns (Pharmacia) The level o f incorporation of radiolabel 
was venfied as before using a scintillation counter (Beckman)
2.5.3.6 P r e h y b r i d i z a t i o n  a n d  H y b r i d i z a t i o n  P r o t o c o l
The dried membrane was placed m a baked hybndization bottle, 10 ml of hybndization 
buffer (Appendix) was added and incubated in a Hybaid roller oven for 2 to 3 hours at 
55°C The prehybndization buffer was then removed and fresh hybndisation buffer 
(preheated to 55°C) containing the nboprobe/DNA-probe (1-2 x 106cpm/ml) was 
promptly added Hybridization was allowed to proceed for 16-24 hours at 55°C
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2.5.3.7 Membrane Washing
Following the overnight incubation the hybridization buffer was removed and the 
membrane was washed successively as follows:
T a ble  2.4 M em bran e  W a sh in g  C o n d itio n s
W ash  so lu tio n T e m pe r a t u r e T im e
IX SSC, 0.1% (w/v) SDS Room temperature 30 s
IX SSC, 0.1% (w/v) SDS 22°C 30 min
IX SSC, 0.1% (w/v) SDS 22°C 30 min
0.1X SSC, 0.1% (w/v) SDS 65°C 30 min
0. IX SSC, 0.1% (w/v) SDS 65°C 30 min
After washing the membrane was removed gently from the hybridization bottle and 
placed in a stomacher bag in a cassette. The blot was kept moist at all times with 0.1X 
SSC, 0.1% (w/v) SDS. The membrane was exposed to X-ray film for 24-96 hr at -70°C. 
Film was developed as described below.
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2.5.4 Rnase P r o te c tio n  assay .
The nbonuclease protection assay (RPA) is a highly sensitive and specific method for the 
detection and quantitation of mRNA species The RiboQuant® RNase protection assay 
system (PharMmgen) was employed dunng this study The procedure is outlined below
Figure 2.2. Outline of Procedure for Ribonuclease Protection Assay
Day Is Probe Synthesis RNA preparation
1  1
Overnight Hybridization
;
RNase treatment and Purification 
Of Protected Probes
Gel preparation
Day 2
1 I
Electrophoresis on Denaturing 
Polyacrylamide Gel
i ~
Autoradiography and /or Phosphonmagmg
Fig 2 2 Overview of the nbonuclease protection assay protocol
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2.5.4.1 PROBE SYNTHESIS
The [oc-32P]UTP, GACU nucleotide pool, DTT, 5X transcription buffer and the template 
DNA set was brought to room temperature prior to setting up the reactions The 
following were added to a 1 5 ml microcentifuge tube for each probe synthesis
Rnasm ljil
GACU pool l\x\
DTT 2juJ
5X transcription buffer 4jil
Template DNA Ijj.1
[x -32P]UTP 10nl
T7 RNA polymerase 1 ¿il
The contents of the tube were mixed by gentle pipetting and centrifuged quickly followed 
by incubation at 37°C for 1 hour The reaction was terminated by adding 2 |il of RNase - 
ijree Dnase mixing gently and incubating at 37°C for 30 mm The following reagents 
were then added to the reactions
EDTA 20 mM 26^1
Tns saturated phenol 26fil
Chloroform isoamyl alcohol (50 1) 25|il 
Yeast tRNA 2\i\
The contents were vortexed into an emulsion and centnfuged for 5 mm at room 
temperature The upper phase was transferred to a fresh tube containing 50jil o f  
chloroform isoamyl alcohol (50 1), the tube was vortexed and microcentnfuged (top 
speed) for 2 mm at room temperature The upper aqueous phase was transferred to a 
sterile 1 5 ml tube to which 50jil of 4M-ammomum acetate and 250jil of ice cold 100% 
(v/v) ethanol was added The tube was inverted to mix and incubated at -70°C for 30 min
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followed by centrifugation at 4°C for 15 mm The supernatant was removed and the 
pellet was washed with lOOpil o f ice cold 90% (v/v) ethanol after which the supernatant 
was removed and the pellet was air-dried for 5-10 mm The pellet was solubilized by the 
addition of 50 nl o f hybridization buffer and gentle vortexing, contents were collected by 
a brief centrifugation Duplicate 1 jil samples o f the labeled probe were quantified in a 
scintillation counter A maximum yield of -3  x 106 Cherenkov counts/|il with an 
acceptable lower limit of -3 x 105 Cherenkov counts/|il was expected The probe was 
stored at -20°C until required Generally probe can only be used for two overnight 
hybridizations when labeled with [oc- P]UTP
2.S.4.2 RNA P r e p a r a t i o n  a n d  H y b r id iz a t io n
RNA was prepared using the RNA isolation method outlined in section 2 6 2 above, 20 
jig of total RNA was used for each probe hybridization Each RNA sample was made up 
to 50 jLtl with DEPC-treated upH2) to which 50 jil o f 4 M ammonium acetate and 250 \i\ 
of ice cold 100% (v/v) ethanol were added The samples were mixed by inverting and 
stored at -70°C for one hr or -20°C overnight The precipitated RNA was collected by 
centrifugation at 12,000 x g for 30 mm at 4°C, the pellet was washed with 90% (v/v) ice- 
cold ethanol After removal of the supernatant and subsequent air-drying, the pellet was 
resuspended in 8 ¡ul o f  hybridization buffer by gently vortexing for 3-4 mm followed by a 
brief centrifugation Two microlitres of the probe was then added to each RNA sample 
and mixed by pipetting A drop of mineral oil was added to each sample and the tubes 
were centrifuged briefly in the microfuge Samples were then placed m a heating block 
for 3 mm which had been preheated to 90°C, and then immediately turned down to 56°C, 
allowing the temperature to ramp down slowly, and incubated for 12-16 hr The heating 
block was then turned down to 37°C prior to RNase treatment and again the temperature 
was allowed to ramp down slowly and then was maintained at 37°C for 15 mm
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An RNase mixture was prepared by adding 2 5 ml of RNase buffer to 6 jil o f RNase A + 
T1 mix, per 20 RNA samples (RNase A 80ng/jil, RNase T1 250 U/jil) The RNA 
samples were removed from the heating block and 100 /|xl of the RNase cocktail was 
added underneath the oil into the aqueous layer (bubble) The tubes were 
microcentnfuged for 10 s and incubated for 45 min at 30°C Before the RNase treatment 
was completed a Proteinase K mixture was prepared (per 20 samples),
Proteinase K buffer 1 X 390 jil
Proteinsase K (10 mg/ml) 30 ¿il
Yeast tRNA (2 mg/ml) 30 |il
The mixture was mixed together and 18 \x\ aliquots were added to a stenle 1 5 ml 
microcentifuge tubes The RNase digests were extracted from underneath the oil and 
transferred to the tube containing the protemsase K mixture (avoiding transfer of oil) 
The RNase/Proteinase K mixture was vortexed bnefly, microfuged quickly and incubated 
for 15 mm at 37°C Tris saturated phenol (65 |il) and 65 \il o f chloroform isoamyl 
alcohol (50 1) were added to the samples, vortexed into an emulsion then centnfuged for 
5 mm at room temperature The upper aqueous phase was extracted, avoiding the 
mterphase, and transferred to a fresh tube to which 120 jil of 4 M ammonium acetate and 
650 jil of ice cold 100% (v/v) ethanol was then added The tubes were mixed by 
inverting and were subsequently incubated at -70°C for 30 mm Samples were 
centnfuged for 5 mm at 4°C, the pellet was then washed with ice cold 90% (v/v) ethanol, 
the supernatant was removed and the pellet was allowed to air-dry for 5-10 mm Pellet 
was resuspended m 5 jil of 1 X loading buffer (provided in kit) Pnor to loading onto the 
gel the samples were heated to 90°C for 3 mm and placed immediately in an ice bath
Five percent (w/v) polyacrylamide-urea gels were prepared according to the formula 
given in appendix A Biorad gel electrophoresis system was used m this study The
2.5.4 3 RNASE Treatments
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plates were washed with detergent, rinsed first with tap water and then with dH20  and 
finally wiped in one direction with tissue soaked with 100% (v/v) ethanol One plate was 
sihconsied using Sigmacote (Sigma) The apparatus was set up, the gel cast and the comb 
inserted as per manufacturer’s instructions Prior to loading of the samples, the gel was 
pre-run in 1 x TBE at a constant power of 50 W for 45 mm -  Ih The wells were washed 
several times with electrophoresis buffer (1 x TBE) to remove unpolymensed acrylamide 
and urea that would otherwise interfere with the electrophoresis o f the sample After 
loading the samples, the gel was electrophoresed at 50 W for approximately 3 h After 
electrophoresis the gel was carefully removed, placed on two sheets of 3MM Whatmann 
paper cut to the size of the gel, covered with Saran Wrap and vacuum dried at 80°C for 1- 
2h The dried gel was then exposed to X-ray film m a cassette with two intensifying 
screens was exposed at -70°C for an appropriate length of time
2.6 W e st e r n  Bl o t  Ana ly sis  
2 6.1 P r e pa r a tio n  o f  C e l l u l a r  P r o t e in
Prior to protein isolation the viability o f the cells was examined and the viable cell count 
determined by trypan blue exclusion as before This method was employed to isolate total 
cellular protein (i e cytoplasmic and nuclear proteins) and was used for the extraction of 
EBNA2, Bfl-1, NotchIC and LMP-1 proteins Cells were pelleted at 1,000 x g for 5 min 
and washed with 5 ml o f ice-cold PBS The cells were then transferred to a microfuge 
tube in 1 ml of ice-cold PBS, pelleted at 5,000 x g for 5 min and all o f the supernatant 
removed Adherent cells were washed twice with 5ml of ice-cold PBS, scraped into 1 ml 
of PBS and then pelleted by centrifugation at 5,000 x g for 5 min The cell pellet was 
dispersed in ice-cold suspension buffer (0 1M Nacl, 0 01M Tns-Hcl pH 7 6, 0 001M 
EDTA pH 8 0, 1 jig/ml aprotinin, l|ig/ml leupeptin and 1 OOjag/ml PMSF) using 200|xl of 
suspension buffer for every 5 x 106 cells An equal volume of 2 x SDS gel loading buffer 
[lOOmM Tns-Hcl pH 7 6, 4% (w/v) SDS, 20% (v/v) glycerol, 10%(v/v) 2- 
mercaptoethanol, 0 2% (w/v) bromophenol blue] was immediately added to the cell 
suspension, after which the sample becomes extremely viscous The sample was then 
placed in a boiling water bath for 10 min and then subjected to somcation for 1 mm on
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full power to shear the DNA The lysate was clarified by centrifugation at 12,000 x g for 
10 mm at room temperature The supernatant was aliquoted and stored at -20°C 
Samples were analyzed by SDS-PAGE, loading approximately 5 x 105 cells per lane
2.6.2 E st im a tio n  o f  P r o t e in  C o n c en tr a tio n
In order to standardize the amount of protein used in SDS-PAGE or EMSA, the 
concentration of protein in the cell extracts was determined using the BC A (bicinchonmic 
acid) protein assay kit essentially according to manufacturer’s instructions The 
‘ microwell plate protocol5 was used A standard curve was constructed using BSA, with 
concentrations ranging from 0 to 2000 |ig/ml using PBS as the diluent The sample 
concentrations were determined within this range with test solutions diluted 1 5 and 110 
in PBS (diluent) As a control for interference m the readings by substances in the 
extraction buffers, similar dilutions o f extraction buffer as with the test solutions were 
included Also, all samples were prepared and assayed in duplicate The BCA assay 
reagent was prepared on the day of use and incubated with the samples in a microwell 
plate at 37°C for 30 mm in the dark Absorbance was measured at 560nm on a plate 
reader and the readings subtracted from the appropriate controls and averaged 
accordingly A standard curve was plotted for the BSA standards (concentration versus 
absorbance) from which the protein concentration for each unknown sample could be 
determined
2.6.3 PROTEIN ELECTROPHORESIS, PREPARATION OF SDS-PAGE GELS
A two phase SDS-PAGE system was used to analyze proteins with a 5% stacking gel and 
either a 10% resolving gel as outlined below
Resolving Gel
10ml 10% (m b  15% (m P
acrylagel
bis-acrylagel
3 33 5 0
1 35 2 025
1 5 M Tns (pH8 8) 2 5 25
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dH20  2.61 0.265
10% (v/v) SDS 0.10 0.10
10% (v/v) APS 0.10 0.10
TEMED 0.01 0.01
Stacking Gel
2.5 ml 5% (mP
acrylagel 0.42
bis-acrylagel 0.168
1 M Tris (pH6.8) 0.312
dH20  1.5475
10% (v/v) SDS 0.025
10% (v/v) APS 0.025
TEMED 0.0025
2.6.4 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE)
An ATTO protein gel electrophoresis system was used in this study. Glass plates were 
washed with detergent, rinsed first with tap water and then with dH20  and finally wiped 
in one direction with tissue soaked with 100 (v/v) ethanol. The gasket was placed about 
the ridged plate, the plates were put together and secured with clamps. The depth of the 
resolving gel was marked on the outer plate. The resolving gel was then poured to within 
2 cm of the top of the larger plate and overlaid with 100% (v/v) ethanol. When set, the 
ethanol was removed and the stacking gel was poured. A clean comb was inserted and 
the gel was allowed to polymerise for 45 min-1 hr. The electrophoresis tank was filled 
with IX Tris-glycine running buffer to the level of the horizontal rubber gasket. After 
polymerisation the gaskets clamp stands and comb were removed. Unpolymerised gel 
was removed by gently rinsing the wells with dH20, the wells were then straightened 
using a loading tip. The prepoured gels were lowered into the buffer at an angle to 
exclude air bubbles from the gel buffer interface. The gel plates were fixed firmly in
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place with the notched plate innermost. The chamber formed by the inner plates was 
filled with IX running Buffer, the samples were loaded and the electrodes were attached. 
The gels were electrophoresed at a constant current of 30 mA per gel for approximately 1 
hr in the case of the 10% resolving gel or lh 30 min in the case of the 15% resolving gel. 
When complete the plates were removed, separated and the gel was either placed in 
transfer buffer prior to western blotting or stained in Coomassie blue. Staining took place 
for 30 min, agitating constantly. The gel was then placed in destain (see Appendix) with 
constant agitation, until all background staining was removed. The destain was changed 
as it became saturated with stain.
2.6.5 WESTERN BLOT ANALYSIS
An SDS-PAGE gel was run as described, with pre-stained markers (New England 
Biolabs). Two pieces of 3MM filter paper were cut to size of the gel as was the 
nitrocellulose membrane. The sponges from the transfer apparatus along with 4 pieces of 
3 MM filter paper cut to size and the SDS gel were soaked in transfer buffer. Two 
sponges were placed on each side of the transfer apparatus and 2 pieces of filter paper in 
turn, on each of these. The gel was placed on one side of the filter paper. The 
nitrocellulose membrane which had been pre-wet in distilled water and then soaked in 
transfer buffer for 5 min was placed on top of the gel, ensuring that no bubbles were 
trapped between any of the layers. The second stack of filter paper and sponges were 
placed on top of the membrane, the transfer apparatus was assembled and placed in the 
blotting apparatus with the gel on the side of the negative (black) electrode and the 
nitocellulose on the side of the positive (red) electrode. Protein transfer was allowed to 
take place at a constant voltage of 80 V for 1 h with the buffer kept chilled by an ice pack 
(placed in the transfer apparatus) and recirculated. After transfer, the apparatus was 
disassembled and the membrane was washed briefly in TBS to remove any traces of gel. 
The membrane was then incubated in Blocking buffer for 1 - 2 h at room temperature 
followed by incubation with the appropriate antibody (diluted in Blocking buffer) at 4°C 
overnight. Sodium azide was added to each antibody solution to a final concentration of 
0.02% (w/v) as a preservative thus permitting reuse of the antibody. In cases where the
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secondary antibody was conjugated to HRP, sodium azide was not added to the primary 
antibody as it interferes with HRP.
Table 2.5 Incubation Conditions for Antibodies Used in Western Blotting
Primary
Antibody
Name Dilution 
In Blotto
Secondary Antibody Dilution 
In Blotto
AntiEBNA2 PE2 1/50 Ap-Conjugated Anti Mouse IgG (Promega) 1/5000
Anti -LMP1 CS1-4 1/100 Ap-Conjugated Anti Mouse IgG (Promega) 1/5000
Antibfl-1 Fl-175 1/200 HRP-Conjugated Anti Rabbit IgG 1/2000
(Amersham Biosciences)
Anti NotchIC Tanl 1/10 AP-Conjugated Anti-Rabbit IgG 1/1000
(Boehringer Mannheim) 1/1000
After overnight incubation, the membrane was washed three times in TBST (0.1%(v/v) 
Tween-20 in TBS) for 10 min and then incubated for 10 min in blocking buffer. The 
filter was then incubated with the appropriate secondary antibody for 1 hr at room 
temperature, followed by washing three times with TBST for 10 min each. All of the 
above incubations were carried out with agitation. Membranes were then placed in a 
clean container and covered with BCIP/NBT(Sigma) substrate in the case of the Ap- 
conjugated complexes or in ECL-Supersignal reagent (Pierce) in the case of the HRP- 
conjugated complexes. The BCIP/NBT container was placed in the dark at room 
temperature without shaking for 30 min or longer if required. The membranes were then 
rinsed in distilled water to stop the reaction, photographed and then wrapped in cling film 
and stored in the dark. After addition of the ECL reagent, membranes were left in 
darkroom conditions for 5 min. The ECL reagent was then removed and membranes were 
wrapped in cling film and exposed to Kodak X-ray film. Autoradiographs were 
developed using the Xomat Developer.
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2.7 Electrophoretic Mobility Shift Assay (EMSA) or Bandshift Assay
2.7.1 P r e p a r a t i o n  o f  N u c l e a r  E x t r a c t s
Nuclear extracts were prepared essentially according to the method of [Dignam, 1983]. 
The composition of all buffers used is described in Appendix. Briefly, 50ml of cells in 
suspension (~2x 10 7 cells) were pelleted at 1,000 x g for 5 min. and washed with 5 ml. 
of ice-cold PBS (without MgCh or CaCk). The pellet of cells was then resuspended in3- 
4 volumes (400ul) of Buffer A and kept on ice for 60 minutes. In this time the cells swell 
and after the 60 minutes the cell suspension was transferred to a 1ml douncer. The cell 
suspension was then homogenized by douncing up and down twenty times. (To 
permeabilize the cell membranes). Samples were then pelleted by centrifugation at 
maximum speed in a Heraeus microfuge at 4 °C for 10 seconds. Next 300ul of Buffer A 
was added to the sample pellets and the samples were vortexed (not resuspended) and 
again centrifuged at 4°C for 10 seconds as before. The supernatant was discarded and the 
pellets were then resuspended in 300ul of Buffer B and incubated on ice for 30minutes. 
Samples were then mixed by vortex and clarified by centrifugation for 20 minutes at 4 °C 
at maximum speed in a Heraeus microfuge. The supernatant contains the nuclear extracts. 
The concentration of protein in the extracts was determined by using the BCA assay and 
the extracts were aliquoted frozen on dry ice and stored at -80° C until use.
2.7.2 N a t u r e  O f  T h e  o l i g o n u c l e o t i d e  p r o b e s  a n d  T h e i r  l a b e l i n g  f o r  u s e  in  
EMSA
Unlabeled double stranded oligonucleotide probes for use in EMSA were purchased as 
single stranded oligonucleotides and then annealed in solution. Pairs of oligos were 
purchased from MWG Biotech and designed such that annealing would leave a 5’ GATC 
overhang. Two pairs of oligonucleotides were used (See Section 2.15 above). The Cp 
oligos represented sequences from -359 to -388 of the Cp promoter that contain the Cp 
CBF1 binding site (5’-GTGGGAA-3’) (Ling et al 1994), while the 36-mer Bflp oligo 
corresponds to -259 to -223 on the bfl-1 promoter which contains the putative CBF1 
binding site from -243 to-249 on the reverse strand (Figure 3.22A). Labeling was based
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on the usage of Klenow DNA polymerase. The enzyme catalyzes the addition of 
mononu-cleotides from deoxynucleoside-5-triphosphates to the 3 -hydroxyl terminus of 
a primer/template DNA. Thus Klenow was used to repair the 55 overhangs generated 
after annealing, while in the process integrating the a 32P labeled dCTP to the 3’ terminus 
of the template oligo. For preparation of the double stranded -Cp and bfLp 
oligonucleotides, equimolar amounts of the complimentary Cp (TOP and BOTTOM) and 
BfLp (TOP and BOTTOM) oligonucleotides were added to TE pH8.5 and placed in a 
heating block at 90°C for 10 minutes to denature the oligonucleotides. The heating block 
was then removed from the apparatus and allowed to cool to room temperature slowly 
(60 -  75 min.) to allow annealing of the oligonucleotides to ensue. The annealed 
oligonucleotides were either used immediately in the labeling reaction or stored at -20°C.
The labeling reaction was performed by adding :
Template DNA (annealed) containing 5’ GATC overhangs 2ul(50ng)
NEB Buffer 2 (Reaction buffer for Klenow Enzyme) 2ul
dATP, dTTP, dGTP(500uM) 2ul(final conc.50uM)
a-32P dCTP (3000Cimol) 5ul
Distilled H20  7ul
Klenow Enzyme 2ul
The reaction was incubated at 37°C for 1 hour after which labeled oligonucleotides were 
purified away from unincorporated labeled nucleotides by spin-column chromatography 
through MicroSpin™ G-25 columns essentially according to manufacturer’s 
specifications (Amersham Pharmacia Biotech). The level of incorporation of radiolabeled 
a-32P dCTP was assayed using a Beckman scintillation counter.
2.7.3 Binding Reaction
The composition of all buffers used in the binding reaction are given in the Appendix 
The binding of nuclear proteins to labeled DNA probe was performed in a reaction 
comprising:
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Binding reaction buffer (4X)
Non-specific competitor DNA poly.dl-dC (ljig/jil) 
BSA (1 mg/ml)
Binding Mix
2|il
2ui
9ul
5 jj.1
Binding Mix
Antibody (R3)(For supershift)
Nuclear Extract (6ug)
Incubate for 5 minutes at room temperature
32t> rvxTA «.«I,« /"on ruin ranfnh
9ul
5ul
Xul
P-labeled DNA probe (20,000 cpm/^il) 
Distilled H20
2ul
20ul
A ‘control reaction’ lacking nuclear extract but containing all other components of the 
binding reaction was also set up. The reaction components were mixed gently and 
incubated at room temperature for 30 minutes. Samples were then loaded onto a 5% 
polyacrylamide gel in TBE. One extra lane with Bromophenol blue was also added so 
that the leading edge of the gel could be visualized.
2.7.4 Supershift Studies
The identity of a protein in a bandshift complex can be verified by incubating the nuclear 
extract with an antibody that recognizes the protein prior to performing the binding 
reaction with the labeled probe. The antibody (R3) binds to the EBNA2-CBF1 complex. 
Depending on whether the antibody recognizes an epitope within the DNA-binding 
domain or elsewhere, the complex formation will either be prevented (observed as only a 
decrease in intensity o f the shifted complex) or further retarded in mobility in the gel 
(termed a ‘supershift’). ‘Supershift’ studies were conducted by incubating the nuclear 
extract (See the binding reaction above) with 5.0|il of an EBNA2 specific antibody (R3). 
Reactions were then analysed by PAGE and visualized by radiography as described 
below.
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2.7.5 Non d en a tu rin g  P o ly a cry la m id e  G el  E l e c t r o p h o r e sis
Resolution of the bandshift complexes were conducted by nondenaturing polyacrylamide 
gel electrophoresis using the Protean II cell system (Biorad). A 5% polyacrylamide gel 
was used.
2.7.6 Prepa r a tio n  o f  t h e  Pr o t e a n  n  C e l l  E l e c t r o p h o r e sis  System
The glass plates, spacers and combs were cleaned with detergent, rinsed thoroughly with 
tap water followed by upFhO, and wiped dry with clean dry tissue paper. 100% (v/v) 
ethanol was poured onto the glass plates and the plates wiped dry with tissue paper. The 
spacers and combs were wiped with tissue paper soaked in 100% (v/v) ethanol. The 
apparatus was then assembled and clamped together according to manufacturer’s 
instructions (Biorad).
2.7.7 C astin g  t h e  G el
A 5% gel was used for the resolution of the bandshift complexes. The composition of the 
gels is outlined in the Appendix. After addition of TEMED to the gel mix, the gel 
solution was poured immediately into the gel mould and the comb inserted. The gel was 
allowed to set for at least an hour, after which the gel mould was removed and placed in 
the electrophoresis tank. The lower chamber of the tank was filled with 1.2 litres of 
electrophoresis buffer (1 X TBE) whilst the upper chamber was filled with approximately 
350 ml of 1 X TBE. The comb was carefully removed and the wells were washed 
thoroughly with electrophoresis buffer to remove any unpolymerised acrylamide that 
would otherwise impair the migration of the sample. The gel was pre-run for 30-40 min 
at a constant voltage of 130V before the samples were loaded and electrophoresis was 
carried out at the same voltage for approximately 4 h at room temperature. It should be 
pointed out that no loading dye was added to the samples as bromophenol blue has been 
reported to disrupt protein-DNA interactions in certain cases (Maniatis et al 1989). It 
was therefore necessary to run just loading buffer containing bromophenol blue into one
120
well of the gel to locate the leading edge of the gel After electrophoresis, the gel was 
vacuum dried for approximately 2hrs and exposed to X-ray film to visualise bandshifts
2.7.8 G e l  D ry in g  a n d  A u to r a d io g r a p h y
After electrophoresis, the buffer was poured out of the electrophoresis tank and the plates 
disassembled A piece of Whatmann 3MM filter paper (cut to size) was placed on top of 
the gel, avoiding air bubbles and the paper lifted gently with the gel attached to it This 
was then covered with cling film and placed in a vacuum gel dryer, with the gel facing 
up The gel was dned at 80°C for 2h Once dry, the gel was placed in a cassette and 
exposed to X-ray film in the dark for at least 12 hours at -80 °C The film was developed 
using an Xomat developing machine
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Ch a pt e r  3 
Re su l t s
Results 
Introduction
3.0. LMPl-Independent Mechamsm(s) Regulate ¿/7-2-mRNA Levels in an EBV- 
Positive Burkitt’s Lymphoma Type HI Cell Line.
EBV positive Group IBL cell lines and many EBV negative BL cell lines can easily be 
induced to undergo apoptosis, (Gregory et a l , 1991) however, group III EBV positive BL 
cell lines such as LCLs which express the complete set of EBV latent proteins, display 
increased resistance to apoptosis induced by a variety o f triggers (Gregory et a l , 1991) 
Although this increased resistance to apoptosis is a result of numerous interactions 
between EBV and members of the cellular apoptosis programme (See Chapter 1), it has 
partly been attributed to an increase m the expression of Bcl2 an anti-apoptotic protein 
which is up-regulated by EBV LMP1, EBNA2 and EBNA3B after EBV infection 
(Henderson et a l , 1991, Liu et a l , 1991, Rowe et a l , 1994, Fmke et a l , 1992, Silins and 
Sculley 1995) Recent studies however, have shown that another bcl2-related anti- 
apoptotic gene, bfl-1, has consistently elevated mRNA levels in EBV positive group in  
relative to group I BL cell lines (D'Souza et a l , 2000) Thus bfl-1 may also be an 
important target for EBV latent genes in mediating the increased anti-apoptotic threshold 
of infected group III BLs and LCLs It has been shown that LMP1 transcriptionally up- 
regulated the bfl-1 gene when expressed independently of the other EBV latent proteins 
(D’Souza et a l , 2000) Nonetheless, since the relative levels of bfl-1 mRNA are much 
higher m type ID cell lines relative to bfl-1 mRNA levels in cells expressing LMP1 only, 
thus LMP1 is not the only EBV latent protein involved in regulating the cellular bfl-1 
gene (Figure 3 1)
Initially a preliminary Northern Blotting experiment was undertaken using total RNA 
samples from three related cell lines, Mutu I an EBV positive BL cell line expressing 
only EBNA1 (the group I phenotype), Mutu ID, a clone of Mutu I cells which have 
drifted to express the entire compliment o f EBV latent genes (group III phenotype), and a 
Mutu HI mutant cell line which no longer expresses LMP1 Steady state levels of bfl-1 
mRNA m these cell lines were detected using an antisense bfl-1 nboprobe complimentary 
to a portion of the transcript from this gene (Figure3 4) Induction levels were
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normalized by analyzing mRNA levels of the housekeeping gene GAPDH in each of the 
cell lines. GAPDH mRNA was detected using a commercially available antisense 
riboprobe. (Pharmingen). It can be seen below (Figure3.1), that significantly elevated 
steady-state levels of bfl-1 mRNA were present in MUTU-III relative to MUTU-I cells. 
However, since the MUTU HI clone, which does not express LMP1, still shows 
significant induction of bfl-1 mRNA levels, other EBV latent proteins may also regulate 
bfl-1 expression.
As EBNA2 is another key effector of phenotypic change in EBV-infected cells, it was 
investigated if the expression of this viral protein alone could contribute to an up- 
regulation of bcl2 family apoptosis-related gene products, including bfl-1.
Figure 3.1. An LMPl-Independent Mechanism Up-Regulates ^/7-i-mRNA Levels in 
an EBV-Positive Burkitt’s Lymphoma Cell Line
U p p e r P a n e l :(N o rth e rn  B lot) 
A n L M P 1 n eg a tiv e  clone of an 
E B V -positive  B L -d e riv e d  cell 
line , (M U T U  - I I I )  show s 
e leva ted  levels o f b f l -1  m R N A  
re la tiv e  to  an isogenic 
c o u n te rp a r t  (M U T U -I) w hich  
exp resses  EB N A 1 as sole EB V  
p ro te in
L o w e r  P a n e l: T a b le  show ing  
EB V  la te n t p ro te in  exp ressio n  
in M U T U -I an d  M U T U -III
Figure 3.1. An LMP 1-independent mechanism up-regulates bfl-l-m R N A  levels in an EBV-positive 
Burkitt’s lymphoma cell line. Left panel. Elevated levels of bfl-1 mRNA are evident in the group III 
relative to the group I BL cells thus EBV latent proteins appear to regulate transcription from the bfl-1 
gene. Although LMP1 independently up-regulates transcription from the bfl-1 gene, (D'Souza et al., 2000),
MUTU-I MUTU-III
EBNA1 EBNA1
EBNA2
EBNA3A/B/C
LMP1
LMP2A/2B
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it appears other EBV latent proteins expressed m the group in  phenotype also regulate bfl-1 activity The 
main candidate here is EBNA2
3.1. Regulation of Expression of bcl-2 Family Members by EBNA2
This study set out to investigate if EBNA2 was capable of directly regulating the 
expression o f bcl-2 family members, in particular bfl-1, at the transcriptional level To 
this end, bcl-2 gene family profiling was performed by nbonuclease protection assay 
using a custom designed set of nboprobes that were antisense to mRNAs of members o f  
this group of genes (henceforth referred to as multiprobe RPA) Several established cell 
lines were then used in which EBNA2 could be either induced or activated in the absence 
ofLMPl
3.1.1 I n d u c ib le  E x p re s s io n  o f  EBNA2, U sin g  t h e  T e t r a c y c l i n e - R e g u l a t e d  
S y s te m  in  S t a b l y - T r a n s f e c t e d  B C e l l  L ines.
In order to ensure expression of EBNA2 as sole EBV protein, the DG75tTA-EBNA2 cell 
line was employed In this cell line EBNA2 expression is tightly regulated by the 
presence or absence of tetracycline (Figure 3 2) The inducible promoter dnvmg EBNA2 
expression contains binding sites for a hybrid tetracycline-regulated trans-activator (tTA) 
that is constitutively expressed in the parental clone DG75tTA Removal of tetracycline 
from the growth medium leads to the binding of tTA to the promoter and the induction of 
EBNA2 expression (Floettmann et a l , 1996) The tetracycline-regulated trans-activator 
(tTA) is derived from a fusion of two genes (tetR and VP 16 trans-activator) and is 
constitutively expressed from a CMV/IE promoter on the pJEF-3 plasmid Expression of 
EBNA2 from the responder plasmid pJEF-31 requires binding of the tTA to a 5’ 
regulatory region containing a minimal promoter The cell line DG75tTA-EBNA2 had 
been generated by stable transfection o f the EBV negative cell line DG75 with pJEF-3 
and pJEF-31 and stable integration was selected by growth in medium containing 
hygromycin-B, G418, and tetracycline (Floettmann et a l , 1996)
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Figure 3.2. EBNA2 Expression is Tightly Controlled by the Presence of Tetracycline 
m the DG75-tTA-EBNA2 Cell Line.
The host cell line DG75 is stably transfected with two plasmids pJEF-3 and pJEF31which 
are selected during cell culture using the drugs Hygromycin and G418 respectively
Figure 3.2 Schematic representation of the tetracycline-regulated gene expression system in the DG75 tTA 
EBNA2 cell line. In the presence of tetracycline the trans-activator cannot bind to the minimal promoter 
driving EBNA2 expression. Conversely, in the absence of tetracycline the tTA trans-activation domain 
binds to the promoter thereby facilitating induction of EBNA2 expression (Floettmann et al ,1996, Gossen 
and Bujard 1992)
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EBNA2 Alone Up-Regulates bfl-1 mRNA and Protein Levels in EBV Negative DG75 
BL Cells.
EBNA2 expression was induced over a 72-hour time course in the DG75-tTA-EBNA2 
cell line, by the removal o f tetracycline from cell culture media Total protein and RNA 
were prepared simultaneously from cells harvested at the indicated tune-pomts post- 
EBNA2 induction, (Figures 3 3 A and 3 3 B) and used m Western blot and multiprobe 
RPA analysis respectively The benefit of using this cell line was that EBNA2 is 
expressed as the sole EBV protein and that its expression is tightly controlled Western 
blotting was earned out to demonstrate the induction of EBNA2 over the course of the 
expenment and to measure Bfl-1 protein levels in response to EBNA2 induction (Figure 
3 3A(i and 11) RPA permitted an investigation of the effects of EBNA2 induction on the 
steady-state levels of mRNA transenbed from the bcl-2 family of apoptosis-related genes 
mRNA levels from the bcbc-L, bcbc-S, bfl-1, bik, bak, bax, bcl-2, and mcl-1 genes were 
thus compared and the inclusion of probes for transenpts from the house-keepmg genes 
L32 and GAPDH allowed quantitative compansons of mRNA levels to be made for each 
time-pomt The multiprobe hAP02 template set (Pharmingen) and T7 RNA polymerase 
were used to synthesize 32P labeled antisense nboprobes complementary to portions of 
transenpts from the apoptosis related genes and the house-keepmg genes The labeled 
probe set was hybndized to 20jig of total RNA sample in solution, and RNase protected 
probe fragments were then resolved on 6% denatunng polyacrylamide gels and detected 
by autoradiography Band intensities were quantified by densitometnc scanning of 
autoradiograms using Kodak imaging software
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Figure 3.3. Induction of EBNA2 as the Sole EBV Protein Leads to an Increase in bfl- 
1 mRNA and Protein Levels in the EBV-Negative BL Cell Line DG75-tTA-EBNA2.
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U p p e r  p a n e l  (A):
(i) Western Blot showing 
EBNA2 induction in the 
DG75-tTA-EBNA2 cell line 
over 72 hours.
(ii) Western blot showing 
Bfl-1 is induced in the 
Dg75-tTA-EBNA2 cell line 
in Response to EBNA2 
induction.
L o w e r  p a n e l  (B):
RPA shows effect of 
EBNA2 induction on 
mRNA levels in Bcl-2 
related genes.
bfl-1 mRNA is up-regulated 
in response to EBNA2 
induction. Bik mRNA is 
down regulated in response 
to EBNA2 induction.
(A) (i) Western blot of DG75tTa-EBNA2 cells induced to express EBNA2 by reculturing cells in the 
absence of tetracycline. EBNA2 induction was carried over 72 hours. Cells were harvested and analysed for 
EBNA2 expression at the times indicated above each lane, (ii) Bfl-1 stimulation in response to EBNA2 
induction was also measured in this cell line by Western Blotting with the FL175 Anti Bfl-1 Antibody 
(Santa Cruz Biotechnology). (B). RPA performed with RNA harvested simultaneously from the samples 
in panel A. mRNA levels from the apoptosis-related genes bclx-L, bclx-S, bfl-1, bik, bak, bax, bcl-2, and 
mel-l were analysed over the 72 hour time-course. Unprotected 32P labelled antisense riboprobes (5000cpm 
per lane) were loaded alongside RPA-processed samples and are shown linked to their smaller RNase- 
protected fragments, which correspond to the level of mRNA in the sample. Exposure to film was for 24 
hours. An increase in bfl-1 mRNA is seen upon EBNA2 induction. Densitometric scanning of relevant 
bands from RPA using GAPDH-corrected induction levels showed a 5-fold induction of bfl-1 mRNA after 
24 hours anda~2 fold reduction in bik-mRNA after 72 hours.
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Induction of EBNA2 was monitored by Western blot analysis using the anti-EBNA2 
murine monoclonal antibody PE2 In these experiments, EBNA2 was usually detected in 
induced DG75tTA-EBN A2 cells at 24 hours and remained detectable up to at least 96 
hours (Figure 3 3A(i)) At 24 hours the level of EBNA2 was comparable to that detected 
in the reference LCL, X50-7 (Figure 3 3 A (i), lane 4) The levels of mRNA transcripts 
from the set of apoptosis-related genes were compared over the 72-hour time course 
following induction of EBNA2 in the Dg7 5tTA-EBNA2 cell line (figure3 3B) A 
significant increase in the level of bfl-1 mRNA can be seen to coincide with EBNA2 
expression The lane for 48hr is overloaded thus although there is an apparent peak in the 
bfl-I mRNA level after 48 hours of EBNA2 induction, after GAPDH correction, the real 
peak in bfl-1 mRNA transcription occurs after 24hours Also, significant induction of  
bfl-lmRNA  occurs at a physiologically relevant level o f EBNA2, comparable to the level 
expressed in a reference LCL X50-7 Western blotting was then earned out with the same 
extracts and the levels o f Bfl-1 protein stimulated m response to EBNA2 activation over 
the time course were measured It can be seen from Figure 3 3A (u) that Bfl-1 levels are 
increased in conjunction with EBNA2 expression at 24 hours Thus Bfl-1 activation is a 
direct and early response to EBNA2 induction in this cell line Another observation was 
that mRNA levels for the bik gene were down regulated over 72 hours in response to 
EBNA2 expression Transcnption from the other apoptosis related genes does not appear 
to be affected by EBNA2 expression in this system In this expenment, the Kodak 
software-imaging system was used to densitometncally scan all relevant bands from the 
RPA shown Results showed a 5-fold increase in bfl-1 mRNA after 24 hours of EBNA2 
induction Levels of bik mRNA decreased just under 2 fold after 72 hours of EBNA2 
induction In all cases results were normalised using GAPDH densitometry values No 
significant changes in mRNA levels from any of the other genes were recorded
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3.1.2. Northern Blot Analysis of EBNA2 Induction of bfl-1 mRNA in DG75-tTA- 
EBNA2
Since RPA gives no indication about the size of a particular mRNA species, Northern 
blots were earned out to determine the size of the bfl-1 transenpt induced by EBNA2
3.1.2 1. Generating the bfl-1 and GAPDH Riboprobes.
A vector, pcDNA3-HA-Bfll containing the bfl-1 cDNA was used to generate the 32P- 
labelled bfl-1 nboprobe used in the Northern blots below (Also Figure 3 1) (Matenals 
and Methods) Figure 3 4 A shows the map of the vector pcDNA3 and the restnction sites 
in the polylinker region into which HA-bfl-1 was cloned (D'Sa-Eipper et a l , 1996) 
Figure 3 4B shows the results of the restriction enzyme analysis used to confirm the 
organization of the DNA fragment encoding HA-Bfl-1 in the vector pcDNA3-HA-Bfl-l 
After punfication and precipitation, the remainder of the BamHI restnction product (lane 
3) was used in an SP6 (Boehnnger Mannheim) dnven m vitro transcnption reaction, and 
labeled with 32P- to synthesize the antisense bfl-1 nboprobe (Figure 3 5B) With respect 
to the GAPDH probe, a commercially available template was purchased (Pharmmgen) 
and the RPA In Vitro transcription kit (Pharmingen) was used to synthesize the GAPDH 
nboprobe, which was also labeled with 32P
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Figure 3.4 Characterizing pcDNA3-HA-Bfl-l
Figure 3.4. A. Map of the expression vector pcDNA3-HA-Bfl-l. The polylinker containing multiple 
cloning restriction sites is flanked by the T7 and Sp6 promoters. The HA epitope was cloned between the 
Hindlll and BamHI sites and the bfl-1 ORF was cloned between the BamHI and Xhol sites in the 
polylinker region. B. Restriction enzyme analysis of pcDNA3-HA-Bfl-l. Lane 1 (M) = DNA molecular 
weight markers (sizes in kb indicated on the left hand side of the photograph.). Lane 2 is the undigested 
plasmid Digestion with BamHI (lane 3), or Xhol (lane 4) linearises the plasmid (Approximately 6.0kb). 
Digestion of the plasmid with BamHI and Xhol excises the 570bp BFL-1 ORF encoding DNA fragment. 
(Lane 5).
A second independent experiment in which EBNA2 was induced in the DG75-tTA- 
EBNA2 cell line by omission of tetracycline from the culture media was performed as 
before. Total protein was harvested in the usual manner and again RNA was harvested 
from the same cells at the same time. Western blot analysis was used to detect the 
expression of EBNA2 over a 72 hour-time course and the effects of EBNA2 induction on 
bfl-1 mRNA levels were analyzed by Northern blotting. Western blotting (Figure 3.5A) 
as before showed EBNA2 expression after 24 hours of induction, these levels remain 
detectable over the 72-hour time-course.
Thirty microgram samples of total RNA from the DG75-tTA-EBNA2 time course in 
3.5B and from control cell lines (in which bfl-1 is known to be expressed, see below) 
were size fractionated on 1.3% formaldehyde-agarose gel and then transferred to
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nitrocellulose membrane (BDH) The labeled antisense bfl-1 nboprobe was hybridized to 
the membrane-bound RNA in 6X SSC, 50% formamide, 1% SDS, 0 1% Tween, lOOptg 
of Escherichia coh tRNA for 24 hours at 55°C Membranes were washed (according to 
materials and methods) pnor to exposure to X-ray film at -70°C Blots were then stripped 
(Materials and Methods), and reprobed with the GAPDH nboprobe (Figure3 5B)
bfl-1 mRNA is up-regulated m response to EBNA2 expression (Figure 3 5B) As before, 
the intensities of relevant bands were estimated after densitometnc scanning and 
corrected for the amount of RNA being analyzed in each lane using GAPDH 
densitometry data The exact level of up-regulation was difficult to establish accurately 
due to the very low levels o f bfl-1 mRNA transcnpt pnor to induction o f EBNA2, 
however densitometry analysis showed a 6 2 fold up-regulation of bfl-1 mRNA at 24 
hours post EBNA2 induction
RNA from the control cell lines IARC 290B, IARC171, X50-7 (LCLs which express all 
the EBV latent genes), AG876 (a type in BL expressing all the latent EBV genes) and 
DG75-tTA-LMPl (in which LMP1 had been induced for 24 hours) were analyzed in the 
same blot Only one bfl-1 mRNA species of 0 8-0 85 kb was detected m all cases 
(controls and DG75 tTA EBNA2) albeit at very low levels in the DG75tTA EBNA2 cell 
line pnor to EBNA2 induction
The size of the observed transcnpt was in agreement with the previously reported size of 
the transcnpt ~ 0 8Kb from this gene (Kenny et a1, 1997) These expenments confirm 
the RPA results in Figure3 3 and show that expression o f EBNA2 as sole EBV protein in 
the EBV-negative BL cell line DG75, leads to an increase in the level of bfl-1 mRNA
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3.5 Northern Blot Analysis of EBNA2 Activation of bfl-1 mRNA
bfl-1 mRNA is Up-regulated in Response to Induction of EBNA2 in the DG75tTA-
EBNA2 Cell Line.
W estern Blot Dg75tTA-EBNA2
A^
 Hours Post EBNA2 Induction
0 24 48 72
Figure 3.5. bJU 1 mRNA is Up-regulated in Response to Induction of EBNA2 in the DG75tTA-EBNA2 Cell 
Line. Protein and RNA from DG75tTA-EBNA2 cells induced to express EBNA2, were harvested
simultaneously and assayed in panels A and B respectively. (A) Western blot analysis of EBNA2
expression in the Dg75tTA-EBNA2 cell line over the 48 hour EBNA2 induction period. (B) Northern
blot analysis of b fl-1 mRNA levels in DG75-tTA-EBNA2 (upon induction of EBNA2) and in LCLS
and type HI cell lines (upper panel). Total RNA was prepared at various time-points after EBNA2
induction (indicated in hours above each lane in all blots in this figure). RNA samples (30ug) were loaded
onto the gel, which was then blotted and probed with antisense bfl-1 riboprobe as described in the text The
blot was exposed to film for 24h. The lower panel of (B) above shows the same blot reprobed with a
GAPDH antisense riboprobe. Simultaneously, (same blot) Northern blot analysis of bfl-1 expression in
IARC 290B, AG876, B172 and DG75tTA-LMPl (in which LMP1 has been induced for 24 hours) was
undertaken. A single ~850kb bfl-1 mRNA transcript was apparent in all cases. This transcript matched the
previously reported size for the transcript from this gene.
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It was important to establish if bfl-1 regulation by EBNA2 was a general phenomenon in 
BL cells and to this end experiments with a similar objective were performed using 
established transfectants of a second well-studied EBV-negative BL cell line, BL41 
These transfectants also used a conditional system, in this system, the function of EBNA2 
was dependent on the presence of estrogen
3.1.3. Estrogen-Regulatable Expression of Functional EBNA2 in BL41-ER/E2- (K3) 
and BL41P3HR1-ER/E2- (9A) Cell Lines.
Fusion of a given protein with the hormone-binding domain of a steroid receptor can 
render protein function dependent on the presence of that hormone (Eilers ei a l , 1989, 
Picard et a l , 1988) Kempkes et a l , 1995a generated EBNA2-estrogen receptor fusion 
constructs by fusing the hormone-binding domain of the estrogen receptor to the N 
terminus of EBNA2, thus rendering EBNA2 functionality and its ability to interact with 
CBF1, dependent on the presence of estrogen They infected the EBV-negative BL- 
denved cell line BL41 with a mim-EBV plasmid carrying the EBNA2 gene that had the 
hormone-binding domain o f the estrogen receptor fused to its N terminus giving rise to 
the BL41-ER/EBNA2-K3 cell line in which EBNA2 function is dependent on the 
presence of estrogen Because of the specific way in which EBNA2 activity can be 
controlled, this cell line, as with DG75-tTA-EBNA2, was useful for this study in 
analysing the individual effects of EBNA2 expression m an EBV and therefore LMP1 
negative background Another similar cell line was also used in this study, namely 
BL41P3HR1-ER/EBNA2-9A This cell line was generated by infection of the BL41 cell 
line with two virions, the EBV-P3HR1 virus genome and the mim-EBV plasmid carrying 
the estrogen fused EBNA2 gene P3HR1 is an EBNA2-deficient strain of EBV (Kempkes 
et a l , 1995a) To activate EBNA2 to its functional form, (in both BL41-ER/E2-K3 and 
BL41P3HR1-ER/E2-9 A) estrogen (P-estradiol) was added to the culturing media to a 
final concentration o f luM, m accordance with previously published studies (Kempkes et 
a l , 1995a)
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Western blotting was first earned out (Figures 3 7A/B 3 8A/B) to show the presence of 
EBNA2 m the BL41-ER/E2- (K3) and BL41/P3HR1-ER/E2- (9A) cell lines EBNA2 was 
activated by adding estrogen to the cells dunng cultunng, and both protein and RNA was 
harvested from the cells at the indicated time-pomts over a 24 hour-time penod 
Activation of EBNA2 in response to the addition of EBNA2 was then analysed by 
examining transcnption from CD21, an EBNA2 target gene, by Northern blotting 
(Figure 3 7C/D, 3 8C/D) It can be seen from the Western blot that there is an increase in 
the level of EBNA2 protein upon addition of estrogen A 2 fold and 2 4 fold increase in 
EBNA2 levels m BL41-ER/2-K3 and BL41P3HR1-ER/E2-9A respectively, was 
calculated from the Western blots after protein loading was corrected for by 
densitometnc scanning o f the blot after Ponceaux staimng (3 7A/B and 3 8A/B) This 
increase in EBNA2 expression is most likely due to the fact that the estrogen responsive 
(ER)-EBNA2 fusion protein is being expressed from an EBNA2-regulated promoter 
(BamHIC) Thus activation of EBNA2 induces it to trans-activate the BamHIC promoter 
controlling its own expression This positive autoregulation of the BamHIC promoter by 
EBNA2 has been reported elsewhere (Jin and Speck, 1992, Rooney et a l , 1992, Sung et 
a l , 1991, Woisetschlaeger et a l , 1991, Kempkes et a l , 1995c) and is in itself evidence 
that addition of estrogen does indeed activate EBNA2 in this expenment
Analysed on the same Western blots was a protein extract from the reference LCL X50-7 
(Lane 9, Figure 3 7A/B, 3 8A/B) This lane was included in the blots as a positive control 
for EBNA2 expression It can be seen from the blots that the EBNA2 detected from the 
fusion protein lysates is a different (larger) size, as expected, to the wild-type EBNA2 
Differences in the size and thus the electrophoretic mobility o f these fusion proteins 
compared to their wild-type counterparts, have been noted elsewhere (Kempkes et a l , 
1995a)
Although it is evident from the Western blot that EBNA2 is expressed, it is only possible 
to determine the functionality of that EBNA2 indirectly, by Northern blotting for CD21
3.1.4. Functional EBNA2 is Expressed in the BL41-ER/E2- (K3) and BL41/P3HR1-
ER/E2- (9A) Cell Lines in Response to Estrogen Addition.
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mRNA, since CD21 is one of the known target genes of EBNA2 m this cell background 
(Cordier et a l , 1990, Kempkes et a l , 1995a) (Figure 3 7C/D, 3 8C/D)
3.1.5. Generating the CD21 DNA Probe.
A vector containing a 1 6Kb portion of the CD21 cDNA was obtained from Dr Bettina 
Kempkes (Table 2 2) Figure 3 6A shows the map of pUC19 and the restriction sites in 
the polylmker region into which a 1 6Kb fragment of CD21 cDNA was cloned (Weiss et 
a l , 1986, Strobl et a l , 2000) Figure 3 6B shows the results of the restriction enzyme 
analysis used to confirm the organisation of the DNA fragment encoding CD21 cDNA m 
the vector pUC19-CD21 The DNA probe used in the CD21 Northern blots was made by 
excision of the CD21 cDNA from pUC19-CD21 by restriction digestion with EcoRl 
(1 6kb, in lane 3) (an extra EcoRl site had been introduced in the sub cloning of the 
CD21 cDNA into pUC19) This 1 6kb fragment was then excised from the agarose gel 
and purified using a microspin column (Promega Wizard system) The probe was then 
labelled with 32P by random pruning using a commercially available kit (Boehnnger 
Mannheim) and punfied over a Sephadex column (Pharmacia) (As for Strobl et a l , 
2000) RNA size fractionation was performed m a denaturing formaldehyde-agarose gel 
followed by blotting and probing with the appropriate radiolabeled probes, as described 
in the materials and methods section 2 5 3
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Figure 3.6. Characterizing PucCD21.
Figure 3.6. Characterizing PucCD21. (A) Restriction Map of the pUC 19 vector into which the CD21 
cDNA was cloned. The 1.6Kb CD21 cDNA insert was cloned between the two restriction sites indicated in 
the multiple cloning site of pUC19, with the insertion of an extra EcoRl site. (B). Restriction digestion 
analysis of pUCCD21. Lane M contains the Invitrogen 1Kb DNA ladder. Lane (i) contains undigested 
plasmid DNA. Lane 2 contains Hindlll digested plasmid DNA resulting in the linearization of the plasmid 
with an expected size of 4.2Kb. Lane 3 contains EcoRl digested pUCCD21. The 1.6Kb CD21 insert is 
clearly visible and this band was excised and used as the template for the synthesis of the CD21 probe 
(Figures 3.7 and 3.8).
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Figure 3.7 EBNA2 is Present in BL41-ER/EBNA2-K3 and its Function is Activated
in Response to Estrogen Addition.
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Figure 3.7. Functional EBNA2 is present in the BL41-ER/E2 (K3) cell line. EBNA2 function was 
activated in the BL41-ER/E2 (K3) cell line by addition of estrogen to the culture media. Total RNA and 
protein was harvested at 0, 3 ,6 , 9 12 and 24 hours post estrogen addition (EBNA2 activation) and after six 
hours in the presence of cyclohexamide (Cx) before and after EBNA2 activation. Panel B Western blot 
showing EBNA2 expression before and after induction over the experimental time course. EBNA2 
activation induces its own expression as it up-regulates the BamHIC promoter thus EBNA2 expression is 
up-regulated over the 24-hour period post activatioa Lane 9 of the Western blot shows wild-type EBNA2 
expression in an LCL X50-7, the Estrogen fusion protein as expected is about 20Kb larger than its wild- 
type counterpart Panel A shows the ponceaux staining of the Blot in panel B. In order to verify that the 
(EBNA2) protein expressed in the cells was functional, transcription from a known target gene of EBNA2 
namely CD21 was analysed by Northern blotting. Panel C. Northern blot showing the up-regulation of 
CD21 in response to EBNA2 activation over the 24hr time course. Panel D shows the ethidium bromide 
staining of the gel used for blotting in panel C.
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Figure 3.8 EBNA2 is Present in BL41P3HR1-ER/EBNA2-9A and its Function is 
Activated in Response to Estrogen Addition.
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Figure 3.8. Functional EBNA2 is present in the BL41P3HR1-ER/E2 (9A) cell line. EBNA2 function 
was activated in the BL41P3 HR 1-ER/E2 (9A) cell line by addition of estrogen to the culture media. Total 
RNA and protein was harvested at 0, 3, 6, 9 12 and 24 hours post estrogen addition (EBNA2 activation) 
and after six hours in the presence of cyclohexamide (Cx) before and after EBNA2 activation Panel B 
Western blot showing EBNA2 expression before and after induction over the experimental time course. 
EBNA2 activation induces its own expression as it up-regulates the BamHIC promoter thus EBNA2 
expression is up-regulated over the 24-hour period post activation. Lane 9 of the Western blot shows wild- 
type EBNA2 expression in an LCL X50-7, the Estrogen fusion protein as expected is about 20Kb larger 
than its wild-type counterpart. Panel A shows the ponceaux staining of the Blot in panel B. In order to 
verify that the (EBNA2) protein expressed in the cells was functional, transcription from a known target 
gene of EBNA2 namely CD21 was analysed by Northern blotting. Panel C. Northern blot showing the up- 
regulation of CD21 in response to EBNA2 activation over the 24-time course. Panel D shows the ethidium 
bromide staining of the gel used for blotting in panel C.
139
The results show a significant elevation of CD21 mRNA levels in response to EBNA2 
activation With respect to the BL41-ERE2(K3) time-course, a biphasic change in 
Cd21mRNA levels over the 24-hour period of EBNA2 activation was observed Levels 
start off high at 3 hours post induction but appear to fall after six hours post EBNA2 
activation Levels then steadily rise again over the time-penod analysed CD21 mRNA 
levels, interestingly do not show the same biphasic pattern for the BL41P3HR1- 
ERE2(9A) samples CD21 mRNA levels rise over the 14-hour time-penod, in response to 
EBNA2 activation (figure3 8D) The lower panel shows the rRNA bands from the same 
ethidium bromide-stained gels used prior to blotting These results demonstrate that (1) 
ER-EBNA2 is present in both BL41-EREBNA2-K3 and BL41P3HR1-EREB9A and that 
(11) EBNA2 function is activated in response to oestrogen in that one of its known target 
genes (namely CD21) is activated in response to the addition of oestrogen
3.1.6. bfl-1 is a Transcriptional Target of EBNA2-Estrogen Fusion Proteins in the 
BL41/ER-EBNA2(K3) and BL41P3HR1/ER-EBNA2 (9A) Cell Lines.
Estrogen-regulatable EBNA2 was functional in the two cell lines (BL41-EREBNA2-K3 
and BL41P3HR1-EREBNA2-9A) since CD21 mRNA levels were up-regulated in 
response to estrogen addition Northern blotting (using the probe from Figure3 5) was 
then used m order to ascertain if bfl-1 was a transcriptional target of EBNA2 in this cell 
background The same RNA used m the CD21 blots above (Figures 3 7C/D and 3 8C/D) 
was used to measure bfl-1 mRNA levels m response to EBNA2 activation over the same 
24 hour-time period Protein extracts were also prepared over the time course and 
Western blotting was earned out to measure Bfl-1 levels in each of the cell lines before 
and after the activation of EBNA2 It can be seen m Figure 3 9 (Panel A) that Bfl-1 
protein was detected m response to EBNA2 activation in both the K3 (Column I) and 9 A 
(Column II) cell lines Similarly to the bfl-1 mRNA, the Bfl-1 protein was detected in the 
K3 cell line 3 hours after EBNA2 activation and after 6 hours m the 9A cell line Figure 
3 9 also shows up-regulation of bfl-1 mRNA in response to EBNA2 activation m both 
BL41-ER/E2 (K3) and BL41P3HR1-ER/E2 (9A) cell lines (Panels BI and BII) The fold 
induction was calculated at 6 2 and 5 8 fold respectively, m the two cell lines The lower
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panel (PanelC) shows GAPDH mRNA levels obtained when the bfl-1 blots were stripped 
and reprobed using the GAPDH probe as before. The bfl-1 mRNA induction values 
recorded, were again measured after correction for loading was accounted for using the 
densitometry data for the GAPDH blots. Once again, RNA from cell lines known to 
express bfl-1 were included in the Northern blots, (Column ID) not only as a positive 
control for the bfl-1 riboprobe itself but also as an aid to showing the transcript obtained 
was the size of the bfl-1 transcript recorded in the literature (Figure 3.9 III). A single 
mRNA transcript of the expected size of 0.8kb was observed.
Figure 3.9. bfl-1 is a Target Gene of EBNA2 in EREBNA2-BL41-K3 and 
EREBNA2-BL41-P3HR1-9A Cell Lines
BL41-ER/E2(K3) BL41P3HR1-ER/E2(9A)
Western Blot I II
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Figure 3.9. Bfl-1 is transcriptionally up-regulated by EBNA2 in BL41-ER/E2 (K3) and BL41P3HR1- 
ER/E2 (9A). Panel A shows the levels of Bfl-1 protein detected in the K3 (Column I) and 9 A (Column II) 
cell lines, in response to EBNA2 activation. Panel B (Columns I and II) shows bfl-1 mRNA levels in 
BL41-ER/E2 (k3) and BL41P3HR1-ER/E2 (9A) respectively in response to EBNA2 activation over a 24- 
hour time-course. Panel B column HI shows the steady state level of bfl-1 mRNA in a range of cell lines 
known to express bfl-1, including IARC 171 and IARC 290B which are LCLs and AG876 which is a type 
III BL cell line, these cell lines act as a positive control for bfl-1 expression. Also shown in this panel are
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the steady state levels of bfl-1 mRNA in the EBV negative DG75tTA-LMPl before and after the induction 
of LMP1, these represent negative and positive controls respectively for the expression of bfl-1 The Bfl-1 
protein was detected in both the K3 and 9A cell lines within 3 and 6 hours respectively, of EBNA2 
activation (Panel A columns I and II) In the case of BL41-ER/E2 (K3)(BI), and BL41P3HR1-ER/E2 
(9A)(BII), bfl-1 mRNA is up-regulated m response to EBNA2 activation over the 24-hour time course In 
the control cell lines bfl-I mRNA is present m relatively high levels in the 2 LCLs and the typelll BL, it is 
also detected in the LMP1 expressing DG75tTA LMP1, but only at very low levels in the DG75tTALMPl 
which has not been induced to express LMP1 In all cases the transcript detected is the same size ~0 8kb 
However a “smile” in columns I and n  is apparent Panel C shows the GAPDH mRNA levels detected in 
the various cell lines after the blots in panel A above were stripped and reprobed Using densitometry data 
to normalise for loading, bfl-1 mRNA increased 6 2 and 5 8 fold in response to EBNA2 activation in BL41- 
ER/E2 (K3) and BL41P3HR1-ER/E2 (9 A) respectively
3.1,7. EBNA2 Specifically Up-Regulates the bfl-1 Gene in the EBV Positive 
BL41P3HR1-ER/E2 (9A) in an LMPl-independent Manner.
Since BL41P3HR1-EREBNA2 9A is actually an EBV-positive (but EBNA2 and LMP1 
negative) cell line and therefore expresses other EBV latent proteins, it was important to 
establish that LMP1 was not induced m response to EBNA2 activation Western blotting 
using the anti-LMPl murme-monoclonal antibody cocktail CS1-4, demonstrated that 
LMP1 was not detected in BL41P3HR1-EREBNA2 9A pre- or post- addition of 
estrogen/EBNA2 activation (Figure 3 10), but was detectable in the control DG75tTA- 
LMP1 cell extract (24 hours post LMP1 induction) Thus, EBNA2 specifically up- 
regulates the bfl-1 gene in the EBV positive BL41-P3HR1-ER/E2 (9A) cell line in an 
LMPl-independent manner
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Figure 3.10. EBNA2 Specifically Up-Regulates the bfl-1 Gene in the EBV Positive
BL41P3HR1-ER/E2 (9A) Cell Line, in an LMPl-Independent Manner.
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Figure 3.10 EBNA2 specifically up-regulates the bfl-1 Gene in the EBV positive BL41P3HR1-ER/E2
(9A) in an LMPl-independent manner. Since BL41P3 HR 1-ER/E2 is EBV infected, Western blotting 
was undertaken to determine if LMP1 was up-regulated in response to EBNA2 activation in this cell line. 
Protein samples used in the Western in Figure 3.8B were also analysed for the presence of LMP1 using the 
CS1-4 anti LMP1 Antibody cocktail. LMP1 was not detected in BL41 an EBV negative Cell Line (Lane 2). 
The ~60Kda LMP1 protein was detected in the DG75tTALMPl extract at 24hours post LMP1 induction 
(Lane3), but not in the BL41P3HR1-ER/E2 (9A) either before (Lane4) or after (lanes 5 and 6) induction of 
EBNA2. Thus EBNA2 up-regulates bfl-1 mRNA in the BL41P3HR1-ER/E2 (9A) cell line in an LMP1 
independent manner.
It is clear from the ensemble of these experiments that EBNA2 up-regulates bfl-1 mRNA 
and protein in (i) B141-EREBNA2-K3 in which it is the sole EBV protein and (ii) in 
BL41P3HR1-EREBNA2-9A in the absence of LMP1 expression. These results 
corroborate the findings in the DG75-tTA-EBNA2 cell line and together the results 
indicate that EBNA2 alone induces bfl-1 mRNA and protein in two well-studied BL cell 
lines, BL41 and DG75. These findings were also confirmed by RPA analysis (See Figure 
3.11 and 3.12).
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3.1.8. Identifying Other Apoptosis-Related Transcriptional Targets of ER-EBNA2 
in BI41-EREBNA2-K3 and BL41P3HR1-EREBNA2-9A.
Having established that bfl~l is indeed a target gene of EBNA2 in these cell lines it was 
plausible to then investigate, in this system, if any of the other apoptosis-related/bcl-2 
family genes were also EBNA2-responsive In order to determine this, RPA was earned 
out as before this time using the hAP02C multiprobe (Pharmingen), a modified version 
of the hAP02 probe set It can be seen from the RPAs (Figures 3 11 and 3 12) for each 
of the above cell lines, that elevated levels of bfl-lmRNA were once again induced in 
response to EBNA2 activation This is evident over the 24-hour time-course examined 
The GAPDH -corrected densitometry data indicated a 5 2 and 5 5 fold induction o f bfl-1 
mRNA transenpts in the K3 and 9A cell lines respectively, in response to EBNA2 
activation (Figure3 11 and 3 12) Interestingly (as in the DG75-tTA-EBNA2 cell line 
Figure 3 3) another apoptosis-related gene, bik, appeared to be down regulated by 
EBNA2 activation No significant changes in the mRNA levels from any of the other 
apoptosis-related genes was observed over the time-course investigated Using 
densitometry data, mRNA levels of the pro-apoptotic bik gene, were reduced by over 
50% m both BL41-ER/E2-K3 and BL41P3HR1-ER/E2-9A, in response to EBNA2 
activation over the 24-hour time-course (Figure 3 11, 3 12) Western blotting to detect 
the expression of Bik was also earned out on protein extracts harvested at the same time 
as the RPA samples, however no protein could be detected in control or sample cell lines 
using the only available antibody (Santa Cruz NBK (bik) Cat No SC 1710) The 
combination of the up-regulation of transcnption form the anti-apoptotic bfl-1 and the 
down-regulation of transcnption from the pro-apoptotic bik gene would suggest that 
EBNA2 expression may have a protective effect on BL cells under conditions where 
apoptosis is induced e g using lonomycin and serum starvation (See Figure 3 64) 
Down-regulation of bik mRNA was much less, and not observed until 72h in the 
DG75Tta-EBNA2 cell line when EBNA2 was induced (See Figure 3 3B)
144
Figure 3.11. Activation of EBNA2 Up-Regulates bfl-l mRNA Levels in an EBV- 
Negative Burkitt’s Lymphoma Cell Line BL41-ER/EBNA2 -K3.
BL41-ER/E2(K3)
H o u rs Post-A dd ition  o f  E strogen
9 12 24
A ffect o f  C yclohexam ide 
6 C x  6 C X e
bel w 
bclx
bfl-l
bad
bik
bak
box
bcl-2
mcUl
L32
GAPDH
b f l - l
b ik
Figure 3.11. EBNA2 Up-Regulates b fl-l mRNA Levels and Down Regulates bik mRNA Levels in an 
EBV Negative BL Cell Line. EBNA2 was activated by addition of estrogen to the culture media as before. 
Total RNA was harvested at the indicated time points in the usual manner and the effect of EBNA2 
activation on the bcl2 family of apoptosis related genes was analysed using multiprobe RPA analysis. Over 
the 24-hour time course, bfl-l mRNA levels were up-regulated (5.2 fold) in response to EBNA2 activation, 
while bik mRNA levels were down regulated (~2 fold) in response to EBNA2 activation. In order to assess 
if induction of bfl-l mRNA was a direct effect of EBNA2 activation, cyclohexamide (Cx), an inhibitor of 
protein synthesis was added and cells harvested after six hours of exposure to cyclohexamide before (6Cx) 
and after (6Cxe) addition of estrogen. Total RNA was extracted in the same way as for other samples and 
RPA performed as described in the materials and methods.
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Figure 3.12. EBNA2 Up-Regulates bfl-1 mRNA Levels in an EBV-Positive Burkitt’s
Lymphoma Cell Line in an LMPl-lndependent Manner.
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Figure 3.12. EBNA2 up-regulates bfl-1 mRNA levels and down regulates bik mRNA levels in an EBV 
positive BL ceU Une in an LMP1 independent manner. EBNA2 was activated by addition of estrogen to 
the culture media as before. Total RNA was harvested at the indicated time points in the usual manner and 
the effect of EBNA2 activation on the bcl2 family of apoptosis related genes was analysed using 
multiprobe RPA analysis. Over the 24-hour time course, bfl-1 mRNA levels were up-regulated (5.8 fold) in 
response to EBNA2 activation, while bik mRNA levels were down regulated (~2 fold) in response to 
EBNA2 activation. Western blotting had been used to show no LMP1 expression occurred in response to 
EBNA2 activation, thus the effects on the transcription from the various genes could be attributed to the 
activation of EBNA2 alone. In order to assess if induction of bfl-1 mRNA was a direct effect of EBNA2 
activation, cyclohexamide (Cx), an inhibitor of protein synthesis was added and cells harvested after six 
hours of exposure to cyclohexamide before (6Cx) and after (6Cxe) addition of estrogen. Total RNA was
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extracted in the same way as for other samples and RPA performed as described m the materials and 
methods
Overall these results demonstrate that the anti-apoptottc gene bfl-1 is a target o f EBNA2 
in a BL-denved cell background EBNA2 up-regulates bfl-1 mRNA levels m an EBV- 
positive cell line in the absence of LMP1 (Figure 3 12) In addition, the pro-apoptotic 
gene bik also appears to be a transcriptional target of EBNA2 in these BL cell lines, as 
the RPA experiments show a reduction of 50% in the steady-state level of its mRNA after 
24 hours in both BL41-EREBNA2-K3 and BL41P3HR1-EREBNA2-9A in response to 
activation o f ER-EBNA2 Transcription from the bik gene is also down regulated in the 
DG75EBNA2tTA system after 72 hours o f EBNA2 expression
3.1.9. Cyclohexamide: Effect of protein synthesis on EBNA2 fusion protein activity.
Cyclohexamide is an antibiotic that inhibits protein synthesis BL41-ER/E2 (K3) and 
BL41P3HR1-ER/E2 (9A) cell lines were treated with 50ug/ml cyclohexamide for six 
hours with and without EBNA2 activation and the samples were analysed by both 
Northern blotting and RPA Cyclohexamide was used to determine if  the effect of 
EBNA2 on bfl-1 mRNA was specific to EBNA2 thus when all new protein synthesis is 
stopped, and EBNA2 alone is activated, EBNA2 alone is responsible for the effect on bfl- 
1 mRNA In figures 3 11 and 3 12 it can be seen that in the presence o f cyclohexamide 
without EBNA2 activation, bfl-1 mRNA is detected only at very low levels however 
upon activation of EBNA2 in the presence o f cyclohexamide an increase in bfl-I mRNA 
is seen These results imply that bfl-1 is a direct target gene of EBNA2
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3.2.0. b flrl Promoter Studies. Effect of EBNA2 on bfl-1 Promoter Activity.
Having established that EBNA2 alone can up-regulate bfl-1 mRNA and protein levels m 
B cell lines, it was then necessary to determine if this up-regulation was due to an 
enhanced rate of transcription from the promoter of the bfl-1 gene In order to investigate 
if increased bfl-1 promoter activity was involved, a suitable bfl-1 promoter-reporter 
construct had first to be generated
Promoter reporter assays are one o f the most common and convenient ways of assessing 
transcriptional activity The activity o f the promoter of interest is assessed by transfection 
of a construct containing the promoter sequence fused to a reporter gene into an 
appropriate cell line Promoter activity in response to a chemical stimulus or a protein 
expressed from another plasmid that is cotransfected with the promoter-reporter construct 
is then measured by assaying for reporter activity Two of the commonly used reporter 
genes in promoter-reporter constructs encode the enzymes chloramphenicol acetyl 
transferase (CAT) and luciferase (luc) However, the greater sensitivity and rapidity of 
luciferase assays has resulted m the popular usage of luobased rather than CAT-based 
promoter-reporter constructs for evaluating transcriptional activity m transfected cells It 
was therefore decided to investigate the regulation of the bfl-1 promoter activity by 
EBNA2 using a luciferase based system
3.2.1. bfUl Luciferase Promoter Reporter Construct -1374/+81 bfl-1 Luc.
The 1 4kb DNA sequence from the 55 transcriptional regulatory region (-1374/+81) of the 
human bfl-1 gene was obtained as a fragment cloned into the promoterless pCAT basic 
plasmid (Zong et a l , 1999) In order to change the reporter context of the p-1374/+81Bfl- 
1-CAT construct to a luciferase based system, a cloning strategy based on replacing the 
CAT gene with the luciferase gene from pGL2-basic vector (Promega) m the pCAT basic 
background was employed The circle maps o f pCAT -basic and pGL2 basic are shown 
in Figure 3 20 The sites in the pCAT basic polylinker into which the -1374/+81 region 
of the bfl-1 gene was cloned are indicated The -1374/+81 Bfl-1 Luc reporter plasmid 
contains the -1374/+81 region of bfl-1 cloned just upstream of the luc gene and was
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constructed m the laboratory by B D’ Souza Using the same strategy as B D’ Souza 
further promoter deletion constructs were generated at a later date (Figure 3 20 )
Figure 3 13 shows the results of the restriction enzyme analysis used to confirm the 
organisation o f the DNA fragment encoding -1374/+81 bfl-1 in the vector -1374/+81 
Bfl-1 Luc
Figure 3.13, Characterizing -1374/+81 Bfl-1 Luc.
Figure 3.13 Characterizing -1374/+81 Bfl-1 
Luc. The EcoRl restriction digestion pattern of p- 
1374/+81 Bfl-1 Luc plasmid confirms the expected 
organisation of the plasmid 
Lane M is the Invitrogen 1Kb DNA Ladder Lanes 
1-3 p-1374/+81 Bfl-1 Luc Lane 1 is undigested 
plasmid DNA Lane 2 shows the EcoRl digestion 
pattern, resulting m a 4 7Kb fragment and a 2 0KB 
fragment Lane 3 shows the BamHl digestion 
pattern Restriction with BamHl linearizes the -  
1374/+81 bfl-1 Luc plasmid resulting in a 6 7Kb 
fragment
3.2.2. Characterising the EBNA2 Expression Plasmids.
Two EBNA2 expression plasmids (pPDL151) and (pPDL152), were obtained (from 
Diane Hayward, Table 2 2) pSG5EBNA2 (also known as pPDL151(Lmg et a l , 1993) 
consists of the wild type B95-8 EBNA2 gene cloned into the SG5 vector (Stratagene) 
pSG5EBNA2WW323SR (also known as pPDL152) had been constructed by replacing 
two tryptophan residues at positions 323 and 324 in the EBNA2 CBF1 binding domain 
with a senne and arginine residue respectively and in so doing abrogating its ability to 
bind CBF1 The mutant gene was then cloned into the pSG5 vector (Ling et a l, 1993) 
Implicit in this mutation was the introduction of an extra Xbal restriction site in the 
pSG5EBNA2WW323SR construct, this extra site was used to distinguish the plasmids by
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restriction analysis prior to use, as shown below Co-transfection experiments with these 
plasmids and the bfl-1 promoter reporter constructs should elucidate not only the 
involvement of EBNA2 but also any possible involvement of CBF1 m trans-activation of 
the bfl-1 promoter by EBNA2 All other gifted plasmids were similarly checked pnor to 
use (Not Shown)
Figure 3.14. Characterising the pSG5EBNA2/pSG5EBNA2WW323SR Expression 
Plasmids.
Figure 3 14 Charactensing the pSG5EBNA2/pSG5EBNA2WW323SR Expression Plasmids Lane 1 1Kb 
DNA Ladder (Invitrogen) Lanes 1, 4 and 7 contain undigested plasmid DNA from the pSG5, 
pSG5EBNA2 and pSG5EBNA2WW323SR expression plasmids Lanes 2, 5 and 8 show bgl II digested 
DNA from the pSG5, pSG5EBNA2 and pSG5EBNA2WW323SR expression plasmids respectively Lanes 
3, 6 and 9 show the restriction pattern for Xbal digestion for the pSG5, pSG5EBAN2 and 
pSG5EBNA2WW323SR expression plasmids respectively Restriction endonuclease digestion with bglll 
linearised the pSGS plasmid to give an expected size of around 4Kb (Lane 2) Both pSG5EBNA2 and 
pSGEBNA2WW323SR had another Bglll site introduced in the course of cloning the 1 6Kb 
EBNA2/EBNA2WW323SR fragments and thus digestion with Bglll excises the 1 6Kb EBNA2 insert thus 
a band of this size should be visible here, another band representing the 4 1Kb pSG5 into which 
EBNA2/EBNA2WW323SR had been cloned should also be apparent (Lanes 5 and 8) Finally only one 
Xba I site is present in pSG5 thus restriction digestion of pSG5 with Xbal linearizes the pSG5 vector to 
create a DNA band at 4 1Kb (Lane 3) In the case of pSG5EBNA2 only the pSG5 Xbal site is present thus 
restriction digestion with Xbal linearizes the pSG5EBNA2 vector generating a DNA band of 5 7Kb * For 
the EBNA2WW323SR mutant, an extra Xbal site has been introduced m the course of the mutagenesis and 
thus another fragment of around 450bp is generated (Lane 9)
M 1 2  3 4  5 6 7 8  9
6 0Kb
1 6Kb
1 0Kb  
0 5Kb
150
Figure 3.15. All DNA used in Transfection Studies was in the same Topological 
Condition and at a Similar Concentration.
w
O
i/i
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Figure 3.15. DNA Used in Transfection Analyses was in the 
Same Topological Condition and at Similar Concentration.
Although not digested, the condition and quality o f the DNA can be 
assessed by resolving the DNA through an agarose gel. This is 
necessary to allow comparison of transfection data for each 
particular experiment. In this case 500ng of DNA from the pSG5, 
pSG5EBNA2 and pSG5EBNA2WW323SR expression plasmids are 
shown after electrophoresis (for 1 hour) through a 1% agarose gel 
made up in IX  TAE.
3.2.3. EBNA2 Trans-Activates the bfl-1 Promoter in BL Cell Lines by a Mechanism 
Requiring CBF1.
pSG5EBNA2 and pSG5EBNA2WW323SR were titrated against the bfl-1 promoter 
reporter construct in co-transfection studies, bfl-1 promoter activity was then analysed 
using the luciferase assay. One, 3,5,7 and lOug of the two EBNA2 expression plasmids 
were transiently co-transfected with lug of the bfl-1 promoter reporter construct, -  
1374/+81 bfl-1 Luc, in the EBV negative cell line DG75.
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Figure 3.16 Titration of pSG5EBNA2 and pSG5EBNA2WW323SR with -1374/+81 
bfl-1 Luc
Figure 3 16. Activity of the Ayï-7-hiciferase promoter construct (-1374/+81 Bfl-1 Luc) Upon Titration 
of pSG5EBNA2 and pSG5EBNA2WW323SR Expression Plasmids lug of the bfl-1 promoter reporter 
was cotransfected mto DG75 cells with varying quantities of pSG5EBNA2 and pSG5EBNA2WW323SR. 
Cells were harvested 48 hr after transfection and analysed for luciferase activity A dose-dependent 
increase m bfl-1 promoter activity was observed m response to co-transfection with increasing quantities of 
pSG5EBNA2 expression plasmid PSG5EBNA2WW323SR only weakly transactivated the bfl-1 promoter 
over the range of quantities assayed Thus binding of the CBF1 transcription factor may be important m 
mediating EBNA2 transactivation of the -1374/+81 bfl-1 Luc promoter * Fold activation with the “empty” 
pSG5 vector (basal transactivation levels) is arbitrarily set to 1 and activation by the pSG5-related 
expression vectors are expressed relative to this This is the case for all subsequent transfection 
experiments
Transfections in the DG75 cell lme were earned out using the DEAE dextran method 
(See Matenals and Methods) unless otherwise stated Bnefly the pnnciple of this method 
of transfection relies on the positively charged diethylaminoethyl (DEAE)-dextran 
interacting with the negatively charged phosphate backbone of DNA The resulting 
complex is then absorbed into cells by endocytosis Because o f the toxicity of the DEAE
T ran s-activa tion  o f the bfl-1 prom oter by pSG 5EBN A2(PD L151) and 
pSG5EBNA2W W 323SR(PD L152)
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dextran this method of transfection is most commonly used in transient transfections 
The total amount of expression plasmid was adjusted in all cases to lOug with the empty 
vector pSG5 Trans-activation rates were determined by standardizing the luciferase 
values obtained with luciferase values recorded from transfections with pSG5 alone A 
plasmid carrying the Lac Z (p7CMV Lac Z) gene was also included in each transfection 
and transfection efficiency was accounted for by measuring beta-galactosidase activity 
(Materials and Methods )
A clear dose dependent increase in bfl-1 promoter activity occurs m response to addition 
of increasing quantities of the EBNA2 expression plasmid pSG5EBNA2 (Figure 3 16) 
Promoter activity increased up to an average of 9 fold with the addition of 7ug of 
pSG5EBNA2 Any further increase in the amount of EBNA2 expression plasmid added 
did not increase trans-activation o f the promoter m this system Thus a 1 7 ratio of bfl-1 
promoter-reporter plasmid EBNA2 expression plasmid was deemed optimal in this 
system Optimal-fold trans-activation was recorded at an average value of 9 3 fold over 
the course of three independent experiments The CBF1- mutant 
pSG5EBNA2WW323SR EBNA2 expression plasmid trans-activated the promoter 
weakly (between 1 2 and 2 02 fold) over the range of concentrations used This result 
indicates that EBNA2 trans-activates the bfl-1 promoter via a mechanism requiring the 
cellular DNA binding protein CBFl/RBP-jk
Total protein was extracted from the transfected cells and Western blotting performed 
using the PE2 antibody to detect the presence of EBNA2, however this antibody did not 
detect EBNA2 in the transiently transfected cells Transfections were scaled up to 
increase protein yields however Western Blotting still proved unsuccessful This problem 
has been experienced elsewhere (Zimber-Strobl et a l, 1994) EBNA2 protein expression 
from these constructs (pSG5 EBNA2 and pSG5EBNA2WW323SR) were detectable 
however after stable transfection in the DG75 cell line (Figure 3 61)
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3,2.4. EBNA2 Trans-activates the bfl-1 Promoter via CBF1 in 2 Other BL Cell 
Lines.
It was important to establish if the trans-activational effect of EBNA2 on bfl-l was a 
feature in other BL cell lines (Figure 3 17) For this reason, similar experiments were 
carried out in two other well-studied BL cell lines, namely BL41 and BJAB (Described in 
materials and methods Table 1 0) Co-transfections for the BJAB cell line were 
performed using the DEAE-dextran method as before BL41 cells were transfected by 
electroporation (see materials and methods) In all cases, cells were harvested 24-48 
hours post-transfection and lysates produced in an identical manner to DG75 cells before 
Activity of the bfl-1 promoter was then assessed using the luciferase assay The 
optimized Promoter expression-plasmid ratio determined in the previous experiment was 
used with lug of -1374/+81 bfl-1 Luc, co-transfected with 7ug of  
pSG5EBNA2/pSG5EBNA2WW323SR expression plasmids As before, fold trans- 
activation values were obtained using Beta-gal corrected luciferase values In both cell 
lines, there is significant trans-activation of the bfl-1 promoter by pSG5EBNA2 In BL41 
the promoter was trans-activated an average of 5 4 fold while m Bjab the fold-trans- 
activation was slightly higher at 5 7 fold pSG5EBNA2WW323SR only weakly trans- 
activates -1374/+81 bfl-1-Luc in both cell lines This data demonstrates the importance 
of the EBNA2 CBF1 binding site for the trans-activational effect of EBNA2 on the bfl-1 
promoter in both B141 and Bjab cell lines
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Figure 3.17 EBNA2 Trans-activation of the bfl-1 Promoter (-1374/+81 bfl-1 Luc) in 
both BL41 and Bjab Cell Lines Requires the EBNA2 CBF1 Binding Domain.
Trans-activation o f the bft-1 promoter -1374/+81-Luc in EBV neagtive
BL cell lines
1 5 
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Figure 3.17 EBNA2 Trans-activates the b f l - 1  Promoter in a Range of BL Cell Lines by a Mechanism 
Dependent Upon its Ability to Bind to CBF1 BL41 and Bjab cells were transfected by electroporation 
and the DEAE-dextran methods respectively One nucrogram of the bfl-1 promoter reporter construct (- 
1374/+81 bfl-1 Luc), was co-transfected with 7ug of pSG5EBNA2 or pSG5EBNA2WW323SR After 48 
hours cells were lysed and promoter activity assessed by the luciferase assay The luciferase assay was 
performed using the Shaeff lummoskan 2000 All values are relative to the activity reported by the pSG5 
vector alone All values are also corrected using B-Gal data It can be seen from the results that EBNA2 
trans-activates the ¿/-/luciferase reporter construct m these two BL cell lines It can be concluded from 
figures 2 2 and 2 3 that EBNA2 trans-activates the b f l - l  promoter m a range of BL cell lines by a 
mechanism dependent upon its ability to bmd to CBF1
3.2.5» Trans-activation of the bfl-1 Promoter by EBNA2 May be a B Cell Specific 
Effect.
It was also necessary to investigate if the EBNA2 trans-activational effect on bfl-1 was a 
B cell specific effect For this reason, similar co-transfection experiments were carried 
out with the EBNA2 expression plasmids and the bfl-1 promoter reporter constructs in a 
T cell line Jurkat, an epithelial cell line C33A and a bovine vascular smooth muscle cell
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line VSMC Each experiment included a transfection with the pGL2-Control vector 
alone, as a control for the efficiency o f transfection (Results not shown) The pGL2- 
Control Vector (Promega) contains an SV40 promoter and enhancer sequences upstream 
of the luciferase gene, resulting in strong luc expression m many types of mammalian 
cells This plasmid is useful m monitoring transfection efficiency in general and is a 
convenient standard for promoter and enhancer activities expressed by pGL2 
recombinants Transfections involving the Jurkat cell line were earned out by the DEAE- 
dextran method Transfections using the C33A cell line were earned out by 
electroporation and transfections involving the vascular cells used the Lipofectamme® 
method of transfection
Figure 3.18. EBNA2 Trans-Activation of the bfl-1 Promoter May be a B Cell 
Specific Effect.
Trans-activation of bfl-1 in a range of cell lines
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Figure 3.18 EBNA2 Weakly Transactivates the bfl-1 promoter -1374/+81 bfl-1 Luc in T, Smooth 
Muscle Cells and Epithelial cells, thus EBNA2 transactivation of the bfl-1 promoter may be a B cell 
specific effect Co-transfections in three cell lines, Jurkat (T cell line), VSMC (a bovine vascular smooth 
muscle cellhene) and C33A (a human epithelial cell line) lug of the -1374/+81 bfl-1 Luc promoter was co­
transfected with 5ug/10ug of EBNA2 or 5ug of EBNA2WW323SRRelative luciferase values were used to 
calulate fold-transacbvation values All results are correceted using B-gal values
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In the T cell line, 5ug of pSG5EBNA2 trans-activated the bfl-1 promoter 1 4 fold, this 
figure increased to 1 6 fold when lOug of pSG5EBNA2 was added, the non-CBFl 
binding pSG5EBNA2WW323SR expression plasmid trans-activated the promoter 1 4 
fold suggesting that CBF1 has no part m the small trans-activational effect of EBNA2 on 
the bfl-1 promoter m this cell context In the vascular smooth muscle cell line, increasing 
the amount of pSG5EBNA2 expression plasmid increased the fold-trans-activation of the 
bfl-1 promoter from 1 2 to 16, however in this cell line the mutant EBNA2 trans- 
activated the bfl-1 promoter to a slightly higher extent than lOug of EBNA2 itself The 
results obtained m this cell line however have larger error bars, as reproducibility 
obtained in the system was low, due to the small number of cells used m the 
Lipofectamme® assay With regard to the epithelial cell Une C33A no significant 
difference m trans-activation o f the bfl-1 promoter occurred by increasing the amount of 
pSG5EBNA2 expression plasmid added In this cell line the promoter was trans-activated 
less than 1 5 fold The mutant EBNA2 pSG5EBNA2WW323SR trans-activated the 
promoter 1 4 fold Low trans-activation o f the bfl-1 promoter was observed m all cases 
despite the efficient (Relative to transfection m B cell lines) trans-activation of the pGL2 
control promoter reporter construct m each of the cell lines
Overall, despite comparable levels o f trans-activation o f the pGL2 control promoter 
reporter m each of the three cell lines, compared to transfections m the B cell lines, the 
bfl-1 promoter was not trans-activated above 1 6 fold and the mutant did not trans- 
activate the promoter above 1 6 fold Although, increasing the amount of pSG5EBNA2 
increased the fold-trans-activation of the promoter m each case, no significant increase in 
trans-activation was observed by increasing the amount of EBNA2 expression plasmid, in 
any of the cell lines therefore there may be no merit m continuing the titration of EBNA2 
m these cell lines In total, these results show non-existant or very low levels of trans- 
activation of the bfl-1 promoter m the non B cell lines used
In order to identify regions on the bfl-1 promoter that mediate trans-activation by 
EBNA2, three luciferase-reporter plasmids (derived from -1374/+81 bfl-1 Luc) were 
generated which contained deletions from the 5* end of the promoter
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In addition to the -1374/+81 bfl-1 CAT plasmid, three other bfl-1-CAT promoter reporter 
plasmids were obtained from Celine Gelinas (Center for Advanced Biotechnology and 
Medicine, University of Medicine and Dentistry o f New Jersey-Robert Wood) These 
plasmids contained various truncated DNA sequences from the bfl-1 promoter cloned 
into the pCAT-basic (Promega) Nucleotides from positions —1240/4-81, -367/+81 and -  
129/+81 respectively from the bfl-1 promoter had been inserted between the Sail and 
Xbal sites m the pCAT-basic vector, in the same manner as-1374/+81 bfl-1 CAT (Zong 
et a l , 1999) As before, relative to CAT assays, luciferase assays are easier to perform, 
non-radioactive and cheaper, and since a full length (-1374/+81 bfl-1 Luc) bfl-1 
luciferase reporter construct had already been generated (D’Souza et a l , 2000) it was 
therefore decided to generate a series of bfl-1 promoter-luciferase reporter constructs for 
the purpose of investigating potential EBNA2-responsive elements within this promoter 
Three luciferase-promoter deletion constructs, -1240/+81 bfl-1 Luc (6 7Kb), -367/+81 
bfl-1 Luc (5 9Kb) and -129/+81 bfl-1 Luc (5 7Kb) were generated according to the 
schematic in Figure 3 20 Briefly, the 3 truncated promoter regions were excised by 
double digestion with Xbal and BamHI of the -1240/+81 bfl-1 CAT, -367/+81 bfl-1 
CAT and -129/+81 bfl-1 CAT constructs respectively, yielding promoter-containing 
fragments of 4 1Kb, 3 3Kb and 3 1Kb respectively These truncated bfl-1 promoter 
sequences were then ligated to the 2 6Kb BamHI -Hindlll-Scal digested fragment of the 
promoterless luciferase reporter plasmid pGL2 BASIC (Promega) which contained the 
luc gene In summary the ligation reaction involved blunt end ligation between the “filled 
in” Xbal and HindUI ends and a “sticky end ligation” between the BamHI ends Seal was 
also used to digest thepGL2-Basic vector to produce fragments of distinguishable sizes 
The same strategy was used to generate the -1374/+81 bfl-1 Luc reporter construct (See 
Flowsheet Figure 3 20) Recombinant vectors were verified by restriction analysis 
followed by agarose gel electrophoresis The presence of an Ecorl site in the luciferase 
gene, as well as one inserted from the promoter containing pCAT basic vector make
3.2.6. Generation of Promoter Deletion Constructs, -1240/+81 bfl-1 Luc, -367/+81
bfl-1 Luc and -129/+81 bfl-1 Luc*
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identification of recombinants relatively simple (Figure 3.19B) These constructs were 
then used in transient co-transfection assays of BL-derived cell lines.
Figure 3.19. Generating bfl-l-luc Promoter Reporter Constructs. -1374/+81 bfl-1 
Luc, -1240/+81 bfl-1 Luc, -367/+81 bfl-1 Luc and -129/+81 bfl-1 Luc.
Figure 3.19. Generating b f l - 1 4 u c  Promoter Reporter Constructs. -1374/+81 b f l - 1  Luc, -1240/+G1 bfl- 
1 Luc, -367/+81 bfl-1 Luc and -129/+81 bfl-1 Luc. (A). Lane M contains the Invitrogen 1Kb DNA 
Ladder. Lanes 1,2 and 3 contain -1240/+81 B fl-IC AT plasmid DNA. Lanes 4 and 5 contain restriction 
digested -367/+81 Bfl-1 CAT plasmid DNA. Lanes 6 and 7 contain restriction digested -129/+81 B fl-1 
CAT plasmid DNA and lanes 8, 9, 10, 11 and 12 contain pGL2 Basic DNA (Separate gel). Lane 1 contains 
undigested plasmid DNA. Lanes 2, 4 and 6 contain BamHI digested plasmid DNA. Restriction digestion 
with BamHI linearized the three CAT reporter constructs generating bands visible at ~5.7Kb for (- 
1240/+81 Bfl-1 Cat), lane 2) at -4.8Kb for (-367/+81 Bfl-1 CAT, Lane 4) and at -4.55Kb for (-129/+81 
Bfl-1 CAT, lane 6). Lanes 3, 5 and 7 contain BamHI-Xbal double digested plasmid DNA. The 4.1Kb 
fragment in lane 3 contains the -1240/+81 region of the bfl-1 promoter. The 3.3Kb fragment in lane 5 
contains the -367/+81 region of the bfl-1 promoter. The 3.1Kb fragment in lane 7 contains the -129/+81 
region o f the bfl-1 promoter. Lane 8 contains the undigested pGL2-Basic DNA. The 5.597Kb pGL2 Basic 
plasmid was digested with H indlll, BamHI and Seal to yield a 2.6Kb Hindlll-BamHI fragment containing 
the luc gene. Lane 8 undigested plasmid DNA, lane 9: H ind lll digested plasmid DNA, lane 10 BamHI
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digested DNA, lane 11 Seal digested plasmid DNA and lane 12, plasmid digested with Hindin, BamHI and 
Seal. A 1% agarose IX  TAE gel was used and electrophoresis was carried out at lOOv for lH r. The 
fragments marked by asterix were then ligated to generate the luciferase reporter constructs
Figure 3.19B. Ecorl Restriction Digestion Pattern of bfl-1 Promoter-Deletion 
Luciferase Reporter Constructs.
EcoRl Restriction Digestion Pattern of Promoter-Deletion Luciferase Reporter Constructs
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(B). EcoRl Restriction Digestion Pattern of bfl-1 Promoter-Deletion Luciferase Reporter Constructs.
In generating the Luciferase resporter constructs. One EcoRl restriction site is present in the luc gene 
(shown in the flowsheet overleaf) and one is present in the promoter-containing fragment from each o f the 
CAT constructs. Restriction with EcoRl should then exicse a 2.0Kb fragment from each of the luciferase 
reporter constructs and the remaining fragments should be 4.7Kb, 3.9Kb and 3.7Kb for the -1240/+81 bfl-1 
Luc, -367/+81 bfl-1 Luc and -129/+81 bfl-1 Luc reporter constructs, respectively. Lane M is the 2-Log 
DNA Ladder.
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Figure 3.20 Generating b fl-l-lu c  promoter reporter constructs. -1374/+81 b fl-l Luc,
-1240/+81 bfl-l Luc, -367/+81 bfl-l Luc and-129/+81 bfl-l Luc.
Steps in Generating bfl-l Luriferase Promoter-Reporter Constructs
-124»«
-12»+« BamHl + Xbal 
Double digest
BamHI+Hindi II 
+ Seal Digestion
Ligation 
< ►
-  .-.à -124ÛN-81 fail-1
I sa  -3G7/+81 bfl-l
I » 129/+81 bfl-l
-1240^ +81 bfl-l Luc (6.7Kb)
-367/+81 bfl-l Luc (5.9Kb)
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Figure 3.20 Generating b f l - l - l u c  promoter reporter constructs. -1240/+81 bfl-l Luc, -367/+81 bfl-l 
Luc and -129/+81 bfl-l Luc. Flow diagram detailing the steps involved in  making the B fl- l luciferase 
reporter constructs. The 4.1Kb 3.3Kb and 3.1Kb promoter containing fragments from the BamHI-Xbal 
digested CAT constructs were ligated to the 2.6Kb /«c-containing fragment of the BamHl-HindlD-Scal 
digested pG12-basic vector, b fl-l luciferase reporter constructs of 6.7Kb, 5.9Kb and 5.7Kb as induicated 
above were generated.
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3.2.7, The bfl-l promoter sequence located between nucleotides -367 and-129 is 
essential for EBNA2 responsiveness in DG75 cells.
Transient co-transfections were earned out m DG75 with pSG5EBNA2 and the senes of 
bfl-l Luc promoter constructs containing the progressive deletions from the 5’ end of the 
promoter desenbed above (Figure 3 20) Transfections were earned out at a promoter to 
expression plasmid ratio of lug o f bfl-l promoter reporter construct to 7ug of EBNA2 
expression plasmid This ratio had been established previously (see Figure 3 16) Cells 
were harvested at 48 hours post-transfection Promoter activity was assessed from 
luciferase assay results obtained using the lummoskan 1400 Results shown are 
representative o f three independent expenments
Figure 3.21 Co-transfections with EBNA2 and a senes of bfl-l promoter constructs containing 
progressive deletions from the 5* end show that sequences between -367 and -129 on the bfl-l promoter 
are essential for EBNÀ2 responsiveness Dg75 cells were transfected with lug of each of the promoter 
constructs and 7ug of pSG5/pSG5EBNA2/pSG5EBNA2WW323SR. Both -1374/+81 bfl-l Luc -and 
1240/+81 bfl-l Luc constructs were trans-activated an average of ~6 5 fold over the course of three
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independent experiments in response to pSG5EBNA2 addition The -367/+81 bfll Luc promoter reporter 
construct was also trans-activated over 5 fold m the same experiments However the smallest promoter 
reporter construct -129/+81 bfll Luc was only very weakly transactivated by pSG5EBNA2 Thus 
sequences between -367 and -129 on the bfl-1 promoter are essential m mediating EBNA2 responsiveness 
to the bfl-1 promoter The pSG5EBNA2WW323SR did not significantly trans-activate any of the promoter 
reporter constructs
From Figure 3 21, it can be seen that both the -1374/+81bfl-l Luc and -1240/+81 bfl-1 
Luc promoter constructs are trans-activated over 6 5 fold by co-transfection with the 
EBNA2 expression plasmid pSG5EBNA2 The -367/+81 bfll Luc promoter reporter 
construct showed an average o f approximately 5 fold trans-activation in the same 
experiments However the shortest promoter construct -129/+81 bfll Luc was trans- 
activated less than two fold when cotransfected with pSG5EBNA2 Thus sequences 
between position -367 and -129 on the bfll promoter are essential m mediating EBNA2 
responsiveness to the bfll promoter In the case of all the promoter reporter constructs, 
substitution of EBNA2 with EBNA2WW323SR (in which CBF1 binding has been 
abolished See Figure 1 7 chapter 1) leads to a decline in trans-activation to less than two­
fold The failure to trans-activate the shortest promoter construct -129/+81 bfl-1 Luc 
coupled with the requirement for a functional CBF1 binding site on EBNA2 itself, 
indicated that trans-activation most likely occurred via a CBF1-dependent mechanism, 
with the involvement of a possible CBF1 binding site located between -367 and -129 on 
the promoter sequence The difference between the activity o f the longer promoter 
sequences (-1374/+81bfll Luc and -1240/+81 bfll Luc) and the activity o f the -367/+81 
portion of the promoter when co-transfected with EBNA2 suggests sequences between 
-1240/+81 bfll Luc and -367/+81 bfll Luc may enhance EBNA2 mediated trans- 
activation of the bfll promoter
i
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Results from the transfections with the promoter deletion constructs indicated that the 
sequence of the bfl-1 promoter between nucleotides-367 and -129 contained elements 
essential for its EBNA2 responsiveness. Analysis of the -367 to -129 region of the 
promoter using Transcription Element Search Software website 
www. cbi 1. upenn. edu/tess. the Matlnspector V2.2 search tool from the Transfac database 
(http://transfac.gbf.de) and also the Alibaba transcription factor prediction database 
(http://www.alibaba2. com), revealed putative transcription factor binding sites for a 
number of relevant transcription factors. Analysis of the sequence between positions -  
367 and -129 indicated that the promoter contained the sequence motif GTGGGAA, in 
the reverse orientation at position -243 to -249 (see Figure 3.22A). This sequence has 
been found in all EBNA2-responsive promoters so far characterized. This motif is part of 
the consensus binding sequence for CBF1 (RBP-jk) (ie. CGTGGGAA; Tun et al 1994). 
Further analysis of the promoter sequence, revealed additional ‘5-GGAA-3’ tracts, the 
core sequence motif known to be central in DNA binding of Ets family transcription 
factors [Karim, 1990]; [Gutman, 1991]. This was identified in four places between -367 
and -129 on the promoter (see Figure 3.22A). Nucleotides adjacent to this core sequence 
partly determine the binding specificity for members of individual members of this 
family and so the Alibaba transcription factor search engine designated the four sites 
either ‘Ets-1’ or ‘PU.1’ binding sites: a putative Etsl binding site at position -213 to - 
204, a ‘double’ Etsl site between positions -176 and -163 and a near consensus PU.l 
binding site at position -143 to -134.
3'2,7.1. Putative CBF1 and Ets-Family Transcription Factor Binding Sites Exist on
the bfl-1 Promoter Sequence.
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Figure 3.22. Putative CBF1 and Ets-Family Transcription Factor Binding Sites
Identified on the bfl-1 Promoter
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Figure 3.22. A number of Possible transcription factor binding sites were identified on the b f l - 1  
promoter. (A). Analysis o f the -367/+81 bfl-1 promoter sequence with Transfac and Alibaba databases 
identified putative transcription factor binding sites on the promoter. (B) shows the relative location of these 
putative transcription factor binding sites within the bfl-1 Luc promoter deletion constructs.
The presence of these potential transcription factor binding sites on the bfl-1 promoter is 
consistent with other EBNA2 responsive elements (E2REs) in EBNA2-responsive 
promoters such as LMP1, CD23, the EBV latent membrane protein (LMP) and EBNA Cp 
promoters. (Wang et a l 1990; Zimber-Strobl et al, 1991; Wang et a l , 1991; Tsang et 
a l , 1991; Fahraeus etal., 1990; Sung et al, 1991; Jin and Speck 1992) (Table 3.1 below 
adapted from Le Roux et a l, 1993; Ling et a l, 1993)
Table 3.1. Sequence Comparison of EBNA2 Responsive Elements of EBNA2 Target 
Genes.
Promoter Homology I (CBF1 sites in EBNA2 responsive 
promoters)
Homology II (PU.l/Ets family binding 
sites in EBNA2 responsive promoters
B fi-r -237G G T GTGGGAA TGT GA-251 -143 AA AGAAAG -134
TPl -255 CTC  GTGGGAA AAT GG-241
-230A C C  GTGGGAA AAT A G -216
Cp -378 G C C GTGGGAA AAA A T -364
CD23 -174 C C T GTGGGAA CTT GC-160
LM Pf -290 G I T GTGGGAA GCG G C -304 -169 AAAGGGGAAGTA -161
-215 G C T GTGGGAA TGC G C -229
Table 3.1. The boxes in the figure above show an alignment of two different sequences (denoted 
homologies I and II) from EBNA2 responsive elements in several promoters. The nucleotide 
coordinates are given relative to the known transcription initiation sites for each promoter. * It is to be 
noted that LMP and bfl-1 promoter sequences are given from the opposite DNA strand relative to the CAP 
site of these promoters.
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The contribution of these sites in facilitating EBNA2 trans-activation of the bfl-1 
promoter was next investigated. To this end site directed mutagenesis was employed to 
“knock out” the relevant possible transcription factor binding sites and thus assess their 
potential contribution to EBNA2 responsiveness on the bfl-1 promoter.
3.2J.2. SITE-DIRECTED MUTAGENESIS OF THE PUTATIVE CBF1-BINDING 
SITE AT -243 to -249
CBF1 binding has been shown to be important in mediating EBNA2 responsiveness in a 
number of promoters including the viral Cp, LMP1, and LMP2 promoters and the cellular 
CD23 promoter. [Zimber-Strobl, 1993]; [Ling, 1993]; [Laux, 1994]; [Ling, 1994]. At 
least one CBF1 site has been identified in all these E2REs, though often interaction with 
other transcription factors is also necessary to induce gene expression [Meitinger, 1994]. 
With regard to bfl-1, the fact that the pSG5EBNA2WW323SR which cannot bind CBF1 
cannot trans-activate the bfl-1 promoter, combined with the presence of a possible CBF1 
binding site in the bfl-1 promoter provide compelling circumstantial evidence that CBF1 
binding likely plays a role in facilitating EBNA2 transactivation of the bfl-1 promoter. 
Thus the CBF1 binding site was initially chosen for mutagenesis and assessment.
The contribution of the putative CBF1-binding site located at -243 to -249 on the bfl-1 
promoter was assessed by generating a bfl-1 promoter construct in which this site has 
been eliminated by site-directed mutagenesis Promega Altered Sites® Mutagenesis 
Kit).(-1374/+81 mCBFl bfll Luc).
A 40bp single stranded oligonucleotide was designed as being complimentary to the 
regions flanking the CBF1 site on the bfl-1 promoter but which included a six base pair 
region of mismatch at the centre corresponding to the CBF1 site (see Figure 3.23 below). 
This region of mismatch was designed to contain the restriction site for the enzyme Xba 
I, so that the mutated DNA sequence could be identified and easily distinguished from 
the wild type promoter, by restriction analysis with this enzyme. The oligo (below) was 
designed to minimize secondary structure formation within itself while also ensuring that 
the altered sequence did not contain any new transcriptional activator sites. The six base
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pairs constituting the core CBF1 recognition sequence in the bfl-1 promoter were 
therefore replaced with the Xbal restriction site TCTAGA.
Figure 3.23. Mutagenesis of the Putative CBF1 binding site of the bfl-1 Promoter
CBFl MUTANT BFL-1 (-1374/+81 BFL-1 MCBF1)
5’-CCTTGTAGATTCGTGGTTCTAGAGTGAAATGGTACAACCC-3’
W ild  t y p e  bfl-1 (-1374/+«1 bfl-1 )
3’-GGAACATCTAAGCACCACCCTTACACTTTACCATGTTGGG-5’
Figure 3.23. Site directed mutagenesis was employed to replace the putative CBFl binding site in the bfl-1 
promoter with an Xbal restriction site.
A diagram o f the complete cloning strategy can be seen in Figure 3.24
1. The full length promoter was excised from the pCAT-basic-1374/+81 after double 
digestion with Xbal and H in d lll.
2. The 1.4kb fragment was inserted into the double digested pAlter-1 mutagenesis 
vector between Xbal and Hindlll. This vector (Figure 3.24) contains a multiple 
cloning site flanked by the opposing SP6 and T7 RNA polymerase promoters 
inserted into the DNA encoding the lacZ alpha-peptide. This allowed blue-white 
screening o f the clones produced. When plated on X-Gal indicator plates, colonies 
containing recombinant plasmids were white against a background of blue 
colonies. The pAlter-1 vector also carried sequences for both ampicillin and 
tetracycline resistance. However the plasmid is ampicillin sensitive because a 
frameshift mutation has been introduced into the ampT gene by removing the Pst I 
site. Thus propagation o f this plasmid and non-mutated bfl-1-p Alter recombinants 
was performed under tetracycline selection.
3. Site directed mutagenesis was then performed on the -1374/+81 bfl-1 pAlter 
recombinants in order to knockout the CBFl consensus binding sequence in the 
bfl-1 promoter. The mutagenesis was carried out by hybridizing single stranded 
DNA to the synthetic mCBFl oligonucleotide (Materials and Methods) that was
168
complimentary to the single stranded template except for the region o f mismatch 
near the centre containing the Xbal site. Following hybridization the 
oligonucleotide was extended with DNA polymerase to create a double stranded 
structure. DNA ligase was then used to seal the nick, and the duplex structure was 
transformed into E  x o li Esl301mutS, a mismatch repair minus strain. Use o f this 
strain prevented repair o f the newly synthesized unmethylated strand.
4. In the course o f the mutagenesis reaction, an ampicillin repair oligonucleotide was 
added thus restoring ampicillin resistance to the mutant strand after mutation had 
occurred. This oligonucleotide was annealed to the single stranded DNA template 
at the same time as the CBF-1-mutagenic oligonucleotide. In this way, the CBF1 
mutant clones could be isolated under positive selection for ampicillin resistance.
5. The bfl -lCBFlmutant sequence and also it unmutated counerpart -1374/+81bfl-l 
(which had also been cloned into pAlter 1 in the same way but not mutated were 
excised from pAlter by double digestion with BamHl and Hindlll. The fragments 
were then cloned directionally between Sma I and Bgl II into the multiple cloning 
site o f pGL2-basic.
6. In this way a paired set o f luciferase promoter reporter constructs (-1374/+81 
wtbfl-1 Luc) and (-1374/+81 mCBFlbfl-1 Luc) were created and the singular 
difference between the two is that one promoter sequence no longer contains the 
CBF1 binding site. The insertion o f an extra Xba I site in the mutant promoter 
proved a useful tool in distinguishing the wild-type promoter from the CBF1 
mutant promoter. The extra Xba I site resulted in the presence o f a 300bp 
fragment in the restriction pattern for the mutant promoter, when digested with 
Xbal, this is not seen for the wild-type promoter.
As these two promoter reporter constructs are a paired set, transfections invoving the 
CBF1 mutated b fll promoter reporter construct (-1374/+81 mCBFl bfll Luc) are 
always done in conjunction with its non-mutated counterpart (-1374/+81 wtbfll Luc). 
In cases where the promoter deletion constructs are used the other (-1374/+81 bfll 
Luc) promoter construct is used as it contains the same background as the deletion 
constructs as described in the flowsheet Figure 3.20
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Figure 3.24(i). Flowsheet of steps involved in generating -1374/+81wtbfl-lLuc and 
1374/+81 mCBFlbfl-1 Luc.
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3.25 Generating -1374/+81 wtbfl-1 Luc and -1374/+81 mCBFlbfl-1 Luc.
A  m - ' is cloned into pAlter 
between Hind III and Xbal
M 1 2 3 4
S
t *  r
1.6 Kb 
1.0 Kb
0.5 Kb
A fter M utagenesis, the H in d lll-B am H I 
F ragm en t o f bfl-1 pA lter/m C B F l bfl-1 pA lter , 
contain ing the wild type and CBF1 m utan t bfl- 
I p rom oters respectively , is cloned between 
the Bglll and S m al sites in pGL2-Basic.
M 1 2 3 4 5 6 7
8.0 K b
6.0  K b
3.0  K b
Figure 3.25. Generating -1374/+81 wtbfl-1 Luc and -1374/+81 mCBFlbfl-1 Luc. (A). The -1374/+81 
Hindffl-Xbal bfl-1 fragment from -1374/+8 lbfl-1 CAT was inserted into the pAlter vector between HindlU 
and Xbal. M= Invitrogen 1Kb DNA Ladder. Lanes 1 and 2 purified plasmid DNA from pAlter. Lanes 3 and 
4 DNA from -1374/+81 bfl-1 pAlter. Undigested DNA is shown in lanes 1 and 3. Lanes 2 and 4 show 
Hindlll-EcoRl restriction digestion pattern. The ~ 1.5Kb bfl-1 insert is clearly visible in lane 4. (B). 
Mutagenesis was undertaken in the pAlter vector and the BamHl-Hindin fragment of -1374/+81 bfl-1 
pAlter and a non mutated counterpart were cloned between the Bglll and Smal sites of pGL2-Basic, 
generating -1374/+81 wtbfl-1 Luc and -1374/+81 mCBFlbfl-1 Luc. M= the NEB 2-Log DNA 
Ladder.Lanes 1-3 pGL2-basic. Lanes 4-&5 -1374/+81 wtbfl-1 Luc and Lanes 6&7 -1374/+81 mCBFlbfll 
Luc. Lanes 1, 4, and 6 = undigested purified plasmid DNA. Lanes 2, 5, and 7 Hindlll Restriction pattern. 
Digestion with Hindlll linearises the pGL2-Basic, -1374/+81 wtbfl-1 Luc and -1374/+81 mCBFlbfl-1 Luc 
DNA to produce fragments of ~5.5Kb, 7.0Kb and 7.0Kb respectively. Lane 3, is the BamHI restriction 
pattern for pGL2-Basic.
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Figure 3.25 C and D. Site Directed mutagenesis of the Putative CBF1 site on the bfl- 
1 Promoter Introduces an extra Xbal site in -1374/+81 mCBFlbfl-1 Luc relative to 
-1374/+81 wtbfl-1 Luc
7.0 Kb
-1374/+81 wtbfl-1 Luc and -1374/+81 
mCBFlbfl-1 Luc have a different restriction 
pattern when digested with Xbal
M 1 2 3 4 5 6 7
U* UH
1.6 Kb
0.5 Kb
P lasm id  DNA from  -1374/+81 w tbfl-1 
D  Luc an d  -1374/+81 m C B F l bfl-1 Luc 
is o f  s im ila r qu a lity  and  
concen tra tion .
1 2
(C). Mutagenesis introduced an extra Xbal site in the -1374/+81 m CBFlbfll Luc relative to the - 
1374/+81 w tb fll Luc reporter construct M= Invitrogen 1Kb DNA ladder. Lanes 1-3 -1374/+81 wtbfl-1 
Luc. Lane 4= empty, Lanes 5-7 -1374/+81 m CBFlbfll Luc. Lanes 1 and 5 undigested plasmid DNA. 
Lanes 2 and 6, restriction digestion with Hindm linenses both promoter reporter construct to generate a 
fragment of the expected size -7.0Kb. Lanes 3 and 7 digestion with Xbal. Only one Xbal site is present in 
wild type promoter reporter construct thus again the -1374/+81 wtbfl-1 Luc is linearised to generate a 
fragment of 7.0Kb upon digestion with eth restriction endinuclease Xbal. Mutagenesis of the putative 
CBF1 site simoultaneously introduced another Xbal site thus digestion with Xbal of the mutated promoter 
reporter construct should result in a fragment of around ~320bp and a fragment of around 6 .68Kb. These 
two fragments can be clearly seen in lane 7. (D). Plasmid DNA from -1374/+81 wtbfl-1 Luc and -  
1374/+81mCBFlbfl-l Luc is of similar qulaity and concentration and may be used in subsequent 
transfection experiments.
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3.2.7.3. The Putative CBFl-Binding Site at -243 to -249 is Essential for EBNA2- 
Mediated Trans-activation of the bfl-1 Promoter in a Range of BL Cell Lines.
Transient co-transfections, were earned out usmg the wild type bfl-1 luciferase reporter 
construct -1374/+81 wtbfl-lLuc) and the bfl-1 CBF1 mutated promoter reporter 
construct -1374/+81 mCBFl bfl-1 Luc The transfections were performed in a range of 
BL cell lines to assess the contribution of the CBF1 binding site m the bfl-1 promoter 
with regard to promoter trans-activation by EBNA2 Initially transient co-transfections 
were earned out m DG75 cells Promoter activity was assessed after 48hr by luciferase 
assay and the results are shown m Figures 3 26 -3  28 It can be seen that mutation of the 
CBF1 binding site in the promoter significantly reduces trans-activation by EBNA2 from 
an average of 5 7 fold to an average of 1 9 fold, thus implying that this putative CBF1- 
bmdmg site is essential for EBNA2-mediated trans-activation of the bfl-1 promoter
Figure 3.26A. Mutation of the Putative CBF1 site on the bfl-1 Promoter, Abolishes 
EBNA2-Mediated Trans-activation of the Promoter in the Dg75 Cell Line.
A
Mutation of the Putative CBF1 Site at Position (-243 to -250) fn the bfl-1 Promoter, Abolishes EBNA2- 
Mediated Ttans-activabon of the Promoter In the DG75 Cell Line.
6
QpSGS 
□ pSG5EBNA2 
■ pSG5EBNA2WW323SR
■o
0
(-1374/+81) wtbfl-1 Luc (-1374/+81) mC8F1bfl-1 Luc
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Figure 3 26. (A). Mutation of the CBF1 site abrogates EBNA2 ability to transacdvate the b j l - 1  
promoter in DG75 Cells. Co-Transfection of pSG5EBNA2 with -1374/+81 wtbfl-1 Luc induces a 5 7 fold 
up-regulalion m promoter activity Co-transfection of the same EBNA2 expression plasmid with -1374/+81 
mCBFlbfl-1 Luc shows only a 1 8 fold trans-activation of the promoter Thus Mutation of the bfl-1 CBF1 
site causes EBNA2 trans-activation of the bfl-1 promoter to fell to less than 2 fold This correlates with the 
inability of the EBNA2 CBF1 binding mutant pSG5EBNA2WW323SR to trans-activate the bfl-1 promoter 
In the case of all transfections luciferase reporter activity obtained with the empty (pSG5) vector was 
arbitrarily assigned a value of 1 0 and beta-gal fold induction values were calculated relative to this 
* Although basal levels of trans-actrvaUon were arbitrarily assigned a value of 1 actual basal levels of 
transactivation were consistenly slightly higher with the mutated promoter (-1374/+81 mCBFlbfl-1 Luc) 
relative to the wild type promoter (-1374/+81 wtbfl-1 Luc) See Figure 3 26B below
Figure 3.26B Basal Levels of Transcription are Higher for the CBF1 Mutant bfl-1 
Promoter (-1374/+81 mCBFlbfll Luc) Relative to the Wild Type Promoter (- 
1374/+81 wtbfll Luc),
B
Basal levels of Transcription ate Higher in the CBF1 mutant (-1374/+81 mCBFI bfl-1 Luc) 
promoter relative to the wild type (-1374/+81 wtbfl-1 Luc) Promoter
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4 i
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0pSG5 
□ p8G5EBNA2 
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(-1374/+81) wtbfl-1 Luc (-1374/+81) mCBFi bfl-1 Luc
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Figure 3.26 B. Basal transcription levels are higher m the -1374/+81 mCBFl bfl-1 luc than the -  
1374/+81 wtbfl-1 Luc promoter. Actual average Beta galaetosidase normalised luciferase values over the 
course of the three independent experiments used for Figure 3 26A are shown. Although m the case of 
3 26A basal transcription which occurs with co-transfection with the pSG5 empty vector is assigned a value 
of 1 0 it can be seen that the basal level of transcription from the mutated promoter (-1374/+81 mCBFlbfl- 
1 Luc) is consistently higher than m the wild type counterpart This may be due to dislocation of the CBF1 
repressor complex from the promoter when its CBF1 binding site is destroyed
In the case of all transfections the basal levels of promoter activity (both mutated and 
wild-type) are normalised to 1 fold when co-transfected with the pSG5 vector However 
it should be noted that the basal levels o f activity of the CBF1-mutated bfl-1 promoter (- 
1374/+81 mCBFlbfl-1 Luc) are consistently marginally higher than the levels recorded 
for the wild type promoter (-1374/+81 wtbfl-1 Luc) This may be due to corruption o f the 
putative CBF1 repressor complex on the promoter allowing higher levels of promoter 
activity even in the absence o f EBNA2 To demonstrate this, the average beta- 
galactosidose normalised luciferase values for the above transfection are shown m Figure 
3 26B
The significance of this mutation was further substantiated m an experiment in which the 
EBNA2 expression plasmid was titrated against the wild type bfl-1 promoter (-1374/+81 
vrtbfl-1 Luc) and the bfl-lCBFl mutant promoter (-1374/+81 mCBFlft/7-7 Luc) in the 
Dg75 cell line (See Figure 3 27 below) It can be seen that EBNA2 cannot trans-activate 
the bfl-1 CBF1 mutant promoter (-1374/+81 mCBFl^/7-7 Luc) above 1 8 fold, despite its 
ability to trans-activate the wild-type bfl-1 promoter (-1374/+81 vAbfl-1 Luc) m a dose 
dependent manner m the same experiment Thus, although functional EBNA2 is 
expressed, as shown by the trans-activation of the wild-type bfl-1 promoter, (-1374/+81 
wtbfl-1 Luc), EBNA2 does not trans-activate the bfl-1 promoter when the CBF1 site at 
position -243 to 249 is altered by site-directed mutagenesis These results combined with 
the inability of the pSG5EBNA2WW323SR mutant (which cannot bind CBF1) to trans- 
activate the bfl-1 promoter, confirm the likely requirement of CBF1 for EBNA2 mediated 
trans-activation of the bfl-1 promoter
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Figure 3.27. EBNA2 Trans-activates the bfl-1 Promoter in a Dose Dependent
Manner
Titration of pSG5EBNA2 Against the (-1374/+81 w tUM  Luc) and (-1374/+81 mCBFIMT-i Luc)
Promoters
1 «
I s
H
Oug 1ug
III IIIl i
□ (-1374MM wtbfl-1 Luc)
■ (-1374MI1 mCBF1bfl-1 Luc)
3ug 5ug 7ug 10 ug 
ug of pSG5EBNA2
Figure 3 27 pSG5EBNA2 Trans-activates (-1374/+81 wtb f l - 1  Luc) in a dose dependent fashion. It 
does not Trans-activate the CBF1 mutant bfl-1 promoter (-1374/+81 mCBFlfyW Luc) at any of the 
quantities used. Titrating the pSG5EBNA2 EBNA2 expression plasmid with the paired bfl-1 promoter 
constructs shows the importance of the promoter CBFlbmdmg site m mediating EBNA2 responsiveness
It was important to establish that the effects observed were reproducible in other well- 
established BL cell lines and to this end a similar series of transfections were earned out 
using the BL41 and BJAB cell lines In all cases 7ug o f the expression plasmids 
pSG5/pSG5EBNA2/pSG5EBNA2WW323SR were transfected with lug of the promoter 
reporter constructs With regard to the BL41 cell line, pSG5EBNA2 trans-activated the 
wild type bfl-1 promoter (-1374/+81 wtbfl-1 Luc) an average of 4 2 fold, this trans- 
activational effect of EBNA2 is reduced to 1 4 fold when the CBF1 binding site in the 
promoter is removed by mutation Figure 3 28 Similar observations were made using the
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/BJAB cell line m which the trans-activation of the promoter is reduced from 4 8 fold to 
1 6 fold upon mutation of the putative CBF-1-binding site The EBNA2 mutant which 
cannot bind to CBF1 (pSG5EBNA2WW323SR) does not trans-activate the bfl-1 or the 
mutated bfl-1 promoter, by a factor of more than 1 6 fold m either cell line These results 
show that this putative CBF1 binding site is a critical DNA element that mediates 
EBNA2 trans-activation of this promoter m BL cells
Figure 3.28. EBNA2 Trans-activation the bfl-1 Promoter m a Range of EBV 
Negative B1 Cell Lines Requires the Putative bfl-1 CBF1 binding site
2
|  4
«
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r
5o
Trans-activation of (-1374/^1 wtJMM Luc) and (-1374/+81 vnCBFIMM Luc) in BL41 and Bjab
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□ pSgS
□  pSG5EBNA2
■ pSG5EBNA2WW323SR
BI41 Bjab
(-1374/+81 wtbfl-1 Luc)
BI41 Bjab
(-1374/+81 mCBF1bfl-1 Luc)
Figure 3*28. Mutation of the CBF1 site in the bfl-1 promoter prevents EBNA2 mediated trans- 
activation m a range of B cell lines In both the B141 and Bjab cell lines pSG5EBNA2 trans-activates the 
wild type bfl-1 promoter (-1374/+81 wtbfl-1 Luc) but fells to trans-activate its CBF1 mutated counterpart (- 
1374/+81 mCBFlbfl-1 Luc) Also the pSG5EBNA2WW323SR mutant, which also cannot bind CBF1 fails 
to trans-activate the wild type bfl-1 promoter These results provide further evidence of the importance of 
CBF1 binding m mediating EBNA2 responsiveness on the bfl-1 promoter
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3.2.8.0 Trans-activation of the bfl-1 Promoter in Response to EBNA2 Activation m 
BL41- ER/EBNA2 (K3) and BL41P3HR1-ER/EBNA2 (9A) Cell Lines.
The importance of the CBF1 site in the bfl-1 promoter for conferring EBNA2 
responsiveness was also examined in the BL41-ER/EBNA2 (K3) and BL41P3HR1- 
ER/EBNA2 (9A) cell lines, where EBNA2 function was controlled by the presence of  
estrogen addition These cell lines are stable transfectants of the BL41 cell line and its 
supennfected derivative BL41-P3HR1 in which EBNA2 is activated in response to the 
addition The two cell lines were transiently transfected with the -1374/+81 wtbfl-1 Luc 
and -1374/+81 mCBFlbfl-1 Luc promoters After transfection the cells were cultured m 
the presence/absence of estrogen (estradiol), harvested and cell extracts were assayed for 
luciferase activity As a control for assaying the functionality of EBNA2 in this system 
one transfection in each cell line was earned out using the pGa981-6 promoter construct 
(Minoguchi et a l , 1997) This plasmid contains 12 CBF1 binding sites (essentially six 
copies of a portion of the TP1 promoter which contains 2 CBF1 binding sites), positioned 
upstream of a minimal (SV40) promoter and luciferase-codmg gene pGa981-6 was 
constructed as described m the legend Figure 3 29 below A partner for the pGa981-6 
plasmid, is pGa50-7 which consists of the same plasmid background as the pGa981 -6 
construct however without the CBF1 inserts (Minoguchi et a l , 1997) Trans-activation of 
the pGA981 -6 vector in the presence of active EBNA2, is relative to trans-activation in 
the absence of estrogen/active EBNA2 which has been arbitranly designated a fold 
activation of 1 This is also true for the pGa50-7 promoter reporter construct
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Figure 3.29. EBNA2 is Functionally Active and Trans-activates the wild type bfl-1
Promoter in the BL41-ER/E2 (K3) Cell Line.
Trans-activation of pGa981-6, pGa50-7, (-1374/+81 wtbß-1 
Luc) and (-1374/+81 mCBFlbfl-1 Luc) by EBNA2, in the 
BL41-ER/E2K3 Cell Line
1 «
B
70
Minus Estrogen (no 
EBNA2 Activation)
1374/+81 w t b f l - 1  Luc) (-1374/+81 m C B Y l b f l - 1  Luc)
□ Plus Estrogen (EBNA2 Activation)
pGa50-7 pGa981-6
Figure 3.29 EBNA2 is Functionally Active and Trans-activates the wild type bfl-1 promoter (- 
1374/+81 wtbfl-1 Luc) but not the CBF1 mutant bfl-1 promoter in the BL41-ER/E2 (K3) cell line In
this case transfection was earned out using electroporatioa Panel (A) shows the trans-activatton of (- 
1374/+81 wtbfl-1 Luc) and (-1374/+81 mCBFlbfl-1 Luc) before and after Estrogen (EBNA2 activation ) in 
the BL41-ER/E2 (K3) cell line Panel B shows that EBNA2 is activated/functional in response to estrogen 
addition in the K3 cell lme as the pGA981-6 promoter reporter construct is trans-activated after estrogen 
additioa * In the case of the bfl-1 promoter reporter constructs, activation of the promoters prior to 
estrogen addition was arbitrarily assigned a fold activation of 1 and activation due to estrogen 
addition/EBNA2 activation was relative to this Similarly the pGa50-7 vector and the pGa981-6 were 
arbitrarily assigned a fold activation of 1 before estrogen addition and fold trans-activation m response to 
EBNA2 activation was calculated relative to this This is the case for all subsequent transfections m the 
stably transfected BL41 cell Lines The pGa981-16 reporter construct was generated using a 50-bp 
oligonucleotide harboring both RBP-J binding sites of the EBV T P l  promoter,
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(GGATCCCGACTCGTGGGAAAATGGGCGG AAG GGCACCGTGGGAAAATAGTAGATCT), which 
was then ligated as a hexamer into plasmid pGa50-7 (Minoguchj et al, 1997)
It can be seen from figure 3 29 that EBNA2 trans-activated the pGa981-6 an average of 
56 fold (relative to transactivation of the prior to estrogen addition set to 1) demonstrating 
the functionality of EBNA2 in the BL41 ER-EBNA2 K3 cell line upon addition of 
oestrogen In the same experiment EBNA2 trans-activated the wild-type bfl-1 luciferase 
reporter construct (-1374/+81 wtbfl-1 Luc) an average of 2 4 fold The CBF1 mutated bfl- 
1 promoter reporter construct was not trans-activated above 1 25 fold Although less 
promoter trans-activation is observed when compared to the transient transfections shown 
previously, the consistently higher trans-activational effect of EBNA2 on the wild-type 
compared to the mutated bfl-1 promoter construct demonstrates an important role for this 
sequence in mediating EBNA2 responsiveness on the bfl-1 promoter The results from 
BL41P3HR1 ER-EBNA2 9A cell line showed similar levels of EBNA2 associated trans- 
activation of the bfl-1 promoter In this case the bfl-1 promoter (-1374/+81 wtbfl-1 Luc) 
was trans-activated an average o f 2 67 fold over the course of three independent 
experiments As before trans-activation of the bfl-1 CBF1 mutant promoter (-1374/+81 
mCBFl bfl-1 Luc) was less than 1 5 fold These results further confirm the requirement 
for the putative CBF1- binding site for EBNA2-mediated trans-activation of the bfl-1 
promoter It can also be seen that in the BL41P3HR1 ER-EBNA2 9A experiment that 
EBNA2 was functional when one compares fold trans-activation of the pGa981-6 
promoter reporter construct before and after estrogen addition
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Figure 3.30. EBNA2 is Functionally Active and Trans-activates the wild type b fl-l
Promoter in the BL41P3HR1-ER/E2 (9A) Cell Line.
Trans-activation of pGa981-6, pGa50-7, (-1374/+81wt/ÿ7-i Luc) and (-1374/+81 mCBFlÄ/7-7) Luc 
by EBNÂ2 in the BL41P3HR1-ER/E2 (9A) Cell Line.
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Figure 3 30. EBNA2 is Functionally Active and Trans-activates the wild type bfl-l promoter (-  
1374/+81 wtbfl-1 Luc) but not the CBF1 mutant bfl-l promoter in the BL41P3HR1-ER/E2 (9A) cell 
line Again electroporation was used to transfect this cell line Panel (A) shows the trans-activation of (- 
1374/+81 wtbfl-1 Luc) and (-1374/+81 mCBFlbfl-1 Luc) before and after Estrogen (EBNA2 activation) 
Panel B shows that EBNA2 is activated/functional in response to estrogen addition in the 9 A cell line as the 
pGA981-6 promoter reporter construct is trans-activated after estrogen additioa As before Fold activation 
of the (-1374/+81 wtbfl-1 Luc and -1374/+81 mCBFlbfll Luc promoters are set to 1 prior to estrogen 
additioa Fold trans-activation of theses promoters as a result of EBNA2 activation arc relative to these 
values The same is true with regard to transactivation of the pGa981-6 and pGaSO-7 reporters Activation 
of these promoters after estrogen addition is relative to their pre-estrogen addition counterparts in which 
fold activation has been set to 1
The relative values recorded for fold trans-activation o f the promoter m the control 
pGa981-16 are lower m the BL41P3HR1 ER-EBNA2 9A cell line than in the BL41 ER- 
EBNA2 K3 cell line and levels of trans-activation of the bfl-l promoter are also much 
lower m this stably transfected cell line background than in the DG75 cell system as well
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as all other transfections in the non stably transfected cell lines such as Bjab and BL41 
This may be due to a number o f reasons,
(1) The ER system cannot be mampulated m the same way as pre-expressed endogenous 
EBNA2 in this case EBNA2 is activated by the presence of estrogen thus, there is 
potentially a limited quantity of EBNA2 relative to the co-transfection system in the 
DG75 (and non stably transfected cell lines) background With regard to the non stably 
transfected cell lines an optimal expression plasmid to promoter reporter ratio has already 
been obtained by titrating the EBNA2 expression plasmid against the promoter reporter 
construct and so optimal trans-activation conditions are easier to manipulate (11) It is also 
possible that the recombinant ER-EBNA2 is a weaker trans-activator than wild type 
EBNA2 for example in Dg75 the pGA981-6 reporter is trans-activated an average of 200 
fold (Not shown) however in these cell lines the average trans-activation of the same 
reporter construct is less than 60 fold m the BL41-ER/E2 (K3) cell line and less than 20 
fold in the BL41P3HR1-ER/E2 (9A) cell line Also (m) with reference to the 
BL41P3HR 1-ER/E2 cell line, this does not express a foil length EBNA-LP (an EBV 
protein known to coactivate certain promoters with EBNA2 See below) which has been 
shown elsewhere to co-operate with EBNA2 as a co-trans-activator of certain promoters, 
nonetheless the lack of EBNA-LP m all other transfections earned out in EBV negative 
cell lines has not hindered EBNA2 trans-activation of the bfl-1 promoter
In summary, the co-transfections involving the EBNA2 CBF1 binding mutant 
(pSG5EBNA2WW323SR), and the bfl-1 CBF1 binding mutant -13747+81 wtbfl-1 Luc in 
a range of BL cell lines indicate a key role for the putative CBF1- binding site for 
mediating EBNA2 trans-activation of the bfl-1 promoter in BL cells
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3.2.9.0, EBNA3A, EBNA3B and EBNA3C Repress EBNA2-Mediated Trans- 
activation of the bfl-1 Promoter.
Previous studies have demonstrated that all three EBNA3 proteins, EBNA3A, 3B and 3C 
can also bind CBF1, negatively regulating the expression o f both EBNA2 and Notch 
target genes including CD21 and the viral LMP2A, LMP1 and Cp promoters (Johannsen 
et a l , 1996, Radkov et a1, 1997, Robertson and Kieff 1995, Waltzer et a l , 1996, Zhao et 
a l , 1996) Furthermore EBNA3C can form complexes with a member of the CBF1 
repression complex HDAC1 (Radkov et a l , 1999) and binding of EBNA3 A to CBF1 has 
been shown to down regulate c-myc expression and EBV transformed lymphoblast 
growth (Cooper et al, 2003) Since CBF1 binding seems to be important m facilitating 
EBNA2 trans-activation of the bfl-1 promoter, it was important to assess the effect of the 
EBNA3 proteins on EBNA2 mediated trans-activation of the bfl-1 promoter To this end, 
co-transfections with EBNA2 and EBNA3 expression plasmids (p7CMV EBNA3A 3B 
and 3C) were undertaken The three EBNA3 expression plasmids consisted o f  
EBNA3 A/3B or 3C cloned into the multiple cloning site of the p7CMV vector Transient 
transfection analysis showed that all three EBNA3s can individually inhibit EBNA-2 
mediated trans-activation of the bfl-1 promoter (Figures 3 31-3 33) These findings, again 
imply a key role for CBF1 in mediating EBNA2 responsiveness to the bfl-1 promoter 
under the conditions examined, as the ability of the EBNA3 proteins to repress EBNA2 
mediated trans-activation is often due to their ability to bind CBF1 and members of the 
CBF1 repression complex
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Figure 3.31 EBNA3A Represses EBNA2 Mediated-Trans-Activation of the bfl-1
Promoter.
p7CMVEBNA3A Represses pSG5EBNA2 Mediated Trans-actlvation of the bfl-1 Promoter
(-1374/+81 wt bfl-1 Luc)
pSg5 (7ug)
pSg5EBNA2 (7ug)
pSG5EBNA2 (7ug) + 
p7CMV3A (0 5ug)
pSG5EBNA2 (7ug) + 
p7CMV3A(1ug)
pSG5EBNA2 (7ug) + 
p7CMV3A(3ug)
pSG5EBNA2 (7ug) + 
p7CMV3A(5ug)
pS65EBNA2 (7ug) + 
p7CMV3A (7ug)
pSG5EBNA2 (7ug) + 
p7CMV3A(10ug)
2 3 4 5 8 7
Fold Trans-activation of (-1374J+&1 wtbfl-1 Luc)
F igu re  3*31 E B N A 3 A  Represses EBN A2-M ed iated  Trans-activation  o f the bfl-1 prom oter
Transfections were earned out m the DG75 cell line Increasing quantities of EBNA3A expression plsmid 
(p7CMV EBNA3A) resulted m a corresponding decrease m trans-activanon of the b f l - 1  promoter by 
EBNA2 These results add further weight to the theory that EBNA2 trans-activates b f l - 1  promoter through 
CBF1 as increasing quantities of EBNA3 A compete with EBNA2 for binding to the CBF1 binding site.
Different quantities of p7CMVEBNA3A, p7CMVEBNA3B and p7CMVEBNA3C were 
all titrated with pSG5EBNA2 against the bfl-1 promoter (-1374/+81 wtbfl-1 Luc) in co- 
transfection studies and all transfections were transfected with the same total quantity of 
DNA equalized by addition of the empty p7CMV vector It can be seen from the results, 
EBNA2 trans-activation is decreased from 6 fold down to ~0 5 fold with addition of 
increasing quantities o f either EBNA3A EBNA3B or EBNA3C expression plasmids 
(Figures 3 30-3 32) EBNA2 trans-activated the bfl-1 promoter an average o f 7 5 fold in
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1the transient transfections above (Figure 3 30) This level o f trans-activation was reduced 
to 2 3 fold upon addition of 0 5ug of EBNA3A expression plasmid Increasing the 
amount of EBNA3A further reduced trans-activation down to a level of 0 3 fold Since 
EBNA3A binds to the CBF1 repressor complex and the addition of EBNA3A affects the 
trans-activation of bfl-1 by EBNA2, one possible conclusion is that bfl-1 promoter trans- 
activation by EBNA2 involves CBF1
Figure 3,32 EBNA3B Represses EBNA2-Mediated Trans-Activation of the bfl-1 
Promoter.
p7CMVEBNA3B Represses pSG5EBNA2-Mediated Trans-activatlon of the bfl-1 Promoter
(-1374/+81 wt bfl-1 Luc)
pSG5
P8G5EBNA2 (7ug)
pSG5EBNA2 (7ug) + 
p7CMVEBNA3B(05ug)
pSG5EBNA2 (7ug) + 
p7CMVEBNA3B (1 Oug)
pSG5EBNA2 (7ug) + 
p7CMVEBNA3B (3 Oug)
pSG5EBNA2 (7ug) + 
p7CMVEBNA3B (5 Oug)
pSG5EBNA2 f7ug) + 
p7CMVEBNA3B (7 Oug)
pSG5EBNA2 (7ug) + 
p7CMVEBNA3B (10 Oug)
h
1 2 3 4 5
Fold Trans-acttvatfon of (-1374/+81 wtbfl-1 Luc)
Figure 3 32 EBNA3B represses EBNA2 mediated trans-activation of the b f l - 1  promoter As with 
EBNA3A, co-transfection with mcreasmg amounts of the EBNA3B expression plasmid resulted m 
corresponding decrease m EBNA2 mediated trans-activation of the bfl-1 promoter (-1374/+81 wtbfl-1 Luc)
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Figure 3.33 EBNA3C Repressess EBNA2-Mediated Trans-activation of the bfl-1
Promoter
EBNA3C Represses EBNA2 Mediated Trans-activation of the bfl-1 Promoter 
(-1374/+81 wtbfl-1 Luc)
pSG5
pSG5EBNA2 (7ug)
PSG5EBNA2 (7ug) + 
p7CMVEBNA3C (0 5ug)
pSG5EBNA2 (7ug) + 
P7CMVEBNA3C (1 Oug)
PSG5EBNA2 (7ug) + 
P7CMVEBNA3C (3 Oug)
pSG5EBNA2 (7ug) + 
P7CMVEBNA3C (5 Oug)
PSG5EBNA2 (7ug) + 
P7CMVEBNA3C (7 Oug)
PSGSEBNA2 (7ug) + 
P7CMVEBNA3C (10 Oug)
1 2  3 4
Fold Trans-actlvatlon of (-1374/+81 wtbfl-1 Luc)
F igu re  3*33. E B N A 3 C  Represses E B N A 2  m ediated T rans-activation  o f the bfl-1 prom oter.
p7CMVEBNA3C was also titrated with pSG5EBNA2 against the bfl-1 promoter in the same manner as for 
EBNA3 A and 3B In this instance EBNA3C, down-regulates EBNA2 trans-activation of the bfl-1 promoter 
(-1374/+81 wtbfl-1 Luc)
EBNA3C however may also be regarded as a trans-activator of viral and cellular genes, 
which up-regulates transcription of the LMP1, CD21 and vimentm proteins via CBF1 and 
CBF1 independent means (Wang et a l, 1990, Allday et a l , 1993, Ring 1994, Zhao et a l , 
2000) Thus transfections were earned out with the three EBNA3 expression plasmids 
and the bfl-1 promoter reporter construct (-1374/+81 wtbfl-1 Luc) and its CBF1 mutant 
counterpart (-1374/+81 mCBFlbfl-1 Luc) It can be seen that on their own EBNA3A 3B 
and EBNA3C could not trans-activate the bfl-1 promoter (-1374/+81 wtbfl-1 Luc) or the 
mutant (-1374/+81 mCBFlbfl-1 Luc) reporter construct (Figure 3 34)
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Figure 3.34 EBNA3A, 3B and 3C Do Not Trans-activate the Wild Type or CBF1
Mutated bfl-1 Promoter.
Trans-activation of the bfl-1 (-1374/+81 wtbfl-1 Luc) promoter and the CBF1 mutant bfl-1 
promoter (-1374+81 mCBF1 bfl-1 Luc), by p7CMVEBNA3A, 3B and 3C
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F igu re  3.34. E B N A 3 A , 3B  and 3C  do not trans-activate the w ild  type bfl-1 prom oter (-1374/+81 
w tbfl-1 Luc) o r the C B F1  m utated bfl-1 prom oter (-1374/+81 m C B F lb fl-1  Luc) in  the Dg75 ce ll line.
The three p7CMVEBNA3 expression plasmids were co-transfected with the b f l - 1  and the CBF1 mutant b f l -  
1  promoters (-1374/+81 wtbfl-1 Luc and -1374/+81 mCBFlbfl-1 Luc respectively) None of the EBNA3 
expression plasmids tians-actrvated either promoters at either concentration used thus although EBNA3C 
has been shown to be a trans-actrvator of certain viral and cellular genes, b f l - 1  does not appear to be one of 
them under these conditions
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3.2.10.0. The Product of the CST RPMS1, also known as RPMS1 Represses EBNA2 
Trans-actlvation of the bfl-1 Promoter in DG75 Cells
In addition to the well-established EBNA, LMP, and EBER genes, Epstein Barr virus 
(EBV) has been found to express various spliced RNAs transcribed rightward from the 
region spanning 150,000 to 161,000 on the B95-8 EBV genetic map This family of viral 
RNAs have been referred to as complementary strand transcripts (CSTs), BamHl A 
rightward transcripts (BARTs), or the BARF0 RNAs (See Introduction Figure 1 14) The 
product of one of these CSTs RPMS1, a nuclear protein, has recently been characterized 
and shown to interact with the DNA-bindmg protein CBF1 (Fries et a /, 1997, Smith, et 
a l , 2000, Zhang et a l , 2001) Studies by Smith et a ly 2000 showed that RMPS1 can 
inhibit transcriptional activation mduced via CBF1 by both EBNA2 and NotchIC 
Our study to date has shown that the bfl-1 promoter is trans-activated by EBNA2 via a 
mechanism that is likely to involve CBF1 To investigate any possible inhibitory effect of 
RPMS1 on EBNA2 trans-activation o f the bfl-1 promoter, transient co-transfections with 
EBNA2 and RPMS1 expression plasmids and the bfl-1 promoter were undertaken One 
microgram of the bfl-1 promoter reporter construct (-1374/+81 wtbfl-1 Luc) and 7ug of 
the EBNA2 expression plasmid pSG5EBNA2 were co-transfected into DG75 cells along 
with increasing quantities of an RPMS1 expression plasmid pcDNA3RPMSl (a gift from 
Prof P Farrell (described by Smith et a l , 2000) In all cases the total amount of DNA in 
each transfection was equalized by addition of either background vectors pSG5 or 
pcDNA3 where appropriate It can be seen from the reporter assay results (figure3 35) 
that RPMS1 can act as an antagonist of EBNA2 transcriptional activation of the bfl-1 
promoter under these conditions Addition of increasing amounts of RPSMl-expression 
vector resulted m a dose dependent reduction in EBNA2-mediated trans-activation of the 
bfl-1 promoter (-1374/+81 wtbfl-1 Luc) In these experiment, EBNA2 trans-activated the 
promoter by 6 9 fold, and this dropped to 2 03 fold upon addition of vector expressing 
RMPS1 Since RPMS1 has been shown to interact with CBF1 via other proteins in the 
repressor complex, the effects of RPMS1 on EBNA2 trans-activation of the bfl-1 
promoter provides further evidence that CBF1 or at least removal of the CBF1 repression 
complex, has a key role in the trans-activation of the bfl-1 promoter by EBNA2
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Figure 3.35. RPMS1 Represses £BNA2-Mediated Trans-Activation of the bfl-1 
Promoter (-1374/+81 wtbfl-1 Luc).
pcDNA3RPMS1 Represses pSG5EBNA2-Mediated Trans-activation of the bfl-1 Promoter 
(-1374/+81 Luc) in DG75 cells
psgfi
PSG6EBNA2 (7ug)
pSG6EBNA2 (7ug) + 
pcDNA3RPMS1 (0 5ug)
pSG6EBNA2 (7ug) + 
pcDNA3RPMS1 (1ug)
PSG5EBNA2 (7ug) + 
pcDNA3RPMS1 (3ug)
PSG5EBNA2 (7ug) + 
pcDNA3RPMS1 (5ug)
pSG5EBNA2 (7ug) + 
pcDNA3RPMS1 (7ug)
PSG5EBNA2 (7ug)+ 
pcDNA3RPMS1 (10ug)
—|---------------------------- 1--------------------- r -
3 4 6
Fold Trans-activation
Figure 3.35. RPMS1 Represses EBNA2 Mediated Trans-activation of the b f l - 1  promoter The
pcDNA3RPMSl expression plasmid was co-transfected in increasing quantities with lug of the b f l - 1  
promoter reporter construct and 7ug of pSG5EBNA2, the EBNA2 expression plasmid Increasing amounts 
of pcDNA3RPMSl resulted in a dose dependent reduction m the trans-activation of the ¿/-/promoter (- 
1374/+81 wtbfl-1 Luc) by EBNA2 Since RPMS1 has been shown to interact with CBF1 via other proteins 
in the repressor complex, the effects of RPMS1 on EBNA2 trans-activation of b f l - 1  implies a key role for 
CBF1 in the trans-activation of b f l - 1  by EBNA2
Overall the repressive effects of EBNA3A, B, C and RPMS1 on EBNA2 mediated trans- 
activation of the bfl-1 promoter imply a crucial role for CBF1 binding in the regulation of  
bfl-1 by EBNA2, as each of these proteins have been shown to inhibit EBNA2 associated 
transact!vation by either binding directly to CBF1 or members of the CBF1 repression 
complex This can be seen clearly in Figure 3 36 where co-transfection with each o f the 
p7CMV EBNA3 expression plasmids or the pcDNA3 RPMS1 expression plasmid down-
189
regulates EBNA2 associated trans-activation o f the bfl-l promoter (-1374/+81 wtbfl-1 
Luc) These results combined with the inability of the pSG5EBNA2WW323SR mutant 
(which cannot bind CBF1) to trans-activate the bfl-l promoter and the inability of 
EBNA2 to trans-activate the bfl-I CBF1 mutant promoter (-1374/+81 mCBFlbfl-1 Luc) 
suggest EBNA2 trans-activates bfl-l via a mechanism involving CBF1 binding Also co- 
transfection of the EBNA3 and RPMS1 expression plasmids does not affect the lack of  
EBNA2 trans-activation observed with the CBF1 mutant bfl-l promoter
Figure 3.36. The Combined Effects of EBNA3A, EBNA3B, EBNA3C and RPMS1 
Imply a Key Role for CBF1 in the EBNA2 Mediated Trans-activation of the bfl-l 
Promoter.
EBNA3A, 3 B , 3C and RPMS1 Repress EBNA2-Mediated Trans-activation of the bff-1 Promoter
(-1374/+81 wtbfl-1 Luc)
3  ^
2 
1 
0 I
pSg6
□  (-1374/+81 wtbfl-1 Luc)
■ (-1374/+81 mCBF1bfl-1 Luc)
i n n m n n
pS65EBNA2 pSG6EBNA2 pSGSEBNA2 pSGSEBNA2 pS6SEBNA2 pSG5EBNA2
(7ug) (7ug)+ (7ug)+ (7ug) ♦ (7Ug)+ WW323SR(7ug)
pcONA3RPMS1 p7CMVEBHA3A p7CNNEBNA3B p7CMVEBNA3C
(3ug) (3ug) (3ug) (3ug)
Fold Trans-activation
Figure 3 36 The Combined Effects of EBNA3A, EBNA3B, EBNA3C and RPMS1 Imply a Key Role 
for CBF1 in the EBNA2 Mediated Trans-activation of the b f l - l  Promoter. In a single experiment each 
of the EBNA3 expression plasmids (p7CMV EBNA3a, 3B and 3C) and the RPMS1 expression plsmid
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(pcdna3RPMSl) repressed HBNA2 mediated transactivation of the bfl-1 promoter The EBNA2 mutant 
psg5EBNA2WW323SR which cannot bmd CBF1 also failed to trans-activate the bfl-1 promoter (- 
1374/+81 wtbfl-1 Luc) EBNA2 trans-activation of the mutant bfl-1 promoter (-1374/+81 mCBFlbfl-1 
Luc) is not affected by addition of the EBNA3 or RPMS1 expression plasmids.
3.2*11.0. LMP1 Trans-activates the bjUl Promoter via a Mechanism Which Does 
Not Require the Putative CBFl-Binding Site at -243.
In separate experiments both EBNA2 and LMP1 have been shown to trans-activate the 
bfl-1 promoter when expressed as the sole EBV protem (Figure 3 37B) The potential for 
co-operativity between EBNA2 and LMP1 was therefore investigated in this regard 
Initially pSGSLMpl was titrated against both the bfl-1 promoter (1374/+81 wtbfULuc) 
and the CBF1 mutant bfl-1 promoter -1374/+81mCBFlbfll Luc (Figure 3 37A) LMP1 
trans-activated both promoters, thus the CBF1 site is not required to confer LMP1 
responsiveness to the bfl-1 promoter Increasing the quantity o f pSGSLMPl DNA 
transfected m the 1 to lOug range examined did not increase the trans-activational effect 
of LMP1 on the bfl-1 promoter LMP1 trans-activated both the mutated and wild type 
promoter constructs to an average o f 4 5 fold over the range of concentrations tested The 
fact that LMP1 can trans-activate the mutated promoter, also demonstrates that the bfl-1 
promoter is still functional in the absence of the CBF1 site at position -264 to-269 and 
that this site is not critical for promoter function m the absence of EBNA2 A second 
similar experiment was also earned out (Figure 3 37B) This expenment is similar in that 
it shows the trans-activational effect of LMP1 on both the wild type (-1374/+81 wtbfl-1 
Luc) and CBF1 mutated promoters (-1374/+81 mCBFlbfl-1 Luc) however also included 
in this expenment is a transfection with both promoters singly and the EBNA2 
expression plasmid pSG5EBNA2 The importance of the CBF1 site for EBNA2 mediated 
trans-activation of the bfl-1 promoter is especially evident when EBNA2 and LMP1 are 
transfected singly m the same expenment (figure 3 37B) Although both pSGSLMPl and 
pSG5EBNA2 trans-activate the wild-type promoter (-1374/+81 wtbfl-1 Luc), only 
pSG5LMPl can trans-activate the CBF1 mutaed bfl-1 promoter (-1374/+81 mCBFlbfl-1 
Luc) EBNA2 trans-activates the wild-type promoter 6 8 fold while LMP1 trans-activates 
the wild type promoter 5 2 fold Again, when the promoter CBF1 binding site is absent,
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EBNA2 trans-activation is reduced to 1 5 fold This is not the case for LMP1, which 
trans-activates the mutated promoter 4 5 fold m the absence of the CBF1 binding site in 
the promoter
Figure 3.37A LMP1 Trans-activates Both Wild-type bfl-1 Promoter (-1374/+81 
wtbfll Luc) and the CBF1 Mutated bfl-1 Promoter (-1374/+81 m CBFlbfll Luc).
A  pSGBLNPI Trans-actrvtes the bfl-1 promoter (-1374/+81 wtbfll Luc) and the bfl-1 CBF1 Mutant Promoter
Figure 3 37(A). LMP1 trans-activates both -1374/+81wtbfl-l Luc and -1374/4«lm CBFlbfl-l Luc 
promoters, over the range of concentrations of LMP1 expression plasmid used. pSG5LMPl was 
titrated against the bfl-1 promoter at various quantities between lug and lOug Transfections were earned 
out m DG75 cells using the DEAE dextran method Quantities of expression plasmid used are as outlined 
m the legend above One of promoter reporter constructs was used m each case All transfections were 
made up to equal quantities of DNA by addition of pSG5 vector
□ (-1374WI wtbfll Luc)
■ (-1374/+81 nrCBF1bfl1 Luc)
pSGS pSG5LMP1(1ug) pSG5lM>1(3ug) pSG6LNP1(6ug) pSGSLMP1(10ug)
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Figure 3.37B. LMP1 Trans-activates the bfl-1 Promoter in a CBF1 Independent
Manner.
B
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7
LMP1 trans-activates the bfl-1 promoter in a C8F1 Independent manner
4
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1
0
pSG5EBNA2(7ug)
□ (-1374/+81 wtbfli Luc) 
■(-1374WM mCBF1bfl1 Luc)
p6G5LMP1(1ug)
Figure 3.37B. LMP1 Trans-activates the bfl-1 Promoter in a CBF1 Independent Manner. DG75 cells 
were transfected using the expression plasmid indicated above (quantities of vector used given m brackets) 
All transfections were earned out using lug of promoter reporter construct Total quantities of DNA in 
each transfection were normalised using pSG5 vector Promoter activity was determined using the 
luciferase assay as before Luciferase values were normalised using the B-Gal assay The results are 
representative of three independent experiments -error bars show variation
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3.2.11.1. EBNA2 and LMP1 Do Not Co-operate to Trans-activate the bfl-1 Promoter
Results from further transfections below showed that co-transfection of pSG5EBNA2 and 
pSGSLMPl did not increase promoter trans-activation In fact co-transfection of 
increasing quantities of LMP1 expression plasmid with a standard 7ug input of EBNA2 
expression plasmid resulted m a dose dependent decrease in EBNA2 mediated trans- 
activation of the bfl-1 promoter
Figure 3.38 EBNA2 Does Not Co-operate with LMP1 to Trans-activate the bfl-1 
Promoter. Co-Transfection with LMP1 reduces EBNA2 Associated Transactivation 
of the bfUl Promoter
Figure 3.38, EBNA2 does not Cooperate with LMP1 to Trans-activate the b f l - 1  Promoter Co- 
Transfection with LMP1 reduces EBNA2 Tramactivation of the b f l - 1  Promoter One nncrogram of 
the bfl-1 luciferase reporter plasmid (-1374/+81 wtbfll Luc) was transfected in each case Both EBNA2 
and LMP1 trans-activated the promter when transfected individually however in the same experiment, co- 
transfection of the LMP1 and EBNA2 expression plasmids resulted m a decrease in promoter activity
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Transfections were earned out in DG75 cells using the DEAE dextran method Expression plasmids were 
transefected according to the quantities indicated m the legend above DNA quantities used m all 
transfections were normalised using the empty SG5 vector Luciferase activity in the co-transfections was 
measured at 48 hours post transfection and the results are expressed as fold activation over the luciferase 
activity seen with pSG5 alone
EBNA2 alone trans-activated the promoter an average of 6 8 fold In the same 
experiments, LMP1 alone trans-activated the bfl-1 promoter an average of 5 2 fold When 
LMP1 was co-transfected with EBNA2, trans-activation of the promoter is reduced 
Addition of even lug of the pSGSLMPl expression plasmid resulted m promoter 
transactivation falling to less than 3 fold Increasing the quantity of LMP1 transfected 
further reduces trans-activation of the promoter until the promoter is no longer activated 
above the background levels obtained with the empty pSG5 vector These results suggest 
that although both EBNA2 and LMP1 can trans-activate the promoter independently, 
they may share some common pathway or interact with each other or impede each other 
from interacting with the promoter
The fact that LMP1 and EBNA2 fail to co-operate and that overexpression o f LMP1 may 
hinder EBNA2-mediated transactivation could imply that both EBV proteins recruit an as 
yet unidentified common transcription factor/promoter element and thus serve to inhibit 
each other by preventing the formation of stable trans-activation complexes
3.2.12*0. EBNA-LP Potentiates the EBNA2 Activation of the bfl-1 Promoter in the 
Dg75 Cell Line.
EBNA-LP, is the first viral gene product to be expressed together with EBNA-2 dunng 
EBV-induced B-cell immortalization (Alfien et a l , 1991) EBNA-LP consists of a 
multirepeat domain (W1W2) and a umque carboxyl-terminal domain (Y1Y2) (See 
Chapter 1 Figure 1 10 and Figure 3 38 below) and is known primarily as a transcriptional 
co-activator of EBNA-2 It has also been shown that EBNA-LP co-operates with EBNA- 
2 m up-regulating the expression o f the essential viral transforming gene product LMP1 
in B cells (Harada and Kieff 1997, Nitsche et a l , 1997) and that EBNA-LP and EBNA-2
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co-operatively stimulate expression of cychn D2 in resting B cells and the progression of 
these cells from GO to G1 in the cell cycle (Sinclair et a l , 1994)
Since EBNA-LP is a known co-activator of EBNA2, the aim of this part of the study was 
to determine if  there were any cooperative effects between EBNA2 and EBNA-LP m the 
trans-activation o f the bfl-1 promoter To this end a number of EBNA-LP expression 
plasmids were obtained (2 paired sets of EBNA-LP expression plasmids and 
corresponding non functional mutants of each EBNA-LP were obtained as gifts from 
Elliot Kieff Chanmng Laboratory, Departments of Medicine and Microbiology and 
Molecular Genetics, Brigham and Women’sHospital and Harvard Medical School, 
Boston, Massachusetts and Paul Ling Division o f Molecular Biology Baylor College of 
Medicine Houston Texas) The construction of these plasmids has been published 
elsewhere (Harada and Kieff 1997, Peng et a l, 2000) however Figure 3 38 below shows 
a brief schematic representation of the main features of the EBNA-LP expression 
plasmids used in this study
Figure 3.38 Map of EBNA-LP showing the exons derived from the EBV long 
internal repeat (W) and from the 3’ unique DNA (Y1 and Y2) and the deletion 
mutants used in this study.
|W011^W2T |W I |> W 2$i W1 |^W 2 fg  W1 |*\W 2tl Y I Y2 1'
--------1
Three Serine Residues 
Replaced with Alamne 
Residues m Each of the W 
2 Repeats (pRSF83)
pSG5IP (4X W Repeats) 
pSG5LPAY2 (4XW Repeats) (pRSPUl)1
pSG5LFRRR47/113AAA2XW Repeats (pJT125)
* Non Functional Matants
Figure 3.38 Map of EBNA-LP showing the exons derived from the EBV long internal repeat (W) 
and from the 3* unique DNA (Y1 and Y2) and the deletion mutants used in this study The W1 and
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W2 exons are 22 and 44 codons, respectively, and together encode 66-ammo-acid repeats All the 
expression plasmids had been generated using the pSG5 vector (Stratagene) The descriptive name for each 
of the plasmids is listed first followed by the actuval lab names which will be used henceforth A wild type 
EBNA Lp with four W repeats, (SG5LP) [Harada, 1997] and a non functional partner for pSG5LP, 
pRSP211 were obtained [Peng, 2000] The mutant partner for SG5LP is known as pRSP211/ SG5LP AY2 
This plasmid contains the four W repeats however theY2 domain has been removed Another EBNA Lp 
expression plasmid was also used, in this case the wild type Lp had two W repeats (pJT125) [Peng, 2000] 
The mutated partner to pJT125 is pRSP83 in this case again the mutant is identical to its wild-type partner 
m that it also contains two W repeats however three of the senne residues in the W2 region have been 
replaced with alanine residues SG5LPRRR47/113AAA (Peng e t  a l , 2000) The two non functional 
mutants had been generated by PCR mutagenesis of EBNA Lp cDNA as descnbed (Peng e t  a l , 2000) 
(Adapted from'Harada and Kiefif 1997 and Peng et a l, 2000)
3.2.12.1* EBNA-LP Co-Operates with EBNA2 to Trans-activate the bfl-1 Promoter 
m the Dg75 Cell Line
In non-EBV infected DG75 cells, transfection of the SV40 promoter driven EBNA2 
expression plasmid (pSG5EBNA2) with the bfl-1 promoter (-1374/+81 wtbfll Luc) 
resulted in eight fold higher luciferase reporter activity than that with the pSgS vector- 
transfected controls as before EBNA2 did not trans-activate the CBF1 mutated bfl-1 
promoter (-1374/+81 mCBFlbfll Luc) Initially experiments were earned out with the 
pSG5-LP expression plasmid containing the 4xW repeats It can be seen from Figure 
3 39A that pSGSLP alone, consistently trans-activated the bfl-1 promoter from 2 fold to 
5 3 fold over the range of concentrations of pSGSLP used dunng transfection This trans­
act! vational effect appears to be dependent on the CBF1 site m the bfl-1 promoter since 
trans-activation of the CBF1 mutated bfl-1 promoter (-1374/+81 mCBFlbfll Luc) is 
reduced by half compared to the trans-activational effect of pSGSLP on the wild-type 
promoter over the range of concentrations of pSG5LP transfected Co transfection 
expenments with pSG5EBNA2 and pSGSLP showed a dose dependent increase in 
EBNA2 mediated trans-activation of the bfl-1 promoter (-1374/+81 wtbfll Luc) in 
response to the addition of increased quantities o f pSG5LP Cotransfection of EBNA-LP
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increases EBNA2 trans-activation of the bfl-1 promoter from around 8 fold (m the 
absence of EBNA-LP) to about forty fold when co-transfected with lOug of pSGSLP
Figure 3.39A. pSG5LP (EBNALp 4X W Repeats) Co-operates with EBNA2 in 
Trans-activatmg the bfl-1 Promoter.
Figure 3 39A EBNA-LP Stimulates EBNA2-Mediated Trans-activation of the b f l - 1  Promoter in a 
Dose Dependent Manner Bfl-1 luciferase reporter plasmids weretransfected into Dg75 cells along with 
the indicated amounts of pSG5EBNA2 and/or pSGSLP Transfections were performed using the DEAE 
dextran method and the total amount of transfected DNA in each sample was equalized with pSG5 vector 
DNA Fold activation relative to that with pSG5 is indicated
The same titrational and co-operation experiments were performed m the Dg75 cell line 
with the shorter pJT125 LP expression plasmid containing just two W repeats and the 
results can be seen m figure 3 39B below The average results of experiments where 
EBNA-LP input was titrated across a 1 to lOug range in the presence or absence o f a
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standard input (7ug) of pSG5EBNA2 can be seen In this experiment as before, 
transfection with pSG5EBNA2 alone compared to the pSG5 vector, results in an average 
increase in promoter activity of about 7 fold Again the mutated promoter reporter 
construct (-1374/+81 mCBFlbfll Luc) was not trans-activated by EBNA2 pJT125 also 
trans-activated the bfl-1 promoter (-1374/+81 wtbfll Luc) m a dose dependent manner 
when transfected in the absence of EBNA2 Luciferase reporter activity increased from 2 
fold to 6 25 fold over the range (1 to lOug) of (pJT125) EBNA-LP expression plasmid 
transfected EBNA-LP trans-activation o f 1374/+81 bfl-1 luc mut (m which the CBF1 
binding site has been removed) was approximately half that seen for the wild type 
promoter Thus the CBF1 site m the promoter appears to play a role m the trans- 
activational effect of (pJT125)/EBNALP on the bfl-1 promoter Co-transfection of 
EBNA2 with EBNA-LP resulted in an increase in promoter activity from 7 fold with 
EBNA2 alone to 85 fold with cotransfection of 5ug of the EBNA-LP expression plasmid 
Thus pJT125/EBNALP increases EBNA2 transactivation o f bfl-1 by an additional factor 
of about 12 The co-operative effect of EBNA-LP on EBNA2 mediated trans-activation 
of the bfl-1 promoter (-1374/+81 wtlbfll Luc) is dose dependent since increasing the 
amount of EBNA-LP expression plasmid increases EBNA2 trans-activation of the 
promoter over the range of EBNA-LP levels tested It should be noted also that 
transfection with the EBNA-LP isoform with just 2 W repeats (pJT125) consistently 
produced higher levels of cooperative trans-activation of the bfl-1 promoter (-1374/+81 
wtlbfll Luc) than its 4X W repeat counterpart pSG5LP Co-transfection of EBNA2 and 
EBNA-LP expression plasmids also showed trans-activation of the bfl-1 CBF1 mutated 
promoter (-1374/+81 mCBFlbfll Luc) however trans-activation recorded is probably due 
to the additive effect of background trans-activation by the two expression plasmids
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Figure 3.39(B). pJT125(EBNALP 2X W Repeats) Co-operates with EBNA2 in 
Trans-activating the bfl-1 Promoter.
Fig 3 39B. EBNA-LP (pJT125) stimulates EBNA2~mediated trans-activation of the bfl-1 promoter in 
a dose dependent manner Bfl-1 luciferase reporter plasmids were transfected into Dg75 cells along with 
the indicated amounts of pSG5EBNA2 and/or pJT125 (psgSEBNALP 2xW Repeats) Transfections were 
performed using the DEAE dextran method and the total amount of transfected DNA m each sample was 
equalized with pSG5 vector DNA Fold activation relative to that with pSG5 is indicated.
Further transfections were earned out in the Dg75 cell line with the non-functiomng 
mutant pairs for each of the EBNA-LP expression plasmids (See Astenx marked panels 
in Figure 3 38) A summary of the results can be seen below in Figure 3 39C The SG5LP 
(pRSP211) mutant pair contains the four W repeats but has no Y2 region, transfection 
with this plasmid alone or in co-transfections with EBNA2, does not trans-activate the 
wild type bfl-1 promoter (-1374/+81 wtbfll Luc) When co-transfected with EBNA2 it 
does not affect EBNA2 mediated trans-activation of the bfl-1 promoter which remains at
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an average of 7 fold Similar results were obtained with the pRSP83 vector This 
expression plasmid is the mutant partner for pJT125 and consists of the EBNA-LP 
isoform which conatins 2 W repeat regions, however it has had a number of senne 
residues replaced by alanine residues rendering it non functional This EBNA-LP 
expression plasmid does not trans-activate the promoter either alone or when co­
transfected with EBNA2 Again co-transfection with pRSP83 does not affect EBNA2 
trans-activation of the wild type bfl-1 promoter 9-1374/+81 wtbfll Luc)
Figure 3.39 C. Summary of EBNA-LP Effects on EBNA2 Mediated Trans-activation 
of the bfl-1 Promoter.
Figure3.39(C). Summary of the effects of pSGSEBNA-Lp and pJT125 on pSG5EBNA-2-mediated 
trans-activation of the wild type b f l - 1  (-1374/+81 wtbfl-1 Luc) and b f l - 1  CBF1 mutant promoters (- 
1374/+81 mCBFlbfll Luc) in DG75 cells Luciferase reporter plasmids were transfected mto Dg75 cells 
along with the indicated amounts of pSG-EBNA-2/pJT125 and/or pSG-EBNA-LP The total amount of 
transfected DNA in each sample wasequalized with pSG5 vector DNA Fold activation relative to that with 
pSG5 is indicated These are representative results of 3 independent experiments. Also shown are the
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effects of the non functional mutants of the two EBNALP isoforms used m these experiments, pRSP211 
and pRSP83
3.2.12.2» EBNA-LP Enhances EBNA2 Mediated Trans-activation of the bfl-1 
Promoter m the Bjab Cell Line.
Transfections were also earned out in another EBV negative B-lymphoma cell line, 
BJAB The results (Figure 3 40) showed much lower levels o f trans-activation for the 
promoter m all cases (only the pJT125 EBNA-LP expression plasmid was used as it had 
showed consistently higher levels of bfl-1 promoter activation m the previous co- 
transfection expenments in DG75 cells) EBNA2 trans-activated the bfl-1 promoter just 
over four fold compared to the pSG5 control vector Although less trans-activation was 
observed m this experiment relative to that presented earlier (4 fold as compared to 
around 8 fold in the DG75 cell line), co-transfection with pJT125/EBNALP increased 
psg5EBNA2 mediated trans-activation o f the bfl-1 promoter (-1374/+81 vAbfll Luc) from 
4 fold to 12 46 fold (Figure 3 40) Thus, in this cell line also, EBNA-LP co-operates with 
EBNA2 to trans-activate the bfl-1 promoter Transfection with the pJT125/EBNALP 
expression vector alone showed a 2 5 fold trans-activation o f the bfl-1 promoter The 
CBF1 mutant bfl-1 (1374/+81 mCBF 1 /^77 Luc) was not trans-activated by EBNA2 the 
EBNA2 mutant (pSG5EBNA2WW323SR) or the EBNALP expression plasmid 
(pJT125) Co-transfection of pSG5EBNA2 and pJT125 with the CBF Mutant promoter (- 
1374/+81 mCBFlbfll Luc) showed a 3-fold trans-activation o f the promoter and again 
this may be due to addition of residual trans-activation by both EBNA2 (pSG5EBNA2) 
and EBNA-LP (pJT125)
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Figure 3.40. EBNA-LP (pJT125), Co-operates with pSG5EBNA2 to Trans-activate 
the bfl-1 Promoter (-1374/+81 wtbfll Luc) in the Bjab Cell Line.
EW4A LP(pJT12$ Cooperateswtth BBNA2 to Trans-acHvate the bfl-1 Promoter (-1374J+81 wttifil Luc) in
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Figure 3 40 pJT125 (EBNALP) stimulates pSG5£BNA2 mediated trans-activation of the bfl-1 
promoter in the Bjab cell line The activating plasmid pSG5EBNA2 and the reporter plasmids (- 
1374/+81 wtbfll Luc) and (-1374/+81 mCBFlbfll Luc) were transfected into Bjab cells with or without 
pJTl25/EBNALp Average fold activity among 2 independent experiments is shown Fold activation is 
relative to that with the pSG5 control vector Error bars indicate standard deviations
In summary, (i) EBNA2 and EBNA-LP co-operate to enhance bfl-1 promoter activity in 2 
EBV negative B cell Lines DG75 and Bjab (11) Co-transfection with the EBNA-LP 
isoform containing only two W1W2 repeats (pJT125) consistently showed a higher level 
of promoter trans-activation compared to the LP lsoform which contained the 4W repeats 
(pSGSLP) (m)Both EBNA-LP isoforms trans-activate the wild type bfl-1 promoter (- 
1374/+81 wtbfll Luc) ( iv)  however, the EBNA-LP mutants lose their background when 
transfected with the bfl-1 CBFI binding mutant promoter reporter(-1374/+81 mCBFlbfll
203
Luc), thus the CBF1 site appears to play a role in the trans-activational effect of EBNA- 
LP on the bfl-1 promoter (v) Although there appears to be a cooperative trans-activation 
of the bfl-1 mutant promoter (-1374/+81 mCBFlbfll Luc) by pSG5EBNA2 and the 
EBNALp expression plasmids, (albeit relatively low), this can be attributed to the 
additive effect of basal trans-activation of the mutant promoter (-1374/+81 mCBFlbfll 
Luc) by the pSG5EBNA2 and pJT125/pSG5LPEBNALp expression plasmids (vi)The 
EBNA-LP mutants pRSP211 and pRSP83 don’t co-operate with pSG5EBNA2 in trans- 
activating the bfl-1 promoter (-1374/+81 wtbfll Luc), neither do they inhibit EBNA2 
trans-activation of this promoter
3.2.13.0 Investigating the Importance of the Putative Ets and Pul Binding Sites in 
the bfl-1 Promoter and their Effect on EBNA2 Associated Trans-activation of the 
bfl-1 Promoter.
Ets proteins have been implicated in the regulation of genes involved in diverse cellular 
processes, such as proliferation, differentiation, development, transformation, and 
apoptosis (Sementchenko and Watson 2000, Yordy and Muise-Helmencks 2000, Li et 
a l , 2000) Ets factors typically consist of a conserved winged helix-tum-hehx DNA- 
binding domain that recognize a core motif 5’GGA(A/T)3’ whose flanking nucleotides 
determine specificity (Sementchenko and Watson 2000) Members of this family include 
Ets-1, Ets-2, PU 1, Fli-1, GABPa, Elf-1, Sap-1, PEA-3, Elk-1, Elk-2, erg and ergB A 
key characteristic that Ets transcription factors display is their ability to regulate 
transcription through interactions with other nuclear factors For example, Ets proteins 
functionally interact with NFkB (Bassuk et a l, 1997), AP-1 (Bassuk and Leiden 1995), 
Pax (Fitzsimmons et a l, 1996), Tax (Dittmer et a l , 1997, Githn et a l , 1993), and Spl 
(Dittmer et a l , 1997, Block et a l , 1996)
PUl(Spi-l) is a transcriptional regulator whose DNA binding domain presents 40% 
identity with the DNA binding domain of the c-Ets-1 So far Pu 1 binding sites have been 
characterised in B cell specific transcription regulatory elements such as the intromc 
enhancer of the immunoglobulin heavy chain The 3’ enhancer of the Ig k (Pongubala et
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a l , 1992) and X light chains (Eisenbeis et a l , 1993) and the promoter of the lg j chain 
(Shm and Koshland 1993) Others have been identified in the promoter regions of 
myeloid specific genes the integrin CDllb (Pahl et a l, 1993), the receptor of the 
macrophage growth factor (Zhang et a l , 1994) and the Fey receptor (Perez et a l , 1994) 
PU 1 functional specificity seems to depend on both the flanking nucleotides adjacent to 
the minimal core RGAA conserved between all PU 1 binding sites presently identified
The c5-GGAA-3’core sequence motif known to be the core DNA sequence involved in 
DNA binding of Ets family transcription factors, (Kanm et a l , 1990, Gutman et a l , 
1991) was identified at four points in the -376/+81 portion of the bfl-1 promoter (See 
Figure 3 22A and B) Transcription factor databases identified three possible ets-1 
binding sites at positions -213, -176, -163 and a possible PU 1 binding site at position -  
143 on the basis of flanking sequences
Since Ets transcription factors interact with other nuclear factors and since PU 1 and Etsl 
transcription factor binding sites have been identified and found to be essential in the 
E2REs of other EBNA2 responsive promoters such as LMP1 [Johannsen, 1996], the 
importance of the putative Ets-1 and PU 1 sites identified on the bfl-1 promoter had to be 
addressed To this end site directed mutagenesis was undertaken to destroy the 5’- 
AGGA-3 ’ consensus sequences which make up the Ets family transcription factor 
binding sites on that portion of the bfl-1 promoter being examined
3.2.13»l.Mutatmg the Putative ets-1 and PU 1 Binding Sites on the bfl-1 Promoter.
Site directed mutagenesis o f Ets-1 binding sites at positions —213 to -204 and two at -  
176 to -163 was undertaken using the Stratagene QuickChange® XL Site Directed 
Mutagenesis Kit The same was also done at the PU 1 site at position -143 to -134 In 
each case the core AGGA binding sequence within the putative Ets and Pul sites ( at 
positions was targeted for mutagenesis The QuickChange® XL Site Directed 
Mutagenesis Kit was used in preference to the Altered Sites Mutagenesis Kit®, which 
was used m constructing the CBF1 mutation in the bfl-1 promoter The major advantage 
of this kit was that there was no need for a specialised mutagenesis vector such as pAlter
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and no need for subsequent subclomng back into the reporter construct of choice In this 
system, mutagenesis was earned out m-situ in the-367/+81 bfl-1 Luc reporter construct 
(See Figure 3 41)
The QuickChange XL system was used to switch ammo acids making up the Ets-1 and 
Pu 1 transcnption factor binding sites and replace these with an alternative sequence of 
ammo acids This completely obliterated any possible binding of these transcnption 
factors The QuickChange XL method was performed using Pfu Turbo® DNA 
polymerase and a thermal cycler
The basic procedure utilises a supercoiled double-stranded (dsDNA) vector with an insert 
of interest and two synthetic oligonucleotide pnmers containing the desired mutation 
(Figure 3 41)
1 In this instance the double stranded vector was the -367/+81 bfl-1 Luc luciferase 
promoter reporter construct and the target sites for mutation were the ets-1 and PU 1 sites 
in the bfl-1 promoter Initially each site had to be mutated individually
2 The bfl-1 luciferase reporter plasmid (-367/+81 bfl-1 Luc) was denatured with high 
temperature, and oligonucleotide pnmers containing the desired mutations were annealed 
to the denatured plasmid The oligonucleotides selected to “knock out” the transcnption 
factor binding sites had to be chosen carefully to ensure a number of things (i)the 
sequences selected could not encode any other relevant transcnption factor binding sites 
(n) the sequences selected had to encode a site recognised by a restnctnon endonuclease 
to allow identification of mutant clones In this case the PstI site was chosen to replace 
the GGAA core of the ets-1 and PU 1 transcnption factor binding sites (in) the sequences 
selected had to assist in ensunng a GC content >40% and a Tm >78°C The 
oligonucleotide pnmers designed to mutagenise each of the Ets-1 and PU 1 binding sites 
are shown m table 3 2 below along with the wild-type promoter sequence
3 The oligonucleotide pnmers, each complementary to opposite strands o f the vector 
were extended dunng temperature cycling by using Pfu Turbo® DNA polymerase Pfu 
Turbo® DNA polymerase replicates both plasmid strands with high fidelity and without
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displacing the mutant oligonucleotide primers. Incorporation of the oligonucleotide 
primers generates a mutated plasmid containing staggered nicks.
5. Following temperature cycling the product was treated with DpnI. The Dpnl 
endonuclease is specific for methylated and hemi-methylated DNA and was used to 
digest the parental DNA template and to select for mutation-containing synthesised DNA 
The nicked vector DNA incorporating the desired mutations was then transformed into 
XL 10-Gold® ultracompetent cells.
Table 3.2. Oligonucleotides Used to Mutagenise the Putative Etsl and PU.l Binding 
Sites.
Site Name and position Sequence
Putative ets-1 binding site 
(-213 to -204). W ild type 5 ’-GGA-TTC-TAA-TTT-CTC- -ATC-CTG-' AT-TTA-AG A-CTT-GC A-AAG- 
CTG-3’
Oligos for mutagenising site at 
(-213 to -204) -213 Fwd 5’-GG A-TTC-T AA-TTT-CTC-CAC-CTG-CAG-C AT-TTA-AG A-CTT-GC A- 
AAG-CTG-3’
-213 Rev 5 ’- CAG-CTT-TGC-AAG-TCT-TAA-ATG-CTG-CACi-GTG-GAG-AAA- 
TT A-G AA-TCC-3 ’
Putative double ets-1 binding 
sites (-176 to -163).W ild type.
5’-GCA-AAG-CTG^AAT-TAA-TCA-CAGGAT-GAG-C.AA-GTG-GCT-TCT-CTG-3’
Oligos for mutagenising double 
site at (-176 to -163) -177Fwd 5 ’ -GC A-AAG-CTG-AAT-T AA -TCA-CAG-GC TGCA-GAA-GTG-GCT- 
TCT-CTG-3’
-177Rev 5’- C AG-AG A-AGC-C AC-TTC -T GC - AGC-CTG-TGA-TT A-ATT-C AG- 
CTT-TGC-3’
Putative PU.l site (-143 to -  
134). Wild type 5 ’-GGA-AGT-GGC-TTC-TCT-GAA-ACA-TT i -TCC-TC T- -ACA-TTT-T-3’
Oligos for mutagenising PU.l 
site at (-143 to -134) -146 FWD 5 ’-GG A-AGT-GGC-TTC-TCT-G AA-AC A-TCT-GC A-GCT-TTC- AC A- 
TTT-T-3’
-146Rev 5’ -A-AAA-TGT -G AA-AGi I GC-AG A-TGT-TTC-AG A-G AA-GCC-ACT- 
TCC-3’
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Table 3.2 Quickchange Mutagenesis Reaction Reagents. This table shows the wild type sequences of the 
various portions of the bfl-1 promoter with the putative Etsl and Pul. sites indicated The core AGGA 
binding sequence recognised by members of the Ets family (including Etsl and Pul) is shown in darker 
colour. In each case the oligonucleotides used in the muatgenesis reactions are shown. The change in the 
sequence introduced by the mutagenesis is indicated also.
Figure 3.41. Schematic Outline of Steps Involved in Quickchange Mutagenesis 
Reactions used to Generate the Etsl and Pul bfl 1 Mutant Promoter Reporter 
Constructs (-213mEtsl bill Luc), (-176mEtsl bill Luc) and (-143mPul bill Luc) 
Respectively.
Schematic Detailing steps in Quichange Mutagenesis Reaction used to Generate 
(-213mEtsl bill Luc), (-177mEtsl bill Luc) and (-143mPul bill Luc)
Mutant Strand Synthesis
Perform thermal cycling to :
(1) Denature DNA template
(2) Anneal mutagenic primers 
containing desired 
mutation
(3) Extend primers and 
incorporate primers with 
PfuTurbo® DNA 
polymerase
Dpnl Digestion of Template
Digest parental methylated 
and hemimethylated DNA 
with Dpnl
Transformation
Transform mutated 
molecule into competent 
cells for nick repair
Figure 3.41. Schematic Outline of Steps involved in Quickchange Mutagenesis Reactions used to 
Generate the Etsl and Pul b f l  1  Mutant Promoter Reporter Constructs (-213mEtsl b ill Luc), (- 
176mEtsl b ill Luc) and (-143mPul b ill Luc) Respectively. The double stranded -367/+81 bill Luc
-367/+81 bfll 
Luc
Mutagenic 
Oligonucleotides
Mutated bfll Promoter 
Reporter Constructs
Mutated bfl-1 Promoter 
Reporter constructs n 
sensitive to Dpnl
Non-Mutant 
Template DNA 
digested by 
% Dpnl
«
Bfl-1 Promoter constructs 
with mutated Etsl/Pu.1 
sites. (-213mEtsl bfll Luc), 
(-176mEtsl bfll Luc) and (- 
143mPul bfll Luc)
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promoter reporter plasmid was used as the template DNA This was denatured at high temperature and each 
of the ohgonuleotides (See Table 3 2) were annealed to the denatured template and incorporated with Pfii 
Turbo DNA polymerase This results m the generation of the desired mutated vectors which contain nicked 
circular strands The methylated and hemimethylated template DNA (isolated from a dam+ E Coli strain 
Dh5a) was then susceptible to Dpnl digestion while the mutated promoter reporter constructs are not The 
Mutant vectors are then transformed into the XLlOGoId cells, which repair the nicks in the mutated 
plasmids
6 The transformed XL-10 gold cells were then grown and scaled up and the plasmid 
DNA harvested using the Qiagen® plasmid DNA extraction kit
The presence of the (putative) Ets-1 and PU 1 site mutations in the promoter were 
assayed by restriction analysis using the PstI restnction endonuclease, as a PstI site had 
been inserted into the possible Ets-1 and PU 1 sites respectively (Figure 3 42) Restnction 
with PstI, lmeansed the (-367/+81 bfll Luc) plasmid resulting m a band at ~5 8kb (Lane 
2) The bfl-1 luciferase reporter construct m which the Etsl site at position -213 had been 
mutagemsed, (-213mEtsl bfllLuc), when digested with PstI yielded bands at 5 634kb 
and ~160bp (Lane 4) PstI Endonuclease restnction of the bfl-1 luciferase reporter 
construct in which the double stes site at position -176 had been mutagemsed (- 
176mEtsl bfll Luc) showed bands at 5 595kb and ~200bp (Lane 6) Digesting the bfl-1 
luciferase reporter construct in which the PU 1 site at position -143 had been mutated, (- 
143mutbfMluc) with PstI resulted in bands visible at 5 568kb and 230bp (Lane 8) These 
restnction patterns are clearly visible m Figure 3 42 below
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Figure 3.42 Restriction Analysis of the (-213m £tsl b fll Luc), (-176mEtsl b ill Luc) 
and (>143mPu.l bfll Luc).
Mutagemsing the Putative Etsl and Pu I Sites 
in (-213mEtslbfl 1 Luc), (-176mEtsl bfl-1 Luc) 
and (-143mPU 1 bfl-1 Luc) respectively, 
introduces an extra PstI site relative to the -367 
bfl-1 Luc reporter construct
M  1 2 3 4  5 6 7 8  M
Figure 3 42. Restriction analysis of the (- 
213mEtsl bfl-1 Luc), (-176mEtsl bfl-1 
Luc) and (-143mPu.l bfl-1 Luc) M= 
Invitrogen 1Kb DNA Ladder Lanes 1 and 
2 -367/+81bfll Luc Lanes 3 and 4 (- 
213mEtsl bfl-1 Luc) Lanes 5 and 6 (- 
177mEtsl bfl-1 Luc) lanes 7 and 8 (- 
143mPU 1 bfl-1 Luc) Undigested purified 
plasmid DNA (Lanes 1, 3, 5 and 7) PstI 
digested DNA (Lanes 2, 4, 6 and 
8) Although the resolution at the top of the 
gel makes size determination difficult the 
gel had to be run this way in order to 
visualise the low molecular weight 
fragments For this reason also an excess 
of DNA was loaded (~500ng) 
Mutagenesis of -367/+81 using the 
Quickchange mutagenesis kit, introduced 
an extra PstI site m each of the three 
regions of interest resulting in fragments of 
the expected sizes
Below is a schematic o f the resulting promoter constructs (Figure 3 43) These constructs 
were then co-transfected with pSG5EBNA2 in the DG75 cell line to assess the 
importance of the individual transcription factor binding sites in contributing to EBNA2 
mediated trans-activation o f the bfl-1 promoter Also included was a transfection with the 
wild type (-1374/+81 wtbfll Luc) and the CBF1 mutant bfll promoter reporter constructs 
(-1374/+81mCBFlbfll Luc)
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Figure 3.43. Location of Putative Transcription Factor Binding Sites and Mutated 
Elements in the (-213mEtsl bfll Luc), (-176mEtsl b ill Luc) and (-143mPU.l b ill 
Luc) Promoter Reporter Constructs.
Location of the Putative Transcription Factor Binding Sites and the Mutated Elements in the
(-213mEtsl bfll Luc), (-177mEtsl bfll Luc) and (-143 mPu.l bfll Luc) Promoter Reporter
Constructs
Putative CBF1 Binding Site 
Putative Etsl Binding Site 
Putative PU1 Binding Site □
Mutagenised Site
-1374/+81 viibfl-1 Luc feC ä ! t
■ m o c o i Luc
-367/+81 bfl-1 Luc
-213mEtsl bfl-1 Luc 
-177mEtsl bfl-1 Luc
-143mPiLl bfl-1 Luc 
-1374/+81 mCBFl bfl-1 Luc
- ■ o r n o J_r Luc
Luc
Er— ■ O - B B O — 1— I Luc
H I 1
r *
Luc
■  ■ ■ ■ I j Luc
Figure 3.43. Schematic indicating the details of the mutated promoter constructs.The blue boxes 
represents the putative CBF1 binding site. The pink boxes represent possible Etsl binding sites and the 
green boxes represent putative PU.l binding sites. The positions of theses sites on the bfl-1 promoter is 
shown by the numbers above each of the respective boxes. The black boxes represent sites which have been 
abolished by mutagenesis.
Each of these promoters was cotransfected with either pSG5EBNA2 or 
pSG5EBNA2WW323SR in DG75 cells. The transfections were performed in the usual 
way by the DEAE dextran method in the optimised ratio of lug of promoter reporter 
construct and 7ug of EBNA2 expression plasmid (pSG5EBNA2). Trans-activation of the 
promoter was assessed using the luciferase assay. It can be seen from Figure 3.44 that
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individually these Ets-1 and the PU 1 binding sites are crucial to EBNA2 mediated trans- 
activation of this portion of the bfl-1 promoter
3.2.13 2. Mutation of the Putative Ets-1 and PU .l Binding Sites Reduces EBNA2 
Mediated Trans-activation of the bfl-1 Promoter
It can be seen from Figure 3 44 that individual mutation of any o f the transcription factor 
binding sites identified, results in a dramatic reduction in EBNA2 mediated trans- 
activation of the bfl-1 promoter When the CBF1 binding site at -243 to -249 is 
destroyed, EBNA2 trans-activation drops from 6 fold down to less than two fold This 
demonstrates the importance of the CBF1 binding site for facilitating EBNA2 trans- 
activation of bfl-1 However, when any of the Ets-1 or PU 1 bmding sites are destroyed 
EBNA2 mediated trans-activation of bfl-1 is also down-regulated Because these 
mutations were earned out m the truncated promoter construct -367/+81bfll Luc (See 
Figure 3 20), any trans-activation data has to be considered relative to trans-activation 
recorded in the -367/+81bfll Luc promoter and not the longer (-1374/+81 wtbfll Luc) 
promoter this was simply included here as a control for EBNA2 activity m the 
transfections EBNA2 trans-activated the truncated -367/+81bfl-l Luc promoter an 
average of 5 5 fold Mutation of the putative Ets-1 binding site at -213 results in a 
decrease in fold transactivation of the promoter (by EBNA2) from 5 5 fold down to less 
than 3 fold This result suggests the Ets-1 site at position -213 on the bfl-1 promoter is 
required for optimal EBNA2 mediated trans-activation o f bfl-1 Mutation of the double- 
Ets-1 transcription factor binding site at position -168 to -177 is more effective in further 
reducing EBNA2 dnven trans-activation of the promoter, with fold activation for the full 
promoter falling from 5 5 fold to less than 2 fold after mutagenesis Levels of trans- 
activation are similar to those observed when the CBF1 binding site is obliterated It can 
be seen from this result that the transcnption factor binding at this site (if there is one), 
either alone or in concert with the other transcnption factors which bind to the promoter 
including CBF1, are required for EBNA2 responsivity m the bfl-1 promoter Similar 
results were obtained when the putative PU 1 binding site was mutated This resulted in a 
drop m EBNA2 mediated trans-activation of the promoter from 5 5 fold to below 2 fold
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In total, the ensemble of these results show that these sites are crucial in facilitating 
EBNA2 mediated trans-activation of bfl-1 One possibility is that these Ets family 
transcription factors complex with CBF1 itself to stabilize the EBNA2-CBF1 binding 
reaction, or conversely they may interact with the CBF1 repression complex thereby 
freeing CBF1 to bind EBNA2 and thus trans-activate the promoter Another possibility is 
that these transcription factor complexes interact with one and other and their action in 
concert with CBF1 is required for EBNA2 mediated transactivation of bfll At present 
the mechanism of interaction of these sets of transcription factors is unknown, although 
their combined action is required to trans-activate another EBNA2 responsive promoter, 
LMP/TP2 (Johannsen et a l , 1995)
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Figure 3.44. The Putative Etsl and Pu.l Transcription Factor Binding Sites on the
bfll Promoter are Essential for EBNA2 Mediated Trans-activation of the bfll
Promoter in the DG75 Cell Line.
Figure 3 44. Putative E tsl and Pu.1 sites are critical for EBNA2 mediated trans-activation of the bfl- 
1 promoter m DG75 cells. Transfections were earned out using the DEAE dextran method In each case 
lug of promoter reporter was co-transfected with the standard 7ug of expression plasmid Quantities of 
DNA transfected were normalized m each transfection by addition of pSG5 DNA Promoter activities were 
measured using the hiciferase assay Luciferase values were equilibrated using the B gal assay in the usual
m anner * Transfections with the other -13747+81 bfll promoter reporter construct (-1374/+81 bfll Luc) ware also undertaken (not 
shown) and the level of trans-activation recorded was similar to that shown for the ( 1374/+81 wtbfll Luc) promoter reporter construct 
which is paired to the CBF1 mutant bfll reporter construct (-1374/+81 mCBFlbfll Luc).
It was also proposed to mutate all combinations of the possible Ets-1 and PU 1 binding 
sites where possible binding sites were knocked out together rather than just singly, 
however this was not undertaken as the dramatic effect of single mutation amply 
demonstrated the importance of each of the putative transcription factor binding sites
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If these Etsl binding sites do play a part in conferring EBNA2 responsiveness to the bfl-1 
promoter, co-transfection of EBNA2 with an expression vector, which expresses a 
dominant negative form of Ets-1, would down-regulate EBNA2 trans-activation of the 
promoter To test this theory a dominant negative expression vector for Ets-1 (pCEP4- 
Ets-ND as described by (Nakada et a l , 1999, Kim et a1, 2000) was obtained, (H Sato 
Dept of Molecular Virology and Oncology Cancer Research Institute Kanazawa 
University) Also obtained was the empty pCEP4 (Invitrogen) vector into which the Ets-1 
expression vector had been cloned The pSG5EBNA2 expression plasmid and various 
quantities of the Ets-1 dominant negative expression plasmid (pCep4eEtsDN) were co­
transfected into DG75 cells and the resulting bfl-1 promoter (-1374/+81 bfll Luc and -  
367/+81 bfll Luc) activity recorded in the usual way using the luciferase assay In all 
cases, the optimized ratio of lug of promoter reporter DNA to 7ug of EBNA2 expression 
plasmid was used In these co-transfection experiments the effect of the dominant 
negative expression plasmid on EBNA2 mediated trans-activation of the bfl-1 promoter 
was assayed against both the-1374/+81 bfl-1 luc and the truncated promoter -367bfl-lluc 
reporter constructs respectively It can be seen from the results (Figure 3 45) that EBNA2 
efficiently trans-activates both the full length and truncated promoter m the absence of 
the Ets dominant negative The promoters are trans-activated 5 fold and 3 9 fold 
respectively Addition of the dominant negative reduced EBNA2 mediated trans- 
activation of both promoters This reduction in trans-activation becomes more and more 
apparent as the quantity of dominant negative inputted is increased Trans-activation 
drops to 1 8 fold with respect to the longer promoter reporter over the range of lug to 7ug 
of dominant negative inputted Trans-activation of the truncated promoter also drops to 
1 63 fold over a 1 to 5ug range of dominant negative inputted Strangely however, at the 
final point m each graph where lOug of dominant negative was inputted, trans-activation 
of the promoters increased back up to 2 8 and 3 2 fold for the longer and truncated 
promoter respectively The quantity of DNA transfected was equalized m all cases by 
addition of the empty pCEP4 vector so this does not explain the result The results shown
3.2 13.3. Further Evidence for the Importance of Ets-1 in EBNA2 Mediated Trans-
activation of the bfl-1 Promoter
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are average values obtained from two independent experiments, but the trend of 
increasing trans-activation at the final time-pomt was consistent m all transfections and 
for both promoters
Figure 3»45.Transfection with an Etsl Dominant Negative Confirms the Importance 
of Etsl m Conferring EBNA2 Responsivity on the bfl-1 Promoter.
Co-transfection with an Ets-1 Dominant Negative (pCep4EtsDN) Reduces EBNA2 Mediated 
Trans-activation of the bfl-1 Promoter in Dg75 cells
Figure 3.45. Transfection with an E tsl Dominant Negative Confirms the Importance of E tsl in 
conferring EBNA2 Responsivity on the bfl-1 Promoter The Ets-1 dominant negative expression plasmid 
was titrated against the full length (-1374/+81bfMluc) and truncated promoter (-367/+81bfl-l) m co- 
transfection experiments Transfections were earned out m DG75 cells. The optimized ratio of lug of 
promoter reporter construct to 7ug of EBNA2 expression plasmid (pSG5EBNA2) was inputted into DG75 
cells Various quantities of the Ets-1 dominant negative expression plasmid (pCEP4EtsDN) were used in 
the co-transfections, the amount of DNA transfected m each case is indicated below the x axis m the graph 
above * In this case trans-activation for the original bfll promoter reporter construct (-1374/+81 bill Luc)
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is shown, again similar levels of trans-activation were seen for the (-1374/+81 wtbfll Luc) promoter 
reporter construct (not shown)
The fact that the dominant negative form of the Ets-1 expression plasmid reduces 
EBNA2 mediated trans-activation o f the bfl-1 promoter under the conditions tested is an 
indication that these sites and the binding of the relevant transcription factors are 
important features in conferring EBNA2 responsivity to the bfl-1 promoter
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3 2.14.0. The bfl-l Promoter is Not Trans-activated by Mouse Notch 1-IC in BL- 
Derived Cell Lines.
EBNA2 is tethered to promoters by interacting with the cellular repressor CBF1 (Henkel 
et a l , 1994, Grossman et a l , 1994, Waltzer et a l , 1994, Zimber-Strobl et a l , 1994) 
This resembles the physiological activation of CBF1-repressed promoters by activated 
Notch receptors (Notch-IC) Since EBNA2 and Notch-IC have been shown to be partially 
interchangeable in regard to activation of target genes in B cell lines via CBF1 
(Hofelmayr et a l , 1999, Hofelmayr et a l , 2001, Strobl et a l , 2000, Gordadze et a l , 
2001), it was essential to investigate possible Notch responsivity of the bfl-l promoter in 
the context of B cell lines To this end, two mouse Notch 1-IC expression plasmids were 
obtained (from Bettina Kempkes Laboratory of Molecular biology and Tumour Genetics, 
GSF National Research Centre for Environment and Health Munich Germany The 
vectors designated the names EDI (an expression plasmid for mouse Notch 1-IC), and 
ED4 (an expression plasmid for mouse NOTCH1-IC in which the RAM domain had been 
removed) were used m various transient transfection assays to determine if Notch 1-IC 
could activate bfl-l promoter activity (See Appendix for plasmid maps) The removal o f  
the RAM domain is important in that it contains a high-affinity binding site for 
transcription factors of the CSL group including CBF1 (Tamura et a l , 1995) (See Figure 
1 8 for schematic of Notch receptor) Also obtained was the “empty” vector for the Notch 
expression constructs pHACSl into which the two Notch-IC sequences had been cloned 
It was sufficient to obtain plasmids expressing the Notch mtracytoplasmic (Notch-IC) 
domain since several studies have demonstrated that truncated Notch molecules 
harboring only the IC domain behave as constitutive active forms of Notch (Fortmi et a l, 
1993, Struhl and Adachi 1998) Thus expression o f Notch-IC should result in effects 
comparable to those induced after activation of Notch by binding of one of it ligands.
Initially, EBNA2 and mouse NOTCH1-IC expression plasmids (pSG5 and pEDl 
respectively) were co-transfected with the pGa50-7 and pGa981-16 vectors (described in 
Figure 3 29) as a control to test for the functionality of both EBNA2 and mouse 
NOTCH1-IC (Figure3 46), in DG75 cells Both EBNA2 and NotchIC expression
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plasmids (pSG5EBNA2 and pEDl respectively) were seen to trans-activate the synthetic 
pGa981-16 vector (relative to fold activation by their respective background vectors 
pSG5 and pHACSl respectively) Thus both these constructs produce functionally active 
EBNA2 and Notch proteins Seven micrograms of the pSG5 EBNA2 expression plasmid 
was co-transfected with lug of the pGa981-16 promoter reporter plasmid and it can be 
seen that luciferase activity associated with the pGa9816 promoter reporter was increased 
9,700 fold compared to transfection with the pSG5 vector alone Similarly, transfection 
with the mouse NOTCH 1-IC expression plasmid pEDl (7ug) up-regulated promoter 
activity m the p981-16 vector by 10,000 fold compared to the control vector pHACSl 
Transfection with 7ug of the ED4 expression plasmid resulted in an average 27 fold 
trans-activation of the multimensed promoter m the pGa981-16 vector Although this is a 
relatively high basal level of trans-activation by the RAM-deleted Notch-IC expression 
plasmid, the values are not significant when compared to the 10,000 fold trans-activation 
with Notch-IC expression plasmid The high level o f background trans-activation, may be 
explained by the fact that another region of the activated Notch receptor, the ankynn 
repeat region which is still intact in the ED4 expression plasmid has also been shown to 
be important for interaction between CBF1 and Notch-IC and may be enhancing trans- 
activation of the pGa981-6 reporter construct No trans-activation of the pGa50-7 reporter 
was reported relative to trans-activation by the empty pHACSl or pSG5 vectors
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Figure 3.46A. Both EBNA2 and Notch-IC are Functional in this Transient
Transfection Assay and Trans-activate the pGa981-6 Reporter Construct in the
Dg75 Cell Line.
Figure 3.46(A). Both EBNA2 and Notch-IC are functional in this Transient Transfection Assay and 
Trans-activate the pGa981-6 Reporter Construct in the Dg75 Cell Line» Transfections were earned out 
in the DG75 cell line using the Deae dextran method As a control to assess the functionality of the 
expression vectors m the experiment, 7ug of pSG5EBNA2 and pEDl (Notch-IC) were cotransfected with 
lug of the pGa981-16 and pGa50-7 reporter constructs Reporter activity was measured using the hiciferase 
assay and results were normalised as usual using Beta galactosidase data Total quantities of DNA 
transfected were equalised using the pSG5 or pHACSI vectors as required * Again fold activation by the 
pSG5 and pHACSI vectors for each of the promoters was set to 1, fold activation recorded for each of the 
promoters was then relative to the appropnate background vector (pSG5 for EBNA2 expression lasmids 
and pHACSI for NotchIC expression plsmids)
The ability o f pSG5EBNA2 and pEDl to trans-activate the pGa981-16 promoter showed 
that both EBNA2 and Notchl-IC were functional in this experiment In this same 
experiment, the pSG5EBNA2 and pEDl mouse-Notchl-IC expression plasmids were co­
transfected with the bfl-1 promoter (-1374/+81 wtbfll Luc) and the CBF1 mutant version
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of the bfl-1 promoter (-1374/+81 mCBFl bill Luc) These are shown on different graphs 
as the scale of trans-activation o f the bf-ll promoter reporter constructs and the control 
plasmid pGa981-6 are vastly different
Figure 3.46(B). Mouse Notch-IC (pEDl) Does Not Trans-activate the bfl~l Promoter 
Over a Range of Quantities Used.
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Figure 3.46(B ) Mouse Notch-IC (pEDl) Does Not Trans-activate the bfl-1 Promoter Over a Range of 
Quantities Used In the same experiments as 3 46A above, the mouse notch expression plasmid pEDl was 
titrated against the bfl-1 promoter reporter constructs (-1374/+81 wtbfll Luc) and (-1374/+81 mCBFIbfll 
Luc) Although both EBNA2 and Notch-IC are functionally active as demonstrated by their ability to trans- 
activate the pGa981~6 reporter construct (3 46A), only pSG5EBNA2 trans-activated the bfl-1 promoter 
The Notch 1-IC expression plasmid (pEDl) M e d  to trans-activate either bfl-1 promoter over the range of 
quantities used m this experiment
Although both EBNA2 and Notchl-IC could trans-activate the CBF1 driven promoter m 
pGa981-6, only EBNA2 is seen to trans-activate the bfl-1 promoter (Figure 3 46B)
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EBNA2 trans-activated the bfl-l promoter (-1374/+81 wtbfll Luc) an average o f 4 8 fold, 
however when increasing quantities o f vector expressing mouse Notch-IC (pEDl) was 
titrated against the bfl-l promoter (Figure 3 46B) it did not trans-activate the bfl-l 
promoter at any quantity over the 1 to lOug range of expression plasmid tested Both 
EBNA2 and mouse Notchl-IC trans-activated the mutated bfl-l promoter very weakly
ED4 was also titrated against the wild type bfl-l promoter (-1374/+81 wtbfll Luc) It did 
not trans-activate the promoter over the range (l-10ug) of expression plasmid (pED4) 
used, indeed higher levels o f this expression plasmid appeared to repress basal levels of 
promoter activity (Figure 3 47) Thus, it can be concluded that m DG75 cells, under these 
conditions, the bfl-l promoter is EBNA2, but not mouse Notch-IC responsive
Figure 3.47. The RAM Deleted Notch-IC Expression Plasmid (pED4) Does Not 
Trans-activate the bfl-l Promoter over a Range of Quantities Used, in the Dg75 Cell 
Line.
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Figure 3 47 The RAM Deleted Notch-IC Expression Plasmid (pED4) Does Not Trans-activate the 
bfl-1 Promoter over a Range of Quantities Used, in the Dg75 Cell Line. In the same manner as for 
pEDl before (Figure 3 46B), ED4 was titrated against the bfl-1 promoter 9-1374/+81 wtbfll Luc) pED4 
did not trans-activate the promoter over the range of concentrations tested It is unsurprising that this 
expression plasmid did not trans-activate the promoter since the CBF1-binding RAM domain has been 
removed
In order to extend the analysis of bfl-1 responsivity to mouse NOTCH1-IC in EBV 
negative BL cell lines, further transfections were earned out in another well-charactensed 
EBV negative BL cell line, BJAB (Figure 3 48) The optimised ratio of expression 
plasmid (7ug) (pEdl/pED4/pSG5EBNA2) to lug of promoter reporter construct (pGa50- 
7/pGa981 -6/-1374/+81 wtbfll Luc/ -1374/+81 mCBFlbfll Luc) was employed here as 
before Transfection of the pSG5EBNA2 expression plasmid activated promoter activity 
m the pGa981-16 construct an average o f 49 fold over the course of three independent 
experiments (relative to fold transactivation by the pSG5 vector) In the same 
experiments, the Notch-IC expression plasmid pEDl trans-activated the pGa981-16 
promoter reporter construct an average of 455 fold (relative to the pHACSl vector) 
Neither pED4 nor the mutant pSG5EBNA2 expression plasmid (pSG5WW323SR, which 
cannot bind CBF1), trans-activated the pGa981-16 promoter in the Bjab cell line None 
of the expression constructs trans-activated the control pGa50-7 construct
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Figure 3.48.(A). EBNA2 and mouseNotch-IC are Functionally Active and Trans-
activate the pGa981-6 Promoter Reporter m the Bjab Cell Line.
Figure 3.48 (A) EBNA2 and mouseNotch-IC are Functionally Active and Trans-activate the pGa981- 
6 Promoter Reporter in the Bjab Cell Line. Similar to Figure 3 46A, the functionality of the EBNA2 
and NOTChl-IC expression plasmids (pSG5EBNA2 and pEDl respectively) was checked by co- 
transfection with the pGa98M6 and pGa50-7 reporter constructs This experiment was earned out m the 
usual maimer with transfection done by the DBAE Dextran method however these transfections were 
earned out m the Bjab cell line In this case agam, both EBNA2 and NOTCH I-IC can trans-activate the 
multimensed promoter in pGA981-16 thus both pSG5EBNA2 and pEDl give nse to functionally active 
EBNA2 and NotchIC which can trans-activate the CBF1 driven pGA981-6 reporter construct
Despite both EBNA2 and NotchIC being fiinctionally active as demonstrated by their 
ability to transactivate the pGA981-6 reporter construct, in the same expenment only 
EBNA2 could trans-activate the bfl-1 promoter in the Bjab cell line (Figure 3 48 B) As 
for Figures 3 46 A and B above the two lots of transfections (although done
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simultaneously) are shown on separate graphs as the scale of trans-activation of the bfl-1 
promoter (-1374/+81 wtbfll Luc) and pGa981-6 promoters are so vastly different 
(Figures 3 48 A and 3 48 B) With respect to bfl-1, (-1374/+81 wtbfll Luc) it can be seen 
that only EBNA2 trans-activated the promoter (Figure 3 48B) In this instance trans- 
activation reached an average of about 4 fold compared to the empty vector pSGS 
Neither pEDl nor pED4 trans-activated the bfl-1 promoter (-1374/+81wtbfllLuc) 
Possibly however titration of the Notch-IC expression plasmid (pEDl) in this cell line 
may give different results No trans-activation above 1 5 fold was recorded with any of 
the expression plasmids when co-transfected with the bfl-1 CBF1 mutant promoter (- 
1374/+81 mCBFl bfll Luc)
Figure 3.48 B. The bfl-1 Promoter (-1374/+81 wtbfl-1 Luc) is an EBNA2 but Not 
mouseNotch-IC Responsive Promoter in the Bjab Cell Line.
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Ram deleted Notch-IC expression plasmids (pEDl and pED4 respectively) were transfected with the wild 
type bill promoter (-1374/+81 wtbfll Luc) and the CBF1 mutant bfl-1 promoter (-1374/+81 mCBFlbfll 
Luc) Despite the feet that Notch-IC appears to be functionally active in view of its ability to trans-activate 
the pGa981-6 reporter (3 48A), Notchlc does not trans-activate either bfl-1 promoter reporter constructs In 
the same experiment EBNA2 (psg5EBNA2) trans-activated the wild type bfl-1 promoter (-1374/+81 wtbfll 
Luc) about 4 fold
These results m accordance with the results obtained in the DG75 cell line show that, like 
the CD23 promoter, bfl-1 is responsive to EBNA2 but not NOTCHIC, at least in the BL- 
derived cell lines tested Smce trans-activation of bfl-1 by LMP1 (D'Souza et a /, 2000) 
and now EBNA2 appears to be a B cell specific effect, it is possible that the cell context 
is important in mediating possible bfl-1 responsiveness to Notch-IC Further work could 
investigate this possibility using transient transfections with Notch-IC expression 
plasmids in a range of non B cell lines
3.2.15 0. Analysis of bfl-1 Promoter Responsiveness m Cell Lines Expressing 
Estrogen-Activated EBNA2 or mouse N otchllC
Transfections were also carried out m the BL41P3HR 1 mNotch-IC-ER (CL31) cell line in 
which (see materials and methods) mouse NOTCH-IC function is dependent on the 
presence of estrogen The two bfl-1 promoter reporter constructs (-1374/+81wtbfll Luc 
and -1374/+81 mCBFlbfll Luc) and the two control reporter constructs (pGa50-7 and 
pGa981-16) were transfected into the (BL41P3HR1 -ER/Notch-IC (CL31) cell line m the 
presence or absence of estrogen Thus the effect of activating mouse Notchl-IC on the 
various promoter constructs could be studied As shown in the figure below (Figure 
3 49A) the promoter carrying the multimenzed CBF1 binding sites (pGa981-6) could be 
trans-activated 250 fold after activation of the mNOTCH-IC-ER by addition of estrogen 
relative to transactivation prior to estrogen addition The negative control pGa50-7 
promoter was trans-activated 31 fold in this cell line in response to estrogen addition 
This effect on the pGa50-7 reporter construct was not observed in either the K3 or 9A 
cell lines m response to estrogen addition and so it is not an artifact of the estrogen itself 
Since EBNA2 activation does not have this effect it may be a Notch specific effect on the 
minimal SV40 promoter in the pGa50-7 vector
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These results (Figure 3 49A) indicate that the mNotch-IC-ER expressed m CL31 is 
functionally active and can be regulated by estrogen In the same experiment, the bfl-1 
promoter and its CBF1 mutant equivalent were also transiently transfected into the CL31 
cell line (Figure 3 49B) The results showed no significant trans-activation of either the 
bfl-1 promoter (-1374/+81 wtbfll Luc) or its CBF1 mutated counterpart (-1374/+81 
mCBFlbfll Luc) m the presence of estrogen suggesting that under these conditions bfl-1 
is not mNOTCH 1 -IC-responsive Again although these transfections were done 
simultaneously, the difference m the scale o f activation of the bfl-1 promoter reporter 
constructs (-1374/+81 wtbfll Luc, -1374/+81 mCBFlbfll Luc) and the control reporter 
constructs (pGa981-6 and pGA50-7), meant the transfections for each pair of promoter 
reporter constructs were depicted on separate graphs
Figure 3.49A. Notch-IC is Functionally Active and Trans-activates the pGa981-6 
Promoter Reporter Construct in the BL41P3HRl-ER/NotchlC (0 3 1 ) Cell Line
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Figure 3 49A. Notch-IC is Functionally Active and Trans-activates the pGa981-6 Promoter Reporter 
Construct m tbe BL41P3HRl-ER/NotchIC (CL31) Cell Line. Transfections were earned out by 
electroporation Ten micrograms of promoter reporter DNA (pGa50-7/pGa981 -6) were transfected into the 
CL31 cell lrne Promoter activity was measured before and after estrogen addition using the luciferase 
assay Transfection efficiency was corrected for using the p-gal assay In the case of each promoter pre 
estrogen luciferase values were assigned a fold transactivation of 1 and fold transactivation of each of the 
promoters in response to estrogen addition/(Notch-IC activation) were relative to this It can be seen that 
NotchIC activation trans-activates both pGa50-7 and pGa981-6 reporters m this experiment thus Notch-IC 
is functionally active One explaination as to why the “empty” pGa50-7 reporter is trans-activated may be 
that the Notch-IC or a downstream target of it trans-activate the minimal SV40 promoter m this construct
Figure 3.49B Despite Notch-IC Being Functionally Active, the bfl-1 Promoter is not 
Notch-IC Responsive in the BL41P3HRl-ER/NotchIC (CL31 Cell Line).
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Figure 3.49B Despite Notch-IC Being Functionally Active, the bfl-1 Promoter is not Notch-IC 
Responsive in the BL41P3HRl-ER/Notch~IC (CL31 Cell Line). Although Notch-IC is active as seen by 
its ability to transactivate the pGa981-6 reporter construct m 3 49A above, in the same experiment 3 49B it 
only weakly trans-activates the bfl-1 promoter reporter constructs (-1374/+81 wtbfll Luc and -1374/+81 
mCBFlbfll Luc) m the CL31 Cell Line
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3.2.16.0. Human NOTCH1-IC and Human NOTCH2-IC Do Not Trans-activate the
bfl-1 Promoter in B Cell Lines.
Human Notchl-IC and Notch2-IC expression plasmids were obtained (Paul Ling Baylor 
Medical school Baylor College Texas) The human NOTCH1-IC expression plasmid was 
named p JT lll, similarly the human Notch2-IC expression plasmid was named pJT112 
Briefly these consist o f the human Notchl-IC cDNA and the Human Notch2-IC cDNA 
respectively, cloned into the EcoRI-BgQI site o f pSG5 upstream o f the luciferase gene 
(Described by Gordadze el a l , 2001) As before, EBNA2 and the Notchl-IC and Notch2- 
IC expression plasmids (pSG5EBNA2 and p JT lll and pJT112 respectively) were co­
transfected in DG75 cells with the pGa50-7 and pGa981-16 vectors as a control to test for 
the functionality o f EBNA2, humanNotchl-IC and humanNotch2-IC in DG75 cells 
Results are shown in Figure 3 50
Figure 3.50A. Human NotchllC, (pJTlll) Human Notch2Ic (pJTU2) and EBNA2 
(pSG5EBNA2) are Functionally Active in the DG7S Cell Line and Trans-activate 
the pGa981-6 Reporter Construct.
A
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Figure 3.50A. Human Notchl-IC, (p JT lll)  Human Notch2-IC (pJT112) and EBNA2 are 
(pSG5EBNA2) Functionally Active m the DG75 Cell Line and Trans-activate the pGa981-6 Reporter 
Construct In order to test the functionality of the proteins expressed by the transfected expression 
plasmids, the human Notchl-IC and human Notch2-IC expression plasmids were cotransfected with the 
pGa981-16 and pGa50-7 reporter constructs This activity was compared to EBNA2 activity in the same 
experiment Transfections were earned out using the DEAE Dextian method and promoter activity was 
measured in the usual way using the luciferase assay again trans-activation by the pSG5 vector alone was 
assigned a fold activation of 1 for each of the promoter reporter constructs transfected Again Fold 
activation by the pSG5 related human notchllC (pJT lll), Notch2IC (pJT112) and EBNA2 
(pSG5EBNA2) expression vectors were relative to this
In all cases 7ug of expression plasmid to lug of promoter reporter, was transfected into 
DG75 cells using the DEAE dextran method The results showed that the transiently 
transfected pJTl 11 transacivated the pGa981-16 promoter reporter vector (containing the 
multimerized CBF1 sites) an average of 505 fold relative to the empty pSG5 vector 
Promoter activity, again relative to the pSG5 vector was increased an average o f475 fold 
by transfection with the pJT112 expression plasmid In the same expenment EBNA2 
(pSG5EBNa2) trans-activated the promoter m the pGa981-16 vector an average of 2341 
fold These results show, that both human Notchl-IC and humanNotch2-IC as well as 
EBNA2 are functionally active m these experiments in the DG75 cell line
Knowing that both pJTlll and pJT112 were expressing functional forms of NOTCH 1 
and 2 respectively, their effects on the bfl-1 promoter were then investigated and so both 
pJTl 11 and pJTl 12 were titrated against the bfl-1 promoter It can be seen from Figure 
3 50 that HumanNotchl-IC did not trans-activate the bfl-1 promoter (-1374/+81 wtbfl-1 
Luc) In fact, transfection of the human Notchl-IC expression plasmid resulted in a 
reduction in basal trans-activation of the bfl-1 promoter compared to co-transfection with 
pSG5 vector alone As a control for transfection efficiency pSG5EBNA2 was also 
transfected and, as before transfection with EBNA2 increased bfl-1 promoter activity an 
average of 7 fold The same titration expenment was earned out using the pJT112 
humanNOTCH2-IC expression plasmid Results from these transfections showed that bfl- 
1 is not human Notchl-IC or human Notch2-IC responsive m this cell line since 
transfection with varying quantities of Notch2-IC/NotchlIC expression plasmid did not
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result in any up-regulation of bfl-1 promoter activity (-1374/+81 wtbfll Luc) As for 
human Notchl, transfection with increasing quantities of human Notch2 expression 
plasmid resulted in a dose dependent reduction in basal levels of promoter activity (See 
Figures 3 SOB and 3 50C) Here, promoter activity was reduced below basal trans- 
activation levels recorded for transfections involving the empty pSG5 vector alone 
Taken together the results for the transfections in DG75, BL41 and Bjab cell lines show 
that although in each case the Notch expression plasmids transfected are producing 
functional proteins, they do not lead to promoter trans-activation Thus, in the BL cell 
lines examined, the bfl-1 promoter is responsive to EBNA2 but not mouse Notch 1-IC or 
human Notch 1-IC or Notch2-IC
Figure 3.50B. Human Notchl-IC Does Not Transactivate the bfl-1 Promoter in the 
DG75 Cell Line.
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Although the human Notchl-IC produces functional Notch-IC in the DG75 cell line as demonstrated by its
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ability to transactivate the pGa981-6 promoter reporter construct in 3 50A above, the bfl-1 promoter (- 
1374/+81 wtbfll Luc) is not transactivated in co-transfections with p JT lll in the DG75 cell line The 
human Notch I-IC expression plasmid (pJT lll) was titrated against the bfl-1 promoter over a range of 
concentrations however it failed to transactivate the bfll promoter (-1364/+81 wtbfll) over the range of 
quantities used Thus bfl-1 may be EBNA2 but not human Notch-IC responsive m the DG75 cell line
Figure 3.50C. Human Notch2-IC Does Not Transactivate the bfl-1 Promoter m the 
DG75 Cell Line.
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Although the human Notch2-IC produces functional Notch2-IC in the DG75 cell line as demonstrated by 
its ability to transactivate the pGa981-6 promoter reporter construct in 3 50A above, the bfl-1 promoter (- 
1374/+81 wtbfll Luc) is not trans-activated m co-transfections with pJT112 in the DG75 cell line The 
human Notch2-IC expression plasmid (pJT112) was titrated against the bfl-1 promoter over a range of 
concentrations as for p JT lll (Figure 3 SOB) Like human Notch 1-IC, human Notch2-IC also failed to
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trans-activate the bfl-1 promoter (-1364/+81 wtbfll) over the range of quantities used Thus bft-l may be 
EBNA2 but not human Notch-IC or Notch2IC responsive m the DG75 cell line
3.2.15.1. Human Notch 2 and mouse Notch 1 Repress EBNA2~Mediated Trans- 
activation of bfl-L
Since both EBNA2 and Notch-IC proteins share affinities for some of the same nuclear 
proteins including CBF1 it is possible that Notch is capable of interacting with CBF1 
when the latter is bound to the bfl-1 promoter, even though significant trans-activation is 
not detectable Its inability to trans-activate the promoter may indicate (l) that the Notch- 
IC trans-activation domain is much weaker than that of EBNA2, or (u) that trans- 
activation via the CBF1 site requires interaction with other additional factors, something 
achieved by EBNA2 but not Notch-IC, or (m) Notch may not bind to or have reduced 
affinity for the CBF1-corepressor complex formed at the -243/-249 site on the bfl-1 
promoter, if, for example, the RBP-J isoform present has weak affinity for Notch proteins 
but not EBNA2 One way to test possible Notch-CBFl interaction on the bfl-1 promoter 
was to co-transfect EBNA2 and Notchexpression plasmids to see if co-expression o f  
Notch and EBNA2 would result m decreased EBNA2-mediated trans-activation This 
competition expenment was earned out for the mouse and human Notchl-IC expression 
plasmids (pEDl, pJT lll) and the human Notch2-IC expression plasmid (pJT112) 
Results shown m Figures 3 51-53 Increasing quantities of pJT lll were co-transfected 
with pSG5EBNA2 and the subsequent trans-activation of the bfl-1 promoter analysed 
using the luciferase assay Figure 3 51
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Figure 3.51. Co-transfection with Human Notchl-lC  (p J T lll) does not Affect 
pSG5EBNA2-Mediated Trans-activation of the bfl-1 Promoter in the DG75 Cell 
Line.
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Figure3.51. Co-transfection with Human Notchl-IC (p JT lll)  does not Affect pSG5EBNA2-Mediated 
Trans-activation of the bfl-1 Promoter m the DG75 Cel! Line. The EBNA2 Expression plasmid 
(pSG5EBNA2) was cotransfected with increasing quantities of the human Notchl-IC expression plasmid 
(pJT lll) and the transactivational affect on the wild typr bfll promoter reporter construct was recorded (- 
1374/+81 wtbfll Luc) No affect adverse or otherwise on EBNA2-mediated transactivation of the bfll 
promoter were seen over the range of quantities of pJTl 11 used
234
The results again show that pSG5EBNA2 trans-activates the bill promoter (-1374/+81 
wtbfll Luc) an average o f 6 8 fold when transfected alone with the promoter (Figure 
3 51) As increasing quantities of pJT lll (from 1 to lOjig) were cotransfected with 
pSG5EBNA2, promoter activity was neither increased nor decreased Overall co- 
transfection with the pJTlll vector expressing humanNotchl-IC did not affect EBNA2 
mediated trans-activation of the bfl-1 promoter (-1374/+81 wtbfll Luc) The same 
titration experiment was earned out with the pJTl 12 construct expressing human notch2- 
IC Interestingly, cotransfection with human Notch 2 decreased pSG5EBNA2 dnven 
activation of bfl-1 by 50% Promoter activity was impeded even when only l^g o f  
Notch2-IC expression plasmid (pJT112) was added Addition of increasing amounts of  
Notch 2 expression plasmid, up to 10 jag did not further reduce EBNA2 mediated 
promoter activity
Figure 3.52. Co-transfection with Human Notch2-IC (pJT112), Down-Regulates 
pSG5EBNA2 Mediated Trans-activation of the bfl-1 Promoter m DG75 Cells.
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Figure 3 52. Co-transfection with Human Notch2-IC (pJT112), Down Regulates pSG5£BNA2 
Mediated Trans-activation of the bfl-1 Promoter in DG75 Cells. The EBNA2 Expression plasmid 
(pSG5£BNA2) was co-transfected with increasing quantities of the human Notch2-IC expression plasmid 
(pJT112) and the affect on EBNA2 mediated transactivation of wild type bill promoter reporter construct 
was recorded (-1374/+81 wtbfll Luc) Addition of even lug of Notch2-IC expression plasmid (pJT112) 
resulted in a 50% decrease in pSG5EBNA2-mediated trans-activation of the bfl-1 promoter (-1374/+81 
wtbfll Luc) Increasmg the quantity of pJT112 did not increase the reduction m EBNA2 mediated 
txansactivation of the bfl 1 promoter In this case the ability orf Notch2 IC to reduce EBNA2 transactivation 
of the promoter may imply that Notch2-IC interacts with either CBF1, a member of the repression complex 
and so competes with EBNA2 to bind CBF1 thereby repressing EBNA2 mediated tactivation of the 
promoter Alternatively it may not bind to bfl-1 via CBF1 at all instead Notch2-IC may just steancally 
hinder EBNA2 interaction with CBF1
One final set of transfections was undertaken comparing the reductive effect Notch co- 
transfection had on EBNA2 mediated trans-activation o f the bfl-1 promoter In this 
experiment 3pg of each o f the Notch expression plasmids were co-transfected with 7|xg 
of the EBNA2 expression plasmid pSG5EBNA2 and bfl-1 promoter activity was assessed 
using the luciferase assay Included in this experiment was the mouse NOTCH1-IC 
expression plasmid EDI Surprisingly, as for the human notch2 expression plasmid, co- 
transfection of this expression vector (EDI) reduced EBNA2 mediated trans-activation of 
the promoter from an average o f 6 fold to 1 6 fold Because of the high degree of  
homology between munne and human species of Notchl it was unexpected that the two 
did not behave similarly m this experiment, however over two independent experiments, 
mouse and not human Notch-IC reduced EBNA2 mediated trans-activation of the bfl-1 
promoter
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Figure 3.53 Co-transfetcion with Human Notch2-IC (pJT112) and mouse Notchl-IC 
(pEDl) but Not Human Notchl-IC (pJTlll), Represses £BNA2-Mediated Trans- 
activation of the bfl-1 Promoter in the DG75 Cell Line.
Co-transfetcion wtth Human Notch2IC (p/T112) and mouse Notch 1IC (pED1) but Not Human NatchllC 
(pJT111), Represses EBNA2-Mediated Trans-activation of the bfl-1 Promoter in the DG75 Cell Line.
9 1 
8
7
6
c o
|  5-
■o * ‘ o
u .
3 
2 
1 
0
pSQ5 pSGSEBNA2(7ug) pSG5EBNA2(7ug) + pSG5EBNA2(7ug) + p$G5EBNA2(7ug) +
pJT111(Hurnan pJT112(Human ED1{mouse Notchl- 
Noteh14C)(3ug) Noteh2-IC) (3ug) IC)(3ug)
Figure 3.53 Co-transfetcion with Human Notch2IC (pJT112) and mouse Notch 1IC (pEDl) but Not 
Human NotchllC (p JT lll) , Represses EBNA2-Mediated Trans-activation of the bfl-1 Promoter in 
the DG75 Cell Line. As a final experiment a nominal amount (3ug) of human NotchllC expression 
plasmid (pJT lll), human Notch2IC expression plasmid (pJT112) and mouse notchIC expression plasmid 
(pEDl) were cotransfected with pSG5EBNA2 and the affect on pSG5EBNA2 mediated trans-activation of 
the bill promoter (-1374/+81 wtbfll luc) was assessed Strangely despite the large degree of homology and 
the shared functions of human and murine notclIC, only the mouse notchl expression plasmid affects 
pSG5EBNA2 mediated transactivation of the bill promoter reducing it by ~50% Similarly the human 
notch2IC expression plasmid reduced EBAN2 mediated transactivation of the bfll promoter by 50%.
Overall these results showed that co-expression of either human Notch2-IC or mouse 
Notchl-IC leads to a reduction m pSG5EBNA2-mediated bfl-1 promoter activity The 
fact that Notch cannot trans-activate the promoter itself but can impair EBNA2 mediated
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trans-activation, may indicate their shared ability to bind to CBF1 and/or other 
component(s) of the Notch nuclear complex on the promoter The ensemble of the results 
to date explicitly shows the importance of the CBF1 binding site in conferring EBNA2 
responsiveness to the promoter Knowing that Notch can bind to CBF1 suggests that 
Notch2IC/mouseNotchlIC may indeed be binding to CBF1 thereby hindering the 
EBNA2-CBF1 mediated trans-activation of the bfl-1 promoter In order to address 
protem-DNA interactions if  Notch is binding CBF1, electrophoretic mobility shift assays 
(EMSA) could be employed However if Notch is binding it is not transactivating the bill 
promoter m the BL cell lines tested, possibly other transcriptional equipment required by 
NotchIC to transactivate the bfll promoter is not available m BL cell lines, one possible 
avenue of investigation to explain this would be to attempt to trans-activate the bfl-1 
promoter with Notch expression plasmids in a different cellular background This was 
attempted in vascular smooth muscle cells with available notch expression plasmids 
however no trans-activational effect was observed in this cell line either (not shown) 
Further experiments could possibly be attempted m T cell lines such as the jurkat cell line 
for example
3.3Ak bfl-1 mRNA levels do Not Change in Response to Activation of mNotchl-IC in 
BL41P3HRlmNotchl-IC-ER (C131).
Both EBNA2 and activated NOTCH-IC trans-activate genes by interacting with 
transcription factors including CBF1 The viral protein EBNA2 may hence be regarded as 
a functional equivalent of an activated Notch receptor Studies by (Strobl et a l, 2000) 
showed that activated Notchl modulates gene expression in B cells similarly to EBNA2 
The aim of this part of this study was to directly investigate the role of Notch in 
regulating the EBNA2 responsive bfl-1 gene, at the RNA level To this end, the 
BL41P3HRl-ER/mNotchIC (CL31) cell line was employed, Notchl was activated m the 
presence of estrogen similar to that described earlier Functionality of the expressed 
Notch was then checked by probing for the presence of a mRNA from a target gene of  
notch namely CD21 (Figure 3 54) Functional mouse Notch 1-IC, was activated by 
estrogen withdrawl over a 24-hour period and CD21 and bfl-1 mRNA levels were
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detected over the same time course by northern blotting (Figures 3 54 and 3 55) The 
CD21 and bfl-1 probes used were identical to those used m the blots m Figures 3 5-3 9 
Also included m the bfll Northern blot (Figure 3 55) were samples from LCLs and type 
Hi BLs as positive controls for cell lines in which high levels o f bfl-1 mRNA is known to 
be present It can be seen from the results that levels of CD21 mRNA increased in 
response to notch activation over the 24 hour penod of estrogen addition (3 54B) Panel 
C of figure 3 54 shows the ethidium bromide stained gel used in the Northern blot and 
was used as a control for loading Despite the fact that the Notch-Ic in this cell line 
(CL31) is functionally active and up-regulates CD21 mRNA levels (Figure 3 54B), in 
Figure 3 55A/B it can be seen that bfl-1 mRNA levels are only transiently up-regulated at 
3 hours post Notch activation the lane for the 6 hour time point is underloaded so this 
effect may still be present at this stage but it cannot be seen from the blot below (if there 
is an effect its over by 9 hours) Bfl-1 levels then fall again to basal levels It can also be 
seen from the results that bfl-1 mRNA was detected m the control cell lines IARC171 
IARC290B AG876 and DG75LMP1 (post LMP1 induction) and at very low levels in the 
Dg75LMPl (pre LMP1 induction)- cell lines (3 55A/B) The fragment size, matches that 
previously reported as for bfl-1 mRNA On addition of cyclohexamide bfl-1 mRNA 
levels are up-regulated both in the presence and absence of activated Notch though 
activation of Notch results m slightly higher levels of bfl-1 mRNA (16 fold) The high 
levels of bfl-1 mRNA in the presence o f cyclohexamide suggest that this chemical which 
inhibits protein sythesis may be stabilising any bfl-1 that is already there however since 
this is not seen in the E2/ER cell lines (k3/9A), it is possible that this effect is a specific
i
effect of the background in this cell line
Overall even though Notch is present and functioning (since CD21 mRNA levels are 
elevated) and bfl-1 mRNA is detectable by the probe in use, Notch activation only 
transiently up-regulates bfl-1 mRNA levels m the CL31 cell line
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Figure 3.54. Notchl-IC is Present and Functionally Active in the BL41P3HR1
ER/mNotchllC (C131) Cell Line.
Western Blot BL41P3HRl-ER/mNotchlIC (C131)
Hours Post Estrogen Addition
0 3 6 9 12 24 6Cx 6Cxe
mNotchllC 
Protein
Northern Blot BL41P3HR1-ER/mNotchllC (C131)
B
CD21
mRNA
Hours Post Estrogen Addition
0 3 6 9 12 24 6Cx 6Cxe
NotchIC is present and and 
functionally active in the CL31 cell 
line.
Western Blotting
Panels A shows the NotchIC protein 
detected before and after estrogen 
addition.
Northern Blotting
Panels B and C show that the 
NotchIC present after addition of 
Estrogen is functional as CD21 
mRNA is up-regulated in response to 
NotchIC Activation.
Figure 3.54. Notchl-IC is Present and Functionally Active in the BL41P3HRl-ER/mNotchlIC (CI31) 
Cell Line. mNotchl-IC was activated in the BL41P3HRl-ER/mNotchlIC (CL31) cell line by addition of 
estrogen to the culture media Total RNA and protein was harvested at 0, 3, 6, 9 12 and 24 hours post 
estrogen addition (mNotchIC activation) and after six hours in the presence of cyclohexamide (Cx) before 
and after Notch activation Panel A Western blot showing mNotchl-IC expression before and after 
induction over the experimental timecourse. In order to verify that the (mNoptchl-IC) protein expressed in 
the cells was functional in response to estrogen addition, transcription from a known target gene of notch 
namely CD21 was analysed by Northern blotting. Panel B. Northern blot showing the up-regulation of 
CD21 in response to mNotchl-IC activation over the 24-hour time course. Panel C shows the ethidium 
bromide staining of the gel used for blotting in panel C. In the same experiment, the affect of mNotch-IC 
activation on bfl-1 mRNA was also assessed (Figure 3.55).
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Figure 3.55. Bfl-1 mRNA and Protein is Only Transiently Up-regulated in the 
BL41P3HRl-ER/mNotchl-IC (CL31) Cell Line in Response to mNotchl-IC 
Activation.
Bfl-1 mRNA and Protein is only transiently up regulated in the 
BL41P3HR1 -ER/mNotch 1 IC (C131) Cell Line in Response to mNotchllC 
Activation.
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Figure 3.55. Bfl-1 mRNA is only transiently up regulated in the BL41P3HRl-ER/mNotchl-IC (C131) 
Cell Line in Response to mNotchl-IC Activation. Panel A shows bfl-1 mRNa levels detcected in the 
CL31 cell line over a 24 hour period in response to mNotchllC activation. Also shown in this panel is the 
bfl-1 transcript detected in a number of LCLs and type III BLs in which bfl-1 is known to be present. The 
effect of LMP1 induction on bfl-1 mRNA can also be seen in the last two lanes as bfl-1 mRNA levels are 
dramatically higher in the case where LMP1 has been induced. Panel B shows the GAPDH mRNA levels 
detected in the lanes in panel A, which were reprobed for GAPDH mRNA after blotting for bfl-1.
Despite mNotchl-IC being functionally active in the CL31 cell line as demonstrated by the upregulation of 
CD21 mRNA in Figure 3.54 above, bfl-1 mRNA is only transiently up-regulated over a 9 hour period in 
response to mNotchl-IC.
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3.4.0. PHYSIOLOGICAL RELEVANCE OF EBNA2 INDUCED EXPRESSION OF BfL-1 IN 
DG75 C e lls .
Type IE BL cell lines expressing the full compliment of EBV latent genes have been 
shown to have a higher apoptotic threshold than their type I counterparts It has been 
shown that LMP1-induced expression of bfl-1 mRNA protected B1 cells against 
apoptosis induced by growth factor-depnvation (D’Souza et a l , 2000) The novel 
findings in this study, which identify bfl-1 as a target gene of the EBV latent protein 
EBNA2, independent of LMP1 expression, suggest regulation of the bfl-1 gene may be 
an important feature of EBV/EBNA2 induced resistance to apoptosis The results 
presented m this study showed a definitive link between EBNA2 expression and the up- 
regulation of bfl-1 at the mRNA and protein levels as well as activation of the bfl-1 
promoter The physiological relevance of EBNA2 induction of bfl-1 in terms of its 
involvement m protection against apoptosis and regulation o f the apoptotic response in 
EBV infected cells, thus had to be investigated
3.41. Dg75 Cells are susceptible to apoptosis only under conditions of 
extreme Serum Depletion.
Initially susceptibility of the Dg75 cell line to apoptosis was first analysed Apoptosis 
was induced by two methods (i) growth factor withdrawal (serum starvation) and (n) 
exposure to toxin (lonomycin) Dg75 cells were cultured m media containing 10% 
(normal supplement) 5%, 1%, 0 5%, and 0 1% foetal bovine serum Cell viability was 
monitored every 24 hours over a seven-day period using trypan blue exclusion (Figure 
3 56) The mechanism of cell death was confirmed as apoptosis by fluorescence 
microscopy after acndine orange staining, designed to specifically detect cell death as a 
result of apoptosis (Figure3 57)
It can be seen from the results obtained that cell viability remained close to 100% when 
the serum concentration was at 10% and 5% Cell viability decreased to just less than 
90% after 7 days incubation in media supplemented with 1% serum at both cell densities
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When serum concentration in the growth media was further reduced to 0 5%, cell 
viability was also reduced with the percentage o f viable cells after 7 days falling to 64% 
again at both cell densities Results using 0 1% serum supplemented growth media 
showed cell viability at 42% and 46% after 7 days in the flasks seeded at lxlO5 cells/ml 
and 5x105 cells/ml respectively Thus growth factor withdrawal resulted in increased cell 
death as represented by the reduction in the number of viable cells after serum starvation 
Cells were seeded at two different densities however both cell concentrations reacted 
similarly to serum starvation conditions suggesting seeding Dg75 cells at the lower cell 
density did not adversely affect cell viability Trypan blue exclusion was used to assess 
cell viability, with live cells appearing colourless Dead cells stain blue due to the uptake 
of the stain as a result of membrane damage Although trypan blue exclusion gives a clear 
picture that cell death is occurring, the actual method of cell death be it necrosis or 
apoptosis is not distinguished
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F i g u r e  3 .5 6 . D g 7 5  c e l l  V ia b il it y  is  R e d u c e d  b y  Se r u m  S t a r v a t io n .
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Figure 3.56. Dg75 Viability is Reduced by Serum Starvation. Dg75 cells were seeded at a density of 1 x 
105 cells/ml and 5 xlO5 cells/ml in A and B above, respectively. Cells were then cultured over a seven day 
period in RPMI1640 supplemented with Pen/Strep and L-glutamine, however, each of the five culture 
flasks (at each cell density) were additionally supplemented with 10% (the usual supplement), 5% 1% 0.5% 
and 0.1% foetal bovine serum. It can be seen that reduction in Growth factor from 10% to 1% had little 
effect however in 0.5% serum cell viability was reduced to 64% (for both cell densities) and in 0.1% serum 
cell viability was reduced to 42% and 46% in the flasks seeded at 1 x 105 cells/ml and 5 xlO5 cells/ml 
respectively.
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In order to determine if the cell death occurring as a result of serum starvation was 
apoptotic, acridine orange staining was employed. Acridine orange is a metachromatic 
dye which differentially stains double stranded (ds) and single stranded (ss) nucleic acids. 
When acridine orange intercalates into dsDNA it emits green fluorescence upon 
excitation at 480-490nm. Conversely, it emits orange fluorescence when it interacts with 
ssDNA or RNA. Samples from flasks containing the 10% serum supplemented media 
were stained as a positive control to show the staining and morphology of healthy cells. A 
cell sample from the 0.1% serum supplemented flask after 7 days was also examined to 
determine if the dead cells observed by trypan blue exclusion were dying by apoptosis. 
Acridine orange staining was carried out as described in the materials and methods 
section. An aliquot of suspension cells were fixed to microscope slides using ice-cold 
acetone. Cells were then stained with acridine orange at a concentration of lOug/ml. 
Slides were viewed directly with a fluorescence ultraviolet light microscope (Zeiss 
Axiskop: camera JVC 3CCd-Cmount); (Figure 3.57).
Figure 3.57. Dg75 Cells Die by Apoptosis Under Conditions of Growth 
Factor Withdrawl/Serum Starvation.
A B
Dg75 in 10% Serum- 
Supplemented Media (7 days)
Dg75 in 0.1% Serum- 
Supplemented Media (7 days)
Figure 3 57. Dg75 Cells die by Apoptosis Under Conditions of Growth Factor Withdrawi/Serum 
Starvation. (B) In order to asses the mode of cell death in 0 1% serum supplemented media, cells were 
fixed and stained using Acndine Orange (lOug/ml) Cell morphology and staining pattern were then viwed 
using a KodakX Flouresence Microscope (A) Cells cultured under normal conditions m 10% 
supplemented media were also stained and visualised m the same way The Diffuse staining pattern of the 
healthy cells emitting a green fluorescence is m contrast to the serum starved cells whose condensed nuclei 
stain a bnght orange colour, characteristic of apoptotic cells
It can be seen from the results that those cells cultured in serum supplemented with 10% 
serum fluoresced green after staining with acndine orange Thus nuclear DNA is intact in 
double stranded form In contrast those cells cultured under conditions of serum 
starvation show tightly stained orange “apoptotic bodies” Thus the nuclear DNA of these 
cells must be single stranded and so apoptosis is occurring There is a noticeable 
difference between the staining pattern of the nuclei of the healthy and apoptotic cells In 
picture (a) nuclei are diffusely stained and appear as large crenated structures with 
moderate green fluorescence while in picture (b) where cells are dying by apoptosis, 
nuclei appear as smaller rounded structures bnghtly fluorescing (orange) as a result of  
chromatin condensation
Dg75 and B cells in general have a relatively high apoptotic threshold and thus the 
method used to induce apoptosis and the cell line in which to induce apoptosis had to be 
considered carefully Studies by Bnmmel et al (1998) used the calcium lonophore 
lonomycm m conjunction with serum starvation to induce apoptosis in the Dg75 cell line 
In an attempt to increase cell death this more stringent assay was utilised In this case 
cells were set up in 0 1% serum supplemented media containing 2ug/ml of lonomycm As 
per the serum starvation experiment, cell death was monitored by trypan blue exclusion 
and the mode of cell death confirmed as apoptosis using acndine orange staining
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Figure 3.58. Treatment of Dg75 Cells with Ionomycin and Serum 
Starvation Produces Rapid Cell Death at Low Serum Concentrations.
Effect of lonomycin(2ug/ml) + Serum Starvation on Dg75 Viability
10% Serum + ionomycin 
2ug/ml)
-*-5% Serum + ionomycin 
2ug/ml)
1% Serum + Ionomycin 
2ug/ml)
0.5% Serum + Ionomycin 
2ug/ml)
-a -  0.1% Serum + Ionomycin 
2ug/ml)
Figure 3.58. Treatment of Dg75 Cells with Ionomycin and Serum Starvation Produces Rapid Cell 
Death at Low Serum Concentrations. Dg75 ceils were cultured as before in RPMI 1640 medium 
supplemented with Pen/Strep and L-glutamine and 10%, 5% 1% 0.5% and 0.1% foetal Bovine serum. 
Since cell death using Growth factor withdrawl alone took 7 days it was decided to add 2ug/ml to each of 
the flasks to increase the rate and or the quantity of cell death. In 10% supplemented media cell viability 
was reduced to 94% over a three day period and in 5% serum supplemented media cell viability was 
reduced to 65% over the same period. Almost total cell death had occurred at the lower serum 
concentrations in the presence of ionomycin.
As shown in Figure 3.58 cells cultured in normal supplemented media containing 10% 
serum treated with ionomycin alone reduced in viability to only 94% over 3 days of  
assessment. Thus at this concentration in the absence of serum starvation ionomycin is 
not particularly efficient in inducing cell death in this cell line. In media supplemented 
with 5% serum, the addition of ionomycin resulted in cell viability dropping to around 
65% after three days. At lower serum concentrations, the addition of ionomycin resulted 
in rapid and almost total cell death (Figure 3.58). The mode of cell death was assessed 
using acridine orange staining (Figure 3.59).
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For comparison, cells were also cultured in 0.1% serum supplemented media and 
assessed for 6 days prior to acridine orange staining. As per the previous experiment, 
(Figure3.59B) cells cultured in 0.1% serum in the absence of ionomycin reduced in 
viability to around 48%. As a positive control, cells were also cultured in 10 % 
supplemented media in the absence of ionomycin and visualised using acridine orange 
staining.ÇFigure 3.59A) It can be seen from the photographic results below that the 
positive control cells in standard supplemented media containing 10% serum in the 
absence of ionomycin grew normally fluorescing green after acridine orange, also cellular 
content is diffusely stained. Cells were monitored every 24 hours and those cells which 
had been both serum starved and treated with ionomycin were visualised with acridine 
orange staining, after 3 days of incubation. (Figure 3.59C). The morphology of these cells 
corresponded to apoptotic cells where cellular dehydration, cell shrinkage is clearly 
visible also, and nuclear condensation and the formation of resulting in bright orange 
flouresence after acridine orange staining.
Figure 3.59. Dg75 Cells are Susceptible to Apoptosis by Treatment with 
Ionomycin and Serum Starvation.
Figure 3.59. Dg75 Cells are Susceptible to Apoptosis by Treatment with Ionomycin and Serum 
Starvation . (C) In order to determine the mode of cell death as a result or treatment with ionomycin and 
serum starvation, cells were stained using Acridine orange as before and visualised as before. (A) as a 
control cells cultured in media supplemented with 10% serum were also stained and compared to the dual 
treated cells in panel (C). Also included were cells cultured under conditions of serum starvation alone.
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Having determined that Dg75 cells are susceptible to apoptosis induced by both serum 
starvation and exposure to lonomycin, it then had to be determined if EBNA2 expression 
in this cell line could protect the cells from apoptosis under these apoptosis-mducing 
conditions It was decided to investigate if EBNA2 expression could protect serum 
starved cells from apoptosis, since exposing the cells to lonomycin and serum starvation 
resulted in such catastrophic and rapid cell death that any protective effect, exerted by 
EBNA2 might not be sufficient to maintain or rescue cell viability
3.4.2. Selection of an Appropriate Concentration of Puromycin to Select 
Transfected/Untransfected Dg75 Cells.
In order to assess possible EBNA2 protection of B cells from apoptosis, as a result of bfl- 
1 induction, and to assess the role of EBNA2/CBF1, in this effect, Dg75 cells were stably 
transfected with the pSG5, pSG5EBNA2 and the pSG5EBNA2WW323SR expression 
plasmids The EBNA2 expression plasmids were co-transfected into Dg75 cells with the 
pGK3puro plasmid which expresses the pac gene The expression of the pac gene confers 
puromycin resistance to transfected mammalian cells expressing it Puromycin is 
particularly useful for the selection as it quickly kills eukaryotic cells that do not contain 
the pac gene Thus puromycin was used to select cell clones expressing the pac gene in 
the hope that those cells would also express the co-transfected EBNA2 expression 
plasmids Subsequent expression of EBNA2 in these cell lines was assessed by Western 
blotting (Figure3 61) below
Initially a “drug curve” had to be established in order to identify that concentration of 
puromycin required to select transfected clones A number of controls were also used in 
this experiment, pSG5 was co-transfected with the pGK3puro plasmid to provide 
information on any basal effect o f transfecting DG75 cells with this vector, thus any data 
collected from transfections with the EBNA2 clones would represent true effects of 
EBNA2 As a control to assist in the selection of an appropriate concentration for the 
drug curve, pSG5 vector was also transfected alone in the absence of the puromycin 
resistance plasmid Thus cells surviving longer than this cell pool should do so due to 
expression of the pac gene in the pGK3puro plasmid
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The drug curve was initially undertaken with untransfected DG75 cells, which were 
grown in RPMI 1640 with 10% FCS until just sub-confluent Cells were then plated in 24 
well culture plates at a concentration of ~ lx  103 cells/ml and grown overnight before 
addition of drug (puromycin) As cells can divide once or twice in selective media which 
can kill them, it was important to seed cells at low density to ensure that cells did not 
reach confluency before selection could take effect After 24 hours puromycin was added 
at various concentrations as follows, 0, 0 25, 0 5, 1 0, 2 0, 5 0, and 10 0 ug/ml and cells 
were grown for 10 days Media was changed every 4 days and cells were observed for 
decline of cell numbers under the inverted microscope after 24 hours and every day 
thereafter It can be seen from the results that treatment with 0 25ug/ml and 0 5 ug/ml 
only reduces viablihty to 75% and 51% respectively over the time course examined while 
treatment with lOug/ml, 5ug/ml and 2ug/ml rapidly kills off the pac negative cells in 2, 3 
and 4 days respectively (Figure 3 60) Treatment with lug/ml gradually kills off all cells 
over a seven-day period Since treatment with lug/ml is less harsh and more gradual than 
that of the higher concentrations this concentration of puromycin was chosen to select the 
stably transfected pools of cells (Figure 3 60)
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Figure 3.60. Puromycin at a Concentration of 1 jig/ml optimally Kills Pac negative- 
DG75 cells over a seven day Period
Drug Curve For Puromycin Selection of Dg75 Cells
Days Post Addition of Puromycin
Figure 3.60. Puromycin at a Concentration of lug/ml optimally Kills Pac negative-DG75 cells over a 
seven day Period. Dg75 cells were cultured in Supplemented RPMI 1640 medium and treated with 
Oug/ml, 0.25ug/ml, 0.5ug/ml,lug/ml, 2ug/ml, 5ug/ml and 10ug/ml puromycin and their viabüity measured 
by trypan blue exclusion over a 10 day period. Treatment with 10ug/ml, 5ug/ml and 2ug/ml completely 
kills off the Dg75 cells in 2 3 and 4 days respectively. While treatment with lug/ml of puromycin 
completely kills cells after 7 days of exposure, treatment with 0.5ug/ml ionomycin reduces viability to 
51% over the same period.. Treatment with puromycin at 0.25ug/ml reduces viability to 75% over the ten 
day period. Treatment with 0.25ug/ml and 0.5ug/ml is not effective in killing the Pac negative cells in this 
time frame. While treatment with 5 ug/ml and 10ug/ml is effective in killing the cells it kills the cells very 
rapidly. Treatment with lug/ml of puromycin kills the cells gradually over a seven day period thus if cells 
are transfected with a pac expressing vector they will have time to divide and express the gene and thus be 
protected from the effects of this antibiotic.
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3.4.3, Stable Transfection of the Dg75 cell line with EBNA2 Expression Plasmids 
pSG5EBNA2 and pSG5EBNA2WW323SR
Dg75 cells were transfected by electroporation using the Biorad x409 as described in the 
materials and methods section The combinations transfected are shown in the table 
below The ratio of expression plasmid to selection marker transfected was 1 5 Three 
micrograms of expression plasmid (pSG5/pSG5EBNA2/pSG5EBNA2WW323SR) and 
fifteen micrograms o f Pac expressing pGK3-Puro were transfected m each case Twenty 
-four hours after transfection, puromycin was added to a final concentration of l^ig/ml 
(The concentration of puromycin, which just killed all pac negative Dg75 cells Figure 
3 60) After 7 days the wells containing the cells transfected m the absence of the 
puromycin resistance expression plasmid, were dead as confirmed by trypan blue 
staining In theory thus the remaining cells should contain the transfected pGK3 puro and 
also the EBNA2 expression plasmids Every 24 hours, trypan blue exclusion was used to 
evaluate cellular viability in wells, which still contained cells Cells were then cultured 
under continuous selection for two weeks In order to test for the presence of EBNA2 in 
the stably transfected cell lines, western blotting was undertaken with lysates extracted 
from the transfected cells Although the PE2 antibody did not detect EBNA2 in 
transiently transfected cells, the antibody did detect the expression of the EBNA2 and 
EBNA2WW323SR protein in the stably transfected cells and the protein appears to be 
expressed at similar levels in both cases, no EBNA2 was detected in the Dg75-pSG5 cell 
line (Figure 3 61 below) The protein may be detected in the stably transfected cells but 
not in the transiently transfected cells due to the fact that a higher number o f cells in the 
stably transfected cell line express the EBNA2 protein as transfected pools o f cells have 
been specifically selected under optimised antibiotic selection conditions
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Figure 3.61. EBNA2 is Expressed at a similar levels in the two Pools of Stably 
Transfected Cells -Dg75-pSG5EBNA2 and Dg75-pSG5EBNA2WW323SR
Figure 3 61. EBNA2 is Expressed at a similar levels in the two Pools of Stably Transfected Cells- 
Dg75-pSG5EBNA2 and Dg75-pSG5EBNA2WW323SR Western Blotting using the PE2 anti EBNA2 
antibody, was earned out on total protein extracts from each of the cell pools Dg75-pSG5, DSg75- 
pSG5EBNA2 and DG75-pSG5EBNA2WW323SR. EBNA2 was detected in both Dg75«pSG5EBNA2 and 
Dg75-pSG5EBNA2WW323SR but not m the Dg75-pSG5 transfectants As a control for EBNA2 
expression, blotting was also earned out on the DG75EBNA2tTA cell Ime 24 hours post removal of 
tetracycline
Mutiprobe RPA analysis was then earned out with extracts from the stably transfected 
cell lines and the effect of EBNA2 expression on A/7-7 mRNA m this system was 
analysed Additionally a number of transient transfections were earned out with these cell 
lines and the bfl-1 promoter reporter constructs as well as the control pGa50-7 and 
pGa981-6 reporter constructs It can be seen from the RPA analysis (Figure 3 62) that as 
before, bfl-1 mRNA is induced 3 1 fold with the expression o f EBNA2 in the DG75- 
pSG5EBNA2 cell lme (in this case 3 1 fold relative to Dg75-pSG5) This is not the case 
in the cells transfected with the pSG5 vector alone Further, bfl-1 mRNA levels, are not 
induced (1 6 fold) by expression of the CBF1 mutant EBNA2 (EBNA2WW323SR) in the 
Dg75-pSG5EBNA2WW323SR cell pool These results again comply with the previous 
findings that EBNA2 mdependantly up-regulates bfl-1 mRNA in this cell lme The 
finding that a cells expressing the CBF1 mutant EBNA2 does not up-regulate bfl-1 
mRNA mdicates that CBF1 may be important at a transcnptional level in mediating 
EBNA2 resposivity to bfl-1 and complies with the promoter study data which strongly
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implicates a role for CBF1 binding in regulating EBNA2 mediated activation of the bfl-1 
promoter In addition, RNA from the MutuI and MutuIH cell lines was also included m 
this RPA and the dramatic increase in bfl-1 mRNA due to expression of the full range of 
EBV latent proteins is evident The up-regulation of bfl-1 mRNA in response to 
expression of the full spectrum of EBV latent proteins (characteristic of type HI cell 
lines) is much higher than that seen by expression of EBNA2 alone thus again 
implicating a major role for other EBV protem(s) m regulating the expression of this 
cellular gene (D’Souza et a l , 2000)
Figure 3.62. B fl-1  mRNA is Induced b y  W ild-Type EBNA2 Expression in t h e  
Dg75-pSG5EBNA2 C e l l  Line b u t  N o t in t h e  Dg75-pSG5EBNA2WW323SR C e l l  
Line
£25
Graphic F^ pnesentaflon of R R ftD ^f^Stafaly transfected Cdlftw ls
0O075fSG5 
□ D075J38GSEBNA2 
■ Dg75iJ8G5EBNA2VW\G23SR
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Figure 3 62 Bfl-1 mRNA is induced by wild type EBNA2 expression in the Dg75-pSG5EBNA2 cell 
line but not in tbe Dg75-pSG5EBNA2WW323SR Cell Line. mRNA levels from the apoptosis related 
genes bclx 1/s, bfl-1, bad, bik, bak, bax, bcl2, and mcl-1 were analysed in each of the cell lines indicated 
bfl-1 mRNA is clearly up-regulated m the Dg75-pSg5EBNA2 cell Ime relative to the Dg75-pSG5 cell lines 
This is not the case in the cell line expressing EBNA2WW323SR in which CBF1 binding has been 
abolished No up-regulation of the mRNA species from any of the other apoptosis related genes was 
recorded
Functionality of the EBNA2 proteins was also examined by co-transfecting each of the 
pools of cells with the wild type and CBfl mutated bfl-1 reporter constructs and the 
pGa50-7 and pGa981-6 reporter vectors The results obtained (Figure 3 63) mirrored 
those of the transient transfections using the pSGS and pSG5EBNA2WW323SR 
plasmids In the case of the stably transfected cell pools only the cells expressing wild 
type EBNA2 (Dg75-p S G5EBNA2) trans-activated the wild type bfl-1 promoter and the 
pGA981-6 promoter reporter The pool of cells expressing the EBNA2WW323SR 
protein (Dg75-pSG5EBNA2WW323SR) failed to trans-activate the wild type bfl-1 
promoter or the pGa981~6 reporter (Figure 3 63) Although fold trans-activation by 
EBNA2 and EBNA2WW323Sr were made relative to trans-activation by pSG5, no 
increase in basal transcription was recorded m the cell line transfected with pSG5 relative 
to untransfected Dg75 Neither the CBF1 mutated promoter nor the pGa50-7 reporter was 
activated in these transfections
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Figure 3.63. The bfl-1 P rom oter is T rans-activated  w hen T ran sfected  in to  
THE Dg75-pSG5EBNA2 C e l l  P o o l, but N o t in th e  Dc75-pSG5EBNA2WW323SR 
C e l l  P o o l.
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Figure 3.63. The bfl-1 promoter is trans-activated when Transfected into the Dg75-pSG5EBNA2 Cell 
pool, but Not in the Dg75-pSG5EBNA2WW323Srexpressing cells. The stably transfected cell pools 
were then transfected with the bfl-1 promoter reporter construct (-1374/+81 wtbfl-1 Luc) and its CBF1 
mutated partner (-1374/+81 mCBF16/7-7 Luc) and activity of the promoter was analysed using the 
luciferase assay In the same experiment, the three indicated pools of cells were also transfected with the 
pGa50-7 and pGa981-6 reporter constructs. In all cases transfections were earned out using the DEAE 
dextran method and lOug of promoter reporter construct was transfected Fold activation represent the 
normalized (for transfection efficiency based on p-galactisidase activity measured from co-transfected 
pCMVlacZ reporter included in all transfections) luciferase activity due to expression of EBNA2 and 
EBNA2WW323SR in the Dg75-pSG5EBNA2 and Dg75-pSG5EBNA2WW323SR cell pools respectively 
All data is an average of three independent experiments and fold activations are relative to trans^activation 
by transfection m the Dg75-pSG5 cell line, which has been adjusted to 1 fold
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3.4.4. EBNA2 Expression May Provide Some Protection from Apoptosis Induced by 
Serum Starvation in the Dg75 Cell Line.
Untransfected Dg75 cells and cells stably transfected with pSG5EBNA2, 
pSG5EBNA2WW323SR and the pSG5 vector alone were then serum starved in 0.1% 
serum and their viability compared after a 6-day period. The mode of cell death was then 
assessed using acridine orange and propidium iodide staining.
Figure 3.64. Expression of EBNA2 Provides a Measure of Protection to Dg75 Cells 
from Apoptosis Induced by Serum Starvation. (Acridine Orange)
10%
Serum
0.1%
Seram
c
DG75-pSG5EBNA2
D
DG75-pSG5EBNA2W W323SR
Average % 
Apoptotic 
Cell Death
65% 62% 38% 49%
Figure 3.64. Stable Expression of EBNA2 in the Dg75 Cell Line Protects these Cells from Apoptosis 
Induced by Serum Starvation. Cells were cultured for 6 days in RPMI 1640 Cell culture media 
supplemented with either 10% or 0.1% foetal bovine serum Culture media was changed every 3 days. Cell 
viability was monitored every 24 hours and the mode of cell death after 7 days was analysed by acridine 
orange staining as before. Column A shows the results for the untransfected Dg75 cell line. Column B 
shows the results for the DG75-pSG5 cell pool and Columns C and D show the results for the DG75- 
pSG5EBNA2 and Dg75-pSG5EBNA2WW323SR cell pools respectively. Although apoptosis is occurring 
in all cases in cultures supplemented with 0.1% serum, the average percentage of cell death was 
consistently lower in the case of both cell pools expressing EBNA2. (Dg75-pSG5EBNA2 and Dg75-
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pSG5EBNA2WW323SR) Further the EBNA2 CBF1 site may be involved in conferring some of this 
protective effect as the percentage cell death in the Dg75-pSG5EBNA2WW323SR cell pool in which 
EBNA2 cannot bind CBF1, consistently showed a relatively higher level of cell death compared to its 
counterpart cell line expressing wild type EBNA2
It can be seen from the results (Figure 3 64) that apoptosis is occurring in all cell lines 
after seven days in 0 1% supplemented media The mode of death can be characterized as 
apoptosis by acridme orange staining which clearly shows the formation of apoptotic 
bodies stained as bright orange punctate dots m the nuclei of the apoptotic cells, also the 
intense orange staining o f the apoptotic cells is in marked contrast to the diffusely stained 
green fluorescence emitted by the healthy cells in 10% supplemented media Cell 
counting was performed and the percentage of apoptotic cells was determined from 
counts on at least 150 cells per individual culture and all cultures were set up in triplicate 
A representative section from a field for each cell line is displayed above After seven 
days under conditions of serum starvation the percentage of apoptotic cells was 
calculated at an average o f 65% and 62% in the untransfected cell line Dg75 and the cell 
pool expressing the empty pSG5 vector, Dg75-pSG5 respectively Apoptotic cell death 
was consistently lower in the two cell pools expressing EBNA2, Dg75-pSG5EBNA2 and 
DG75-pSG5EBNA2WW323SR, suggesting EBNA2 confers a measure of protection 
from apoptosis on these pools o f cells in vitro A slight increase in the anti-apoptotic 
threshold was consistently recorded for the Dg75-pSG5EBNA2 cell pool relative to the 
Dg75-pSG5EBNA2WW323SR cell pool suggesting CBF1 binding, or a downstream 
consequence of this, may be involved in this protective effect In the case of this study 
EBNA2 has been shown to up-regulate the anti-apoptotic Bfl-1 protein in this cell line 
and it is therefore likely that EBNA2 induced up-regulation of bfl-1 may be involved in 
the EBNA2 mediated resistance to apoptosis here
In order to better quantitate the number o f cells apoptosing, Flourescence Activated Cell 
Sorting (FACS) analysis was undertaken The results obtained using the acndme orange 
analyses are mirrored by the results obtained from the same cell lines stained with 
propidium iodide and studied using FACS analysis (Figure 3 65) Initially measurements 
made in these analyses were forward light scatter and side light scatter, respectively
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Forward light scatter provides some information on the relative size o f individual cells, 
whereas side light scatter provides some information on the relative granularity of 
individual cells In this case these two are combined to identify the light scatter pattern 
emitted by a healthy population of cells and this is compared to the characteristic light 
scatter pattern emitted by condensed, shrunken apoptotic cells The sets of data are 
presented as dot plots In each of the cell lines Dg75, Dg75-pSG5, Dg75-pSG5EBNA2 
and Dg75-pSG5EBNA2WW323SR, a 1* 107 sample o f cells m 10% serum was analysed 
by trypan blue and FACS, the trypan blue analyses showed over 95% cell viability for 
each of the cell lines and correlates with the healthy diffusely stained cells stained by 
acridine orange in Figure 3 64 above Using FACS the light scatter pattern of 10,000 cells 
from each of the cell lines was then analysed after staining with Propidium Iodide It can 
be seen that the cell populations for the healthy cells are predominant in the upper right 
quandrants for the dot plots for each cell line, represented in Figure 3 65 below At, BI, Cl 
and DI Over 96%, 94%, 94% and 91% of the cell populations are present in the upper 
right quadrant for the healthy Dg75, DG75-pSG5, Dg75-pSG5EBNA2 and Dg75- 
pSG5EBNA2WW323SR cell lines respectively These data show a relatively high level 
of forward light scatter indicating relatively large healthy cells After six days m media 
supplemented with only 0 1% serum, the population of cells for each of the cell lines 
shifts to the left towards the origin suggesting a decrease in size, characteristic of cells 
undergoing the latter stages of apoptosis Cells in the lower right quandrant are also 
apoptotic indicated by their reduction in forward scatter (size) however they have not 
reached the same level o f gross nuclear condensation indicative of the latter stages of 
apoptosis characterised by the cells shown in the lower left quadrant The side scatter 
parameter on the Y-axis indicates the relative granularity of the cells In the case of each 
of the cell lines serum starvation results in a reduction m granularity indicated by the shift 
in the population of cells vertically downwards In the early stages of apoptosis, apoptotic 
cells should increase m granularity due to the formation of apoptotic bodies, and thus an 
increase in light scattered in the right angle (Side) direction However in the latter stages 
of apoptosis, the intensity of light scattered at both forward and right angle (side) 
directions is decreased Although this reduction in light scattered at both forward and 
right angles may be characteristic of necrosis this is not the likely cause of cell death here
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as the mode of cell death was determined by acridme orange staining which specifically 
detects apoptosis Due to the high anti-apoptotic threshold of this cell line, especially 
stringent conditions were required to induce apoptosis, namely serum starvation for six 
days after which point a large population of the cells are in the late stages of apoptosis 
The mode of cell death was verified as apoptosis by acndine orange staining and the 
number of cells apoptosmg was quantified by FACS analysis It can be seen after serum 
starvation that over 77% and over 83% of Dg75 and Dg75-pSG5 cells respectively have 
shifted into the lower left quadrant indicative of undergoing the latter stages of apoptosis 
(Figure 3 65) In the two cell lines expressing EBNA2, the percentage of cells m this 
quadrant is increased from less than 1% m 10% supplemented media to over 39% and 
58% in the Dg75-pSG5EBNA2 and Dg75-pSG5EBNA2WW323SR cell lines 
respectively Thus the two cell pools expressing EBNA2 have a lower number of cells 
apoptosmg relative to the two Dg75 cell pools not expressing EBNA2 These results 
show therefore that expression of EBNA2 in the Dg75 cell line correlates with a measure 
of increased resistance to apoptosis as induced by serum starvation Additionally, in the 
cell pool m which EBNA2-CBF1 mutant is expressed this protective effect is consistently 
somewhat reduced since -58% of these cells display the characteristic apoptotic light 
scatter profile relative to -39% of the cells expressing wild type EBNA2 (Dg75- 
pSG5EBNA2)
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F ig u r e  3.65. E x p r e s s io n  o f  EBNA2 P r o v id e s  a  M e a s u r e  o f  P r o t e c t io n  f r o m  
A poptosis I n d u c e d  b y  Se r u m  St a r v a t io n  in  Dg75 C e l l s , b y  a  M e c h a n is m  
w h ic h  m a y  I n v o l v e  C B F l .  (P r o p id iu m  I o d id e ).
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F igu re 3 65. E xpression  o f EBN A 2 P rovides a m easure o f P rotection  from  A pop tosis Induced  by 
Serum  S tarvation  in  D g75 C ells by a  M echanism  w hich  m ay In volve C B F l. (Propidium  Iod ide).
Using FACS analysis with the BD FACsCAkbur, light scatter m the forward and right angle (Side) 
directions was measured and representative dot plots were generated with CellQuest software (BD) The 
indicated cell lines were cultured in 10% and 0 1% serum supplemented RMPI1640 media and the light
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scatter patterns analysed where forward scatter (FSC-H) indicates the relative size of the cells and side 
scatter (SSC-H) indicates the granularity of the cells Quadrants were subjectively placed on each of the dot 
plots and the percentage of cells in each quadrant deconvolved by CellQuest software(BD) The shift of 
the cell population vertically downwards and towards the ongrn is representative of cells in the late stages 
of apoptosis Apoptosis was verified by Acndine orange staining (Figure 3 64) as this scatter pattern may 
also be elicited from necrotic cell populations
3.4 5. EBNA2 EXPRESSION INCREASES THE POPULATION OF DG75CELLS IN THE G0/G1 
PHASE OF THE CELL CYCLE.
Further to the previous results, after propidium iodide staining, the percentage of cells m 
Gl, S phase and G2/M of the cell cycle was calculated by subjectively applying markers 
which provide a measurement of the percentage of cells in each phase Cell samples from 
the cells cultured m 10% serum supplemented media were analysed The data is 
displayed in histogram format with the intensity of fluorescence from the Propidium 
iodide stained cells on the X-axis, representing the number of cells The percentage of 
cells in each phase of the cell cycle was calculated by CellQuest software and is shown 
with its corresponding histogram It can be seen that in the two cell lines which do not 
express EBNA2, Dg75 and Dg75-pSG5 that the percentage of cells in the G0/G1 phase 
of the cell cycle is 60% and 62% respectively with 12 8 and 12 3% of cells m the S 
phase In the two cell lines expressing EBNA2, Dg75-pSG5EBNA2 and Dg75- 
pSG5EBNA2WW323SR, the number of cells in the G0/G1 phase is just over 72% in 
each case, also the percentage of cells in the S phase is reduced to 6 7 and 6 6% 
respectively These data show that expression of EBNA2 in the Dg75 cell line causes 
some accumulation o f cells in the G0/G1 phase The physiological antiproliferative effect 
of this has been noted m lymphocytes elsewhere and may be due to EBNA2 up- 
regulation of c-myc (Kempkes et a l , 1995b) The percentage of cells in the G2/M, or 
pre-Gl/apoptotic phase, were not altered
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Figure 3.66 EBNA2 expression in creases th e  population  o f  D g 7 5 ce lls  in th e  
GO/Gl phase o f  th e  c e l l  c y c le .
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Figure 3 66 EBNA2 expression increases the population of Dg75cells in the G0/G1 phase of 
the cell cycle. Flourecence from the PI stained cells is used to generate histograms depicting the DNA 
content of the cells representative of the passage of cells through the cell cycle The peaks representing 
each phase of the cell cycle and the percentage of cells in each phase is shown It can be seen that m the 
cell pools expressing EBNA2 Dg75-pSG5EBNA2 and Dg75-pSG5EBNA2WW323SR (Panels C and D
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respectively), that there is an increase (-10%) in the number of cells in the G0/G1 phase of the cell cycle 
and a 50% reduction in the number of cells in the S phase of the cell cycle relative to the cells m which 
EBNA2 is not expressed, Dg75 and Dg75-pSG5 (Panels A and B respectively) Thus EBNA2 expression 
causes cells to accumulate m the G0/G1 phase of the cell cycle
3.4.6. EBNA2 EXPRESSION REDUCES THE NUMBER OF PRE-G1/APOPTOTIC CELLS 
UNDER CONDITIONS OF SERUM STARVATION - FURTHER EVIDENCE FOR THE 
PROTECTIVE EFFECT AFFORDED BY EBNA2 EXPRESSION IN DG75 CELLS.
The cellular DNA content can be measured following cell fixation that leads to a partial 
leakage of degraded DNA within apoptotic cells As a consequence, apoptotic cells 
contain reduced DNA content and can be recognised, following staining of cellular DNA 
with Propidium Iodide, as cells with low DNA stamabihty (sub G0-G1 peak) It can be 
seen from the results (Figure 3 67), that after serum starvation, the percentage of 
apoptotic cells m the EBNA2 positive cell line Dg75-pSG5EBNA2 is -48% Expression 
of EBNA2 results m a diminished sub G0-G1 peak m the EBNA2 positive cell line 
Dg75-pSg5EBNA2 relative to the EBNA2 negative DG75-pSG5 cell pool which shows 
-70% apoptotic cells Thus a lower proportion of cells are apoptotic in the EBNA2 
expressing Dg75-pSG5EBNA2 cell line than the EBNA2 negative DG75-pSG5 cell line 
these results comply with the light scatter data, which also suggest a higher proportion of 
apoptotic cells m the EBNA2 negative cell lines relative to the EBNA2 positive cell lines 
These data further imply a role for EBNA2 and thus possibly bfl-1 in the protection of 
Dg75 cells from apoptosis induced by growth factor withdrawal
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Figure 3,67 EBNA2 EXPRESSION REDUCES THE NUMBER OF PRE Gl/APOPTOTIC CELLS 
UNDER CONDITIONS OF SERUM STARVATION
EBNÀ2 Expression Reduces the Proportion of SubGO/Gl(apoptotic) Cells 
Under Conditions of Serum Starvation
B
Dg75-pSG5EBNA2 Dg75-pSG5
Figure 3.67 EBNA2 expression reduces  th e  num ber o f  p re  G 1/apoptotic c e l l s  under 
cond itions o f  serum  s ta rv a tio n . Dg75 cells were serum starved by culturing in 0 1% serum 
supplemented media, and fixed and stained as before using PI Cell fluorescence was then measured by 
FACS analysis (FacsCalibur, BD) and the resulting histograms generated using CellQuest software It can 
be seen under these conditions that expression of EBNA2 in panel (A) above offers some protection from 
apoptosis indicated by the reduction m the pre G1 peak to -48%, relative to the cell line m which EBNA2 
is not expressed (Panel B) where over 70% of cells are m this region.
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3.5.0. Introduction
EMSA is widely used in studying the sequence specific binding of nuclear proteins such 
as transcription factors and is based on the observation that complexes of protein and 
DNA migrate through a non-denaturing polyacrylamide gel more slowly than free double 
stranded DNA fragments or oligonucleotides. The gel shift assay is performed by 
incubating a purified protein or a complex mixture of proteins (such as nuclear extracts) 
with a 32P labelled DNA fragment containing the putative protein-binding site, followed 
by analysis on a non denaturing ployacrylamide gel. The specificity of the DNA binding 
protein for the putative binding site is established by competition experiments using 
unlabeled DNA fragments or oligonucleotides containing a binding site for the protein of  
interest or other unrelated DNA sequences. Supershift analysis can also be performed by 
preincubating the nuclear extract with an antibody to a protein suspected to be present in 
the complex formed with the labelled oligonucleotide. If the antibody specific protein is 
present, the radiolabeled protein-DNA complex may be diminished, or “shifted” up the 
gel due to the increase in size as a result of antibody binding, depending on whether the 
antibody binds to the DNA binding region of the protein or not.
The results presented so far indicate that increased transcriptional activity of the bfl-1 
gene partly accounts for the EBNA2-mediated up-regulation of steady state levels of bfl-1 
mRNA and Bfl-1 protein, in B cells. The finding that the transactivation of the bfl-1 
promoter is dependent on EBNA2 binding CBF1 suggests that this transcription factor 
may be involved in mediating EBNA2 responsivity on the bfl-1 promoter (Figure 3.16). 
Furthermore, deletion analysis of the 5’ region of the gene suggests that the major 
elements mediating transcriptional activation of the bfl-1 gene by EBNA2 are located 
between positions -367 and -129. (Figure 3.21) (positions are relative to the 
transcriptional start site proposed by Zong et al 1999). A transcription factor search of the 
bfl-1 promoter using Transcription Element Search Software (www. cbil. upenn. edu/tess) 
as well as Transfac/Mat Inspector (Matlnspector V2.2) and Alibaba 
(http ://www. alibaba2. com) software had revealed the presence of a potential CBF1
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binding site at position -243 (GTGGGAA) m the reverse orientation (bp -243 to -249) 
See Figure 3 22
The potential involvement of the CBF1 site at position -243 of bfl-1 in the EBNA2 -  
induced enhancement of bfl-1 promoter activity was investigated by EMS A using nuclear 
extracts prepared from DG75-tTA-EBNA2, BL41-ER/EBNA2 and BL41P3HR1- 
ER/EBNA2 cells before and after induction or activation o f EBNA2 Since the studies of 
the kinetics of induction o f bfl-lmRNA by EBNA2 m these cells indicated that the 
magnitude of induction was maximal by 24 hours post induction, (Figures 3 3 3 11 and 
3 12), nuclear extracts were prepared from each of the cell lines at the earlier time point 
of EBNA2 induction or activation of 20hr, when bfl-1 mRNA levels are still increasing
3.5.2.O. Lack of Demonstrable Binding of an EBNA2-Activated CBF1 Complex to 
the CBF1 site on the Cp Promoter and the Putative CBF1 site at Position -243 to -  
249 of the BFI^ I Promoter Region, in DG75-tTA-EBNA2 Cells.
As a preliminary experiment, the effect of EBNA2 induction on CBF1 binding activity in 
DG75-tTA-EBNA2 cells was assessed To this end EMSA was performed with nuclear 
extracts prepared from DG75-tTA-EBNA2 cells before and 20hr after induction of 
EBNA2 and a pair of 30bp oligonucleotides containing the consensus CBF1 binding site 
along with the natural flanking sequence from the Cp promoter corresponding to bp-359 
to -388 (Ling et a l , 1994) The same study also showed that EBNA2 can form a stable 
complex with this Cp-bound CBF1 m an EMSA This pair of oligonucleotides will 
henceforth be referred to as the Cp probe for the purposes of this thesis A titration 
experiment of the amount of nuclear protein used in the binding reaction with the Cp 
probe was first conducted to establish optimal binding conditions Four protein DNA 
complexes were formed designated Cl C2 C3 and C4 (Figure 3 68) A faint band 
designated Cl a was also observed To determine if these complexes were EBNA2 
specific, the binding experiment was repeated but with pre incubation o f the nuclear 
extract with an EBNA2 specific antibody R3 This antibody does not bind to the EBNA2 
CBF1 binding domain thus binding of EBNA2 to the Antibody does not interefere with
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EBNA2 binding to the radiolabeled Cp probe containing the consensus CBF1 site 
(Kempkes et a l , 1995, Zimber Strobl et a l , 1994) If the complexes are EBNA2 specific 
binding of the antibody to the complex will increase the size of the complex and retard 
the electrophoretic mobility of the complex, in other words “shift” the complex up the 
gel None of these complexes were “shifted” by the addition of an EBNA2 specific 
antibody thus these complexes do not contain EBNA2 As EMSA analyses have been 
published elsewhere using this probe, it had been expected that a high molecular weight 
EBNA2 specific complex would have been visulahsed as published previously Despite 
the fact that this experiment failed to show the anticiated complexes, further EMSA were 
undertaken with nuclear extracts from the Dg75-tTA-EBNA2 cell line before and after 
EBNA2 induction to determine whether nuclear proteins could bind to the putative CBF1 
site at position -243 to -249 of the bfl-1 promoter EMSA was performed using a 36bp 
pair of oligonucleotides derived from the bfl-1 promoter sequence that includes the 
putative CBF1 site at position -243 to -249 This oligonucleotide shall heneceforth be 
referred to as the Bfl-1 probe for the purposes o f this thesis Again three complexes were 
visualised after separation by non-denatunng plyacrylamide gel (5%) electrophoresis, 
however, again these three complexes failed to “shift” in response to premcubation with 
an EBNA2 specific antibody Similar results were obtained with both the Cp and bfl-1 
probes using extracts from the K3 and 9A cell lines before and after activation of 
EBNA2 Thus no direct interaction between EBNA2 and CBF1 could be shown in this 
study Shown below is a representative gel using the Cp probe and extracts from the 
Dg75-tTA cell line The four non-specific complexes are complexes are labeled (Figure 
3 68)
Although EBNA2 has been shown to bind to the Cp CBF1 site in EMSA analyses by 
others the experiments presented here failed to detect any interaction between EBNA2 
and the Cp CBF1 binding site or EBNA2 and the putative CBF1 binding site Since the 
“control” expenment involving the Cp probe failed to bind CBF1 m the cell extracts used 
it may be that binding conditions in this system have not been optimised In the case of 
the putative CBF1 binding site it is possible that EBNA2 affinity for the Bfl-1 CBF1 site 
is too weak to bind or be detected by these analyses If other transcription factors are 
involved in the transactivational effect of EBNA2 on the bfl-1 promoter it may be
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beneficial to use a longer oligonucleotide spanning a larger section o f the bfl-1 promoter 
to include the putative sites for the PU 1 /Etsl factors Although no direct interaction 
between EBNA2 and the putative CBF1 binding site could be detected by EMSA 
analyses, transient transfection data and promoter deletion data already presented 
indicates that CBF1 binding has a key role m the EBNA2 mediated up-regulation of 6/7- 
1
Figure 3.68, L a c k  o f  D em onstrable Binding o f  an EBNA2-Activated CBF1 
Complex t o  th e  CBFl s ite  on  th e  Cp P rom oter R egion in DG75-tTA-EBNA2 
C e lls .
Eg75fTArEHNA2
(M*g>
Q»Ftobe +EBNA2 +EHVA2+R3 -EBNA2 
1 2 3 4
Figure 3.68, EMSA Analyisis with a 30bp Oligonucleotide Spanning the CBFl site Present in the Cp 
Promoter for Nuclear Protein CBFl Binding Activity lOOug of nuclear extracts prepared from 
umnduced DG75-ITA-EBNA2 cells or from cells 20hr post induction of EBNA2 were incubated with the
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32P labelled Bfl-1 probe After separating the protein-DNA complexes by non-denaturing plyacrylamide gel 
(5%) electrophoresis (140V 3-4Hrs), the shifted bands were visualized using autoradiography No EBNA2- 
mduction-specific complexes were formed however four protein-DNA complexes designated Cl, C2 C3 
and C4 were visualised pre and post EBNA2 induction in the Dg75-tTA-EBNA2 cells
C o n c l u s io n
The ability of EBNA2 to provide cell survival signals by up-regulating the expression of 
the anti-apoptotic protein Bfl-1 is very significant from the standpoint of the mechamsm 
of EBV persistence in the memory B cell in peripheral blood In lymphoid follicles, bfl-1 
transcript has been detected in germinal centres, which are the sites for B cell 
proliferation and differentiation Indeed long-lived B cells are distinguished by elevated 
expression of bfl-l/Al In this regard, Bfl-1 might be viewed as a key determinant of cell 
fate for immature peripheral B cells The strong induction of bfl-1 transcripts by 
proinflammatory cytokines in endothelial leukemic and hemopoietic cells is consistent 
with a role for protecting them from apoptotic extinction (Choi et a l , 1995, Karsan et 
a l , 1996, Lin et a l , 1993, Moreb and Schweder 1997) In vivo, EBV positive tonsillar 
memory B cells express a restricted pattern of latent gene transcripts which resembles the 
pattern of latent gene expression detected in EBV-related tumours (Babcock and Thorley- 
Lawson 2000) Thus EBNA2 associated induction of the antiapoptotic Bfl-1 may be 
important m terms of the EBV associated malignancies in which EBNA2 is expressed
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C h a p t e r  4  
D i s c u s s i o n
D is c u s s io n
A major component of the infection strategy of EBV is its suppression of the cellular 
apoptotic programme (Allday 1996, Klein et a l , 1994) which functions primarily to 
ensure persistence in a latent state in the memory B cell compartment of infected 
individuals (Reviewed by Gregory et a l , 1995) In vitro, type IBL cell lines (expressing 
only EBNA1) and various EBV-negative BL cell lines can readily be induced to apoptose 
by a variety of triggers including growth factor withdrawal, Ca+ lonophore treatment and 
over-expression o f the p53 tumour suppressor gene, (Henderson et a l , 1991, Okan et a l ,
1995) however type III BL cell lines expressing the full compliment of EBV latent genes 
have been shown to have a higher apoptotic threshold than their type I counterparts 
Similarly EBV negative cell lines converted to the type ID phenotype after infection with 
the B95-8 strain of the virus showed increased resistance to apoptosis (Gregory et al, 
1991) Thus expression of the full spectrum of EBV latent genes reduces susceptibility to 
apoptosis This increased anti-apoptotic threshold has been partly attributed to the up- 
regulation of Bcl2 m infected BL cells A number o f EBV latent genes have been shown 
to regulate the expression of Bcl2 including LMP1 EBNA2 and EBNA3B (Henderson et 
a! , 1991, Liu et a l , 1991, Rowe et a l , 1994, Finke et a l , 1992, Silins and Sculley 1995) 
Although Bcl2 is important in conferring the anti-apoptotic effects of EBV infection, 
numerous other studies implicate Bcl2-independent mechanisms, that may afford infected 
cells increased resistance to apoptosis (Milner et a l , 1992, Pezzella et al, 1990, Rowe et 
a l , 1994)
Recent studies in our laboratory showed that another anti-apoptotic member of the Bcl-2 
family, bfl-1, is expressed at high levels in LCLs and type III cell lines relative to type I 
cell lines (D'Souza et a l , 2000) The physiological or functional relevance of bfl-1 
expression was shown in the same study using transfection analysis, which showed 
expression o f bfl-1 m a type I (MutuI) cell line protected these cells from apoptosis under 
sub-optimal growth conditions Thus bfl-1 must also be considered as an important 
element in conferring increased resistance to apoptosis on EBV infected cells LMP1 has 
been shown to up-regulate a number of anti-apoptotic proteins including Bcl-2, A20 and
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Mcl-1 (Rowe et a l , 1994, Fries et a l, 1996, Laherty et a l , 1992, Wang et a l , 1996) and 
now LMP1 has been shown to up-regulate bfl-1 expression in the EBV negative BL cell 
line Dg75 (D'Souza et a l , 2000) Nonetheless the same experiments also suggest LMP1 
independent mechanisms may regulate bfl-1 expression in EBV infected cells as although 
bfl-lmRNA  levels are increased m response to LMP1 induction in Dg75-tTA-LMPl, the 
levels of bfl-1 mRNA do not reach the same levels as those in a typical type HI BL 
(MutuIII) expressing the complete set of EBV latent proteins This left the possibility 
that other EBV latent proteins may stimulate or co-stimulate bfl-1 up-regulation (D'Souza 
et a l , 2000) Further to this, a preliminary experiment m which northern Blotting was 
earned out with an LMP1-negative type in  cell line revealed bfl-1 mRNA levels were 
still elevated relative to a type I EBV positive cell line (MutuI) (Figure 3 1) As EBNA2 
is the second major effector of phenotypic change in EBV infected cells, EBNA2 was a 
likely candidate for regulating bfl-1 expression
This thesis presents the novel findings that EBNA2 up-regulates expression of the 
cellular bfl-1 gene by increasing transcription from the bfl-1 promoter in a B cell specific 
manner and that this up-regulation is likely to involve a mechanism requiring the cellular 
transcription factor CBF1 and possibly members o f the Ets transcription factor family 
Despite the fact that EBNA2 and activated Notch/Notch-IC overlap m the subset of genes 
which they regulate through their shared ability to interact with CBF1, the evidence 
presented here also suggests that, like CD23, bfl-1 may be responsive to EBNA2 but not 
Notch-IC
In order to assess the role o f EBNA2 in regulating the bfl-1 gene and other bcl2 family 
members, it was essential to have a system in which EBNA2 could be expressed as the 
sole EBV protein independently o f other EBV latent proteins For this reason two 
different systems were employed, where (i) EBNA2 expression was induced in the 
absence of tetracycline and (u) EBNA2 was activated by addition of estrogen
Although previous studies (Floettmann et a l , 1996) using the tet-regulatable system 
mainly focused on the effects of LMP1 induction on expression of cell surface receptors
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involved in mediating cell signaling responses affecting cellular activation and 
proliferation, these studies also demonstrated that this system was suitable for expressing 
EBNA2 in a tightly controlled fashion in BL cells and was thus suitable for studying the 
phenotypic changes induced by EBNA2 expression in a BL cell environment
Initial experiments in this study, using the DG72-tTA-EBNA2 cell line, revealed the 
novel finding that when present as sole EBV protein, EBNA2 expression led to an 
increase in bfl-1 mRNA and protein levels and these results were verified by both RPA 
and Northern blot analyses (Figures 3 3 and 3 5) The increase in the level of bfl-1 mRNA 
could have been attributable either to an increased rate of transcription from the promoter 
of the bfl-l gene or a stabilizing effect o f EBNA2 on bfl-1 mRNA Although LMP1 
expression has been shown to stabilize the bfl-1 transcript (D'Souza et a l , 2000), the 
possibility that EBNA2 expression was m some way stabilizing bJl-lmRNA was unlikely 
for a number of reasons, (i) all evidence suggests that the primary function of EBNA2 is 
as a ftvms-activator of viral and cellular genes (11), the fold-activation o f the bfl-1 
promoter in transfection experiments is similar (6-8 fold) to the increase m bfl-1 mRNA 
induction in response to EBNA2 expression seen in Northern Blot and RPA analyses and 
(111) this induction occurs immediately upon activation of EBNA2 in BL-denved cell 
lines (after 3hours) (Figures 3 11 and 3 12) and when EBNA2 is detectable m the Dg75- 
tTA-EBNA2 cell line after 12 hours (RPA Figure 3 3 lane not shown) Thus bfl-1 
induction appears to be an early and direct effect of EBNA2 expression These results 
comply with several lines of evidence, which indicate that bfl-1 and its mouse homologue 
Al are early response genes (Lin et a l , 1993, Hu et a l , 1998) Also the significant 
induction of bfl-1 mRNA levels m response to EBNA2 expression were observed at a 
time-point when physiologically relevant levels of EBNA2 are observed, since bfl-1 
mRNA up-regulation is seen where EBNA2 levels are comparable to endogenous levels 
in a typical LCL (X50-7)
A 5 fold induction of bfl-1 mRNA in response to EBNA2 expression was recorded m 
conjunction with EBNA2 expression after 24 hours, Bfl-1 protein was detected at low 
levels pnor to EBNA2 induction but levels were immediately up-regulated in response to
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EBNA2 activation with a 5 fold induction detected after 24 hours (Figure 3 3) Although 
multiprobe RPA analysis provided a quantitative way of measuring bfl-1 mRNA 
induction, northern blotting was earned out to confirm the increase in the level of bfl- 
7mRNA and to determine the size the transenpt from the bfl-1 gene (Figure 3 5) One bfl- 
1 mRNA of 8Kb was detected in all cases, in agreement with the previously reported 
size of the transenpt from this gene using Northern blotting (Kenny et a l , 1997) 
However recent studies employing reverse-transenptase polymerase chain reaction (RT- 
PCR) and pnmers specific for bfl-1 cDNA revealed two bfl-1 transenpts The onginal 6/7- 
1 transenpt, and a second transenpt that encodes a shorter protein bfl-1 S (Ko et a l , 
2003) Using gene mapping and splicing site prediction databases, Ko et al, 2003 suggest 
a 3-exon structure for the bfl-1 gene The production o f transcnptional vanants of bfl-1 
was found to result from the alternative inclusion or exclusion of the 56bp exon II The 
shorter transcript encodes a 175 amino acid protein while the longer transcript codes for a 
163 ammo acid protein The longer transenpt encodes a shorter protein since the 
inclusion of exon II results m early translational termination by an upstream stop codon 
(Ko et a l , 2003) The suggested three exon structure of bfl-1 and splicing involved make 
it similar to that of ICH1 (Caspase 2) which similarly consists of three exons and 
produces two splice vanants, Ich-1 a pro-apoptotic protein and Ich-lS an anti-apoptotic 
protein produced by exclusion of a 61 bp exon (Ko et a l , 2003) Both bfl-1 proteins 
however have anti-apoptotic properties and have been shown to protect against apoptosis 
in a vanety of cell types (D'Sa-Eipper and Chinnadurai 1996, Karsan et a l , 1996, Zong et 
a l , 1999, Wang et a l , 1999, Ko et a l , 2003) However the two vanants may do this by 
different mechanisms since the Bfl-1 S protein is directed to the nucleus and lacks the 
trans-membrane domain common to anti-apoptotic members o f the Bcl2 family including 
bfl-1 (Ko et a l , 2003) It is important to note that the Northern blotting and RPA 
expenments presented in this thesis would not have distinguished between the two bfl-1 
transenpts as (i) they are almost identical in length and (11) the RPA probe used is from 
the 5’ end of the bfl-1 mRNA where no sequence differences exist between the two 
vanants Hence the degree to which either splice vanant is induced by EBNA2 yet 
remains to be determined.
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A second system was also used, in which the expression of functional EBNA2 was 
controlled by the presence o f estrogen Using the BL41-K3 and BL41/P3HR1-9A cell 
lines, it has been shown that EBNA2 fusion protein is virtually inactive in the absence o f  
estrogen (Kempkes et a l , 1995a) However in the presence of hormone, the EBNA2 
fusion protein is activated to its functional form and functions as wild type EBNA2 in 
that it up-regulates the expression of the cell surface markers CD21 and CD23 and trans­
act! vates known EBNA2 responsive promoters including LMP1, TP1, TP2, BamHl C 
and W promoters (Kempkes et a l , 1995a) The interaction of EBNA2 with CBF1 is also 
rendered dependent on the presence o f estrogen m these cell lines (Kempkes et a l , 1995, 
Strobl et a l , 2000) Activation of the EBNA2 fusion protein m these cell lmes was 
verified by probing for the induction of CD21 (a known target gene of EBNA2) by 
Northern blotting, which showed up-regulation after only 3 hours following EBNA2 
activation (Figures 3 7 and 3 8) The activated EBNA2 fusion protein also up-regulated 
6/7-7mRNA and protein levels in both cell lmes and again the effect was almost 
immediate to EBNA2 activation suggesting the effect on bfl-1 is an early and direct effect 
of EBNA2 activation (Figure 3 9) These results confirm that hfl-1 is an EBNA2 
responsive gene, this time using a second well-worked EBV-negative B-cell line (BL41)
Since LMP1 is a target gene of EBNA2 (Abbot et a l , 1990, Fahraeus et a l , 1990, Wang 
et a l , 1990, Zimber-Strobl et a l , 1991) and EBNA2 trans-activates the LMP1 promoter, 
it had to be verified that the effect of EBNA2 activation on bfl-1 mRNA in the 
BL41/P3HR1 9A cell line was indeed due to activation of EBNA2 and not EBNA2- 
mduced LMP1 Thus Western blotting was earned out on extracts from the BL41/P3HR1 
9A cell line (Figure 3 10) It can be seen however that LMP1 is not detected in this cell 
line pnor to or post-activation of EBNA2, thus implying that LMP1 is not involved m the 
up-regulation of bfl-lmKNA  in this cell line The fact that (1) both native EBNA2 
(expressed in the Dg75tTA EBNA2 cell line) and the ER-EBNA2 (in the BL41 K3 cell 
line) both up-regulated the bfl-1 gene in the absence of other EBV latent proteins and (u) 
the observation of elevated bfl-lmKNA  m an EBV positive but LMP1 negative cell line 
(BL41P3HR1 9A), provided compelling evidence that EBNA2 trans-activates this gene 
in an LMP1 independent manner Although LMP1 has been shown to independently up-
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regulate a number of the same genes as EBNA2 including CD21, CD23 and more 
recently bfl-1 (Wang et a l , 1990, Peng et a l , 1992, Kieff E 1996, D'Souza et a l , 2000), 
the ensemble of results presented so far, also adds the bfl-1 gene to the list of cellular 
genes which can be independently activated by expression of either LMP1 or EBNA2 
Other genes however such as the cellular BATF gene are EBNA2 but not LMP1 
responsive (Johansen et a l , 2003)
Although EBNA2 expression generally results in the transcriptional up-regulation of  
LMP1 this is not the case for the BL41P3HR1-9A cell line, and the molecular basis for 
this has yet to be investigated It is possible that the LMP1 gene has been inactivated by 
mutation or deletion, in any case the absence of detectable levels of LMP1 even after 
activation of a functional EBNA2 capable of up-regulating both bfl-1 and CD21 
independently, provides further evidence that bfl-1 is directly responsive to EBNA2 
These results are further confirmed by the RPA analyses in Figures 3 11 and 3 12
Cyclohexamide (an inhibitor of translation) was added to the E2/ER and ER-mNotch-IC 
cell lines, in the presence or absence of estrogen, and six hours later, samples were taken 
for mRNA analysis (m accordance with StrobI et a l , 2000) Although very faint bands 
were visible in the Northern blot experiments, analysis o f the 6/7-7mRNA transcripts in 
the RPA analyses showed significant induction of bfl-1 upon activation of EBNA2 and 
mNotch-IC m the presence of cyclohexamide in the estrogen responsible cell lines This 
suggests that upon activation of these trans-activators, an up-regulatory effect on bfl-1 
occurs in the absence of new protein synthesis (Figures 3 11 and 3 12) Since activation 
of mNotch-IC did not appear to up-regulate 6/7-7mRNA, the effect of cyclohexamide is 
more difficult to interpret though possibly, cyclohexamide is indirectly stabilising bfl-1 
mRNA molecules by preventing the re-synthesis of short-half life proteins that otherwise 
promote its degradation (Figure3 55)
Apart from up-regulation of 6/7-imRNA, the mRNA species from another Bcl2 family 
member bik, is down regulated m response to expression or activation of EBNA2 
(Figures 3 3, 3 11 and 3 12) Bik is a 185 amino acid pro-apoptotic protein member of the 
Bcl2 family It is thought of as the minimal death module since it only contains the BID
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homology domain prevalent in pro-apoptotic members of this family (Boyd et a l , 1995, 
Elangovan et a l, 1997) As with other pro-apototic members o f the Bcl2 family including 
Bak and Bax, (Oltvai et a l , 1993, Chittenden et a l , 1995), Bik heterodimenzes with anti- 
apoptotic proteins Bcl2 and Bcl-xi via its BH3 domain (Boyd et a l , 1995, Tong et a l , 
2001) and their pro-apoptotic activities are restrained by post-translational modifications 
that cause their sequestration from pro-apoptotic proteins such as Bcl2 (reviewed by 
(Puthalakath et a l , 2002) Expression of bik triggers apoptosis in a range o f cell lines and 
is up-regulated by expression o f p53 and a number of tumour suppressing therapeutic 
agents including doxorubicin in lymphoma cell lines (Mathai et a l , 2002, Panaretakis et 
a l , 2002) Bik expression has also been shown to induce apoptosis in a range o f epithelial 
chemoresistant human tumor cell lines (Tong et a l , 2001, Radetzki et a l , 2002) In the 
case of the experiments presented here, the combination of an up-regulatory affect on the 
anti-apoptotic bfl-1 gene and a down-regulation of the pro-apoptotic gene bik is not 
contradictory, and fits well with the concept that the apoptotic threshold o f cells is 
controlled by the ratio of pro- and anti-apoptotic proteins expressed therein (reviewed by 
Korsmeyer 1995) In any case the combination of up-regulation of bfl-1 and down 
regulation of bik would suggest a cellular environment with increased resistance to 
apoptosis
Bfl-1 has been shown to interact with a number of pro-apoptotic proteins including Bax 
and Bad (Bae et a l , 2001) Another pro-apoptotic protein Bid has been shown to interact 
with Bfl-1 in vitro thus preventing it interacting with other pro-apoptotic proteins Bak 
and Bax (Werner et a l , 2002) The regulation of the bik gene by EBNA2 expression is a 
subject that ments further investigation which is ongoing in the laboratory, but for the 
purpose of this study was not pursued any further It can be concluded that, at the mRNA 
level, none of the other Bcl2 family members were affected by EBNA2 induction in the 
Dg75tTaEBNA2, BL41K3, or BL41P3HR19A cell lmes (Figures 3 3, 3 11, 3 12)
EBNA2 trans-activates a number o f viral and cellular genes including the EBNAs 
themselves (EBV BamHIC and W promoters), LMP1, LMP2A, and the cellular CD21, 
CD23, c-fgr, c-myc and EBD/BLR2 genes (Woisetschlaeger et a l , 1990, Sung et a l ,
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1991, Abbot ei a l , 1990, Fahraeus ei a l , 1990, Wang et a l , 1990, Zimber-Strobl et a l , 
1991, L au xeia /, 1994, Calender ei a l , 1987, Wang e/ a l , 1987, Cordier ei a l , 1990, 
Knutson ei a /, 1990, Patel ei a /, 1990, Burgstahler et a l , 1995, Kaiser ei a l , 1999) 
More recently another cellular gene called BATF, has been identified as a trans- 
activational target of EBNA2 (Johansen ei a l , 2003) The ensemble of the results 
presented m this thesis adds bfl-1 to the list of cellular genes trans-activated by EBNA2
The EBNA2 responsive elements for the Cp, LMP1, LMP2 CD21 and CD23 promoters 
have all been characterized (Woisetschlaeger ei a l , 1990, Sung et a l , 1991, Abbot ei a l , 
1990, Fahraeus ei a l , 1990, Wang et a l , 1991) and are known to contain at least one 
CBF1 binding site (Zimber-Strobl ei a /, 2001) CBF1 binds to the DNA sequence 
5’GTGGGAA3’ (Ling ei a l , 1994, Tun ei a l , 1994), and this sequence was identified in 
each of the promoters above The relevance and importance of CBF1 binding is that 
EBNA2 does not bind directly to DNA but is targeted to responsive promoters via this 
cellular protein CBFl/RBP-jk (Ling e ta l, 1993, Waltzer e ta l, 1994)
The contribution of CBF1, in mediating the EBNA2 responsivity of the bfl-1 promoter 
was assessed m two ways, (i) by assessing the requirement of the EBNA2 CBF1 binding 
site m region CR5 of the EBNA2 protein (Figure 3 16) (Ling ei a /, 1993) and (11) by 
assessing the requirement of any putative CBF1 binding sites on the bfl-1 promoter itself 
Transient transfections were performed using a pair of EBNA2 expression plasmids, 
pSG5EBNA2 (PDL151) and pSG5EBNA2WW323SR (PDL152) (Ling et a l, 1993) The 
latter expresses an EBNA2 mutant that can no longer bind to CBF1 The data from these 
and further transfections using a senes of bfl-1 promoter reporter constructs, (Figures 
3 16-3 21) led to the delineation of a region between -367 and -129 (containing a 
potential CBF1 binding site at position -243/-249 on the bfl-1 promoter (Figure 3 22) In 
order to assess the contribution of this motif to EBNA2 responsiveness o f the bfl-1 
promoter, site directed mutagenesis of this site was performed and transient transfections 
were also undertaken with these paired promoter reporter constructs (Figures 3 26-3 30) 
The results presented m this study show that both the EBNA2 CBF1 binding site (region
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CR5) and the novel CBF1-binding motif on the promoter were essential for mediating 
EBNA2 trans-activation of the bfl-1 promoter, thereby implying a critical role for CBF1 
in this process
Limited studies with the bfl-1 promoter have been published One has shown that NF-kB 
is required for mediating TNF-a induced up-regulation of the bfl-1 promoter (Zong et a l ,
1999) The same study also showed that expression o f the NF-kB subunit c-rel also led to 
the induction of bfl-1 promoter activity and that this activity was mediated by binding to 
an NF-kB site at position -833 of the promoter (Zong et a l , 1999) Numerous other 
groups have also identified bfl-1 as an NF-kB responsive gene (Grumont et a /, 1999, 
Wang et a l , 1999, D'Souza et a l , 2000, Cheng et a l , 2000) More recent studies 
however have also shown that regulation of the bfl-1 promoter activity may be more 
complex than originally anticipated with an NF-kB dependent enhanseosome-hke 
complex binding to the 5’ regulatory region of the bfl-1 promoter, and that this 
enhanseosome complex includes the transcription factors NF-kB, API, C/EBPP, HMGI- 
C and p300 (Edelstein et a l , 2003) To date, no CBF1 dependent mechanisms of 
regulating the bfl-1 promoter have been reported however, and this study provides the 
first evidence that CBF1 is required to mediate EBNA2 associated up-regulation of the 
bfl-1 promoter, at least in a B cell context
In this study, transient transfections using a luciferase 6/7-7-promoter reporter construct 
showed a dose dependent increase m bfl-1 promoter activity in response to EBNA2 
expression (Figure 3 16) However expression of the mutant EBNA2 which no longer 
binds CBF1 (Ling et a l , 1993, Ling et a l , 1995) only just trans-activated the promoter 
above basal levels over a range of quantities o f vector tested (Figure 3 16) EBNA2 
trans-activated the bfl-1 promoter m two other well-worked EBV-negative cell lines 
(Bjab and BL41), while the inability of the CBF1 binding mutant of EBNA2 to 
substantitively trans-activate the bfl-1 promoter was also repeated in these cell lines 
(Figure 3 17) These results led to the conclusion that bfl-lwiRNA up-regulation seen m 
the RPA and Northern blot analyses (Figures 3 3, 3 5, 3 9, 3 11 and 3 12) was occurring
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by trans-activation of the bfl-1 promoter and that this process required EBNA2-CBF1 
binding
Because of the B cell tropism o f EBV, (reviewed by Faulkner 2000), many of the studies 
involving EBNA2 are undertaken m a B cell derived background, however EBNA2 can 
trans-activate genes in a cellular environment of non B cell lineage thus B cell specific 
transcription factors are not essential m mediating EBNA2 effects on certain genes, such 
as LMP1 and CD21 in the T-cell lines Jurkat and 293T (T cells) (Larcher et a l , 1995, 
Peng et a l , 1993, Wang et a l , 2000) Nonetheless, EBNA2 also up-regulates certain 
genes in a B cell specific manner, including BATF (Ko et a l , 2003) In order to 
investigate if the effect of EBNA2 on the bfl-1 promoter was a B cell specific effect, 
similar transient transfections were undertaken in a limited range of cell lines including T 
cell, epithelial and smooth muscle cell lines The results imply that trans-activation o f the 
bfl-1 promoter may be a B cell specific effect with little trans-activation of the bfl-1 
promoter reporter construct observed in any of the other cell lines (Figure 3 18) The 
inability of EBNA2 to trans-activate the bfl-1 promoter m non B cell background may 
indicate that B cell specific transcription factors may be essential in facilitating EBNA2 
mediated trans-activation of the bfl-1 promoter Interestingly, using Transcription 
Element Search Software (TESS), putative consensus binding sites for B cell and 
macrophage specific members of the Ets family of transcription factors (Klemsz et a l , 
1990) Etsl and PU 1 were also identified at various positions on the bfl-1 promoter 
(Figure 3 22), and the failure o f EBNA2 to trans-activate the bfl-1 promoter in non-B cell 
lines may imply a key role for these B cell specific transcription factors m conferring 
EBNA2 responsiveness on the bfl-1 promoter
Site directed mutagenesis of the putative CBF1 binding site was undertaken and a pair of  
bfl-1 promoter luciferase reporter constructs were generated, (-1374/+81 wtbfl-1 Luc and 
-1374/+81 mCBFl&/7-7 Luc), identical except for the abolition of the CBF1 binding site 
in one reporter construct (-1374/+81 mCBF 1 bfl-1 Luc) (Figures 3 23-3 25) Transient 
transfection studies with the paired promoter reporter constructs demonstrated the 
requirement of the putative CBF1 site (at position -243 to -249) on the bfl-1 promoter
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was essential for conferring EBNA2 responsiveness on the bfl-1 promoter (Figures 
3 26A and 3 27) Co-transfection with the vector expressing wild-type EBNA2 resulted in 
a consistent up-regulation o f the promoter however the CBF1 mutated promoter was only 
very weakly trans-activated (Figure 3 27) These results combined with the fact that the 
non-CBFl binding EBNA2 mutant expression plasmid (pSG5EBNA2WW323SR), does 
not trans-activate the wild type bfl-1 promoter, all imply a crucial role for CBF1 in 
mediating the EBNA2 induced activity o f the bfl-1 promoter This requirement was also 
demonstrated in other BL cell lines BL41 and Bjab and the same trend was apparent in 
the estrogen responsive cell lines where activated EBNA2 consistently trans-activated 
(albeit to a lesser extent), the wild type but not the CBF1 mutated bfl-1 promoter reporter 
construct (Figures 3 28-3 30) Although neither EBNA2 nor the CBF1 mutated EBNA2 
trans-activate the mutant bfl-1 promoter, co-transfection o f the mutated bfl-1 promoter 
with an LMP1 expression plasmid (pSGSLMPl) resulted in average of 4 5 fold trans- 
actiavtion Thus, although essential to EBNA2 trans-activation, the putative CBF1 site at 
position -243 to -249 is not an essential basal element required for of bfl-1 promoter 
activity (Figure 3 37B)
In the absence of EBNA2/Notch-IC, CBF1 acts as a repressor o f transcription (Hsieh et 
a l , 1995, Hsieh et a l , 1996) It does so in part by tethering a histone deacetylase co- 
repressor complex to the promoter (Dou et a l , 1994), (Hsieh et a l , 1995, Waltzer et a l , 
1995, Kao et a l , 1998, Zhao et a l , 2000) A number o f proteins have been identified as 
members of the CBF1 repression complex, these include, SMRT and HDAC1 (Kao et a l , 
1998), and CIR, Sap30, and HDAC2 (Hsieh et a l , 1999) as well as SKIP (Zhou et a l , 
2000, Zhou et a l , 2000) (Figure 1 6) Some o f the members o f the repression complex 
including Sin3A and SMRT were identified in the CBF1 HD AC repression complex due 
to then* association with other HD AC-associated repression complexes (Hassig et a l , 
1997, Heinzel et a l , 1997, Laherty et a l , 1997, Nagy et a l , 1997) CBF1-HDAC 
repression is thought to be attributable to histone deacetylation which leads to chromatin 
remodelling and destabilization of transcription factor TFHD-TFHA interactions (Olave 
et a l , 1998) EBNA2 masks CBF1 repression by binding to the repression domain of  
CBF1 and then introducing its trans-activation domain which induces transcriptional
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activation o f target promoters (Hsieh et a l , 1995, Hsieh et a l , 1996) (Figure 1 6) 
EBNA2 also interacts with the SNF-SWI complex which is also involved m chromatin 
remodelling and this, in conjunction with dislocation of the HD AC repression complex 
may assist in making target promoters more accessible to the EBNA2 trans-activation 
domain (Wu et a l , 1996)
EBNA2 has also been shown to interact with SKIP in vitro and competes with SMRT for 
contacts on both CBF1 and SKIP, since different elements within EBNA2 confer the 
binding ability o f EBNA2 to CBF1 and SKIP respectively it is likely that contacts on 
both SKIP and CBF1 are required for effective EBNA2 targeting to DNA (Zhou et a l , 
2000, Ling et a l , 1993) SKIP was also demonstrated to interact with other members of 
the CBF1 repression complex including CIR, HDAC2, such that a new model for the 
CBF1 repression complex was constructed (See Figure 1 6 adapted from Zhou et a l ,
2000) Ultimately the ability of EBNA2 to bind CBF1 and SKIP and thereby displace the 
CBF1-associated repression complex from target promoters is a model which, due to the 
apparent importance of CBF1, may apply to EBNA2-mediated trans-activation of the bfl- 
1 promoter
Optimal activation o f promoters by EBNA2 often requires cooperation by other 
transcription factors in addition to CBF1 (Meitmger et a l , 1994) In the LMP1 promoter, 
multiple transcription factor binding sites have been identified One transcription factor, 
PU 1/Spi-B, which also interacts directly with EBNA2, has been found to be essential in 
mediating EBNA2 activation o f LMP1 (Johannsen et a l , 1995, Laux et a l , 1994) It has 
also been shown that a POU domain protein is involved m the EBNA2 mediated trans- 
activation o f LMP1 (Sjoblom et a l , 1995) In the Cp promoter, the EBNA2 responsive 
element also contains a CBF2 binding site adjacent to the CBF1 binding site and this also 
contributes to EBNA2 responsiveness (Ling et a l , 1993, Fuentes-Panana et a l , 1998) 
Also, in the LMP2A promoter, beside CBF1, two other as yet unidentified proteins bind 
to the EBNA2 responsive element to contribute to EBNA2 responsiveness (Hofelmayr et 
al, 1999) These data may be significant in the case o f the bfl-1 promoter in that 
sequence analysis of the promoter sequence, identified three putative Etsl and one
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possible PU 1 binding site(s) in close proximity to the crucial putative CBF1 consensus 
site The arrangement and proximity o f multiple transcription factor binding sites in the 
EBNA2 responsive element of the bfl-1 promoter is reminiscent of EBNA2 responsive 
elements in other EBNA2 target promoters including the Cp, CD23, LMP1 and Tpl 
promoters (Table 3 1 - adapted from Le Roux et a l, 1993) Sequence alignment of the 
EBNA2 responsive elements in each of these promoters and the bfl-1 promoter reveals 
the presence of 2 regions of homology, firstly the core GTGGGAA sequence which 
recognizes/binds CBF1 (Zimber-Strobl et a l , 1993) which was identified (in the reverse 
orientation) on the bfl-1 promoter This motif has been identified in each of the other 
EBNA2 responsive promoters shown in Table 3 1 A possible PU 1 consensus binding 
site was also identified on the bfl-1 promoter and sequence analysis shows this site as 
similar to the PU 1 site found in the EBNA2 responsive LMP1 promoter The LMP1 
PU 1 site is also highlighted Table 3 1 (Ling et a l , 1993) Thus the EBNA2 responsive 
element in the bfl-1 promoter has a similar arrangement to other known E2REs in well- 
studied EBNA2 target promoters including the Cp, LMP1 and CD23 promoters
The trans-activational effect of EBNA2 is generally due to its binding of CBF1 which 
subsequently binds to cognate DNA sequences thereby making the EBNA2 trans­
act! vation domain available to target promoters, (Grossman et a l , 1994, Henkel et a l , 
1994) EBNA3 inhibition of EBNA2-CBF1 mediated trans-acti vation of target promoters 
is based on the interaction o f the EBNA3 proteins with CBF1 and members of the CBF1 
repression complex, (Zhao et a l , 1996, Robertson et a l , 1995, Daibies-Tran et a l , 2001, 
Knight et a l , 2003) therefore any inhibitory affect of the EBNA3 proteins on EBNA2 
mediated trans-activation of the bfl-1 promoter, would further imply a key role for CBF1 
in facilitating EBNA2 trans-activation o f bfl-1 To investigate this, DG75 cells were 
transfected with the EBNA2 expression plasmid pSG5EBNA2 and the bfl-1 promoter 
reporter constructs (-1374/+81 wt bfl-1 Luc and -1374/+81 mCB¥\ bfl-1 Luc) Increasing 
quantities o f the EBNA3 expression plasmids were also added A dose dependent 
decrease in EBNA2 mediated trans-activation o f the bfl-1 promoter was recorded upon 
addition of increasing quantities of each of the EBNA3A, 3B and 3C expression 
plasmids (Figures 3 31-3 33) These results again indicate a key role for CBF1 in
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mediating the EBNA2 trans-activational effect on the bfl-1 promoter These results 
comply with the findings o f others, which show the EBNA3 proteins repress EBNA2- 
CBF1 mediated trans-activation of target genes including LMP1 TP2 Cp (Robertson et 
a l , 1995, Zhao et a l , 1996, Johannsen et a l , 1995, Le Roux et a l , 1994) and recently c- 
myc (Cooper et a l, 2003)
Several lines of evidence are consistent with the possibility that EBNA3A, 3B and 3C 
regulate the transcription o f genes with CBF1 binding sites EBNA3A, 3B and 3C can 
bind to CBF1 in vitro and in yeast cells (Marshall et a l , 1995, Robertson et a l , 1995) can 
associate with CBF1 in human lymphoblasts (Robertson et a l , 1995, Robertson et a l ,
1996) and can specifically block EBNA2 trans-activation of the LMP1, LMP2 Cp, CD21 
and CD23 promoters in transient transfection assays (Le Roux et a l , 1994, Marshall et 
a l , 1995, Robertson et a l , 1995, Lin et a l , 2002, Zhao et a l , 1996, Dalbies-Tran et a l , 
2001) It has also been shown that EBNA3C interacts with HDAC1 and 2 and another co- 
repressing member of the CBF1 repression complex Sm3 A (Radkov et a l , 1999, Knight 
et a l , 2003) This interaction suggests that the association o f EBNA3C with CBF1 may 
also include complexing with HDACs and another molecule (ProTa) containing 
deacetylase activities in EBV-transformed cells (Knight et a l , 2003) Thus, apart from 
binding to this complex and preventing CBF1 from recognizing cognate DNA sequences, 
EBNA3A may also actually stabilize the CBF1 repression complex similarly to RPMS1 
(See figure 1 14 chapter 1) In any case the negative effects of EBNA3A or 3C on 
EBNA2 mediated trans-activation of the bfl-1 promoter provides strong evidence that 
CBF1 and the CBF1 repression complex are involved
The EBNA3 proteins have also been shown to have trans-activational properties 
EBNA3C can trans-activate some EBNA2-responsive genes including LMP1 in G1 
arrested cells and CD21 in EBV negative BL cells (Allday 1996, Wang et a l , 1990) 
Also, similarly to EBNALP, EBNA3C has been shown to cooperate with EBNA2 in 
trans-activatmg the LMP1 promoter in EBV negative cells (Lm et a l, 2002) EBNA3B 
can up-regulate CD40 and vimentin expression m non EBV infected BL cells (Silms and 
Sculley 1994) and stable co-expression o f the three EBNA3s in EBV negative DG75
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cells up-regulates pleckstnn (Kienzle et a l , 1999) Also EBNA3C has a glutamine- 
prolme nch domain that can functionally substitute for the EBNA2 acidic domain 
transcriptional activation (Cohen et a l , 1991, Marshall et a l , 1995) EBNA3A and 3B 
are distantly homologous to 3C however these also have similar glutawme-prohne nch 
regions and therefore may also exert their trans-activational functions in the same manner 
(for sequence companson see Sample et a l , 1990) As a result of their trans-activational 
ability and in order to assess any effect of the EBNA3 proteins on the bfl-1 promoter, 
each of the EBNA3 expression plasmids were individually co-transfected with the wild 
type and CBF1 mutated bfl-1 promoters m the absence o f EBNA2 expression vector 
Despite their trans-activating abilities, it can be seen m Figure 3 34 that EBNA3A 
EBNA3B and EBNA3C did not trans-activate the bfl-1 promoter (-1374/+81 wtbfl-1 Luc) 
or its CBF1 mutated counterpart (-1374/+81 mCBFlA/7-7 Luc)
Epstein-Barr virus (EBV) has been found to express vanous spliced RNAs transcribed 
nghtward from the region spanning nucleotide positions 150,000 to 161,000 on the EBV 
B95-8 genome These have been referred to as complementary strand transcnpts (CSTs), 
BamHl A nghtward transcnpts (BARTs), or the BARF RNAs (Chen et a l , 1999) The 
function of the BARTs is unknown Deletion of the 2tomHI-A region of the genome does 
not affect EBV immortalization o f B cells in vitro indicating that the BARTs are unlikely 
to contnbute directly to immortalization On the other hand, the consistent expression o f  
these transcnpts in EBV-associated epithelial and B-cell tumors suggests that they are 
making some contribution in vivo One such putative protein, RPMS, is nuclear in 
transfected cells (Chen et a l , 1992, Smith et a l , 2000) and was shown to bind to CBF1 
in glutathione-S-transferase (GST) affinity assays and to interfere with EBNA2 and 
Notch-IC activation o f reporters containing CBF1 binding sites in transient-expression 
assays (Smith et a l , 2000, Zhang et a l , 2001)
Since RPMS1 is known to interfere with EBNA2 trans-activation o f target promoters 
which require CBF1, an expression plasmid containing RPMS1 was transfected with 
EBNA2 expression vector and a bfl-1 promoter reporter construct (-1374/+81 vttbfl-l 
Luc) (Figure 3 35) It can be seen that RPMS1 potently down-regulated EBNA2-
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associated trans-activation of the bfl-1 promoter in a dose dependent manner These 
findings corroborate the involvement of a CBF1-associated complex in EBNA2 mediated 
trans-activation of the bfl-1 promoter since the ability o f RPMS1 to interfere with 
EBNA2 trans-activation is due to its involvement with CBF1 and Cir as well as other 
members of the co-repressor complex and subsequent stabilization o f this repressor 
complex (Zhang et a l , 2001) These results again comply with previous results obtained 
with the EBNA3 expression plasmids, which also interact with CBF1 and members of the 
repressor complex
RPMS1 binds to CBF1 and co-localizes in the nucleus and further evidence for the direct 
interaction of CBF1 and RPMS1 m vivo comes from the ability o f RPMS1 to relocate a 
mutant CBF1 from the cytoplasm to the nucleus of transfected lymphocytes (Zhou et a l ,
2001) In binding to CBF1, RPMS joins the EBNA2 and EBNA3A, -3B, and -3C 
proteins as an EBV-encoded protein that interacts with CBF1 and consequently has the 
potential to modify the Notch signaling pathway The ability of RPMS 1 to counteract the 
trans-activational effect of EBNA2 and Notch-IC mediated trans-activation is due to the 
fact that RPMS1 competes with SKIP for binding to CIR (Zhang et a l , 2001) SKIP is a 
component of the CBF1-corepressor complex and is an important cofactor for both 
EBNA2 and Notch-IC activation o f CBF1-repressed promoters since interaction between 
SKIP and SMRT is important m tethering the HD AC co-repressor complex to CBF1 
(Zhou et a l , 2000, Zhou et a l , 2001) One interpretation of these experiments is that 
changing the SKIP-CIR interaction in some way disadvantages the EBNA2-SKIP or 
Notch-IC-SKIP interaction and prevents a stable association ofEBNA2 or Notch-IC with 
CBF1 (Fig 1 8) In the case of the data in this study, the negative effect of RPMS 1 on 
EBNA2 mediated trans-activation of the bfl-1 promoter, provides further substantiation to 
the theory that CBF1 and the CBF1 repression complex are involved in regulating 
EBNA2 associated stimulation of bfl-1
Although both EBNA2 and LMP1 can independently trans-activate the bfl-1 promoter, 
and LMP1 can trans-activate the CBF1 mutated bfl-1 promoter, EBNA2 and LMP1 do 
not cooperate to trans-activate the bfl-1 promoter (Figure 3 38) EBNA2 and LMP1 have 
been shown to cooperate in the regulation of the cellular CD21 and CD23 promoters
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[Wang, 1990], however, this was not found to be the case with the bfl-1 promoter, in fact 
addition of increasing quantities of an LMP1 expression plasmid resulted in a dose 
dependent decrease in EBNA2-associated trans-activation o f the bfl-1 promoter (Figure 
3 38) Although LMP1 has been shown to have a cytotoxic effect on ceil growth in 
certain transfection assays, (Martin et a l , 1993), and even a cytostatic effect on cell 
growth under stable expression conditions (Floettmann et a l , 1996) it is not likely that 
this is the case here as similar increasing quantities o f LMP1 (in the absence of EBNA2) 
did not result in a significant reduction in bfl-1 promoter activation and all transfection 
results were normalised by correcting for P-galactosidase activity (Figure 3 37A) These 
results with the bfl-l promoter may suggest that some common element is required by 
both EBNA2 and LMP1 to trans-activate the bfl-1 promoter, thus competition between 
EBNA2 and a downstream signaling target of LMP1 for binding o f this common element 
may inhibit promoter trans-activation Alternatively, binding of either EBNA2 or an 
LMP1 responsive protein may modify the transcription factors involved rendering them 
inaccessible to the other Since LMP1 can trans-activate the CBF1 mutated bfl-1 
promoter, that particular CBF1 binding site is not a candidate for the common element 
used by both EBNA2 and LMP1, however other transcription factors which both EBNA2 
and LMP1 use to trans-activate other promoters may be candidates here, including API 
and members of the Ets/PU 1 family LMP1 activation of the p38 mitogen activated 
protein kinase (MAPK) pathway targets transcription factors such as ATF2 (reviewed m 
Nebreda et a l , 2000) and API, which are required to facilitate LMP1 activation of IL6 
and IL 8 promoters (Eliopoulos et a l , 1997) Recent studies which show that EBNA2 
trans-activates the BATF gene in B cells (Johansen et a l , 2003) may suggest a possible 
role for API as an import factor m mediating LMP1 activation of the bfl-1 promoter 
(which appears to be a B cell specific effect) since EBNA2 up-regulation o f BATF (a 
member of the API family) inhibits API target gene expression by heterodimenzing with 
jun and competing with Fos Jun complexes for binding to API consensus sequences 
Thus LMP1 may require API sites in the bfl-1 promoter to exert its trans-activational 
effect and in the presence of EBNA2 activation of BATF1 this may not be possible 
Interestingly putative API sites have also been identified at the 5s end of the ¿/77- 
promoter (Edelstein et a l , 2003), and the same study also showed that both Apl and
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CEBPP were important members of the NFk-B dependent enhanseosome complex on the 
bfl-1 promoter again indicating the possibly complex transcriptional requirements of the 
bfl-1 promoter Although an API site has been identified at the 5’ end of the promoter at 
position -864, (Edelstem et a l , 2003) it is possible that more proximal as yet unidentified 
transcription factor binding sites may also be involved m heterodimerizing with CBF1 or 
Nf-kB in conferring EBNA2 or LMP1 responsivity on the bfl-1 promoter In agreement 
with this, other recent experiments in our laboratory have shown that the elimination by 
mutation of an additional novel API-like binding site in the bfl-1 promoter leads to a 
significant loss of LMP-1-associated trans-activation, indicating a role for this 
transcription factor m this context
Another family of transcription factors with which EBNA2 associates to direct it to target 
promoters is the Ets family of transcription factors whose members include Spi-l/PU 1, 
Ets-1, and Spi-B Indeed EBNA2 activation o f the LMP1/TP2 promoter is mediated by 
CBF1, PU 1 and Spi-B (Johannsen et a l , 1995, Laux et a l , 1994) This family of 
transcription factors has also been shown to interact with API and NF-kB, both 
downstream targets of LMP1 signaling, suggesting a possible role for Ets family 
members (Bassuk et a l , 1995, Thomas et a l , 1997) m mediating LMP1 effects on the 
bfl-1 promoter If the putative Ets-l/PU 1 sites identified on the bfl-1 promoter are 
targeted by both EBNA2 and downstream signaling elements of LMP1, binding of one or 
other (i e EBNA2 or a downstream signaling element of LMP1) may be inhibiting 
binding of the other or causing transcription factor modification which inhibit use for the 
other protein In any case the possibility o f a common portal required by both EBNA2 
and LMP1 in addition to CBF1 and NF-kB binding is a likely scenario and one which is 
supported by the requirement of both EBNA2 and LMP1 for numerous transcription 
factors in the trans-activation o f target promoters
EBNA-LP has been found to cooperate with EBNA2 in the trans-activation of the 
LMP1/LMP2 and EBV BamHl C latency promoters, (Harada and Kieff 1997 and 
Nitsche et a l , 1997) The molecular basis for EBNA-LP mediated enhancement of 
EBNA2 trans-activation of promoter activity is still not folly understood although the 66
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amino acid repeat domains within EBNA-LP are required for this augmenting effect 
(Harada and Kieff 1997, Nitsche et a l , 1997) and the same studies also map the critical 
EBNA2 domain for interaction with EBNA-LP to the EBNA2 activation domain between 
ammo acids 425 and 487 (Figure 1 7) EBNA-LP has also been shown to cooperate with 
EBNA2 to stimulate cyclin D2 expression and induce transition from the G° to G1 phases 
of the cell cycle during the immortalisation o f resting B-lymphocytes by EBV (Sinclair et 
a l , 1994).
In order to assess any cooperative function of EBNA2 and EBNA-LP in the trans- 
activation of the bfl-1 promoter, transient transfection assays were performed in which 
EBNA2 and EBNA-LP expression plasmids were co-transfected into DG75 cells (Figure 
3 39A) This study showed that both EBNA-LP expression plasmids, pSG5LP and 
pJT125 (containing four and two W repeats respectively) significantly enhanced EBNA2 
activation of the bfl-1 promoter in a dose dependent manner in DG75 and Bjab BL cell 
lines (Figures 3 39A, 3 39B, 3 40) Two EBNA-LP expression plasmids were used, one 
of which expressed an EBNA-LP with two W repeats, pJT125 (Peng et a l , 2000) and the 
other which expressed an EBNA-LP containing four W repeats pSG5LP (Harada and 
Kieff 1997) The isoform containing four W repeats is generally accepted as the standard 
EBNA-LP expression plasmid (Nitsche et a l , 1997), while the isoform containing two W 
repeats has been found to contain the minimum number of W repeats required for trans- 
activation of the LMP1 and Cp promoters Thus EBNA-LP expression plasmids 
expressing this two W repeat isoform (pJT125) and one expressing the four W repeat 
isoform (pSG5LP) were employed (Harada and Kieff 1997, Nitsche et a l , 1997, Peng et 
a/,2000)
Transient transfection data from this study revealed that although both EBNA-LP isoform 
co-operated with EBNA2 to trans-activate the bfl-1 promoter, (Figures 3 39A-C) the 
shorter EBNA-LP isoform with only two W2 domains consistently resulted in higher 
levels o f trans-activation of the bfl-1 promoter than its longer (4xW repeat) counterpart, 
this may be due to higher levels of EBNA-LP expression by the shorter protein (which 
could be determined by Western blotting), or it may be that the smaller protein is more 
potent and binds more efficiently Nonetheless these data correlate with the findings of 
others who also found higher activity with the shorter isoform (Nitsche et a l , 1997, Peng
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et a l , 2000) With regard to which isoform is the more relevant m vivo, this has yet to be 
identified To date EBNA-LP has not been found to have any independent trans- 
activational effect on viral or cellular promoters however in this study, EBNA-LP was 
found to trans-activate the bfl-1 promoter 4 to 6 fold in a dose dependent manner in the 
absence of EBNA2 Further to this, the trans-activational effect of EBNA-LP on the bfl-1 
promoter was found to depend upon the CBF1 consensus sequence on the bfl-1 promoter 
as EBNA-LP trans-activation o f the CBF1 mutant bfl-1 promoter (-1374/+81 vAbfl-1 
Luc) was less than 2 fold It can be seen from the results that this was the case for both 
isoforms of EBNA-LP assayed (Figure 3 39A, B and C)
It can be seen from Figure 3 39C that deletion of the Y2 domain abolished the co- 
activating function of EBNALP in the trans-activation of the bfl-1 promoter These 
results are reminiscent of the findings o f others, which showed deletion o f the EBNALP 
Y2 domain (in the context of the (WiW2)2 Y1Y2 isoform) abolished its co-activating 
functions in augmenting EBNA2 mediated trans-activation of the Cp and LMP1 
promoters (Nitsche et a l , 1997, McCann et a l , 2001) Thus the Y2 domain also appears 
critical in mediating the EBNA2 cooperation activity in trans-activating the bfl-1 
promoter in the context of the (WiW2)4 Y1Y2 isoform Other studies involving mutational 
analysis of EBNA-LP revealed that EBNA-LP expression plasmids expressing an EBNA­
LP protein lacking the entire 45-amino-acid Y1 Y2 unique domain still cooperated with 
EBNA2 in trans-activating the LMP1 promoter but that the co-operative function of 
EBNA-LP was reduced with a mutant EBNA-LP expression plasmid expressmg an 
EBNALP lacking the Y2 domain (Nitsche et a l , 1997) More recent studies using 
EBNALP constructs lacking the Y2 domain demonstrated that deletion of the Y2 domain 
either alone or together with Y1 led to a complete loss o f co-operative function, despite 
nuclear localization as identified using immunofluorescence (McCann et a l , 2001)
Another mutant EBNALP expression plasmid in which conserved serine residues in each 
of the two W2 repeats were substituted for alanines (residues 49 50 and 51m the first W2 
repeat and residues 115, 116 and 117 in the second W2 repeat), was also used (Figure 
3 38) This construct, pRSP83 (Peng et a l , 2000) failed to cooperate with EBNA2 in
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trans-activating the bfl-1 promoter These senne residues at positions 49 50 and 51 in 
the W2 repeat domains have been shown to be important in mediating the EBNA2- 
cooperative function to EBNALP, on other EBNA2 responsive promoters (Peng et a l ,
2000), similarly mutation of these residues abolishes EBNA-LP EBNA2 co-operativity 
for the trans-activation of the bfl-1 promoter These results comply with other studies, 
(Peng et a l , 2000, McCann et a l , 2001), which also show this mutagemsed EBNA-LP 
had no EBNA2 co-operativity due to the fact that the mutant proteins no longer localized 
exclusively to the nucleus
The importance of serme residues in conferring EBNA2 co-operativity on EBNA-LP 
suggests that phosphorylation may be an important feature of the relationship between 
EBNA-LP and EBNA2 and on the basis o f the data m this study, (Figures 3 40) using the 
pRSP83 construct, phosphorylation may also be important in facilitating the cooperative 
function between EBNA-LP and EBNA2 m the trans-activation of bfl-1
Although CBF1 binding has been shown to be crucial in mediating EBNA2 trans­
act vation of a number of target promoters including LMP1, CD21, Cp and possibly c- 
myc, (Woisetschlaeger et a l , 1990, Sung et a l , 1991, Laux et a l , 1994) it is often 
insufficient on its own to confer optimal EBNA2 responsivity on target promoters 
(Meitinger et a l , 1994) Apart from CBF1 a number of additional transcription factors 
including CBF2 and AUF1 (Fuentes-Panana e ta l , 1998, Fuentes-Panana e ta l , 2000) are 
critical m mediating EBNA2 responsivity on the Cp promoter and additional transcription 
factors are required in the EBNA2 trans-activation o f the LMP2A promoter (Hofeimayr 
et a l , 1999) Additionally, two members of the Ets family of transcription factors, 
PU 1/Spi-l and Spi-B have been found to interact with EBNA2 in the trans-activation o f  
the LMP1/TP2 promoters (Johannsen et a l , 1995, Laux et a l , 1994) In an attempt to 
identify a role for other possible transcription factor binding sites on the bfl-1 promoter, 
sequence analysis using a number of online databases revealed the presence o f putative 
Etsl and PU 1 binding motifs located in close proximity to the consensus CBF1 binding 
site already identified (Figure 3 22) Both PU 1 and Ets-1 are members of the Ets family 
of transcription factors The identification o f a number of putative Ets-1 and Pu 1 binding 
sites in close proximity to each other and proximal to the CBF1 consensus sequence on
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the bfl-1 promoter, is reminiscent of the EBNA2 responsive elements in other EBNA2 
responsive promoters (Table 3 1) It is possible therefore that EBNA2 (and possibly 
LMP1) mediated trans-activation o f the bfl-1 promoter may require downstream targeting 
of the putative Etsl and PU 1 sites identified on the bfl-1 promoter This may explain the 
inhibiting property of LMP1 expression on EBNA2 activation o f the bfl-1 promoter, as 
both may compete through different mechanisms to target these same sites thereby 
competitively inhibiting the trans-activational effect of the other Site directed 
mutagenesis was undertaken and putative etsl sites at nucleotide positions -213, -176 
and a putative PU 1 site at position -143 were mutagemsed with the core GGAA motif o f  
these Ets family transcription factors replaced by the GCAG (Table 3 2) Transient 
transfections with these etsl/PU 1 mutant bfl-1 reporter constructs (-213 m Ets\bfl-l Luc, 
-176 mEtsl/yj-/ Luc and -143 mPU \bfl-1 Luc) and the pSG5EBNA2 expression 
plasmid showed that all three putative Ets-1 sites and the putative PU 1 site contributed to 
mediating optimal trans-activation of the bfl-1 promoter by EBNA2 (Figure 3 44) 
Mutation of the ‘double’ Ets-1 consensus sequence at position -176 on the bfl-1 
promoter, reduced EBNA2 trans-activation of the bfl-1 promoter from 6 5 fold to less 
than 2 fold, similarly mutation of the putative PU 1 consensus sequence at position -143 
reduced EBNA2 trans activation of the bfl-1 promoter from 6 5 fold to about 2 fold 
Mutation of the putative Ets-1 binding site at position -213 also reduced EBNA2 trans- 
activation of the bfl-1 promoter, but to a lesser extent from 7 fold to about 3 5 fold 
(Figure 3 44) In the case of all three mutant expression plasmids, the trans-activational 
effect of EBNA2 was compared to the trans-activational effect of EBNA2 on the 
truncated -367/+81 bfl-1 Luc reporter construct as it was in this background that the 
mutagenesis was performed These data may imply that similar to the LMP1 promoter, 
EBNA2 may trans-activate the bfl-1 promoter via recruitment by both CBF1 and PU 1, as 
well as other transcription factors namely Ets-1 which may also be involved in targeting 
EBNA2 to the bfl-1 promoter
Modulation of gene expression by ETS family members can involve combinatorial 
interactions with other transcription factors, including Spl, AP-1, c-myb, Nf-kB and 
CBF1 (Bassuk et a l , 1997, Eisenbeis et a l , 1995, Nagulapalli et a l , 1995, Thomas et 
a l , 1997, Sementchenko et al, 2000) Ets proteins including PU 1 (also known as Spi-1)
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and Ets-1 most often bind DNA as monomers however they interact with other cellular 
DNA-binding proteins to form ternary protein-protein complexes, (Fitzsimmons et a l , 
1996, Thomas et a l , 1997) sometimes in the activation of B cell and lymphoid specific 
promoters (Fitzsimmons et a l , 1996, Nagulapalli et a l , 1995 Pongubala et a l, 1992, 
Thomas et a l , 1997) Further to this, NF-kB , API and Etsl synergistically combine to 
trans-activate the GM-CSF promoter (Granulocyte-Macrophage colony stimulating 
Factor) Since these transcription factor often act in concert with other transcription 
factors in trans-activating target genes it is therefore likely that in the case o f both LMP1 
and EBNA2 a number of these transcription factors m combination as well as CBF1 or 
Nf-kB are required to trans-activate the bfl-1 promoter Similarly to the LMP1 promoter 
(Johannsen et a l , 1995), EBNA2 trans-activation of the bfl-1 promoter, may require a 
combination of transcription factors including PU 1 and CBF1 Interestingly, EBNA2 
trans-activation of the LMP1 promoter occurred only in B cells but not m T or epithelial 
cell lines tested (Johannsen et a l , 1995) Similarly EBNA2 trans-activation of the bfl-1 
promoter only occurred in B cells, not m the T or muscle cell lines tested (Figure 3 18) 
The fact that the trans-activational effect of EBNA2 on both bfl-1 and LMP1 promoters, 
in transient transfections appears to be limited to B cell lines (Figure 3 18 and (Johannsen 
et a l , 1995) and that LMP1 trans-activation o f the bfl-1 promoter is also B cell specific 
(D'Souza et a l , 2000) may indicate that B cell specific transcription factors such as PU 1 
and Etsl are required to mediate the effects of EBNA2 and LMP1 on the bfl-1 promoter 
The identification of possible binding sites for the B cell and macrophage specific Ets 
family of transcription factors on the bfl-1 promoter mdicates that these may be the likely 
B cell specific factors required
Further evidence for the requirement o f Ets-1 in mediating EBNA2 trans-activation of the 
bfl-1 promoter came from transient transfection data using a dominant negative Ets-1 
expression plasmid (Figure 3 45) This dominant negative expression plasmid contains 
the cDNA sequence encoding human Ets-1, which lacks the transcription activation 
domain and corresponds to ammo acids residues 306 ±441, (which has been introduced 
into the pCEP4 expression plasmid, Invitrogen) (Nakada et a l , 1999, Kim et a l , 2000) 
Co-transfection of the dominant negative expression plasmid (up to 7ug) with the
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pSG5EBNA2 expression plasmid resulted in a dose dependent reduction in EBNA2 
associated trans-activation of the bfl-1 promoter EBNA2 mediated trans-activation of 
the bfl-1 promoter was reduced from over 5 fold to less than two fold with addition of 
increasing quantities of the dominant negative expression plasmid Unexpectedly, 
addition of lOug of the dominant negative reproducibly partially restored EBNA2 trans- 
activation of the bfl-1 promoter to 3 fold A similar trend was also observed with the 
truncated -367/+81 bfl-1 Luc promoter A possible explanation as to this effect is that 
over-expression of the dominant negative leads to some indirect effect resulting in 
blocking expression of itself, or possibly the dominant negative molecule loses activity 
through dimenzation when the protein is present in high concentration This phenomenon 
however, has not been reported in similar experiments elsewhere, in other studies 
expression of the dominant negative was shown to down regulate Ets-1 target genes uPA, 
(urokinase type plasminogen activator) and MMP family members (matrix 
metalloprotease) (Nakada et a l , 1999) Nonetheless the combined effects of the Ets-1 
dominant negative results, and mutation o f the putative Ets-1 sites on the bfl-1 promoter, 
are evidence of an important role for Ets-1 and PU 1 sites, particularly the double Ets-1 
site at position -176 to -163 on the bfl-1 promoter, in facilitating EBNA2 mediated trans- 
activation of this promoter
Notch-IC activates the transcription of CBF1 repressed promoters by displacing the 
SMRT-Histone deacetylase co-repressor complex by binding to CBF1 and SKIP via its 
Ram and Ankyrin repeat domains respectively (Zhou et a l , 2000) Similarly, EBNA2 
activates transcription through binding to CBF1 and SKIP, members of the CBF1 
repression complex, thereby displacing the co-repressor complex to facilitate access to its 
trans-activation domain (Zhou et a l , 2000) Specific regions of EBNA2 designated Cr5 
and Cr6 (Figure 1 7) specifically interact with SKIP and CBF1 respectively (Hsieh et a l , 
1995, Zhou et a l , 2000) Although there is no obvious sequence homology between 
EBNA2 and Notch, they interact with similar regions o f CBF1 and replace repressor 
proteins by their trans-activation domains Thus the interaction of EBNA2 and CBF1 
mimics Notch binding to CBF1 therefore the early steps in EBV immortalization may 
mimic an aspect of Notch signaling (Hsieh et a l , 1995, Kao et a l , 1998, Zhou et a l ,
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2000) In addition both Notch-IC and EBNA2 activated transcription can be negatively 
regulated by EBVRPMS andKyoT2 (Zhang ei a /, 2001, Tamguchi ei a / , 1998) The set 
of promoters, which is regulated by Notch-IC and EBNA2, is overlapping but not 
identical It has been shown, that EBNA2 can activate the Notch-IC responsive Hesl 
promoter Similarly both EBNA2 and activated Notch suppress differentiation of the 
myogenic cell line C2C12 by activation of Hesl (Sakai et a l , 1998, Kuroda et a l , 1999) 
Since EBN A2~medi ated immortalization o f human B cells is dependent on its interaction 
with and function through CBF1, (Yalamanchih et a l , 1994) it raises the possibility that 
dysregulated Notch function may also immortalize B cells In Burkitts lymphoma cell 
lines infected with a mutant EBV lacking EBNA2, activated Notchl can mimic EBNA2s 
ability to activate CD21 expression and down regulate Ign transcription (Strobl et a l ,
2000) also both EBNA2 and activated Notchl induce the BATF gene in EBV negative 
cells (Johansen et a l , 2003), however, in contrast to EBNA2, activated Notchl fails to 
activate either CD23, c-myc or the LMP1 viral protein (Strobl et a l , 2000) Further to 
this, activated Notchl can only transiently maintain proliferation of lymphoblastoid cell 
lines that lack EBNA2 expression but continue to express LMP1 (Hofelmayr et a l ,
2001) Thus although both EBNA2 and activated Notch activate target genes through 
CBF1, not all EBNA2 responsive genes are Notch-IC responsive genes and vice versa 
Since CBF1 appears to be critical in mediating EBNA2 reactivity on the bfl-1 promoter, 
it was plausible then, that Notch-IC might also activate bfl-1 expression via CBF1. In 
order to determine if bfl-1 was also responsive to activated Notch as well as EBNA2, a 
number of transient transfections were performed Up-regulation of bfl-1 at the protein 
and mRNA levels, in response to Notch-IC activation, was also examined using Western 
blot and RPA analyses Although both the EBNA2 (pSG5EBNA2) and Notch-IC (EDI) 
expressed functional EBNA2 and Notch-IC proteins, as demonstrated by their ability to 
trans-activate the pGA981-6 reporter containing a total o f 12 CBF1 sites, only 
pSG5EBNA2 trans-activated the bfl-1 promoter (Figures 3 46A and 3 46B) The mouse 
Notch-IC expression plasmid was titrated over a range o f quantities in co-transfections 
with the bfl-1 promoter and failed to activate the bfl-1 reporter construct (Figure 3 46B) 
The RAM domain in the Notch receptor has been shown to mediate the interaction 
between CBF1 and Notch-IC (Zhou et a l , 2000) and unsurprisingly the RAM deleted
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mouse Notch-IC expression plasmid ED4 also failed to trans-activate the bfl-1 promoter 
(Figure 3 47) Similarly despite the functionality of EBNA2 and Notch-IC in another B 
cell line Bjab, again shown by their ability to trans-activate the synthetic pGA981-6 
reporter construct, only EBNA2 could trans-activate the bfl-1 promoter (Figure 3 48A) 
Comparable experiments were also earned out in the BL41-P3HR1 -mNotch-IC (CL31) 
cell line, where mouse Notch-IC activation was induced by addition o f estrogen The bfl- 
1 promoter (-1374/+81 wt6/7-7 Luc), its CBF1 mutated partner (-1374/+81 mCBF 16/7-7 
Luc) and control reporter constructs, pGa981-6 and pGa50-7 vectors were transfected 
into the estrogen responsive cell line and the levels of trans-activation o f the promoters 
assessed m the usual way by the luciferase assay As per the other transient transfections 
in the Dg75 and Bjab cell lines, although Notch-IC (in this case activated by the addition 
of estrogen) trans-activated the pGa981-6 vector, it failed to trans-activate either bfl-1 
promoter reporter constructs (Figure 3 49B) Taken together these results suggest that 
bfl-1 is an EBNA2 but not a mouse Notchl responsive gene in B cell lines In order to 
extend this analysis, human Notch 1-IC and human Notch2-IC expression plasmids were 
also obtained and co-transfected with the appropriate promoter constructs in the Dg75 
cell line Results obtained here were similar to those obtained with the mouse Notch-IC 
expression plasmids Although both human NotchllC and human Notch2IC trans- 
activated the pGa981-6 vector demonstrating their ability to function in this B cell 
background, neither trans-activated the bfl-1 promoter (Figures 3 50A-C) Since both 
EBNA2 and Notch-IC proteins share an affimtiy for CBF1 it is possible that Notch is 
capable of interacting with CBF1 when the latter is bound to the bfl-1 promoter, even 
though significant trans-activation is not detectable Its inability to trans-activate the 
promoter may indicate (i) that the Notch-IC trans-activaion domain is much weaker than 
that of EBNA2, or (u) that trans-activation via the CBF1 site requires interaction with 
other additional factors, something achieved by EBNA2 but not Notch-IC, or (111) Notch 
may not bind to or have reduced affinity for the CBF1-corepressor complex formed at the 
-243/-249 site on the bfll promoter One way to determine if a Notch-CBFl interaction 
is occumng on the bfl-1 promoter was to co-transfect EBNA2 and Notch expression 
plasmids to see if co-expression of Notch and EBNA2 would result m decreased EBNA2- 
mediated trans-activation This competition experiment was earned out for the mouse and
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human Notch-IC expression plasmids (pEDl, pJT lll) and the human Notch2-IC 
expression plasmid (pJT112) Increasing quantities of pJTlll/pJT112/EDl were co­
transfected with pSG5EBNA2 and the subsequent trans-activation of the bfl-1 promoter 
analysed using the luciferase assay Despite sharing 70% homology and functional 
homology as reported to date, human Notchl-IC did not significantly repress EBNA2 
mediated trans-activation o f the bfl-1 promoter suggesting it may not interact or at least 
does not impede EBNA2 interaction, with CBF1 Although this effect could also be due 
to Notch interaction with another element in the bfl-1 promoter which may effect EBNA2 
trans-activation In contrast to co-transfection with human Notch2IC (pJTl 12) and mouse 
Notchl-IC (EDI) which reduced EBNA2 mediated trans-activation of the bfl-1 promoter 
by -50% and -70% respectively Although this result does not prove an interaction with 
CBF1 it showed that Notch2 and mNotchl-IC are in some way impeding EBNA2 trans- 
activation o f the bfl-1 promoter, which may be due to competition for binding to the 
CBF1 site, or other EBNA2-cntical sites on the bfl-1 promoter Northern blot and 
Western blot analyses using the C131 cell line suggest that any effect of Notch-IC 
activation on bfl-1 mRNA and protein is transient and complete after 6 hours 
Unfortunately due to inconsistencies with the gel loading, it is difficult to see the effect of 
Notch-IC activation on bfl-1 mRNA after 3 hours in Figure 3 55, however after Notchl- 
IC activation for 3 hours, bfl-1 mRNA is up-regulated 4 5 fold relative to pre activation 
levels These results suggest that bfl-1 mRNA is transiently up-regulated by Notch-IC 
activation and these results are also supported by western blotting which shows a 2 fold 
increase in bfl-1 protein at six hours after Notchl-IC activation Again this up-regulation 
is transient with protein levels decreasing to pre-activation levels by 9 hours The 
discrepancy between the Western and Northern blotting results and the promoter reporter 
data may suggest that transfection conditions need to be optimised to see the early 
transient effect o f mNotch-IC activation on bfl-1 Transfections were generally harvested 
48hr post transfection, by which time any transient effect of Notch-IC may no longer 
have been detectable
Bfl-1 is an anti-apoptotic protein which has been shown to protect cells from apoptosis 
induced by p53, serum starvation and TNFa-induced cytotoxicity It also exhibits
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proliferative and potent cooperative transforming properties in vitro (D’Souza et a l , 
2000, D'Sa-Eipper et a l , 1996, Karsan et a l , 1996 and Zong et a l , 1999) Functional 
dissection of the bfl-1 protein has revealed that (D'Sa-Eipper e/ a l , 1998) the BH1, 2 and 
4 domains are essential m conferring the anti-apoptotic and transforming properties of 
this protein The fact that mutations which abolish the anti-apoptotic function also abolish 
the oncogene co-operating function also suggest that both of these functions are linked 
(D'Sa-Eipper et a l , 1998, D’Sa-Eipper et a l , 1996)
Elevated levels of bfl-1 mRNA are a feature of EBV infected cell lmes and the EBV 
latent protein LMP1 has been found to up-regulate bfl-1 mRNA in EBV negative BL cell 
lines (D’Souza et a l, 2000) Although LMP1 is in part responsible for the EBV induced 
up-regulation o f bfl-1 mRNA in EBV positive cell lines, other EBV proteins are also 
likely to play a role in regulating the bfl-1 gene (D'Souza et a l , 2000) This is apparent 
since steady state levels o f bfl-1 mRNA m LCL and type in  BL cell lines are 
dramatically higher than in cell lines in which LMP1 alone is induced (D’Souza et a l ,
2000) Physiologically, the up-regulation of bfl-1 mRNA by LMP1 in BL cell lines has 
been shown to protect them from apoptosis induced by growth factor withdrawal 
(D’Souza et a l , 2000)
The results presented in this study indicate for the first time that expression of the anti- 
apoptotic bfl-1 gene is up-regulated by the EBV latent protein EBNA2 The physiological 
effect of this in BL cells was then investigated Initially the susceptibility of Dg75 cells to 
apoptosis had to be determined Dg75 cells displayed a relatively high anti-apoptotic 
threshold, although apoptosis was induced in Dg75 cells using growth factor withdrawal 
by culturing cells in 0 5% and 0 1% serum supplemented media (Figure 3 56) Apoptosis 
was also induced by simultaneously serum starving cells and exposing them to 
lonomycm Cell viability was assessed using trypan blue exclusion and the mode of cell 
death was analysed using Acndine orange staining (Figure 3 57) Apoptotic cells were 
identified by their distinctive morphology and staining pattern, appearing condensed and 
fluorescing brightly Healthy cells on the other hand are larger and more diffusely stained 
(Gregory et a l , 1991) (Figure 3 56) Having ascertained that DG75 cells could be 
triggered to apoptose by serum starvation, this cell line was stably transfected with 
EBNA2 expression plasmids and the protective effect afforded by EBNA2, and thus bfl-1
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induction in this cell line in response to growth factor withdrawal, was analysed by 
acndine orange staining and Flow Cytometry It was observed that pSG5EBNA2 and 
pSG5EBNA2WW323SR expression afforded some protection of these BL cells from 
apoptosis (Figures 3 64 and 3 65) Percentage cell death was quantified by counting 
apoptotic cells after acridine orange staimng and it can be seen that cell death is reduced 
from over 60% in cells not expressing EBNA2 to 38% in cells expressing wild type 
EBNA2 Expression of the EBNA2WW323SR protein, also consistently reduced cell 
death (49%), relative to cells not expressing EBNA2 however the protective effect was 
consistently lower than that seen in the EBNA2-expressing cell line DG75-pSG5EBNA2 
(Figure 3 64) These results suggest that CBF1 binding, or a downstream effect of this 
may be involved m mediating this anti-apoptotic effect in Dg75 cells Since EBNA2 up- 
regulates bfl-1 and this induction of 6/7-7 requires CBF1, 6/7-7 may have a key role in 
mediating this anti-apoptotic effect of EBNA2 expression m the DG75 cell line EBNA2 
however has also been shown to up-regulate the expression of the proto-oncogene c-myc 
in lymphocytes (Kempkes et a l , 1995) and this may also have a role m this protective 
effect Further to this EBNA2 up-regulation of 6/7-7 may also be involved in increasing 
the anti-apoptotic threshold of EBV infected cells (Gregory et a l , 1991) The anti-death 
property of EBNA2 expression has been shown elsewhere, when EBNA2 expression 
protected transfected B cells from Nur 77 induced apoptosis (Lee et a l , 2002)
FACS analysis is a more quantitative method for detecting apoptosis, thus, in this study 
the stably transfected cell lines (Dg75-pSG5, Dg75-pSG5EBNA2 and Dg75- 
pSG5EBNA2WW323SR) were stained with propidium iodide and using light scatter 
data, the percentage of apoptotic cells was calculated with CellQuest software 
(BectonDickinson) It can be seen in Figure 3 65 that both cell pools expressing EBNA2 
(Dg75pSG5EBNA2 and Dg75pSG5EBNA2WW323SR) and both cell pools not 
expressing EBNA2 (Dg75 and Dg75-pSG5) apoptose under conditions of serum 
starvation however, the percentage of cells dying is reduced m those cell lines expressing 
EBNA2 In the Dg75 cell line and the Dg75-pSg5 cell line, -77% and -83% of cells 
respectively, are apoptotic after seven days in serum deprived media, however in the 
Dg75-pSG5-EBNA2 and Dg75-pSG5EBNA2WW323SR cell lines, the percentage of 
apoptotic cells respectively, is -39% and 58% respectively Thus EBNA2 expression
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provides a measure of protection from growth factor withdrawal induced apoptosis in 
Dg75 cells CBF1 may be also have a role in this protective effect as again, the 
percentage of cells apoptosing was consistently higher in the cell line m which the CBF1- 
bmding defective EBNA2 was expressed, compared to the cell line m which wild type 
EBNA2 is expressed It can also be seen from Figure 3 66 that EBNA2 expression results 
in an accumulation of cells in the G1 phase, this effect has been noted elsewhere and may 
be due to the combined up-regulation of c-myc (Kempkes et a l , 1995a) as well as bfl-1 in 
this cell line Levels of c-myc and bfl-1 protein in this cell line could be detected by 
Western blotting It is also possible that pro-apoptotic proteins such as bik are also being 
down-regulated in response to EBNA2 expression as seen in Figure 3 3 In effect the 
combined up-regulation of anti-apoptotic and down regulation o f pro-apoptotic proteins 
by EBNA2 expression is likely to be responsible for the relative resistance to apoptosis, 
of these EBNA2 expressing cells
EBNA2 trans-activation of the EBV latency C promoter, the LMP1 promoter and the 
cellular CD23 promoters is dependent on an interaction with the DNA-binding protein 
CBF1 for promoter targeting (Ling et a l , 1993, Ling et a l , 1994) Since a CBF1 binding 
deficient EBNA2 cannot trans-activate the bfl-1 promoter (Figure 3 16) and site directed 
mutagenesis of the putative CBF1 binding site on the bfl-1 promoter at nucleotide 
positions -243 to -249 also abolishes EBNA2 trans-activation of the bfl-1 promoter, 
(Figure 3 26A), it is likely that CBF1 binding may play a role in the EBNA2 mediated 
trans-activation of the bfl-1 promoter It was therefore important to determine by 
EMSA/bandshift assay if  CBF1 and EBNA2/CBF1 interactions were occurring at the -  
243A249 CBF-1 like binding site on the bfl-1 promoter Initially as a control, the effect of 
EBNA2 induction on CBF1 binding activity m DG75-tTA-EBNA2 cells was assessed by 
EMSA using a double-stranded oligonucleotide containing the CBF1 binding site 
between nucleotide positions -359 to -388 on the Cp promoter (Ling et a l , 1994) which 
has previously been shown to form a stable complex with EBNA2 in EMSA analyses 
(Ling et a l , 1994) However this study failed to detect any direct interaction between 
EBNA2 and the CBF1 binding site on the Cp promoter As this interaction has been 
previously published it was expected that documented high molecular weight protein 
DNA complex would have been detected Thus conditions in the binding reaction may
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need to be optimized in order to facilitate protein-DNA interaction Similarly this study 
failed to detect any direct interaction between EBNA2 and CBF1 at the putative CBF1 
binding site on the bfl-1 promoter This may again be due to sub-optimal binding 
conditions or, the bfl-1 binding site in question may have a low affinity for CBF1 
Another possibility is that further transcription factors are required to mediate the 
EBNA2/CBF1 reaction on this promoter Smce the results show that members of the Ets 
family may have a role in mediating EBNA2 associated activation of the bfl-1 promoter, 
they may be candidates here Despite the fact that EMSA analyses failed to demonstrate a 
direct interaction between the putative bfl-1 CBF1 and EBNA2, the weight of evidence 
from transient transfection data and mutagenesis of the promoter shows that CBF1 has a 
critical role in mediating EBNA2 activation of bfl-1
Summary
It has already been shown that regulation o f the cellular bfl-1 gene (also known as A I) is 
an important EBV-host cell interaction that promotes resistance to programmed cell death 
(or apoptosis) in a BL-denved cell line LMP1 has been shown to regulate the expression 
of this gene and the signalling pathway used by the EBV Latent Membrane Protein 1 
(LMP1) to regulate bfl-1 expression has been characterized
This thesis presents a second mechamsm, independent of LMP1, by which EBV regulates 
bfl-1 mRNA levels We show that the EBV nuclear antigen 2 (EBNA2), a second major 
effector of phenotypic change in the infected cell, can trcms-activate the bfl-1 promoter 
through interactions with components of the cellular Notch signalling pathway The 
mam findings of this study include
• Induction of EBNA2 expression using a tetracycline-based regulation system, 
leads to increased bfl-1 mRNA levels in an EBV-negative BL-denved cell line
• When EBNA2 is expressed as an inactive fusion with the hormone-binding 
domain of the estrogen receptor, the steady-state level of bfl-1 mRNA increases 
upon activation of EBNA2 function by addition of oestrogen
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• EBNA2 irons-activates the bfl-1 promoter in BL cell lines by a mechanism that is 
dependant upon its ability to bind CBF1, a DNA-bmding nuclear component of 
the cellular Notch signalling pathway
• A novel CBF-l-like binding site is present on the bfl-1 promoter that is essential 
for EBNA2-mediated tams-activation
• EBNA2-mediated /ra/w-activation is modulated by other EBV latent proteins that 
are known to co-operate with EBNA2 (such as EBNA-LP), or that have been 
shown to interact with the CBF1-co-repressor complex (EBNA3A, 3B, 3C and 
RPMS)
• LMP1 and EBNA2 do not cooperate to /raws-activate the bfl-1 promoter and may 
require a common factor to exert their trans-activational effect on bfl-1
• Activated Notch receptor (Notch-IC), of which EBNA2 is regarded as a viral 
functional homologue, does not iram-activate bfl-1 in BL-denved cell lines
• Novel Etsl and PU 1 like binding sites are present on the bfl-1 promoter which 
have a critical role in EBNA2 /mm-activation
• EBNA2 induced up-regulation o f Bfl-1 in an EBV negative BL cell line may 
provide some protection from apoptosis triggered by growth factor withdrawal
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A p p e n d i x
SOLUTIONS FOR DNA MANIPULATION
TE buffer
10 mM Tns-Cl
Im M  EDTApH8 0
Solutions for mmi-preparation of plasmid DNA 
Solution I
50 mM Glucose
25 mM Tns Hcl (pH 8 0)
10 mM EDTA (pH 8 0)
Solution I I  (Prepared fresh)
0 2 M  NaOH
1 % (w/v) SDS
Solution m
60 ml 5 M  potassium acetate
11 5 ml Glacial acetic acid
28 5 ml Distilled water
The resulting solution is 3 M  with respect to potassium and 5 M  with respect to acetate
DNase-free RNase
RNase A (1 mg/ml ) in stenle water
Heat to 100°C for 30 mm Cool slowly and store -20°C
Solutions for Maxipreparations of DNA -  Qiagen Buffers
Buffer PI (Resuspension buffer)
50 mM Tns-cl, pH 8 0
b
10 mM EDTA
100 *ig RNase A
Store at 4°C after the addition of RNase A
Buffer P2 (Lysis buffer)
200 mM Sodium Hydroxide
1% (w/v) SDS
Prepared fresh and stored at room temperature
Buffer P3 (Neutrahziation buffer)
3 0 M  Potassium acetate pH 5 5
Stored at 4°C
Buffer QBT (Equilibnation buffer)
750 mM NAcl
50 mM MOPS pH 7 0
15% (v/v) Isopropanol
0 15% (v/v) TitonX-100  
Stored at room temeprature
Buffer QC (Wash buffer)
1 0 M  NAcl
50 mM MOPS pH 7 0
15% (v/v) Isopropanol
Stored at room temperature
50% (v/v) Glycerol 
25 ml Distilled
25 ml Glycerol
Autoclaved and stored at room temperature
c
0.5M ED TA
186 1 g EDTA
800 ml Distilled water
6 g NaOH pelletes
pH to 8 0 with 5 M  NaOH Volume was adjusted to 1 L with water
50XTAE
242 g 
57 1 ml 
100 ml 
Adjusted to
10X TBE
108 g Tns
50 g Bone acid
40 ml 0 5 M  EDTA pH 8 0
Adjusted to IL  with water
Ethidium bromide
0 1 g/10 ml water (10 mg/ml)
Stored in dark at room temperature
Agarose gel loading dye
40% (w/v) sucrose 
0 25% (w/v) bromophenol blue
BACTERIAL GROW TH M EDIA  
LB agar
10 g Tryptone
5 g Yeast extract
5 g NacL
Tns
Acetic acid 
0 5 M  EDTA pH 8 0 
IL  with water
d
15 g Agar technical
Autoclaved and plates stored at 4°C
LB Agar Plus Ampicillin
Ampicillin was added to a final concentration of 100 i^g/ml to LB agar (50°C)
Plates were stored at 4°C
Tetracycline stock
5mg /ml 50mg of tetracycline (Sigma) was added to 10ml of 80% ethanol 
LB Agar Plus Tetracycline
Tetracycline was added to a final concentration of 12 S i^g/ml to LB agar (50°C)
Plates were stored at 4°C
LB broth (per L)
10 g Bacto-tryptone
5 g Yeast extract
5 g NAcl
Autoclaved and stored at 4°C
LB Ampicillin broth
Ampicillin was added to LB broth to a final concentration of 100 jig/ml from stock 
solutions (100 mg/ml in d^O , stored at -20°C) Stored at 4°C
LB Tetracycline broth
Tetracycline was added to LB broth to a final concentration of 10pig/ml from stock 
solution (5mg/ml m 80% ethanol)
SOB medium (per L)
20 g Trytpone
e
5g
0 5 g
10 ml
Yeast extract 
Nacl
KCl (250 mM)
Adjusted pH to 7 0 with 5 M  NaOH 
Autoclaved, cooled to -5°C and added 
10 ml IM M g d U  
Stored at 4°C
SOC medium (per L)
1 L SOB
7 5 ml 50% glucose (filter sterilised)
Stored at 4°C
Ampicillin stock solution (50 mg/ml)
50 mg of ampicilhn per ml of stenle H2O 
Filter sterilised and stored at -20°C
Buffers for Use with the Promega Altered sites I I  In  Vitro Mutagenesis System.
2M Ammonium Acetate (pH 4 6)
15 4g of ammonium acetate dissolved in 50ml dl H2O Brought to pH 4 6 with glacial 
acetic acid and then to a final volume of 100ml with dl H2O
7 5M Ammonium Acetate (pH 7 5)
57 18g ammonium acetate dissolved in 50ml dl H2O Brought to pH 7 5 NaOH and then 
to a final volume of 100ml with dl H20
Annealing 10X Buffer 
200mM Tns-cl-(pH7 5) 
lOOmMMgCh 
500mM NaCl 
Kinase 10X buffer
f
700mM Tns-Cl (pH 7 6) 
lOOmMMgCh 
50mM DTT
TFB1
30mM potassium Acetate 
lOmM CaCl3 
50mM MnCb 
lOOmMRbCl 
15% Glycerol
Adjust pH to 5 8 with 1M acetic acid Filter sterilize (0 45um) Astrored at room 
temperature
TFB2
lOOmM MOPS or PIPES (pH 6 5)
75mM CaCl2 
lOmMRbCl 
15% glycerol
Adjust pH to 6 5 with 1M KOH Filter Stenhze and store at room temperature 
CELL CULTURE MEDIA/SOLUTIONS
Supplemented R PM I (200 ml)
176 ml RPMI 1640
20 ml Foetal calf Serum (Decomplemented -50°C for 30 mm)
2 ml 200 mM L-glutamine
2 ml Penicillin/Streptomycin (1000 U/ml-1000 (.ig/ml)
Supplemented DM EM  High Glucose (C33A)
178 ml DMEM high glucose with L-glutamine
20 ml Foetal calf Serum (Decomplemented, 50°C for 30 min)
g
Pemcilhn/Streptomycin (1000 U/ml-1000 jig/ml)
10X Phosphate Buffered Saline (PBS)
14 24 g Na2HP04 2H2O (8 mM)
2 04 g KH2P04(1 5mM)
80 0 g NAcl (137 mM)
2 0 g KCI (2 7 mM)
pH 7 5 and make up to 1 litre
Diluted 1 m 10 m stenie distilled water and used at a 1 X  working concentration
Geneticin G418 (stock solution 50 mg/ml) for tetracycline inducible cell lines
0 1 g Geneticin
2 ml R P M I1640
Filter sterilised using a 0 2 micron filter, ahquoted and stored at -20°C 20 jxl of the 
stock solution was added per ml of media to give a final concentration of 1 mg/ml
Geneticin G418 for addition to Estrogen responsive cell lines.
BL41-ER/EBNA2 (K3) Kept m permanent selection by addition of G418 to a final 
concentration of 1 6mg/ml from stock solution
BL41P3HR1-ER/EBNA2 (9A) Kept m permanent selection by addition of G418 to a
final concentranon of 1 2mg/ml from stock solution
Hygromycm B (stock solution 50 mg/ml supplied)
Ten micro litres of the stock solution was added per ml of media to give a final
concentration of 500 |ig per ml Stored at 4°C
Hygromycm for addition to the estrogen responsive cell line C131
BL41P3HR1 -ER/mNotchIC (C131) Kept in permanent selection by addition of 
Hygromycm to a final concentration of 0 8mg/ml from stock solution
Tetracycline (stock 5 mg/ml)
5 mg
1 ml
Tetracycline 
100% Ethanol
Stored at -20°C, 1 1^ of tetracycline was added t o5 ml of media to give a final 
concentration of 1 \ig  per ml
Ionomycin (stock solution)
2mM in DMSO 
Stored m aliquots at -20°C
Estrogen. Stock solution.lOmg/ml
lOOmg B-estradiol (Sigma) was added to 10ml of 70% ethanol
Estrogen for activation of EBNA2 or Notch.
Estrogen was added to a final concentration of luM  from stock solution
Cyclohexamide
Prepared as a 50mg/ml stock in dl H20
Cyclohexamide was added to a final concentration of lOmg/ml to stop protein synthesis
Solutions for modified DEAE-Dextran Transfection Protocol 
T.E.
10 mM Tns (pH 7 4)
1 mM EDTA
Prepared fresh on the day of use using autoclaved of Tns and EDTA It is important to 
ensure that the pH of the Tns is at 7 4 room temperature pnor to use
TBS
25 mM
5 mM
137 mM
Tns (pH 7 4)
Nacl
KC1
0 7 mM CaCl2
0 5 mM MgCl2
0 6 mM Na2HP04
Prepared from autoclaved stocks, aliquoted and filtered before use Again the pH of the 
Tns is critical
DEAE Dextran
1 mg/ml in TBS, prepared fresh and filter sterilised 
ß-gaiactosidase assay
100 x Mg solution
O lM M g c h  
4 5 M  2-mercaptoethanol 
Stored at -20°C
1 x ONPG substrate (o-nitrophenyl ß-D-galactopyranoside)
4mg/ml in 0 1M sodium phosphate buffer pH7 5 
Stored at -20°C
SOLUTIONS FOR PROTEIN ISOLATION
Suspension buffer
0 1 M  
0 01 M
0 001 M
1 jag/ml 
100ng/ml 
Stored at 4°C
1
Nacl
Tns-Cl (pH 7 6) 
EDTA (pH 8 0) 
leupeptm 
PMSF
2X SDS gel loading buffer
100 mM Tns-cl
10% 2-mercaptoethanol
4% (w/v) SDS
0 2% (w/v) Bromophenol blue
20% (v/v) Glycerol
Two times loading buffer was prepared without 2-mercaptoethanol and stored at room 
temperature 2-mercaptoethanol was added just pnor to use from a 14 4M (100%) stock
Protease Inhibitors (stock solutions)
2 mg/ml Leupeptm m water
0 1 M  PMSF (phenylmethylsulfonyl fluoride) in isopropanol
Stored at -20°C (PMSF was stored away from light)
SOLUTIONS FOR SDS PAGE/WESTERN BLOTTING
1M  
1 5 M  
10% (w/v) 
10% (w/v) 
Acrylagel 
Bis-acrylagel 
TEMED
Tns-Cl pH 6 8 
Tns-Cl pH 8 8 
SDS
Ammomum persulphate (APS)
10X Tns glycine running buffer (500 ml)
15 138 g Tns
71 125 g Glycine
5 0 g SDS
Made up to 500 ml with distilled water
Destain
100 ml Acetic acid
k
400 ml 
500 ml
Methanol 
Distilled water
Coomassie blue stain
1 g Coomassie blue R
200 ml Destain
Transfer Buffer (10X slock solution)
30 3g Tns
144 2g Glycine
Adjusted to pH 8 3, made up to 1 L with distdled water, stored at room temperature
Transfer Buffer ( IX  working Solution)
100 ml 10X Stock Solution
200 ml Methanol
700 ml Distilled H20
Stored at 4°C
TBS (IX )
6 1 g Tns
8 8 g Nacl
Made up to 1 L with distilled water and adjusted to pH 7 5 with HC1 
Autoclaved and stored at room temperature
TBST (0.1%, v/v)
1 L TBS (as above)
I  ml Tween 20
Blotto
IX  TBS (as above)
0 05% (v/v)Tween 20
1
5% (w/v) non-fat dry milk (Marvel)
0 02%NaN3
Sodium azide (10%) (w/v)
lg NaN3
10ml Distilled water
REAGENTS FOR RNA ANALYSIS 
RNA sample buffer
50 % (v/v) Deionized formamide
8 3 % (v/v) Formaldehyde
0 027 M  MOPS pH 7 0
6 7 mM Sodium acetate
RNA loading buffer (containing ethidium bromide)
50% (v/v) High grade glycerol
1 mM EDTA (pH 8 0)
0 4 % (w/v) Bromophenol blue
0 1 jig/ml Ethidium bromide
Aliquoted and stored at -20°C
5 X  MOPS Buffer (Formaldehyde gel running buffer)
0 1MMOPS (pH 7 0)
40 mM Sodium Acetate 
5 mM EDTA (pH 8 0)
20 6g of 3 -(TV-morphohnoj propanesulfomc acid (MOPS) was dissolved m 800 ml of 
DEPC treated 50 mM sodium acetate The pH of the solution was adjusted to 7 0 using 2 
M  NaOH 10 ml of DEPC-treated 0 5 M  EDTA (pH 8 0) was added and the volume of 
the solution was adjusted to 1L using DEPC-treated H2O The 5X solution was filter 
sterilised through a 0 2 micron filter prior to use
m
Formaldehyde gel
1 part Formaldehyde 
3 5 parts agarose m DEPC H2O
0 68 g Agarose
35ml DEPC H20
The agarose solution was boiled until fully dissolved and allowed to cool to 60°C The
following were then added
11ml 5X MOPS buffer
10 ml Formaldehyde
56 ml Final volume
The gel was cast m a fume hood and allowed to set for approximately 45 mm The gel 
was electrophoresed in IX  formaldehyde gel running buffer
RNA loading buffer
50% (v/v) High grade glycerol
Im M  EDTA (pH 8 0)
0 25% (w/v) Bromophenol blue
0 25% (w/v) Xylene cyanol FF
DEPC-treated overnight, autoclaved and stored at room temperature
20XSSC
175 3g Nacl
88 2g NaCitrate
pH to 7 0 using a few drops of 10M NaOH and made up to 1 litre using up H20  DEPC 
treated and autoclaved Stored at room temperature
Hybridization Buffer
50% (v/v) Deionized formamide
6X SSC
n
1% (w/v) SDS
0 1% (v/v) Tween 20
100 jag/ml tRNA
Prepared fresh prior to use stored at room temperature
REAGENTS FOR RIBONUCLEASE PROTECTION ASSAY 
Five percent denaturing polyacrylamide gel
A five percent denaturing polyacrylamide gel was prepared for resolution of labelled 
riboprobes and analysis of protected RNA fragments The following formula was 
employed to determine the amount of acrylamide and bis-acrylamide required
Va = volume of acrylamide
Vb = volume of bis-acrylamide
Vt = total volume of gel mix (150 ml)
C = % crosshnkmg
A = % gel
Va =Ayt Vb = ACVt
30 200
Va= 5*150/30 =25 ml Vb = 5*5 2*150/200 = 19 5 ml
5 % Denaturing PAGE
63 g Urea
25 ml Acrylamide
19 5 ml Bisacrylamide
15 ml 10XTBE
Made up to 150 ml with up H2O
Ninehundred jil of 10% (w/v) APS and 150 \ü  TEMED were added, and mixed briefly, 
before pouring
o
10X TBE (per 500 ml)
54 g Tns base
27 5 g Bone acid
20 ml 0 5 M  EDTA (pH 8 0)
One X  concentration was used for polyacrylamide gel preparation
10% (w/v) Ammonium persulphate
0 1 g APS/ml ultra pure H20
Elution Buffer
0 5M ammonium acetate 
10 0 mM Magnesium acetate 
lm M ED TA pH 8 0 
0 1% SDS
made up in DEPC-treated upH20
Developer (5 L)
1 50 L H20
1 25 L Developer
2 25 L H20  
Stirred for 2 mm
Fixer (5 125 L)
3 625 L H20
1 250 L A fixer
0 250 L B fixer
Stirred for 2 mm
P
REAGENTS FOR EMSA
Nuclear Protein Extraction buffers
Buffer A Final Cone Stock for 10'
Hepes pH 7 9 (NaOH) lOmM 1M 1ml
KC1 lOmM 2M 500ul
MgCl2 1 5M 1M 150ul
H20 98 5m
Make aliquots of 10ml each
Before use add 50ul ofDTT (1M)
50ul Pefabloc (Roche) to each aliqout
Buffer B
Hepes pH 7 9 (NaOH) 20mM 1M 2ml
Glycerol 86-88% 25ml
NaCl 5M 8 4ml
MgCl2 1M 150ul
EDTA(pH8 5) 0 5M 40ul
Make aliquots of 10ml each 
Before use add 50ul ofDTT  
50ul Pefabloc
Poly (dl-dC).Poly (dl-dC) (stock)
DissolvelO U in 393 5 jxl ultrapure H2O 
Store m aliquots at -20°C
Nuclear extracts were quick frozen and stored in liquid Nitrogen Protem content was 
assayed by the BCA assay
Reagents for Shift Reaction
Binding buffer (4 x) Final Concentration Stock For 10ml
Hepes (pH 7 9) 40mM 1M 400ul
EDTA (pH 8) 4mM 0 5M 80ul
KCL 800mM 1M 8ml
Ficoll 16% 1 6g
lml aliquots were then frozen
DTT was added to a final concentration of 4mM
And Pefabloc was added as before
BSA was made up to lmg/ml m dl H2O
Bandshift polyacrylamide gel
The formula used to calculate the volume of Accugel [40% (291)
Acrylamide Bisacrylamide solution] used to prepare a gel of a given percentage is as 
follows
Va = volume of accugel to be used (ml)
Vt= Total volume of gel casting solution required (ml)
X  = % gel desired
V a - c a c x )
40
For a 4% or 5% gel of 50 ml volume
Solution (stock) Volume (ml)
4% 5% 8%
r
Accugel 5 0 6 2 10 0
lOxTBE 5 0 5 0 5 0
Water (ultrapure) 39 9 38 7 34 9
Then, 5\x\ of 1M DTT was added to the gel mixture followed by 50mg of APS and 15ja1 
of TEMED and the gel mixture swirled briefly and poured into the gel mould The comb 
was then inserted and the gel allowed to set for at least 45 mm
Binding Reaction. (20ul)
Binding Buffer 4X 5ul
Poly dldC 2ul
BSA(lmg/ml) 2ul
Binding Mix) 9ul
Binding Mix 9ul
Antibody Sul
Nuclear Extract 1 Oug
Incubated for 5 minutes at room temperature 
32P labelled oligonucleotide, l-2ul
dl H20  20ul
Incubated for 30 minutes at room temperature
Loaded onto a 4-6% pAA gel in TBE one extra lane contained Bromophenol Blue to 
visualise the leading edge of the gel
In supershift reactions, nuclear extracts and Antibody were incubated at room 
temperatrure for 30 minutes prior to addition of labelled oligonucleotide
s
